GD2001/[ZIP_CODE]/12 CONFIDENTIA L
ViiV Healthcare group of companies APV20002
1Division: World wide Development
Retention Category: GRS019
Information Type: Protocol Amendment
Title: APV20002: A 48 Week Phase II, Open -label, 2 -cohort, 
Multicentre Study  to Evaluate the Pharmacokinetics, Safet y, 
Tolerability  and Antiviral Activity  of GW 433908 and 
GW433908/RTV When Administered to HIV -1 Infected 
Protease Inhibitor (PI) Naïve and PI -Experienced Pediatric 
Subjects aged 4 weeks to <2 y ears
Compound Number: GW433908
Effective Date: 20-NOV-2019
Protocol Amendment Number:  [ADDRESS_273695]: HIV infection, pediatric, protease inhibitor, fosamprenavir, GW433908
Author:  
Copy right 2019 ViiV Healthcare group of companies.  All rights reserved.  Unauthorised 
copy ing or use of this information is prohibited.
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
ViiV Healthcare group of companies APV20002
2Revision Chronology:
GD2001/[ZIP_CODE]/00 2002 -SEP-20 Original
GD2001/[ZIP_CODE]/01 2003 -AUG -05 Amendment No. 1: 
Study  Design changes including 
lowering of the age limit from 6 weeks 
to 4 weeks 
Revision of study  obje ctives and 
endpoints Update schedule of 
assessments and interim anal yses
Addition of new data from other FPV 
studies
Changes related to initial dose 
selection and dose adjustment criteria
To update the definition of study  drug 
overdose
To update the subjec t management 
options
GD2001/[ZIP_CODE]/02 2004 -MAY -10 Amendment No. 2:
To change the Exclusion Criteria No 8 
to any  Grade 3 or greater laboratory  
abnormality
GD2001/[ZIP_CODE]/03 2005 -JUL-01 Amendment No. 3:
To add a new dose recommendation for 
Cohort 1A
To tempor arily close Cohort 1B
To revise the stud y design to allow 
simultaneous enrolment of Cohort [ADDRESS_273696] their 
treatment switched to a boosted 
regimen only  in countries where RTV 
solution is locally  available for long -
term use
To provide clarification regarding the 
maximum age allowed for each cohort 
in Inclusion Criteria No 1. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
ViiV Healthcare group of companies APV20002
3GD2001/[ZIP_CODE]/04 2005-AUG -03 Amendment No. 4:
To add information regarding the 
removal of the unboosted FPV 
Cohort 1 Arm B from the study .
This amendment was sent to the Food 
and Drug Administration (FDA) only 
and was not sent to the sites for 
implementation.
GD2001/[ZIP_CODE]/0 5 2007 -JUL-05 Amendment No. 5:
Defers enrolment of subjects in the 
unboosted FPV cohorts (Cohort 1 Arm 
B and Cohort 2 Arm B)
Increases the dose of FPV to 6 0 mg /kg 
at the Week 2 visit for subjects in 
Cohort 1 Arm A
Revises the PK visits and sampling 
times f or subjects in Cohort 1 Arm A 
and adds plasma samples for 
determining unbound APV 
concentrations
Increases the single doses for Cohort 2 
Arm A SDV to FPV 4 5 mg /kg and 
RTV 7 mg/kg
Revisions to the concurrent 
medications; rifabutin and pheny toin 
no longer ex cluded
Updates information on rash and 
abacavir h ypersensitivity reaction
Updates sponsor contact [CONTACT_227375] (2004)
Updates background information, 
removes redundancies and corrects 
minor inconsistencies in the pr otocol.
GD2001/[ZIP_CODE]/06 2007 -NOV -20 Amendment No. 6:  Corrects the 
inaccuracies in the stud y drug dosing 
tables and an inconsistency  in 
exclusion criteria no. 9 (per 
amendment 5)
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
ViiV Healthcare group of companies APV20002
4GD2001/[ZIP_CODE]/07 2009 -JUN-02 Amendment No. 7:   To add a dose 
recommendation for subjects recruited 
into Cohort 2 Arm A.  Update to the 
number of subjects to be recruited into 
Cohort 2 Arm A.  Remove the Single 
Dose Visit from the assessment flow 
chart for subjects in Cohort 2 Arm A.  
Include the option to use local 
laboratories f or haematology  and 
clinical chemistry  with Sponsor 
approval.
GD2001/[ZIP_CODE]/08 2009 -NOV-23 Amendment No. 8:
To revise the dose recommendation for 
new subjects enrolled into Cohort 1, 
Arm A to FPV/RTV 45/ 7 mg /kg BID, 
with no increase to 60/ 7 mg /kg BID at 
Week 2.
To update the number of subjects to be 
recruited into Cohort 1, Arm A.  
To provide additional dosing advice for 
existing subjects in Cohort 1, Arm A 
receiving FPV/RTV 60/ 7 mg/kg.
To provide guidance on dosing for 
subjects when reaching [ADDRESS_273697] for 
liver enzy mes in the event of grade 3 or 
> value to determine eligibility
GD2001/[ZIP_CODE]/[ADDRESS_273698] -25 Amendment No. 9: 
Tospecify  a change of study  sponsor.
To provide information on an external 
review committee. 
To update recruitment status. 
To clarify  guidance on dosing for 
subjects reaching 2 years and 6 y ears 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
ViiV Healthcare group of companies APV20002
5of age during the stud y
GD2001/[ZIP_CODE]/10 2011 -MAR -28 Amendme nt No. 10: 
To amend information on propy lene 
glycol content in FPV oral suspension 
to include contribution from liquid 
flavours.
To close unboosted FPV Cohorts 1B 
and 2B and amend stud y objectives and 
endpoints accordingl y.
To correct study  sponsor inform ation.
GD2001/[ZIP_CODE]/[ADDRESS_273699] -26 Amendment No.11: 
To include information on 3TC and 
ABC tablets to be provided by  [CONTACT_227376] .
To update the list of drugs not to be co -
administered with FPV and RTV.
To provide option to discontinue PK 
sampling and monitoring of plasma 
APV, FPV and RTV concentration on 
an individual basis once a subject has 
reached and exceeded 2 years and has 
initiated the 23/ 3 mg /kg BID dosing 
regimen
To update section on posting of 
information on publicly  available
clinical trials registers and publication
GD2001/[ZIP_CODE]/1 2 20-NOV -2019 Amendment No. 12
To include additional RTV formulation 
options as the oral solution is being 
discontinued in South Africa and 
provide updated FPV and RTV dosing 
tables for children >[ADDRESS_273700] of drugs not to be co -
administered with FPV and RTV and 
provide additional information on rash 
management and suspected abacavir 
hypersensitivity  1. FPV Pediatric 
GD2001/[ZIP_CODE]/[ADDRESS_273701] been added ; sites 
are also now advised to refer to these 
and local labels for summaries of the 
available data
Thesection regarding reporting of 
SAES was moved to Section 7.9 and 
the previous Section 7.9 (Regulatory  
Reporting Requir ements For SAEs) 
was moved to Section 7.8
After 2013 , viral load measurements, 
are being performed using the Abbott 
Realtime HIV -1 assay  due to 
manufacturer discontinuation of the 
[COMPANY_002] Amplicor assay
Assent forms will be obtained from 
subjects still enrol led in the study  as of 
Nov 1, 2019 as the subjects are now of 
an age where they  can provide a ssent 
(consent originall y provided by [CONTACT_227377]) 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
8SPONSOR INFORMA TION PAGE
Title: A 48 Week Phase II, Open- label, 2 -cohort, Multicentre Study to 
Evaluate the Pharmacokinetics, Safet y, Tolerability and Antiviral 
Activity  of GW433908 and GW433908/RTV When Administered 
to HIV -1 Infected Protease Inhibitor (PI) Naïve and PI -Experienced 
Pediatric Subjects aged 4 weeks to <2 years.
Study  Number: APV20002
This study  is sponsored by  [CONTACT_227378] L imited and ViiV Healthcare Company .  
GlaxoSmithKline is responsible for impleme nting and managing all aspects of this study .
ViiV Healthcare [LOCATION_006] L imited
[ADDRESS_273702]
Middlesex
TW8 9GS
[LOCATION_006]
Telephone: +44 (0)[ADDRESS_273703]
Research Triangle Park
North Carolina [LOCATION_003]
[ZIP_CODE] -3398
Telephone: +[PHONE_4805]
GlaxoSmithKline
Five Moore Drive 
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]- 3398, [LOCATION_003]
Telephone: + 001 -[PHONE_4806].
GlaxoSmithKline
Iron Bridge Road
Stockley  Park, Ux bridge, Middlesex, UB11 1BT, [LOCATION_006]
Telephone: +44(0)[PHONE_4807]
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate 
compan y (or designee). Where applicable, the details of [COMPANY_004] and contact [CONTACT_227379].
Medical Monitor Contact I nformation :
, MD PhD
ViiV Healthcare
[ADDRESS_273704]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
9P.O. [ZIP_CODE]
Research Triangle Park [LOCATION_003] [ZIP_CODE]
Mobile: 
Regulatory  Agency  Identify ing Number(s): US IND 58,627
[COMPANY_003]
GD2001/[ZIP_CODE]/[ADDRESS_273705] to ensure that site 
staff receives the appropriate information throughout the stu dy. 
Investigator Signature [CONTACT_227472]2001/[ZIP_CODE]/[ADDRESS_273706] ION................................ ................................ ................................ ....28
1.1. Background ................................ ................................ ................................ 28
1.2. Rationale ................................ ................................ ................................ ....28
1.3. Fosamprenavir ................................ ................................ ............................ 30
1.3.1. FPV Neonatal Toxicology ................................ ............................ 30
1.3.2. FPV Pediatric Clinical Data ................................ .......................... 31
1.4. Ritonavir ................................ ................................ ................................ .....31
1.5. Abacavir ................................ ................................ ................................ .....31
1.6. Lamivudine ................................ ................................ ................................ .32
2.STUDY OBJECTIVES AND ENDPOINTS ................................ .............................. 32
2.1. Study Objectives ................................ ................................ ......................... 32
2.2. Study Endpoints ................................ ................................ .......................... 33
3.INVESTIGATIONAL PLAN ................................ ................................ ..................... 34
3.1. Study Design ................................ ................................ .............................. 34
3.2. Study Population ................................ ................................ ......................... 39
3.2.1. Inclusion Criteria ................................ ................................ .......... 39
3.2.2. Exclusion Criteria ................................ ................................ ......... 40
3.2.3. Other Study Eligibility Criteria Considerations .............................. 41
3.3. Treatment During Study ................................ ................................ .............. 41
3.3.1. Study Drugs ................................ ................................ ................. 41
3.3.2. Background NRTI Options Provided by [CONTACT_35316] ............ 42
3.3.3. Background ART Not Provided by [CONTACT_35316]/ViiV 
Healthcare ................................ ................................ ................... 43
3.3.4. Rationale for Study Drug Dose Selection ................................ .....43
[IP_ADDRESS]. Rationale for Drug Dose Selection for Cohort 1 
(6 months to 2 years) ................................ .................. 44
[IP_ADDRESS]. Rationale for Drug Dose Selection for Cohort 2 
(4 weeks to 6 months) ................................ ................ 46
3.3.5. Dosages and dosing ................................ ................................ ....50
[IP_ADDRESS]. Dosage Regimen Adjustment Criteria ......................... 51
3.3.6. Target Plasma APV Exposure ................................ ..................... 52
[IP_ADDRESS]. Pharmacokinetic Targets for a Dose Increase ............ 52
[IP_ADDRESS]. Pharmacokinetic Targets for a Dose Reduction .......... 52
3.3.7. Overdose and Toxicity management ................................ ............ 52
[IP_ADDRESS]. Over dose ................................ ................................ ....52
[IP_ADDRESS]. Toxicity Management ................................ ................. 54
[IP_ADDRESS]. Specific Events ................................ ........................... 55
[IP_ADDRESS]. Abacavir Hypersensitivity Reaction ............................. [ADDRESS_273707] Management Options ................................ ...................... 62
3.3.9. Study Treatment Assignment ................................ ....................... 63
3.3.10. Concurrent Medications and Non -Drug Therapi[INVESTIGATOR_014] ....................... 63
[IP_ADDRESS]. [COMPANY_004] Supplied Background NRTI Options ................... 65
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
124.STUDY DRUG MANAGEMEN T................................ ................................ ............. 69
4.1. Study Drug Packaging and Labeling ................................ ........................... 69
4.2. Study Drug Handling ................................ ................................ ................... 69
4.3. Study Drug Accountability Procedures ................................ ........................ 71
5.MEASUREMENTS AND EVA LUATIONS ................................ ............................... 71
5.1. Time and Events Schedule ................................ ................................ ......... 71
5.2. Screening and Enrolment ................................ ................................ ........... 72
5.3. Demographic and Baseline Characteristics ................................ ................. 72
5.4. Study Drugs and Background NRTIs ................................ .......................... 73
5.5. Efficacy ................................ ................................ ................................ .......73
5.6. Health Outcomes ................................ ................................ ........................ 74
5.6.1. Humanistic Outcomes ................................ ................................ ..74
5.7. Bioanalysis and Pharmacokinetic Samples ................................ ................. 75
5.8. Safety ................................ ................................ ................................ ......... 78
5.9. Premature Discontinuation ................................ ................................ .......... 79
5.9.1. Premature Discontinuation from the Study ................................ ...79
5.10. Follow Up ................................ ................................ ................................ ....80
6.DATA ANALYSIS METHOD S................................ ................................ ................ 81
6.1. Sample Size Determination ................................ ................................ ........ 81
6.2. General Considerations ................................ ................................ .............. 81
6.2.1. Analysis Popu lations ................................ ................................ ....81
6.2.2. Interim Analysis ................................ ................................ ........... 82
6.2.3. Other Issues ................................ ................................ ................ 82
6.3. Efficacy ................................ ................................ ................................ .......83
6.3.1. Efficacy Measurements ................................ ................................ 83
6.4. Viral Resistance Testing ................................ ................................ ............. 83
6.5. Health Outcomes ................................ ................................ ........................ 83
6.5.1. Humanistic Outcomes ................................ ................................ ..83
6.6. Pharmacokinetics ................................ ................................ ....................... 84
6.6.1. Bioanalysis ................................ ................................ .................. 84
6.6.2. Pharmacokinetic Parameters ................................ ....................... 84
6.6.3. Statistical Analysis ................................ ................................ .......85
[IP_ADDRESS]. Descriptive Statistics ................................ .................. 85
[IP_ADDRESS]. Assessment of Variables Correlated with 
Plasma APV PK ................................ ......................... 85
6.7. Pharmacokinetics/Pharmacodynamics ................................ ....................... [ADDRESS_273708] Results ................................ ............................... 86
7.AEsAND SAE s................................ ................................ ................................ ......87
7.1. Definition of an AE ................................ ................................ ...................... 87
7.2. Definition of a SAE ................................ ................................ ...................... 88
7.2.1. Events or Outcomes Not Qualifying as SAEs ............................... 89
7.3. Lack of Efficacy as an AE or SAE ................................ ............................... 89
7.4. Clinical Laboratory Abnormalities and Other Abnormal Assessments 
as AEs and SAEs ................................ ................................ ....................... 89
7.5. Method, Frequency, and Time Period for Detecting AEs and SAEs ............ 90
7.6. Documenting AEs and SAEs ................................ ................................ ......90
7.7. Follow -up of AEs and SAEs ................................ ................................ ........ 91
GD2001/[ZIP_CODE]/[ADDRESS_273709] Informed Consent ................................ ........................... 95
8.2.5. Investigator Reporting Requirements ................................ ........... 95
8.3. Posting of Information o n Clinicaltrials.gov ................................ .................. 95
8.4. Study Monitoring ................................ ................................ ......................... 95
8.5. Quality Assurance ................................ ................................ ....................... 96
8.6. Study and Site Closure ................................ ................................ ............... 97
8.7. Records Retention ................................ ................................ ...................... 97
8.8. Provision of Study Results to Investigators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publication .................... 98
8.9. Information Disclosure and Inventions ................................ ........................ 98
8.10. External Review Committee ................................ ................................ ........ 99
9.REFERENCES ................................ ................................ ................................ .....100
10.TABLES ................................ ................................ ................................ ............... 104
11.APPENDICES ................................ ................................ ................................ ......106
11.1. Appendix 1:  1994 CDC Revised Classifi cation System for HIV 
Infection in Children < 13 years of Age ................................ ..................... 106
11.2. Appendix 2:  Declaration of Helsinki (Only Applicable to European 
Sites) ................................ ................................ ................................ ........ 110
11.3. Appendix 3:  Grading of Laboratory Test Abn ormalities -DAIDS 
Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Publish Date: December 2004 ................................ ..................... 114
11.4. Appendix 4:  Grading of Clinical Adverse Experiences -DAIDS 
Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Publish Date: December 2004 ................................ ..................... 120
11.5. Appendix 5:  Dosing Table for FPV Oral Suspension ................................ 134
11.6. Appendix 6:  Dosing Table for RTV Oral Solution, Powder, 
Capsules and Tablets ................................ ................................ ............... 137
11.7. Appendix 7:  Country Specific Requirements ................................ ............ 140
11.8. Appendix 8:  Protocol Amendment 1 ................................ ......................... 141
11.9. Appendix 9:  Protocol Amendment 2 ................................ ......................... 143
11.10. Appendix 10:  Protocol Amendment 3 ................................ ....................... 144
11.11. Appendix 11:  Protocol Amendment 4 ................................ ....................... 146
11.12. Appendix 12:  Protocol Amendment 5 ................................ ....................... 147
11.13. Appendix 1 3:  Protocol Amendment 6 ................................ ....................... 152
11.14. Appendix 14:  Protocol Amendment 7 ................................ ....................... 157
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
1411.15. Appendix 15:  Protocol Amendment 8 ................................ ....................... 185
11.16. Appendix 16:  Protocol Amendment 9 ................................ ....................... 216
11.17. Appendix 17:  Protocol Amendment 10 ................................ ..................... 244
11.18. Appendix 18:  Protocol Amendment 11 ................................ ..................... 259
11.19. Appendix 19:  Protocol Amendment 12 ................................ ..................... 270
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
15ABBREVIA TIONS
3TC lamivudine, EPI [INVESTIGATOR_227283], ZIAGEN
AE adverse event
AGN Agenerase , amprenavir
ALP alkaline phosphatase
ALT alanine aminotransferase (SGPT)
APV amprenavir
ART antiretroviral therap y
AST aspartate aminotr ansferase (SGO T)
AUC  area under the plasma concentration versus time curve 
from time [ADDRESS_273710] quantifiable concentration during a dosing 
interval at stead y-state
AUC τ,ss area under the concentration versus time curve during a 
dosing interval, τ, at steady -state
BID twice dail y
Cavg,ss The average concentration during a dosing interval, , at 
steady -state 
CD4+ helper -inducer T -lymphocy te surface antigen
CD8+ cytotoxic -suppressor T -lymphocy te surface antigen
CDC Centers for Disease Control and Prevention
CLss the apparent plasma clearance at stead y-state 
Cmax maximum plasma concentration
Cmax,ss maximum concentration at stead y-state
Cmin,ss minimum concentrat ion during a dosing interval
CPMP Committee for Proprietary  Medicinal Products
CPK creatine phosphokinase
CRF case report form
Cτ,ss concentration at the end of a dosing interval, τ, at steady -
state
CVb coefficient of variability
CYP cytochrome P450
DQ data query
DNA deox yribonucleic acid
ECG electrocardiogram
eDQ electronic data query
EFZ efavirenz
EISR Expedited I nvestig ator Safet y Report
ERC External Review Committee
FDA Food and Drug Administration (US)
FPV fosamprenavir, GW433908, 908, Telzir, L exiva
GCP good clinical practice
GD2001/[ZIP_CODE]/[ADDRESS_273711]
LDL low density  lipoprotein
LOD limit of detection
LPV/RTV lopi[INVESTIGATOR_054]/ritonavir, Kaletra
LSLV last subject’s last visit
MCV mean corpuscular volume
NFV nelfinavir
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse t ranscriptase inhibitor
NVP nevirapi[INVESTIGATOR_227284] y
RNA ribonucleic acid
RT reverse transcriptase
RTV ritonavir, Norvir
SAE serious adverse event
SCA standard clarification agreement
SDV single dose visit
t1/[ADDRESS_273712] time to reach C max,ss
tmin,ss the time that C min occurs 
WBC white blood cell
z Theapparent terminal plasma elimination rate -constant 
ZDV zidovudine
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
17Trademark Information
Trademarks of ViiV Healthcare Trademarks not owned by [CONTACT_227380][INVESTIGATOR_227285] R Norvir
TRIZIV IR Winnonlin
ZIAGEN
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
18PROT OCOL SUMMA RY
Agenerase (AGN, amprenavir, APV) was a protease inhibitor (PI ) developed for the 
treatment of HIV disease.  Although AGN demonstrated antiviral activity  and was 
generall y safe when given in combination with other antiretroviral agents to subje cts at 
all stages of HIV infection, the pi[INVESTIGATOR_227286] (1.5mL/kg BID) wasless than optimal and could impact 
long term adherence to therap y.  To reduce the pi[INVESTIGATOR_227287], a 
tablet and oral suspension formulation of fosamprenavir (FPV, GW433908, L EXIVA™/ 
TELZI R™), the phosphate ester prodrug of APV, wasdeveloped to facilitate dosing of 
adult and pediatric HIV -1 infected patients. The safet y and efficacy of FPV -containing 
regimens was demonstrated in three Phase III clinical trials in adults .
The use of combination therap y with 3 drugs, including either a PI [INVESTIGATOR_1660] a non -nucleoside 
reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor, plus a dual nucleosid e 
reverse transcriptase inhibitor (NRTI) backbone is the current standard of care for and is 
recommended for initial treatment of most HIV -infected adults and children [ DHHS , 
2019; EACS , 2018; Panel on Antiretroviral Therapy  and Medical Management of HIV -
Infected Children; 2019]. There remains a need for additional therapi[INVESTIGATOR_227288], in particular there are limited choices for a third agent to be given in 
combination with two NRT Is, and the choices are even more limited in children <[ADDRESS_273713] 4 y ears of age who were unable to 
swallow AG N capsules.  This restriction in use was due mainly  to concerns about the 
large volume of excipi[INVESTIGATOR_840], including PEG400 and propy lene gl ycol, required for dosing 
[Agenerase Package Insert, 2005]. Further, due to the high prop ylene gl ycol content in 
AGN oral solution and the high ethanol content of ritonavir (RTV) oral solution, co -
administration of AGN oral solution and RTV oral solution was contraindicated.  At the 
holder’s request, the Marketing Authorisation for AGN was withdrawn in the EU on 
April 29, [ADDRESS_273714] 18, 2009.
The FPV oral suspension incorporates less prop ylene gl ycol than AGN oral solution
thereb y facilitating its administration to children of all ages and allows co -administration
with RTV oral solutio n.  The FPV oral suspension is also easier to formulate than APV 
with an increased concentration (5 0 mg /mL vs. 1 5 mg /mL) allowing a significant 
reduction in the total volume of FPV oral suspension required per dose compared to AGN 
solution. 
APV20002 is ev aluating the pharmacokinetics (PK), safety , tolerability  and antiviral 
activity  of FPV when administered to HIV -1 infected PI -naïve and PI -experienced 
pediatric subjects aged 4 weeks to <2 years.  FPV will be administered as either the sole 
PI [INVESTIGATOR_227289].  Subjects in this study  will be enrolled in 2 age 
cohorts (Cohort 1: 6 months to <2 years, and Cohort 2: 4 weeks to <6 months) in order to 
determine FPV and FPV/RTV dosage regimens for pediatric subjects at various stages of 
physiologic development. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
19Dose Rationale
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspension formulation. I n children, the FPV oral suspension is recommended 
to be administered with food. 
APV20002 was desi gned to determine FPV/RTV regimens for pediatric subjects 4 weeks 
to<2 years of age that would deliver plasma APV exposures proven to be safe and 
effective in adults. 
In a small subset of five subjects aged 6 months to <2 y ears (Cohort 1, Arm A) who 
received FPV/RTV 45/ 7 mg /kg BID, plasma APV AUC(0 -) was approximately  48% 
lower, Cmax 26% lower, and C 29% lower than the adult target values.  Conversel y, 
RTV levels appeared to be similar between these pediatric subjects and adult 
comparators.  Based on th ese results, Amendment 5 (05 -Jul-2007) was undertaken to 
initiate dosing with FPV/RTV 45/7 mg /kg BID for two weeks (to allow collection of 
additional data on this regimen) and then increase the dose to FPV/RTV 60/ 7 mg /kg BID 
(to collect data on a higher do se regimen) for the duration of the study .  
Subsequent to Amendment 5, eleven additional subjects have been enrolled in Cohort 1, 
Arm A.  APV PK was evaluated at Week 2 (sampling predose, 2h, and 4h post dose) for 
the FPV/RTV 45/ 7 mg /kg BID regimen and at Week 8 (sampling predose, 1, 2, 4, 6, 8h 
post dose) for the FPV/RTV 60/ 7 mg /kg BID regimen.  Plasma APV C values were 
collected at all subsequent visits.  APV PK parameters for newl y enrolled subjects in 
Cohort 1A (6 months to <2 y ears) are compared to t hose for the subjects of this age group 
previously  report as well as adult counterparts.
APV Cmax and C following FPV/RTV 45/ 7 mg /kg BID were higher in the eleven 
newly  enrolled subjects than in the original five subjects who received the same dose.  
Howe ver, upon re- evaluation of data for the original subjects who received 45/ 7 mg /kg 
BID, one subject ( ) had extremely  low PK parameter values at Week [ADDRESS_273715] 
from the originally  enrolled group, the geometric mean Cmax for the remaining 4 
subjects is increased from 4.16 g/mL to 6.07 g/mL, more consistent with adult values 
and more similar to the geometric mean Cmax at 7.5ug.mL of the newl y enrolled subjects
receiving 45/ 7 mg /kg BID at Week 2.  Geometric mean AUC(0 -) is increased from 
19.3g*h/mL  (n=5) to 31.2 g*h/mL  (n=4), again much closer to the adult target values; 
AUC(0 -) following 45/ 7 mg /kg BID could not be determined at Week 2 for newly  
enrolled subjects due to limited sampling scheme.  Overall geometric mean (95% CI) C 
was increased from 1.54 g/mL (1.13, 2.09 g/mL, n=5) to 1.81 g/mL (1.40, 2.33 g/mL  
n=4), also closer to adult targets and newly  enrolled subjects.
APV parameters following FPV/RTV 60/ 7 mg/kg BID in subjects 6 months to <2 y ears 
were significantly  higher than adult target parameters.  Geometric mean APV AUC(0 -) 
and Cmax following FPV/RTV 60/ 7 mg /kg BID were 1.8 -fold and 2.6- fold higher than 
the geometric mean values in adults.  
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
20Per pr otocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24 month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/ RTV 60/ 7 mg /kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consistently  high C values 
follo wing FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator and [COMPANY_004].    
Plasma APV PK d ata are available from the first 12 subjects enrolled in Cohort 2 Arm A 
(4 week to <6 month age group) .  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat administration of FPV/RTV BID at 
individualized dosage r egimens ranging from FPV 30 -60 mg /kg and RTV 7 -10 mg /kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 weeks to <6months of age had higher 
plasma APV Cmax and AUC values, b ut similar C12 (single dose) and lower C (repeat 
dose) values compared with those historically  observed for adults.  Repeat dose plasma 
RTV Cmax and AUC values were similar to historical adult data, but plasma RTV C 
values were lower in the pediatric sub jects.  As plasma APV C is important for long -
term efficacy  and minimization of resistance development, it is important to try  to 
achieve plasma APV C values in pediatric subjects similar to those achieved with the 
approved FPV/RTV 700/10 0 mg BID regimen in adults.  I t is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefore 
per Protocol Amendment 7, an increase in the RTV dose from 7 mg /kg BID to 10 mg/kg 
BID for all subsequentl y enrolled subjects was recommended.  These subjects will 
initiate dosing with FPV/RTV 45/ 10 mg /kg BID and have serial PK sampling at Week 2 
and trough sampling on subsequent visits. Additionally ,a single dose visit (SDV) is no 
longer required for newly  enrolled subjects 4 weeks to <6 months of age (Cohort 2 Arm 
A).  
Per Protocol Amendment 10, enrolment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is closed.  Based on the PK data from the age -specific FPV/RTV 
cohorts, the dose volumes of unboosted FPV oral suspen sion necessary  to administer the 
calculated therapeutic dose in children aged <[ADDRESS_273716] been added for 
the South African sites.  The RTV dosing is based upon the weight of the child and 
include RTV supplied as 100 mg tablets, capsules or powder s/sachet s.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
21STUDY OBJECTIVES
Primary
To define the FPV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1 infected PI -naïve pediatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5).  This objective has been removed with 
enrolment into the unboosted co horts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
To define the FPV/RTV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate th e safet y and tolerability  of FPV/RTV when administered as a 
component of combination therap y in HIV -1 infected pediatric subjects aged 
4weeks to <2 years. The objective to evaluate the safety and tolerability of FPV 
BID dosage regimens has been removed a s per Protocol Amendment 10.
Secondary
To evaluate the antiviral activity  of FPV/RTV in combination with NRTI  therap y in 
HIV-1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the immunologic activity  of FPV/RTV in combination with NRTI  
therapy in HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To assess sy stemic exposure to FPV when administered to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose 
administration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in plasma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrence of 
adverse events
To assess subject adherence and parent/guardian per ceptions of stud y medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381]) 
The secondary objectives to evaluate the antiviral and immunologic activity of FPV 
have been remove d as per Protocol Amendment 10.
STUDY ENDPOINTS
Primary
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV BID (deferred per amendment 5). This endpoint has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
22Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unbound APV C ,ss and percent protein binding
The incidence and nature of adverse events, labo ratory  abnormalities, and treatment 
–limiting toxicities
Proportion of subjects who permanentl y discontinue FPV/RTV due to adverse 
events.  The endpoint ‘Proportion of subjects who permanently discontinue FPV 
due to adverse events’ has been removed as per Protocol Amendment 10.
Secondary
Proportions of subjects with plasma HIV -1 RNA levels <400copi[INVESTIGATOR_014]/mL at each study  
visit
Change from Baseline in plasma HIV -1 RNA at each study  visit (absolute values and 
time-averaged)
Proportion of subjects with 1.0 log10 decrease in plasma HIV -1 RNA at each study  
visit
Change from Baseline in the percentage of CD4+ ly mphocy tes at each study  visit 
(absolute values and time -averaged)
Plasma FPV concentrations
Plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose admi nistration of 
FPV/RTV BID
Relationship of steady -state plasma APV PK parameters to changes in plasma HIV -1 
RNA concentrations, CD4+ percentages and/or the occurrence of adverse events
Subject adherence and parent/guardian perceptions of study  medications
Incidence of viral resistance (where permissible by  [CONTACT_227381]) 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
23STUDY DESIGN
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in the relevant age groups.  In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subj ects 
may continue to receive FPV until they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART. Per 
protocol amendment 12; only subjects at sites in South Africa remain enrolled as supplies 
of oral FPV suspension are not commercially  available in South Africa . Subjects 
successfull y completing 48 weeks of therap y and receiving clinical benefit who weigh 
less than 39 kg may  continue to receive FPV oral suspension provided by  [CONTACT_23983]. O nce 
subjects reach a weight of 39 kg, South African treatment guidelines permit the use of the 
FPV tablets in children weighing ≥[ADDRESS_273717] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273718] been on different dosing regimens.
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10 has been 
closed.
Recruitment Status for A PV20002 –from Oct 2003 (FSFV) to Jul 2011 ( cutoff for 48 
week CSR
Age
(yrs)
CohortsNo.of Subjects originally 
plannedCumulative enrolment and 
current status
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 261enrolled
11ongoing2
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 281enrolled
14ongoing2
1.A total of 59 patie nts were enrolled but 5 discontinued after receiving single dose of FPV; c urrent total enrolled 
patients exceeds the original cohort target because of dose changes in previous amendments
2. Ongoing as of cutoff for 48 week CSR (July 2011)
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
24Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 10, enrolment in the 
Arm B cohorts (unb oosted FPV) is closed.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.  
Refer to Section 3.1(Figure 1and Figure 2) for schematics o utlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A: Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendmen t 8, all new subjects who enrol in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and Wee k 8 (over 8 -12 
hours; 12 hour sample optional).
Cohort 2 (4 weeks to <6 months)
Per Amendmen t 7, all new subjects who enrol in Cohort 2 Arm A will commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the initial 12 
subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in 
Cohort 2 Arm A will undergo plasma PK serial sampling over 8 -12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experienced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
25Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 y ears) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendm ent 10, enrolment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is closed.  Based on the PK data from the age -specific FPV/RTV 
cohorts, the dose volumes of unboosted FPV oral suspension necessary  to administer the 
calculated therapeutic dose in children aged <2 years would be approximately  twice the 
boosted dose volumes.  Enrolment into the unboosted FPV cohorts is therefore not 
advised due to these large volumes of FPV oral suspension that would need to be 
administered as they  could result i n poor adherence, likely  leading to an inadequate 
virologic response and subsequent resistance .
PLANNED SA MPLE SIZE
The sample size of 48 subjects was selected as an appropriate number to allow an 
accurate description of plasma APV PK, safet y and tolerabil ity of FPV BID, (N=24 for 
PK and safet y; enrolment closed per Amendment 10) and FPV/RTV BID, Arm A (N=24 
for PK and safet y).  Safety and tolerability assessment of the FPV/RTV BID regimen 
(Arm A) will be for the duration of the study  or until a subject per manentl y discontinues 
study  drug.  If less than [ADDRESS_273719] been made in view of required dose adjustments as 
specified in previous amendments.
STUDY POPULA TION
HIV-1infected pediatric subjects 4 weeks to <2 years of age with screening plasma 
HIV-RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the 
study . 
Following Amendments 5 and 8, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  25 subjects in total to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks 
to <6 months) will enro l approximately  29 subjects in total to receive FPV/RTV BID. 
Enrolment in the unboosted FPV BID cohorts (Arm B ) is closed.
Subjects enrolled to receive FPV/RTV (Arm A) may  be PI -naïve or PI -experienced.  PI -
experienced subjects will be eligible for Arm A if they  have previously  been treated with 
3 PIs.  Prior therapy  with a RTV -boosted PI [INVESTIGATOR_227290]  1 prior 
PI [INVESTIGATOR_227291] d ose was below that recommended for use as an antiretroviral 
agent.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
26Prior treatment with NRTI s is permitted and subjects are eligible if an active background 
regimen of two NRTIs can be constructed.  For treatment -experienced subjects, prior 
treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) and PI s is 
permitted, however, to be eligible for this study  subjects must discontinue their NNRTI 
use at least [ADDRESS_273720] 5 da ys prior to administration of FPV.  Subjects will NOT be permitted to receive 
concurrent NNRTI therapy  while participating in this study .  In addition, concurrent PI 
[CONTACT_157835] y other than the study treatments described in this protocol will NOT be permitted 
during the course of this study .
STUDY DRUGS AND DOSA GES
Study  drugs are defined as FPV and RTV.  FPV will be administered as a 5 0 mg /mL 
(43.2mg/mL APV molar equivalents) oral suspension.  RTV will be administered as an 
80 mg /mL oral solution , as a 100 mg c apsule or tablet, or as a 100 mg powder 
packet/sachet .  Choice of appropriate formulation will depend on participant’s weight, 
availability  of formulation and participant/caregiver preference.  Both the FPV and RTV 
oral formulations should be administered with food.  If vomiting or spi[INVESTIGATOR_227292] 30 minutes of administration, parents/guardians should be instructed to re -
administer the study  medications.   
Refer to the Dose Rationale section of the Protocol Summary  for information on dosing 
in eac h cohort.
Background A ntiretroviral Therapy  Options Provided by  
[CONTACT_227382] 3TC will be provided as optional background therap y.  Refer to local 
prescribing information for use of ABC and 3TC.
MEA SUREMENTS A ND EV ALUATIONS
Schedules showing the timing of stud y procedures and laboratory evaluations for all 
subjects are shown in Section 10.  Subjects will attend the clinic at Screening (within 
approximately  21 day s prior to Baseline/Day  1), Day  1 (Baseli ne), and Weeks 2, 4, 8, 12, 
16, 24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects who successfull y complete 4 8weeks on 
therap ymay continue to receive FPV oral suspension provided by  [CONTACT_227383] , weigh 39 kg or more, or according to prior agreements 
between [COMPANY_004] and participating stud y sites for provision of ART.  A follow -up visit will 
be performed 4 weeks after the permanent discontinuation of study  drug.
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluatio n of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Plasma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
27every  12 weeks thereafter. Protocol amendment 11 (effective dat e October 26, 2012) 
provided the option to discontinue PK sampling once a subject ha dreached and exceeded 
2 years and ha dinitiated the 23/ 3 mg /kg FPV/RTV BID dosing regimen .  PK sampling 
was discontinued after approval of the amended protocol in South Af rica. 
Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected over 8 -12 
hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, [ADDRESS_273721] had been enrolled in the study  for more than 48 
weeks .
To measure the unbound concentration of APV, additional plasma trough PK samples 
will be collected prior to FPV/RTV BID dosing at Weeks 2, 16 and 36 for Cohort 1 Arm 
A subjects and at Weeks 8 and 16 for Cohort 2 Arm A subjects.
Plasma storage samples may  be collected from all study  participants, where permitted by  
[CONTACT_227384], at the Day  1, Weeks 12, 24, 36, 48, every  12 weeks thereafter, 
and premature discontinuation visits.  These samples may  be used for retrospective HIV -
1 viral resistance anal ysis or for repeat laboratory  evaluations as needed.  A plasma 
sample for viral resistance anal ysis may  be collected from subjects at the Screening visit 
per the investigator’s discretion if needed to guide selection of an active NRTI  
background regimen.  An additional plasma sample for viral resistance analysis may  be 
collected [ADDRESS_273722] management criteria listed 
in Section 3.3.8 .
The scheduled laboratory evaluations will involve collection of a maximum blood 
volume of 7mL /kg in any 56 -day period .  A maximum of 3mL /kg of blood will be 
collected at an y one study visit from children 4 weeks to <[ADDRESS_273723] adherence to stud y medications will be measured at Day 1, W eeks 2, 
12, 24, 48 , and at the time of premature discontinuation visits, and parent/guardian 
perceptions of stud y medications will be measured at Weeks 2, 24, and 48, and at the 
time of premature discontinuation visits.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
281. INTRODUCTION
1.1. Background
Agenerase (AGN, amprenavir, APV) was a protease inhibitor (PI ) for the treatment of 
HIV disease.  Although AGN demonstrated antiviral activity  and was generally  safe 
when given in combination with other antiretroviral agents to subjects at all stages of 
HIV infection, the pi[INVESTIGATOR_227293] (1.5mL/kg BID) were less than optimal and may  have impact edlong 
term adherence to therapy.  To reduce the pi[INVESTIGATOR_227294], a tablet 
and oral suspension formulation of fosam prenavir (FPV, GW433908, LEXIVA/ 
TELZI R), the phosphate ester prodrug of APV, were developed to facilitate dosing of 
adult and pediatric HIV -1 infected patients. 
The safet y and efficacy  of three FPV -containing regimens has b een demonstrated in three 
Phase III clinical trials, APV30001 (antiretroviral [ART] -naïve subjects), APV30002 
(ART -naïve subjects), and APV30003 (PI -experienced subjects). [GlaxoSmithKline 
Document Number GM2002/[ZIP_CODE]/00 , Study  APV30002; GlaxoSmithKline Document 
Number RM2002/[ZIP_CODE]/00 , Study  APV30001; GlaxoSmithKline Document Number 
RM2002/[ZIP_CODE]/00 , Study APV30003].  Based on these studies, four dosing regimens in 
adults are approved in the [LOCATION_002] (US) for ART -naïve subjects :FPV 140 0 mg
BID, FPV 700 mg BID + ritonavir (RTV) 10 0 mg BID or FPV 140 0 mg QD + RTV 20 0 
mgQDor FPV 140 0 mg QD + RTV 10 0 mg QDand for PI -experienced subjects :FPV 
700 mgBID + RTV 10 0 mg BID.  In Europe, the FPV 70 0 mg BID + RTV 10 0 mg BID 
regimen was approved for PI -naïve or experienced HIV -1 infected adults.  A further 
study  in ART -naïve adults (ESS100732, KL EAN) demonstrated non -inferiority  of FPV 
700 mg BID + RTV 10 0 mg BID compared to lopi[INVESTIGATOR_054] (L PV)/ RTV (Kaletra) BID 
[GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00 , Study ESS100732].
1.2. Rationale
The use of combination therap y with 3 drugs, including either a PI [INVESTIGATOR_1660] a non -nucleoside 
reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor, plus a dual nucleoside 
reverse transcriptase inhibitor (NRTI) backbone is the current standard of care for and is 
recommended for initial treatment of most HIV -infected adults and ch ildren [ DHHS , 
2019; EACS , 2018; Panel on Antiretroviral Therapy  and Medical Management of HIV -
Infected Children; 2019].  There remains a need for additional therapi[INVESTIGATOR_227288], in particular there are limited choices for a third agent to be given in 
combination with two NRTI s, and the choices are even more limited in children <2 y ears 
of age. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
29At the time the APV20002 study  was collectin gthe primary  outcome data ( through Week 
48),in the NNRTI class, efavirenz (EFZ) and nevirapi[INVESTIGATOR_050] (NVP) were available as liquid 
formulation s.  NVP is associated with rare but potentially  life threatening adverse 
reactions whilst EFZ is associated with neurops ychiatric adverse reactions 
[Viramune Package Insert, 2010] [ Sustiva Package I nsert, 2010].
Similarly , at the time the APV20002 study was collecting the primary  outcome data 
(through Week 48), in the PI  [CONTACT_71963] , six agents -APV, indinavir (IDV), nelfinavir (NFV), 
RTV lopi[INVESTIGATOR_054]/ritonavir (LPV/RTV), and darunavir were approved for use in HIV -1 
infected children.  APV has subsequentl y been discontinued. The lower age limits for 
which these PIs were approved for use varies between countries .
LPV/RTV is aPI [INVESTIGATOR_227295].  Several studies support the 
use of L PV/RTV in children.  An earl y stud y in children 6 months to 12 y ears of age 
demonstrated the antiviral activity  of LPV/RTV over a 24 week period, wit h plasma 
HIV-1 RNA levels of <400 copi[INVESTIGATOR_014]/mL  being achieved in 82% of ART -naïve children and 
66% of children with a mixture of NRTI -experience and NRTI + PI -experience, and 
accompan ying improvements in CD4+ ly mphocy te counts, after 24 weeks of therap y 
[Violari , 2000] .  In a later study , 100 children ages 6 months to 12 y ears who were either 
ART naïve or ART -experienced but NNRTI naïve, received L PV/RTV as part of an ART 
regimen.  At Week 48, 79% of subjects had plasma HIV-1 RNA levels of <400 
copi[INVESTIGATOR_014]/mL  with corresponding mean increases in CD4+ cell counts from baseline [Post, 
2010; Ross , 2015; Saez -Llorens , 2003 ]. Recently , data on the use of LPV/RTV in infants 
<6 weeks of age has been presented.  In this stud y, 8 infants ages ≥14 days to ≤[ADDRESS_273724] dose LPV/RTV over 24 weeks.  L PV/RTV AUCs were significantl y 
lower than seen in an older cohort ages 6 weeks to 6 months, y et the regimen resulted in 
virological suppression (plasma HIV -1 RNA <400 co pi[INVESTIGATOR_014]/mL )in7/8 subjects [ Pi[INVESTIGATOR_1946] , 
2007]. 
Although the se PI [INVESTIGATOR_227296] -[ADDRESS_273725] display  limitations, such as lack of suitable 
formu lations, inflexible dosing schedules and clinical side effects. For instance, no liquid 
formulation is available for indinavir and it is more difficult to assure adequate fluid 
intake to avoid renal complications in children than in adults.  The powder for mulation of 
nelfinavir is difficult to administer to children, and consequentl y the adult tablets are used 
which results in a restrictive dosing schedule [ Gibb , 2000b].  The major limitations to the 
pediatric formulati on of RTV are the taste, vomiting as an adverse event and high alcohol 
content [ Panel on Antiretroviral Therap y and Medical Management of HIV -Infected 
Children. Use of Antiretroviral Agents in Pediatric HIV Infection.  Updated April 1 6, 
2019. Available at 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed August 
20, 2019.
Pelton ,1998]. Although Kaletra is now widely  used in treating HIV infected children, the 
pediatric liquid for mulation of L PV/RTV does have a similar alcohol content (42%) to 
that in the RTV liquid (43%) [ Kaletra Package Insert, 20 19; Norvir ,Package Insert, 
2019]. 
GD2001/[ZIP_CODE]/[ADDRESS_273726] ify the need for new and improved potent PI  [INVESTIGATOR_227297].
The FPV oral suspension incorporates less prop ylene gl ycol than AGN oral solution 
which allows administration to children of all ages and co -administration wi th RTV oral
solution. FPV is easier to formulate than AGN, with an increased concentration (5 0 
mg/mL vs. 1 5 mg /mL) allowing a significant reduction in the total volume of FPV oral 
suspension required per dose compared to AGN solution.  Thus, FPV oral suspe nsion 
offers an improved vehicle for delivering amprenavir compared to AGN oral solution.
The safet y, tolerability , pharmacokinetic characteristics, and antiviral activity  of FPV in 
combination with RTV in HIV -1 infected pediatric subjects between 2 to 18 years of age 
were studied in protocols APV20003 and APV29005.
APV20002 is evaluating the pharmacokinetics (PK), safety, tolerability and antiviral 
activity  of FPV when administered to HIV -1 infected PI -naïve and PI -experienced 
pediatric subjects aged 4 wee ks to <2 years.  FPV will be administered as either the sole 
PI [INVESTIGATOR_227298].  Subjects in this study  are enrolled in 2 age 
cohorts (Cohort 1: 6 months to <2 years, and Cohort 2:  4 weeks to <6 months) in order 
to determine FPV and F PV/RTV dosage regimens for pediatric subjects at various stages 
of phy siologic development. 
1.3. Fosamprenavir
FPV is the phosphate ester prodrug of APV which is hy drolyzed to APV and inorganic 
phosphate as it is absorbed through the gut epi[INVESTIGATOR_2130].  Plasma FP V exposure (AUC) 
was <0.6% of the corresponding plasma APV exposure when FPV was administered for 
2-4 weeks in HIV -1 infected, treatment -naïve adult subjects [GlaxoSmithKline Document 
Number RM2001/[ZIP_CODE]/00 , Study  Report for APV20001].  
1.3.1. FPV Neonatal Toxicology
Toxicity  studies of up to [ADDRESS_273727] been performed with FPV in neonatal 
and juvenile rats [GlaxoSmithKline Document Number RD1999/[ZIP_CODE]/00 , Study  
R40576; GlaxoSmithKline Document Number RD2000/[ZIP_CODE]/00 , Study  R40877; 
GlaxoSmithKline Document Number RD2002/0004 5/01].  In these studies, 
administration of FPV to neonatal and j uvenile rats (starting at 4 day s of age) at doses up 
to 300 mg/kg/day  (213 mg/kg/day  APV equivalents) resulted in only  slight changes 
indicative of an effect on the liver (increased serum liver enzy mes and increased liver 
weights).  Renal h yaline droplet a ccumulation seen in male rats was due to 2u-globulin 
nephropath y, and hence of limited toxicological relevance to humans [ Durham , 2002].   
FPV doses 553mg/kg/day  (389 mg/kg/day  APV equivalents) led to hig h mortality .
The ages of animals during both the initial phases of the FPV general toxicity  studies and 
the specific studies investigating effects in juvenile animals, are considered representative 
of administration to pediatric patients in the clinic.  I nthese studies, there were no effects 
on the development of young animals and no evidence of an increased susceptibility  of 
young animals to the effects of FPV.  Therefore ,no such effects were predicted, nor have 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
31they been observed, during clinical use.  Thus, the results from toxicology studies in both 
juvenile and adult animals indicate that the safety  profile of FPV in children is unlikely  to 
be different to that seen in adult patients and support the safe clinical use of FPV in HIV -
infected infants and children.
1.3.2. FPV Pediatric Clinical Data
Pharmacokinetic, safet y, and antiviral response data in pediatric subjects 2 to 18 y ears of 
age receiving FPV with or without RTV are available from Study  APV29005 [Fortuny , 
2014], and Study  APV20003 [Chadwick , 2007] .  Additionally , 48 week data from the
pediatric subjects <2 years of age receiving FPV/RTV in Study  APV20002 have also 
been reported [Cotton , 2014 ;Ross , 2015 ].  Overall the safet y profile of fosamprenavir 
with and without ritonavir in paediatric patients was comparable to that observed in adult 
clinical studies. Refer to the local product information for summaries of the available 
data from these studies.
1.4. Ritonavir
Ritonavir (Norvir, RTV) is an HIV protease inhibitor discovered and developed by 
[CONTACT_227385].  RTV is most commonly  used at reduced dosages in combination 
with other protease inhibitors as a pharmacokinetic enhancer.  In this study, RTV will be 
used to enhance plasma concentrations of APV.  Because the dose of RTV as a 
pharmacokinetic enhancer in this study  will be a small fraction of the approved dose for 
antiviral effect, selective pressure and the development of RTV resistant HIV -1 is 
unlikely . 
RTV has been licensed for use as an antiretroviral agent in subjects >1 month of age or 
older and is also licensed for use in combination with lopi[INVESTIGATOR_054] (Kaletra) in boosted PI  
[INVESTIGATOR_227299] 6 months and 2 y ears of age in the [LOCATION_003] and E urope, 
respectivel y.
Refer to the local Norvir prescribing information for complete information regarding 
RTV.
1.5. Abacavir
Abacavir (ZIAGENTM, ABC) is a carbocy clic 2’,3’ -ene nucleoside analog that inhibits 
replication of HIV -1.  It is triphosphory lated intra cellularly  to a carbocy clic guanosine 
analog which is a potent inhibitor of the viral reverse transcriptase (RT).  
The most commonly  reported adverse events include nausea, fever, lethargy , fatigue, 
headache, vomiting, diarrhea, rash and decreased appetit e.  In general, adverse events 
have not been treatment limiting and the majority  were mild or moderate in severit y.  
Grade [ADDRESS_273728] been reported with the use of antiretroviral 
GD2001/[ZIP_CODE]/[ADDRESS_273729] been in women. 
In clinical s tudies, approximately  5% of patients receiving ABC develop a 
hypersensitivity  reaction which in rare cases has proved fatal.  See Section [IP_ADDRESS] for 
specific information regarding Hy persensitivity  Reaction iden tification and management .
ZIAGEN is licensed for treatment of pediatric subjects of at least 3 months of age in the 
[LOCATION_003], the European Union, and South Africa.  Refer to local ZIAGEN prescribing 
information for complete information regarding ABC.
1.6. Lamivudin e
Lamivudine (EPI[INVESTIGATOR_227300], 3TC), is a dideox ynucleoside analogue (negative enantiomer) 
inhibitor of HIV reverse transcriptase approved as a treatment for HIV -infection in 
combination with other antiretrovirals.  It is phosphory lated intracellularl y to its 
triphosphate form and acts as a chain terminator.
Lamivudine is generall y safe and well tolerated, with the most commonly  reported 
clinical adverse experiences being headache, nausea, vomiting, diarrhea, fatigue, malaise, 
insomnia, fever, abdominal pain, arth ralgias , alopecia, and rash.  Laboratory 
abnormalities reported for patients receiving the 3TC/ZDV combination include anemia, 
neutropenia and/or thrombocy topenia.  Pancreatitis has been observed in some patients 
receiving lamivudine although it is unclear whether this was due to the drug treatment or 
the underl ying HIV disease.  Lactic acidosis and severe hepatomegaly  with steatosis have
been reported with the use of anti -retroviral nucleoside analogues alone or in 
combination, including lamivudine, in the treatment of HIV infection.  In some patients, 
these events have occurred within a few weeks of initiating combination therap y.  
EPI[INVESTIGATOR_227301] 3 months of age in the [LOCATION_003], 
Europe, and South Africa.  Refer to loca l EPI[INVESTIGATOR_227302] R prescribing information for complete 
information regarding 3TC.
2. STUDY OBJECTIVES A NDENDPOINTS
2.1. Stud y Objectives
Primary
To define the FPV BID dosage regimens which will provide target stead y-state 
plasma APV exposure to HIV -1 infected PI -naïve ped iatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5) .  This objective has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
To define the FPV/RTV BID dosage regime ns which will provide target steady -state 
plasma APV exposure to HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
33To evaluate the safet y and tolerability  of FPV/RTV when administered as a 
component of combination therap y in HIV -1 infected pediatr ic subjects aged 
4weeks to <2 years.  The objective to evaluate the safety and tolerability of FPV 
BID dosage regimens has been removed as per Protocol Amendment 10.
Secondary
To evaluate the antiviral activity  of FPV/RTV in combination with NRTI  therap y in 
HIV-1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the immunologic activity  of FPV/RTV in combination with NRTI  
therap y in HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To assess sy stemic exposure to FPV when administere d to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose 
administration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in pla sma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrence of 
adverse events
To assess subject adherence and parent/guardian perceptions of stud y medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381])
The secondary objectives to evaluate the antiviral and immunologic activity of FPV 
have been removed as per Protocol Amendment 10.
2.2. Stud y Endpoints
Primary
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose a dministration of 
FPV BID (deferred per amendment 5).  This endpoint has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unbound APV C ,ss and percent protein binding
The incidence and nature of adverse events, laboratory  abnormalities, and treatment -
limiting toxicities
Proportion of subjects who permanentl y discontinue FPV/RTV due to adverse 
events.  The endpoint ‘Proportion of subjects who permanently discontinue FPV 
due to adverse events’ has been removed as per Protocol Amendment 10.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
34Secondary
Proportions of subjects with plasma HIV -1 RNA levels <400copi[INVESTIGATOR_014]/mL at each study  
visit
Change from Baseline in plasma HIV -1 RNA at each study  visit (absolute values and 
time-averaged)
Proportion of subjects with 1.0 log10 decrease in plasma HIV -1 RNA at each study  
visit
Change from Baseline in the percentage of CD4+ ly mphocy tes at each stud y visit 
(absolute values and time -averaged)
Plasma FPV concentrations
Plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Relationship of steady -state plasma APV PK parameters to changes in plasma HIV -1 
RNA concentra tions, CD4+ percentages and/or the occurrence of adverse events
Subject adherence and parent/guardian perceptions of study  medications
Incidence of viral resistance (where permissible by  [CONTACT_227381])
3. INVESTIGA TIONAL PLA N
3.1. Stud y Design
APV20002 is an inter national, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully  completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is appro ved in the relevant age groups. In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV until they  no longer derive clinical benefit or according to 
prior a greements between [COMPANY_004] and participating study  sites for provision of ART. Per 
protocol amendment 12; only  subjects at sites in South Africa remain enrolled as supplies 
of oral FPV suspension are not commercially  available in South Africa. Subjects 
success fully completing 48 weeks of therap y and receiving clinical benefit who weigh 
less than 39 kg may  continue to receive FPV oral suspension provided by  [CONTACT_23983]. Once 
subjects reach a weight of 39 kg, South African treatment guidelines permit the use of the 
FPV t ablets in children weighing ≥39 kg and these subjects will be withdrawn as FPV 
tablets are commerciall y available in South Africa.  
Single dose visit s(SDV s)for both Cohort [ADDRESS_273730] been modified in pr evious protocol amendments (3, 5, 7 and 
8).  Protocol amendment 10 allows for the discontinuation of collection of samples for 
GD2001/[ZIP_CODE]/[ADDRESS_273731] been on 
different dosing regimens.
Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10 has been closed.
Table 1 Recruitment Status for A PV20002 –from Oct 2003 (FSFV) to Jul 2011 
(cutoff for 48 week CSR)
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumulative enrolment and 
current status
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 261enrolled
11ongoing2
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 281enrolled
14ongoing2
1.A total of 59 patients were enrolled but 5 discontinued after receiving s ingle dose of FPV; c urrent total 
enrolled patients exceeds the original cohort target because of dose changes in previous amendments
2. Ongoing as of cutoff for 48 week CSR (July 2011)
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2 years) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 10, enrolment in the 
Arm B cohorts (unboosted FPV) is closed.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV as sessments.
Refer to Figure 1and Figure 2for schematics outlining the stud y design for Cohort 1 
Arm A and Cohort 2 Arm A, respectivel y.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
36Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additiona l subjects in this age group are required to undertake SDV 
assessments. 
Arm A:  Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years) 
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and  Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information.  Existing 
subjects in Cohort 1 Arm A whose dose of FPV was increased to 6 0 mg /kg BID at Week 
[ADDRESS_273732] their dose adjusted based on ongoing viral load, 
pharmacokinetic and safety  assessments. 
Cohort 2 (4 w eeks to <6 months)
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will commence 
appropriate multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  
1 without undertaking a SDV.  The dose is be based on the Week 2 plasma PK data from 
the initial 12 subjects in Arm A SDV of Cohort 2 who underwent single dose 
assessments.  Subjects in Cohort 2 Arm A will undergo serial plasma PK sampling over 
8-12 hours (12 hour sample optional) at the Week 2 visit.
Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 10, enrolment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is closed.  Based on the PK data from the age -specific FPV/RTV 
cohorts, the dose volumes of u nboosted FPV oral suspension necessary  to administer the 
calculated therapeutic dose in children aged <2 years would be approximately  twice the 
boosted dose volumes.  Enrolment into the unboosted FPV cohorts is therefore not 
advised due to these large volu mes of FPV oral suspension that would need to be 
administered as they  could result in poor adherence, likely  leading to an inadequate 
virologic response and subsequent resistance .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
37Figure 1 Study  Design for Cohort 1 A rm A : PI-naïve or PI -experienced subjects 6 months to <2 y ears of age

GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
38Figure 2 Study  Design for Cohort 2 A rm A : PI-naïve or PI -experienced subjects 4 weeks to <6 months of age

GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
393.2. Stud y Population
HIV-1 infected pediatric subjects 4 weeks to < 2years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A (6 months to <2 y ears) was to enro lapproximately  
4 additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks to <6 months) 
will enro l approximately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is closed.
Subjects enrolled to receive FPV/RTV (Arm A) may  be PI -naïve or PI -experienc ed.  PI -
experienced subjects will be eligible for Arm A if they  have previously  been treated with 
3 PIs.  Prior therapy  with a RTV -boosted PI [INVESTIGATOR_227290]  1 prior 
PI [INVESTIGATOR_227303]. 
Prior treatment with NRTI s is permitted and subjects are eligible if an active background 
regimen of two NRTIs can be constructed.  For treatment -experienced subjects, prior 
treatment with non -nucleoside reverse transcriptase inhibitor s (NNRTIs) and PI s is 
permitted, however, to be eligible for this study  subjects must discontinue their NNRTI 
use at least [ADDRESS_273733] will be eligible for inclusion in this study onl y if all of the following criteria 
apply :
1.Male or female 4 weeks to <2 y ears of age. 
Cohort 1 (6 months -<2 years): Subjects must be <2 y ears of age at the Week 2 visit 
therefore the maximum age at screening is 22 months.
Cohort 2 (4 weeks -<6 months): Subjects must be <[ADDRESS_273734] to participate in the trial.
3.Screening plasma HIV -1 RNA level 400copi[INVESTIGATOR_014]/mL .
4.Subjects, who, in the investigator’s opi[INVESTIGATOR_1649], and following viral resistance testing if 
conducted, are able to construct an active NRTI b ackbone regimen consisting of [ADDRESS_273735] meet one of the following criteria:
Therap y-naïve or PI -naïve subjects (defined as having received less than one 
week of an y PI).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
40PI-experienced subjects defined as having prior experience with no more than
three PIs.  Prior RTV -boosted PI  [INVESTIGATOR_227304] y one PI [INVESTIGATOR_227305].
3.2.2. Exclusion Criteria
A subject will notbe eligible for inclusion in this study  if any of the following criteria 
apply :
1.Prior history  of having received AGN.
2.NNRTI therap y within 14 day s prior to study  drug administration (single or 
multiple -dose) or anticipated need for concurrent NNRTI therap y during the study 
period.
3.PI [INVESTIGATOR_227306] 5 day s prior to study  drug administration (applicable onl y for 
subjects undergoing single dose visits)
4.Subjects and/or parents/legal guardians who, in the investigator’s opi[INVESTIGATOR_1649], are not 
able to comply  with the requirements of the study .
5.Subject is in the initial acute phase of a CDC Clinical Category  C event or infection 
(per 1994 classification) at Baseline.  Subject may be enrolled provided they  are 
receiving treatment for the infections, such treatment not being contraindicated with 
FPV, and subjects a re clinically  improving at the Baseline visit. 
6.Presence of a malabsorption sy ndrome or other gastrointestinal dy sfunction which 
might interfere with drug absorption or render the subject unable to take oral 
medication.
7.Presence of an y serious medical cond ition (e.g., hemoglobinopathy , chronic anemia, 
diabetes, cardiac d ysfunction, hepatitis, or clinically  relevant pancreatitis) which, in 
the opi[INVESTIGATOR_871], might compromise the safet y of the subject.
8.Any acute laboratory  abnormality  at screen which, in the opi[INVESTIGATOR_871], 
should preclude the subject’s participation in the study  of an investigational 
compound.  If subjects are found to have an acute Grade [ADDRESS_273736] from study  participation.
9.Grade 3 or higher (>5x ULN) serum aminotransferase levels (alanine 
aminotransferase, ALT and/or aspartate aminotransferase, AST) within 28 d ays prior 
to study  drug administration and / or clinically  relevant hepatitis within the previous 
6months. A single repeat test is allowed to determine eligibility .
10.Treatment with radiation therap y or cy totoxic chemotherapeutic agents within 
28days of st udy drug administration or an anticipated need for such treatment within 
the study  period.
11.Treatment with immunomodulating agents (e.g., sy stemic corticosteroids, 
interleukins, interferons) or an y agent with known anti -HIV activity  (e.g., 
hydroxyurea or fo scarnet) within 28 day s of study  drug administration.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
4112.Treatment with an y of the following medications within 28 day s prior to receiving 
study  medication or the anticipated need during the study :
Amiodarone, astemizole, bepridil, bupropi[INVESTIGATOR_2394], cisapride, clora zepate, clozapi[INVESTIGATOR_050], 
diazepam, dihy droergotamine, encainide, ergonovine, ergotamine, estazolam, 
flecainide, flurazepam, lovastatin, meperidine, methy lergonovine, midazolam, 
pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], propafenone, propox yphene, quinidine, simvastatin, 
terfenadine, and triazolam (these drugs have been excluded for safety  reasons).
Carbamazepi[INVESTIGATOR_050], dexamethasone, phenobarbital, primidone, rifampin, St Johns 
Wort, (these drugs have been excluded because they  have the potential to 
decrease plasma protease inhibitor concen trations).
Note: per Protocol Amendment 11, the list of drugs not to be co -administered with 
FPV and RTV has been updated (see Section 3.3.10 , “Concurrent Medications and 
Non-Drug Therapi[INVESTIGATOR_014] ”).  As recruitment is closed, the exclusion criteria have not 
been amended.
13.Treatment with other investigational drugs/therapi[INVESTIGATOR_6523] 28 day s prior to 
receiving stud y medication (note: treatments available through a Treatment IND or 
other expanded -access mechanism will be ev aluated on a case -by-case basis in 
consultation with [COMPANY_004] ).
14.History  of drug or other allergy  which, in the opi[INVESTIGATOR_871], 
contraindicates participation in the trial or known hy persensitivity  to an y study  
medications (e.g. documented h ypersensi tivity  to a nucleoside analogue).
3.2.3. Other Study  Eligibility Criteria Considerations
In order to assess an y potential impact on subject eligibility  with regard to safet y, the 
investigator must refer to the following document(s) for detailed information regard ing 
warnings, precautions, contraindications, adverse events, and other significant data 
pertaining to the stud y drugs: Such documents may include, but are not limited to, the 
local product information or the International Product I nformation.
3.3. Treatment Du ring Study
3.3.1. Study Drugs
Study  drugs are defined as only  the medications under study  (FPV and RTV).  Other 
antiretroviral therapi[INVESTIGATOR_014] (including ABC and 3TC provided b y [COMPANY_004]) will not be 
considered stud y drugs but will be considered background antiretroviral th erapy (NRTIs) 
and thus a concurrent medication.  Record background NRTI s, including ABC and 3TC, 
on the Background Antiretroviral Therap y page in the case report form (CRF).
In this stud y FPV ,oral s uspension will be provided by  [CONTACT_23983].  In all countries, RTV oral 
solution, powder, tablets or capsules will be obtained locall y and reimbursed if acceptable 
to regulatory  authorities.  [COMPANY_004] will provide RTV by  [CONTACT_227386], or [COMPANY_004] may  provide RTV if local supplies are not availa ble and RTV is 
able to be obtained from other countries. Both FPV and RTV will be considered stud y 
GD2001/[ZIP_CODE]/[ADDRESS_273737].
The FPV 50 mg/mL (43.2mg/mL  APV molar equivalents) suspension is a white to off -
white bubblegum and peppermint flavo ured suspension for oral administration using a 
dosing s yringe.  Each mL of suspension contains 50mg of FPV ,equivalent to 43.2
mg/mL  of APV.  The suspension contains the following inactive ingredients: 
hydroxypropylmethy l cellulose, poly sorbate 80, methy lparaben, propy lparaben, 
propy lene gl ycol ( overall 2 0 mg /mL), sucralose, calcium chloride, flavo urs and purified 
water.  The FPV oral suspension is manufactured by  [CONTACT_227387], Ontario, 
Canada.
The RTV oral solution manufactured b y Abb vie contains 8 0 mg /mL of RTV in a 
peppermint and caramel flavo ured vehicle and will be administered via a dosi ng syringe.  
The RTV solution contains the following inactive ingredients: ethanol, water, poly oxyl 
35 castor oil, prop ylene gly col, anh ydrous citric acid, saccharin sodium, peppermint oil, 
cream y caramel flavour ing and FD&C Yellow No. 6.
The RTV 100 mg oral powder /sachets manufactured by  [CONTACT_227388] : copovidone, sorbitan monolaurate, and colloidal silicon dioxide , and are
sugar-free.
The 100 mg RTV tablets manufactured b y Abbvie contains the inactive ingredients
copovidone , anh ydrous dibasic calcium phosphate, sorbitan monolaurate, colloidal 
silicon dioxide, and sodium steary l fumarate. The film coating contains: hypromellose, 
titanium dioxide, poly ethylene gly col 400, hy droxy propy l cellulose, talc, poly ethylene 
glycol 3350 , colloidal silicon dioxide, and poly sorbate 80. The 100 mg RTV tablets are 
white ,film-coated ,ovaloid tablets and are sugar -free.
The 100 mg soft gelatin RTV capsules manufactured by  [CONTACT_227389] 100 
mg (SSSS enantiomer) ; other ingredients i nclude ethanol (12 % v/v), buty lated 
hydroxytoluene (antioxidant), oleic acid, poly oxyl [ADDRESS_273738] 3 months of age who are determined to be susceptible to ABC and/or 3TC. 
Susceptibility  will be determined by  [CONTACT_227390]/or investig ator 
interpretation of screening resistance viral genot ype data, if available.
ABC and 3TC oral solutions are licensed for the treatment of pediatric subjects of at least 
3 months of age in the [LOCATION_003], the European Union, and South Africa.   Scored 3TC tablets
are licensed in the [LOCATION_003], the European Union, and South Africa for the treatment of 
pediatric subjects weigh ing greater than or equal to 14 kg for whom a solid dosage form 
is appropriate .  Scored ABC tablets are licensed in the [LOCATION_003] and the European Union f or 
the treatment of pediatric subjects weigh ing greater than or equal to 14 kg for whom a 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
43solid dosage form is appropriate.  Scored ABC tablets will only be provided by  [CONTACT_227391] a licen se has been granted there.
The ABC oral s olution contains 20 mg/mL  of ABC in aqueous solution and the inactive 
ingredients strawberry  and banana flavours, citric acid (anh ydrous), meth ylparaben, 
propy lparaben, propy lene gl ycol, saccharin sodium, sodium citrate, and sorbitol solution. 
The ABC oral solution is manufactured by  [CONTACT_227387], Ontario, Canada.
The ABC tablet contains ABC sulfate equivalent to 300 mg ABC and the inactive 
ingredients colloidal anhy drous silica, magnesium stearate, microcry stalline cellulose, 
and sodium starch gly colate, T ype A. The tablet iscoated with a film that is made of 
methy lhydroxyprop ylcellulose, poly sorbate 80, synthetic y ellow iron oxide , titanium 
dioxide, and triacetin. ABC tablets are manufactured by  [CONTACT_227392], Hertfordshire, 
[LOCATION_008].
The 3TC o ral solution contains 10 mg /mL of 3TC in aqueous solution and the inactive 
ingredients strawberry  and banana flavours, citric acid (anh ydrous), meth ylparaben, 
propy paraben, propy lene gl ycol, sodium citrate (dihy drous) and sucrose (20% w/v).  The 
3TC oral s olution is manufactured b y [COMPANY_004] in Mississauga, Ontario, Canada .
The 3TC tablet contains [ADDRESS_273739] permanentl y discontinues study medication, [COMPANY_004] will no 
longer provide background 3TC and ABC medications .
3.3.3. Background A RT Not Provided by [CONTACT_35316] /ViiV 
Healthcare
[COMPANY_004] /ViiV Healthcare will not provide or reimburse bac kground ART other than ABC or 
3TC.
3.3.4. Rationale for Study  Drug Dose Selection
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspension formulation.  I n children, the FPV oral suspension is recommended 
to be a dministered with food due to the following considerations:
Children tend to eat frequently  throughout the day
Parents may  wish to enhance adherence, medication intake and mask taste by 
[CONTACT_227393]2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
44FPV will be co -administered with ritonavi r, which is recommended to be 
administered with food.
In adults, the FPV oral suspension formulation delivered an equivalent plasma APV 
AUC(0 -) and 14.5% higher Cmax compared to the FPV tablet formulation 
[GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00 , Study  APV10024] 
Administration of the FPV suspension with food reduced plasma APV AUC(0 -) by 
29% and C max by 46% [GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/00 , Study
APV10016].
[IP_ADDRESS]. Rationale for Drug Dose Selection for Cohort 1 (6 months to 2 y ears)
APV20002 was designed to determine FPV/RTV regimens for pediatric subjects 
1to24months of age that would deliver plasma APV exposures proven to be safe and 
effective in adult s.
In a small subset of five subjects aged 6 months to <2 y ears (Cohort 1, Arm A) who 
received FPV/RTV 45/7 mg/kg BID, plasma APV AUC(0 -) was approximately  48% 
lower, Cmax 26% lower, and C 29% lower than the adult target values.  Conversel y, 
RTV levels a ppeared to be similar between these pediatric subjects and adult 
comparators.  Based on these results, Amendment 5 ( 5 July  2007) was undertaken to 
initiate dosing with FPV/RTV 45/ 7 mg /kg BID for two weeks (to allow collection of 
additional data on this reg imen) and then increase the dose to FPV/RTV 60/7 mg/kg BID 
(to collect data on a higher dose regimen) for the duration of the study .  
Subsequent to Amendment 5, eleven additional subjects have been enrolled in Cohort 1, 
Arm A.  APV PK was evaluated at Wee k 2 (sampling predose, 2h, and 4h post dose) for 
the FPV/RTV 45/7 mg/kg BID regimen and at Week 8 (sampling predose, 1, 2, 4, 6, 8h 
post dose) for the FPV/RTV 60/7 mg/kg BID regimen.  Plasma APV C values were 
collected at all subsequent visits.  APV PK pa rameters for newl y enrolled subjects in 
Cohort 1A ( 6 month s to <2 y ears) are compared to those for the subjects of this age group 
previously  report as well as adult counterparts in Table 2.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
45Table 2 Summary  of Plasma A PV PK in pediatric subjects for Cohort 1 (6 
months to 2 y ears)
APV 
ParameterNewly enrolled 
6 months to <2 yearsOriginal 6 months to <2 years
FPV/RTV
45/7 mg/kg
BIDHistorical 
Adult
FPV/RTV 
700/100 mg 
BID
(n=159)5FPV/RTV 4 5/7
mg/kg BID 
(n=11)FPV/RTV 60/7
mg/kg BID
(n=7)2
(n=5)3 (n=4)4
AUC(0 -)
g*h/mL1NA66.9
(31.5, 142)
[82]
(19.2 –140)19.3
(4.64, 79.9)
[165]
(2.77 –58.1)31.2
(15.7, 62.1)
[45]
(21.8 –58.1)37.0
(35.1, 38.9)
[33]
(15.7 –95.9)
Cmax
g/mL17.50
(5.27, 10.7)
[56]
(4.54 –28.6)14.8
(8.09, 27.1)
[73.0]
(4.79 –29.6)4.16
(1.35, 12.8)
[113]
(0.92 –9.29)6.07
(3.27, 11.3)
[40]
(4.07 –9.29)5.62
(5.35, 5.92)
[33]
(2.47 –13.3)
C
g/mL11.92
(1.12, 3.31)
[96]
(0.48 –5.28)3.57
(2.42, 5.25)
[99]
(1.09 –16.4)1.54
(1.13, 2.09)
[117]
(0.055 –8.15)1.81
(1.40, 2.33)
[80]
(0.246 –8.15)2.17
(2.05, 2.30)
[38]
(0.75 –5.83)
1. Geometric Mean (95% CI) [CVb%] (min –max)
2. N=6 for AUC(0 -) and N=20 for C (across Weeks 8 - 24)
3. N=38 for C (across Weeks 2 -48)
4. N=32 for C (across Weeks 2 - 48)
5. N=158 for AUC(0 -)
APV Cmax and C following FPV/RTV 45/7 mg/kg BID were higher in the eleven 
newly  enrolled subjects than in the original five subjects who received the same dose.  
However, upon re -evaluation of d ata for the original subjects who received 45/7 mg/kg 
BID, one subject ( ) had extremely  low PK parameter values at Week [ADDRESS_273740] 
from the originally  enrolled group, the geometric mean Cmax for the remaining 4 
subjects is increased from 4.16 g/mL to 6.07 g/mL , more consistent with adult values 
and more similar to the geometric mean Cmax at 7.5 ug/ mL of the newl y enrolled 
subjects receiving 45/7 mg /kg BID at Week 2.  Geometric mean AUC(0 -) is increased 
from 19.3 g*h/mL(n=5) to 31.2 g*h/mL(n=4), again much closer to the adult target 
values; AUC(0 -) following 45/7 mg/kg BID could not be determined at Week 2 for 
newly  enrolled subjects due to limited samp ling scheme.  Overall geometric mean (95% 
CI) Cwas increased from 1.54 g/mL (1.13, 2.09 g/mL , n=5) to 1.81 g/mL  (1.40, 
2.33g/mL , n=4), also closer to adult targets and newly  enrolled subjects.
APV parameters following FPV/RTV 60/7 mg/kg BID in subjec ts 6months –2 years old 
were significantly  higher than adult target parameters.  Geometric mean APV AUC(0 -) 
and Cmax following FPV/RTV 60/7 mg/kg BID were 1.8 -fold and 2.6- fold higher than 
the geometric mean values in adults.  
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
46Per protocol amendment 8, since APV parameters following FPV/RTV 45/7 mg/kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/7 mg/kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/7 mg/kg BID at Week 2.  Some subjects with consistently  high C values 
following FPV/RTV 60/7 mg/kg BID have had their dose reduced to FPV/RTV 45/7
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/7
mg/kg may  have their dose modified at the discretion of the investigator and [COMPANY_004].    
[IP_ADDRESS]. Rationale for Drug Dose Selection for Cohort 2 (4 weeks to 6 months)
Plasma APV PK data are available from the first 12 subjects enrolled in Cohort 2 Arm A 
(4 week to <6 month age group).  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat admini stration of FPV/RTV BID at 
individualized dosage regimens ranging from FPV 30 -60mg/kg and RTV 7 -10mg/kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 weeks to <6months o f age had higher 
plasma APV Cmax and AUC values, but similar C12 (single dose, Table 3) and lower C 
(repeat dose, Table 4) values compared with those historically  observed for adults.  
Repeat dose plasma RTV Cmax and AUC values were similar to historical adult data, but 
plasma RTV C values were lower in the pediatric subjects ( Table 5).  As plasma APV 
Cis important for long -term efficacy  and minimization of resistance development, it is 
important to try  to achieve plasma APV C values in pediatric subjects similar to those 
achieved with the approved FPV/RTV 700/10 0 mg BID regimen in adults. Although 
FPV/RTV 60/ 10 mg /kg exhibited  APV C ,ss, most similar to adults ( Figure 3), the APV 
Cmax for this regimen was considered unnecessarily  high ( Figure 4).  The RTV 10 
mg/kg in the FPV/RTV 60/ 10 mg /kg regim en provided the most consistently  high RTV 
C,ss values as compared to 30/7 and 45/ 7 mg /kg (Figure 5).  It is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefo re 
per Protocol Amendment 7, an increase in the RTV dose from 7 mg /kg BID to 10 mg/kg 
BID for all subsequentl y enrolled subjects was recommended.  These subjects will 
initiate dosing with FPV/RTV 45/ 10 mg /kg BID and have serial PK sampling at Week 2 
and tr ough sampling on subsequent visits. Additionally  a SDV is no longer required for 
newly  enrolled subjects 4 weeks to <6 months of age (Cohort 2 Arm A).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
47Table 3 Summary  of Single Dose Plasma A PV PK in Pediatric Subjects <6 
months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV 45/ 7 mg/kg
(N=11)1,3,4Adult Subjects
FPV/RTV 700/10 0 mg
(N=17)2
Cmax ( g/mL) 9.74
(5.67, 16.2)3.65
(2.54, 6.76)
AUC(0 -) (g.h/mL) 57.5
(20.2, 111)35.2
(20.8, 114)
C8h (g/mL) 2.64
(0.819, 5.86)1.10
(0.451, 2.20)
C12h ( g/mL)2 1.13
(0.41, 3.76)1.19
(0.659, 1.92)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Data for pediatric Subject  was excluded because exposures were very hig h: Cmax: 30.9 g/mL, AUC(0- ): 
335g.h/mL, C8hr: 16.9 g/mL.
4. C12h is extrapolated value for pediatric subjects and observed value for adult subjects
Table 4 Summary  of Repeat Dose Plasma A PV PK in Pediatric Subjects 
<6months old an d Adults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV BID
(N=9)1,3-5Adult Subjects
FPV/RTV 700/10 0 mg
(N=14)2
Cmax ( g/mL) 8.90
(2.07, 12.1)4.76
(2.47, 7.68)
AUC(0 -) (g.h/mL) 41.0
(16.2, 70.4)28.3
(17.9, 43. 1)
C8h (g/mL) 2.05
(1.10, 3.25)1.58
(0.816, 2.64)
C(g/mL)3 0.970
(0.438, 1.95)1.46
(1.06, 2.20)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4 ), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject  was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
48Table 5 Summary  of Repeat Dose Plasma RTV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma RTV
PK ParameterPediatric Subjects 
1 to <6 months
FPV/RTV BID1Adult Subjects
FPV/RTV
700/10 0 mg BID2
(N=9)3-5 (N=8) 3-5 (N=24)
Cmax ( g/mL) 1.28
(0.228, 7.70)0.999
(0.228, 2.11)1.24
(0.520, 3.84)
AUC(0 -) (g.h/mL) 6.66
(0.922, 28.8)4.67
(0.922, 14.30)5.59
(2.88, 14.4)
C8h (g/mL) 0.270
(0.021, 1.05)0.239
(0.021, 1.05)0.260
(0.068, 0.614)
C(g/mL)6 0.075
(NQ, 0.496)0.069
(NQ, 0.496)0.165
(0.010, 0.610)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10010
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Data summarized excluding Subject who had high RTV Cmax and AUC values.
6. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
Figure 3 Week 2 Plasma A PV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 months (30/7, 45/7 and 60/10 mg/kg) Compared 
to Adults (700/10 0 mg )
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
49Figure 4 Week 2 Plasma A PV Cmax Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )

GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
50Figure 5 Week 2 Plasma RTV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
Per Protocol Amendment 10, enrolment of the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is closed.
Following receipt and review of PK results from subjects in Cohorts [ADDRESS_273741] basis. 
3.3.5. Dosages and dosing
FPV and RTV will be administered according to the doses described in Section 3.3.4 and 
in Section [IP_ADDRESS] .
Both the FPV and R TV formulations should be administered with food.  If vomiting or 
spi[INVESTIGATOR_227307] 30 minutes of administration, parents/guardians should be 
instructed to re -administer the study  medications.
The recommended dose of ABC solution is 8 mg /kg BID (up to a maximum of 600
mg/day ).
For ABC tablets, the recommended dose is one -half of a scored tablet taken twice dail y in 
children weighing between 14 kg and 21 kg and one -half of a scored tablet taken in the 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
51morning and one whole tablet taken in the evenin g in children weighing between 21 kg 
and 30 kg.
The recommended dose of 3TC solution is currently  4 mg /kg BID (up to a maximum of 
300mg/day ).The dosing recommendation in the local label should be followed.
For 3TC tablets, the recommended dose is one -half of a scored tablet taken twice dail y in 
children weighing between 14 kg and 21 kg and one -half of a scored tablet taken in the 
morning and one whole tablet taken in the evening in children weighing between 21 kg 
and 30 kg.
[IP_ADDRESS]. Dosage Regimen A djustment Crite ria
Dose A djustment Due to Subject Weight
Due to subjects’ growth throughout the duration of the study , the dose of all drugs 
administered must be recalculated at each visit and the total daily  dose adjusted according 
to the child’s weight and the recommen ded dosage regimen.  Dose adjustments should 
occur when the dose would change b y 10% from the subject’s prior calculated dose.
Dose adjustments due to weight change should be delay ed until after completion of the 
PK sampling to ensure that sampling is con ducted at steady -state.
Dose A djustment Due to Subject Phy siological Development
Subjects will not automatically  change dosage regimens as they  increase in age between 
[ADDRESS_273742] A ge exceeding 2 and 6 y ears
Subjects reaching and exceeding 2 years of age during the stud y should transition to the 
lower dose of FPV and RTV to 23 mg/kg and 3 mg/kg BID respectivel y.  The change in 
dosage c anbe staged gradually  over multiple visits and will be based on ongoing viral 
load, pharmacokinetic and safet y assessments, at the investigator’s discretion.
Subjects reaching and exceeding 6 years of age may  transition to the lower dosage 
regimen (FPV 18 mg/kg and RTV 3 mg/kg BID) in accordance with the regimen 
approved for this age group. This dose change can be implemented gradually  as the 
subject ‘grows into’ the new dose or at the time of their 6thbirthday  at the investigator’s 
discretion.
In consul tation with the investigator, [COMPANY_004] may  discontinue PK sampling and monitoring 
of plasma APV, FPV and RTV concentration on an individual basis once a subject has 
reached and exceeded 2 years and has initiated the 23/ 3 mg /kg BID dosing regimen after 
Week 48 . Any further dosing changes would follow the approved dosing 
recommendations without PK sampling, including a transition to FPV/RTV 18/3mg/kg 
BID at 6 y ears.  Note: after Protocol Amendment 11 became effective, PK sampling and 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
52monitoring of plasma APV, FPV and RTV concentration on an individual basis was 
discontinued. 
3.3.6. Target Plasma A PV Exposure
[IP_ADDRESS]. Pharmacokinetic Targets for a Dose Increase
Single Dose
The lower limit of the target plasma APV exposure for subjects receiving a single dose of 
FPV is defined as a plasma APV AUC value of 16.8g.h/mL .  This target represents 
the 25thpercentile observed in adults receiving FPV 139 5 mg in APV20001.
The lower limit of the target plasma APV exposure for subjects receiving single doses of 
FPV + RTV is a 12 -hour conce ntration of 0.800 g/mL .  This target represents the 25th
percentile observed in adults receiving single doses of FPV 700 mg + RTV 10 0 mg in 
APV10013.
Steady -State
The lower limit of the target plasma APV exposure for subjects receiving a FPV (without 
RTV) regimen is defined as a plasma APV C ,ssvalue of 0.25g/mL.  This target 
represents the 25thpercentile observed in adult subjects receiving FPV 1395 mg BID for 
2-4weeks in APV20001.
The lower limit of the target plasma APV exposure for subjects receivi ng a FPV/RTV 
regimen is defined as a plasma APV C ,ssvalue of 1.48g/mL .  This target represents 
the 25th percentile observed in adult subjects FPV 70 0 mg BID + RTV 10 0 mg BID in 
APV10010, APV10011, APV10012, APV10013, and APV10022. 
[IP_ADDRESS]. Pharmacokinetic Targ ets for a Dose Reduction
No dose -limiting toxicities have been observed in adults receiving FPV or FPV + RTV. 
However, to ensure that children in this study , APV20002, do not maintain 
concentrations higher than those observed in adults, an upper limit to t he plasma APV PK 
target has been set.  The upper limit of the target is a plasma APV AUC ,ssvalue of 61.68
h*ug/mL at the Week 2 visit and a plasma APV C ,ssvalue of 3.52ug/mL at subsequent 
visits (where onl y trough sampling is conducted).  Plasma APV AU C,ssand C ,ssvalues 
are highl y correlated, supporting the use of C ,ssvalues at visits subsequent to Week 2.
3.3.7. Overdose and Toxicity management
[IP_ADDRESS]. Overdose
Experience with either FPV or AGN overdose is very  limited, therefore [COMPANY_004] does not 
recommend an y spec ific treatment in the event of an overdose.  It is not known whether 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
53APV can be removed b y hemodialy sis.  The investigator should use clinical judgment in 
treating the overdose.
Experience of acute overdose with RTV is limited.  One patient in a clinical t rial took 
RTV 150 0 mg /day for [ADDRESS_273743] supportive 
treatment applied as required.
An overdose is an y dose greater than those described below for each study drug.  For the 
purposes of this study , an overdose is not considered a n adverse event 
(AE, seeSection 7.1) unless it is accompanied b y a clinical manifestation associated with 
the overdose.
Definition of Overdose
FPV: An overdose of FPV will be defined as 1.[ADDRESS_273744] 6 -10 subjects or 1.5 x the overall dose recommendation made for the remaining 
subjects in cohort. 
RTV:  a daily  dose of >30 0 mg
ABC:  a dail y dose of >60 0 mg
3TC:   a daily  dose of >30 0 mg
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[IP_ADDRESS]. Toxicity  Management
For the purpose of toxicity  management, information is provided pertaining to the 
antiretroviral medications supplied for this study  by [CONTACT_23983] (i.e., FPV ,RTV, ABC and 
3TC).  All Adverse Events and Serious Adverse Events must be recorded and reported 
according to Section 7of this protocol.
The following toxicity  management guidelines are intended to ensure the safety  of each 
subject.  Should the investigator have compelling evidence that an adverse event does 
NOT appear to be causall y related to the stud y drug(s), dosing with stud y drug(s) may  
remain unaltered.  Application of these guidelines is discretionary ; a stepwise approach to 
the evaluation or management of a subject with severe findings may  not be consistent 
with best clinica l care. 
Decisions regarding sequential reintroduction of study  drugs or temporary  interruption of 
one or more but not all drugs within the antiretroviral therap y (ART) regimen should be 
made with the understanding that these changes may  result in incomple te viral 
suppression and selection of resistant virus.  Every effort should be made to minimize the 
time that less than the full combination of study  drugs is being administered.  Subjects 
undergoing toxicity  management should be evaluated at weekl y interv als.  Interruption of 
PI [INVESTIGATOR_227308].  Subjects intolerant to their 
study  PI [INVESTIGATOR_227309] . 
Subjects who are intolerant to any  component of their background NRTI therapy  may  
change to ano ther NRTI as directed b y the investigator.  All changes to the treatment 
regimen must be accurately  recorded on the study drug changes page and the background 
antiretroviral therap y page of the CRF. 
General management guidelines based on the protocol Toxi city Grades follow.  For a 
detailed discussion about specific events, please see Section [IP_ADDRESS] “Specific Events”. 
Specific events covered include rash management, nausea/vomiting and 
hypertrigly ceridemia/ hype rcholesterolemia.  Adverse events that occur during the trial 
should be evaluated b y the investigator and graded according to the toxicity grades 
provided in Section 11.3, Appendix 3 and in Section 11.4, Appendix 4 (2004 DAIDS 
Tables).
Grade 1 or Grade 2 Toxicity/Adverse Event
Subjects who develop a Grade 1 or 2 AE or toxicity  may  continue all study drugs and 
background antiretroviral drugs without alteration of the dose at the discretion of the 
investigator (see Section [IP_ADDRESS] ).  Subjects who choose to withdraw from study  due to a 
Grade [ADDRESS_273745] study  withdrawal and follow -up evaluations completed.
Grade 3 Toxicity/Adverse Event
In general, subjects who develop a Grade [ADDRESS_273746] all study  drugs 
and background antiretroviral drugs withheld and be re -evaluated each week until the AE 
returns to Grade 2 or less.  Specific events (rash, nausea and vomiting, h yperlipi[INVESTIGATOR_035]/ 
hypercholesterolemia) are discussed in Section [IP_ADDRESS] .  If the investigator has compelling 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
55evidence that the AE has not been caused b y the study  drug(s), dosing may  continue.  
Once the AE returns to Grade [ADDRESS_273747] should be able to, if necessary , 
receive prompt medical evaluation.
Should the same Grade 3 AE recur after 4 weeks, the management scheme outlined 
above may  berepeated.  However, if the same Grade 3 AE recurs within 4 weeks, stud y 
drug(s) must be permanently  discontinued if the investigator considers the AE related to 
study  drug.  Subjects experiencing Grade [ADDRESS_273748] dose of study  drug.
Subjects who develop Grade 3 clinicall y asymptomatic laboratory  abnormalities should 
be investigated for all potential non -drug related causes and stud y drug(s) may be 
continued if the investigator has compelling evidence that the abnormality  is not related 
to the study  drug(s).
Grade 4 Toxicity/Advers e Event
Study  drug will be permanently  discontinued in subjects who develop a Grade 4 AE or 
toxicity .  However, if the investigator has compelling evidence that the AE is not causally  
related to the stud y drug(s), dosing may continue after discussion with and assent from 
[COMPANY_004] .  Subjects experiencing Grade [ADDRESS_273749] dose of study  drug.
Subjects with Grade 4 clinically  asymptomatic laboratory  abnormalities should be 
investigated for all potentially  non-drug related causes and study  drug(s) may  be 
continued if the investigator has compel ling evidence that the toxicity  is NOT related to 
the study  drug, following discussion with [COMPANY_004] .
[IP_ADDRESS]. Specific Events
Rash
Erythematous or maculopapular cutaneous eruptions, with or without pruritus, may  occur 
during therap y with FPV.  Most rashes are mild or m oderate in severity  and will 
generall y resolve spontaneously.  Appropriate antihistamine (e.g. cetirizine 
dihydrochloride) may  reduce pruritus and hasten the resolution of rash. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
56Severe and life -threatening skin reactions, including Stevens -Johnson sy ndrom e, were 
reported in less than 1% of subjects included in the FPV clinical development program.  
FPV should be permanently  discontinued in case of severe rash, or in case of rash of 
moderate intensit y with systemic or mucosal s ymptoms. 
A total of 700 adult subjects received FPV either alone or in combination with RTV in 
Phase III clinical trials.  Rash, regardless of causality  or grade, occurred in 25% and 9% 
of ART -naïve adult subjects receiving FPV BID (Study  APV30001) and FPV/RTV QD 
(Study  APV30002), res pectivel y.  In PI -experienced adult subjects in Study  APV30003, 
7% of subjects receiving FPV/RTV experienced rash.  Within the FPV treatment arm of 
APV30002, three subjects (<1%) were permanently discontinued due to rash.  No 
permanent discontinuations due to rash were reported in APV30001 or APV30003. 
In an integrated safety  analy sis of pediatric studies APV29005 and APV20003 in subjects 
2 to 18 y ears of age receiving FPV or FPV/RTV, rash (all grades, regardless of causalit y) 
occurred in 19% (27/144) of s ubjects, when all rash -related preferred terms were 
considered.  There were few cases of drug -related rash events. Most rash events were 
Grade [ADDRESS_273750] the Investigator as soon as possible if they  develop a rash while 
on study .
Subjects who develop rash of an y grade should be evaluated for the possibility  of an 
ABC HSR or a serious skin reaction such as Stevens -Johnson Sy ndrome (SJS), Toxic 
Epi[INVESTIGATOR_13031] (TEN) or Ery thema Multiforme. SJS, TEN and Ery thema 
Multiforme have been reported very  rarely  in patients taking ABC -containing products.  
These patients generall y do not have the cluster of additional sy mptoms (e.g., 
gastrointestinal and respi[INVESTIGATOR_696] ) that characterize the ABC HSR, but they  do have 
features ty pi[INVESTIGATOR_227310].
If a serious skin reaction develops, ABC (and / or all other concurrent medication(s)
suspected in the Investigators causalit y assessment) should be discontinued, and the 
subject should not be re -challenged with an y ABC -containing medicinal product (i.e., 
TRIUMEQ, ZIAGEN, TRIZIVIR, EPZI COM or KIVEXA).
As many  products other than abacavir a lso cause rash and/or serious skin reactions, all 
other medicinal products that the subject is receiving should also be reviewed and 
discontinued as appropriate.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
57Study  treatment should be managed as outlined in the following table:
Rash Management
EventAction to be Taken
FPV BID or FPV/RTV BID ABC 3TC
Grade [ADDRESS_273751] has no 
constitutional symptoms (f ever, 
malaise, fatigue, headache), ABC 
may be continued at the 
investigators discretion with the 
warning to discontinue immediately 
and permanently if other signs 
and/or symptoms consistent with 
HSR appear.  The subject should 
be advised to contact [CONTACT_227394], if any 
systemic signs or symptoms 
worsen, or if mucosal involvement 
develops.Therapy can 
continue
Grade 1 rash with 
symptoms indicating multi -
organ involvement 1Discontinue FPV BID or 
FPV/RTV B ID.  Therapy 
should not be reinitiated 
unless the investigator has 
compelling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently 2
Subjects should be treated as 
clinically appropriate and followed 
until resolution of t he AE.Therapy can 
continue
Grade 2 rash alone Therapy can continue Follow Grade 1 rash alone 
instructionsTherapy can 
continue
Grade 2 rash with 
symptoms indicating multi -
organ involvement 1Discontinue FPV BID or 
FPV/RTV BID.  Therapy 
should not be rein itiated 
unless the investigator has 
compelling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently [ADDRESS_273752] the physician immediately if 
rash fails to resolve (after more than 
two weeks ), if there is any 
worsening of the rash, if any 
systemic signs or allergic symptoms 
develop, or if mucosal involvement 
develops.Discontinue 3TC.  
Therapy should 
not be reinitiated 
unless the 
investigator has 
compelling 
evidence that the 
rash is not cause d 
by 3TC.
Grade 3/4 rash alone or 
with symptoms indicating 
multi -organ involvement 1Discontinue FPV BID or 
FPV/RTV BID and do not 
reinitiate therapy 3
Subjects should be treated 
as clinically appropriate and 
followed until resolution of 
the AE.Discontinu e ABC immediately and 
permanently 3
Subjects should be treated as 
clinically appropriate and followed 
until resolution of the AE.Discontinue 3TC 3
Subjects should 
be treated as 
clinically 
appropriate and 
followed until 
resolution of the 
AE.
1.Symptoms incl ude: systemic symptoms (fever, GI symptoms including nausea, vomiting, diarrhea or 
abdominal pain) or allergic symptoms, or mucosal involvement, or severe tiredness, achiness or generally ill 
feeling.  
2.ABC therapy should be permanently stopped and another NRTI therapy should be initiated.
3. Medications should be permanently stopped and the subject withdrawn from the trial. .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
58Adjunctive treatment:
For Grade 1 or 2 rash, antihistamines (see Section 3.3.10 for potent ial interactions) 
or topi[INVESTIGATOR_227311].  S ystemic corticosteroids are not 
recommended for Grade 1 or 2 rash, as steroid therap y ma y mask the appearance of 
other sy mptoms leading to the diagnosis of hy persensitivity  to ABC.
Subjects who develop a Grade 3 (vesiculation, moist desquamation, or ulceration) or 
4 rash (exfoliation, mucosal involvement, or target lesions [ery thema multiforme]) or 
any evidence of Stevens -Johnson Sy ndrome should have all study  drugs 
discontinued and assessed appropriatel y.  If Grade 3 or 4 rash is accompanied by 
[CONTACT_227396] s ymptoms, study  medications should be permanentl y discontinued.  
Steroids may  be used for treatment of the event. 
Nausea and vomiting
Upper gastrointestinal adverse events may  be reduced by  [CONTACT_227397] a meal, 
and by  [CONTACT_117354] a steady  oral intake, e.g., pretzels or other dry  bread.  Subjects who 
experience potentiall y treatment limiting nausea or vomiting should be treated with 
anti-emetics.  No dose reduction or modification of any study medication (i.e., FPV or 
RTV) will be allowed for the management of adverse events.
Hypertriglyceridemia/ hypercholesterolemia
There is currentl y no guidance available for the treatment and/or occurrence of 
cardiovascular disease in HIV -[ADDRESS_273753] ed children.  Please see recent recommendations 
[Dube , 2003] for full discussion of management of hyperlipi[INVESTIGATOR_227312] V 
therap y.
During the study , management of these events should be at the investigator’s discretion.
[IP_ADDRESS]. Abacavir Hy persensitivity  Reaction
In clinical studies, conducted before the introduction of screening for the HLA -B*5701 
allele, approximately  5% of subjects receiving ABC develop a h ypersensitivity  reaction 
(HSR) that in rare cases has proved fatal.  Howev er, in the PENTA 5 stud y [Gibb ,2000a] 
only 1 of the 92 ART -naïve, sy mptomatic children, aged 3 months to 16 y ears who were 
treated with a regimen containing ABC developed a classical h ypersensitivity  reaction.  
In CNAA3006, which uti lized an ABC containing backbone, ABC HSR was observed in 
2% of pediatric subjects. The risk for abacavir HSR to occur is significantly  increased for 
patients who test positive for the HLA -B*[ADDRESS_273754] 
been reported at a lower frequency  in patients who do not carry  this allele. In the 
prospective stud y CNA106030 (PREDI CT-1), the use of pre -therap y screening for the 
presence of HLA -B*5701 and subsequentl y avoiding ABC in HLA -B*5701 positive 
patients, significantl y reduced the in cidence of clinically  suspected ABC HSR from 7.8% 
(66 of 847) to 3.4% (27 of 803) (p<0.0001) [ Mallal , 2008]. I n clinical studies EPZ108859 
(ARIES) and CNA109586 (ASSERT), 0.8% (4/515) and 3.1% (6/192) of subjects who 
were HLA -B*5701 negative and who received ABC developed a clinically  suspected 
ABC HSR, respectively  [Post,2010; Squires ,2010]. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
59It is recommended that any  HIV-infected patient without prior exposure to abacavir be
screened f or HLA -B*5701 allele. Screening is recommended prior to re -initiation of 
abacavir in patients of unknown HLA -B*[ADDRESS_273755] previously  tolerated 
abacavir . Use of abacavir in patients known to carry  the HLA -B*[ADDRESS_273756] remain the basis of clinical decision making. Even in the 
absence of the HLAB* [ADDRESS_273757] fever and/or rash as 
part of the s yndrome; however reactions have occurred without rash or fever.
Symptoms can occur at any  time during treatment with ABC, but the sy mptoms usually  
appear within the first six weeks of initiation of treatment (median time to onset 11 day s).  
The sy mptoms worsen with continued therapy  and can be life -threatening.  These 
symptoms usually  resolve shortly after discontinuation of ABC.
Frequently  observed signs and sy mptoms include fever, rash, malaise or fatigue, 
gastrointestinal s ymptoms such as nausea, vomiting, diarrhea, or abdominal pain, and 
respi[INVESTIGATOR_227313] d yspnea, sore throat, cough.  Other signs and sy mptoms 
include my algia, arthralgia, edema, phary ngitis, headache, pa resthesia or my olysis.
Some subjects with hy persensitivity  were initially thought to have onset respi[INVESTIGATOR_227314] (pneumonia, bronchitis, phary ngitis), a flu -like illness, gastroenteritis, or 
reactions to other medications.  This delay  in diagnosis of h ypersensitivity  has resulted in 
ABC being continued or re -introduced, leading to more severe hy persensitivity  reaction 
or death.  Therefore, the diagnosis of h ypersensitivity  reaction should be carefull y 
considered for patients presenting with sy mptoms of these diseases.  If h ypersensitivity  
reaction cannot be ruled out, no medicinal product containing ABC (ZIAGEN, 
TRIZIV IR, KIVEXA, TRI UMEQ or an y other ABC -containing product) should be 
restarted.
Physical findings may  include rash (usually  maculopapular or urticarial), 
lymphadenopathy  or mucous membrane lesions (conjunctivitis, mouth ulceration) . 
Abnormal chest x -ray findings may  also present (predominantly  infiltrates, which can be 
localized).  Laboratory  abnormalities may  include elevated liver function tests (such as 
hepatic transaminases), increased creatine phosphokinase or creatinine levels, and 
lymphopenia.
Anaph ylaxis, hy potension, liver failure, renal failure, adult respi[INVESTIGATOR_227315].
Subjects who develo p a hypersensitivity reaction must discontinue ABC and must 
NEVER be rechallenged with any medicinal product that contains ABC (ZIAGEN, 
TRIZIVIR , KIVEXA, TRIUMEQ or any ABC -containing product ).  Restarting an y 
ABC -containing product following a hy persensit ivity reaction results in a prompt return 
of sy mptoms within hours.  This recurrence of the hypersensitivity reaction may be 
GD2001/[ZIP_CODE]/[ADDRESS_273758] been infrequent repor ts of hy persensitivity  reactions following reintroduction 
of ABC, where the interruption was preceded b y a single key s ymptom of 
hypersensitivity  (rash, fever, malaise/fatigue, gastrointestinal or a respi[INVESTIGATOR_29197]).
On very  rare occasions hy persensiti vity reactions have been reported in patients who 
have re -started therap y, and who had no preceding sy mptoms of a hypersensitivity  
reaction (i.e., patients previously  considered to be abacavir tolerant) .
Management of Hy persensitivity  Reactions 
Patients developi[INVESTIGATOR_227316]. 
If a hypersensitivity reaction is diagnosed the ABC -containing product MUST be 
discontinued immediately .  The subject’s parent/legal guardian should be aske d to 
return all unused supplies of the ABC -containing product for disposal to prevent an 
accidental re -challenge.
An ABC -containing medicinal product (ZIAGEN, TRIZIVIR or any ABC -
containing fixed dose combination), MUST NEVER be administered following a 
hypersensitivity reaction, as more severe symptoms will recur within hours and may 
include life -threatening hypotension and death. 
To avoid a delay  in diagnosis and minimize the risk of a life -threatening hypersensitivity  
reaction, the ABC -containing produc t should be permanentl y discontinued if 
hypersensitivity  cannot be ruled out, even when other diagnoses are possible (respi[INVESTIGATOR_227314], flu -like illness, gastroenteritis or reactions to other medications). 
Symptomatic support for ABC hy persensitivity  may be indicated.  This should include, 
for example, administration of intravenous fluids to patients who develop hypotension. 
Antihistamines or corticosteroids have been used in cases of ABC hy persensitivity , 
however there are no clinical data demonstrati ng the benefit of these in the management 
of the reaction. 
Laboratory  and other investigations which may  be useful in the evaluation and treatment 
of ABC h ypersensitivity  include, but may  not be limited to, measurement of AL T, AST, 
creatine phosphokinase, serum creatinine and white blood cell differential count and 
chest x -ray, if respi[INVESTIGATOR_227317].
Special considerations follo wing an interruption of abacavir therapy
If therap y with ABC has been discontinued and restarting therap y is under c onsideration, 
the reason for discontinuation should be evaluated to ensure that the patient did not have 
symptoms of a hy persensitivity  reaction.  If hypersensitivity reaction cannot be ruled 
out, no medicinal product containing ABC (ZIAGEN, TRIZIVIR , KIVE XA, 
TRIUMEQ or any ABC -containing fixed dose combination) should be restarted.
GD2001/[ZIP_CODE]/[ADDRESS_273759] where the interruption was preceded by a single key 
symptom of hypersensitivity (rash, fever, malaise/fatigue, gastrointestinal symptoms or a 
respi[INVESTIGATOR_20321]).  If a decision is made to restart any ABC -containing product in 
these patients, this should be done only under direct medical supervision. 
Rarel y, pat ients who have stopped ABC for reasons other than s ymptoms of HSR have 
also experienced life -threatening reactions within hours of re -initiating abacavir therap y. 
Subjects must be made aware that HSR can occur with reintroduction of ABC or an y 
other medic inal product containing abacavir and that reintroduction of ABC or any  other 
medicinal product containing abacavir should be undertaken onl y if medical care can be 
readil y accessed.
Screening for carriage of the HLA -B*5701 allele is recommended prior to re -initiation of
ABC in patients of unknown HLA -B*[ADDRESS_273760] positive for the HLA B*[ADDRESS_273761]’s parents/legal guardians are fully informed 
regarding the following information on the hypersensitivity reaction:
Subjects’ parents/legal guardians must be made aware of the possibility  of a 
hypersensitivity  reaction to ABC that may  result in a life threatening reaction or 
death.
Parents/legal guardians of subjects developi[INVESTIGATOR_227318] a hy persensitivity  reaction MUST CONTACT [CONTACT_124775].
Parents/legal guardians must be reminded that subjects who are h ypersensitive to 
ABC must never take any ABC -containing medicinal product s(ZIAGEN, 
TRIZIV IR, KIVEXA, TRI UMEQ or any ABC -containing fixed -dosecombination)
again.
In order to avoid restarting the ABC -containing product, the parents/legal guardians 
of subject s who have experienced a h ypersensitivity reaction should be asked to 
return the remaining oral solution to the pharmacy .
Parents/legal guardians of subjects, who have stopped an ABC -containing product 
for an y reason, and particularly due to possible adver se reactions or illness, must be 
advised to contact [CONTACT_124776].
Each parent/legal guardian should be reminded to read the Package Leaflet included 
in the pack.
Parents/legal guardians should be reminded of the importance of removing the Alert 
Card included in the pack, and keepi[INVESTIGATOR_227319].
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
62Reporting of Hy persensitivity  Reactions
All cases of potential ABC hy persensitivity  should be reported as Serious Adverse Events 
(SAE) (see Section 7.8).  In addition to reporting the case as an SAE, the HSR CRF 
should be completed and sentto [COMPANY_004] within one week of the onset of the 
hypersensitivity  reaction. 
Stevens Johnson Sy ndrome, Toxic Epi[INVESTIGATOR_227320], Toxic Epi[INVESTIGATOR_227321] y in patients taking ABC -
containing products.  These patients generally  do not have the cluster of additional 
symptoms (e.g., gastrointestinal and respi[INVESTIGATOR_696] ) that characterize the ABC 
hypersensitivity  reaction, but they  do have features ty pi[INVESTIGATOR_227310]. 
If a serious skin reaction develops, the ABC -containing product should be discontinued, 
and the patient should not be rechallenged with any ABC -containing medicinal product 
(ZIAGEN, TRIZIVIR , KIVEXA, TRIUMEQ or anyABC -containing fixed dose 
combination).
As many  products other than ABC also cause these serious skin reactions, all other 
medicinal products that the patient is receiving should also be reviewed and discontinued 
as appropriate.
Management of Rash That is NotAccompanied by  [CONTACT_227398] y grade should be evaluated for the 
possibility  of a h ypersensitivity  reacti on or a serious skin reaction such as Stevens 
Johnson Sy ndrome, Toxic Epi[INVESTIGATOR_227322] y as outlined above.  Rash may  be caused by  [CONTACT_2111][INVESTIGATOR_227323] y of the major 
antiretroviral classes, or by  [CONTACT_227399] s commonly  used as concurrent medications, 
such as cotrimoxazole.  As it is not possible to provide an exhaustive list of products that 
may cause rash in this protocol, please consult the product information leaflets for other 
products for information rela ting to rash. 
The rash and an y associated sy mptoms should be reported as adverse events (See 
Section 7.1) and appropriate toxicity  ratings should be used to grade the events. 
If the etiology  of the rash can be definitively  diagnosed as being due to a specific medical 
event or a concomitant medicinal product, routine management should be performed and 
documentation of the diagnosis provided. 
3.3.8. Subject Management Options
If subjects experience the following criter ia:
less than 1 log10 copi[INVESTIGATOR_014]/mL  reduction in plasma HIV -1 RNA b y Week 12, or
0.7 log10 copi[INVESTIGATOR_014]/mL rise from the nadir of plasma HIV -1 RNA, or
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
63a persistent decrease of five percentiles in CD4% in children with a baseline CD4% 
of less than 15%, or criteria a s specified in local guidelines, the investigator should 
consider whether a change in therap y and stud y discontinuation is warranted. 
Investigators are urged to follow country  specific guidelines where they  exist when 
making decisions about the management of subjects (e.g., when to switch therap y).
Subjects meeting one of the criteria defined above (first occurrence onl y and providing 
that the subject’s plasma HIV -[ADDRESS_273762] 1000copi[INVESTIGATOR_014]/mL ) should return, at the 
discretion of the investigator, to the clinic within [ADDRESS_273763] develops an AIDS diagnosis (CDC stage C) or other evidence of disease 
progression such that the treating clinician believes that changing therap y is required 
even though the above criteria have not been met, the investigator should contact [CONTACT_227400] a case by  [CONTACT_413]. 
3.3.9. Study Treatment A ssignment
Subject Number
After the parent/guardian has signed the informed consent form (ICF), each subject being 
screened for stud y enrolment will be assigned a subject number.  This number will be 
given sequentially  in chronological order of subject presentation according to a numerical 
roster provided to the site by  [CONTACT_23983].  The subject number will b e used to identify  each 
subject for the duration of the study .  Once a subject number has been assigned to a 
subject, it cannot be re -assigned to an y other subject. 
Treatment Number 
The treatment number will be used to identify  the specific study  drug re gimen initiated by  
[CONTACT_423].  Once a treatment number has been assigned to a subject, it cannot be 
reassigned to an y other subject.
Allocation of treatment numbers and consequently treatment assignments will be made 
via a [ADDRESS_273764] be 
recorded on the CRF for the duration of the trial.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
64Hematological supportive therap y with G -CSF, GM -CSF, or ery thropoietin will be 
permitted.
Other experimental agents, immuno modulators, cytotoxic chemotherap y or radiation 
therap y ma y not be administered during the stud y (see Section 3.2.2 . Exclusion Criteria); 
an exception will be made for local therap y or radiation treatment for Kap osi’s sarcoma.
Because vaccines may  cause a temporary  increase in the level of plasma HIV -1 RNA, it 
is recommended that a vaccine, if necessary , be given during or immediately  after a 
scheduled visit.  This approach will minimize the risk of non -specific i ncreases in the 
level of plasma HIV -1 RNA at the next scheduled assessment.  HIV immunotherapeutic 
vaccines are not permitted at an y time point during the stud y.
IMPORTANT: For other potential interactions alway s refer to the product information 
for an y drug used in combination therapy .
Fosamprenavir and Ritonavir
FPV and RTV are metabolized in the liver by  [CONTACT_9058] P450 3A4 (CYP3A4).  APV 
and RTV are predominantly  CYP3A4 inhibitors. When FPV and RTV are co -
administered, the ritonavir metabolic drug inter action profile may  predominate because 
ritonavir is a more potent CYP3A4 inhibitor. The full prescribing information for 
ritonavir must therefore be consulted prior to initiation of therap y with FPV and RTV.
Caution should be used when co -administering med ications that are substrates, inhibitors, 
or inducers of CYP3A4.  In addition, RTV has an affinity  for other cy tochrome P450 
isozy mes including CYP2D6, CYP2C9, CYP2C19, CYP2A6, CYP1A2 and CYP2E1, 
and appears to increase the activity  of glucuronosy l transfe rases. 
FPV and RTV should not be co -administered with alfuzosin ,amiodarone , astemizole , 
bepridil , bupropi[INVESTIGATOR_2394], cisapride , clorazepate , clozapi[INVESTIGATOR_050], diazepam , dihydroergotamine,
encainide , ergonovine , ergotamine , estazolam, flecainide , flurazepam , halofantrin e, 
lovastatin , meperidine, methy lergonovine , midazolam , pi[INVESTIGATOR_3924] , pi[INVESTIGATOR_18234], 
propafenone , propox yphene, quinidine , ketaconazole, rifampi[INVESTIGATOR_2513], PDE5 inhibitors 
including sildenafil , simvastatin , terfenadine and triazolam . Co-administration may  result 
in compe titive inhibition of metabolism of these medications and may  cause serious or 
life-threatening adverse events. Co -administration of FPV or FPV/RTV with rifabutin 
results in significant increases in plasma rifabutin levels, therefore the dose of rifabutin 
should be reduced b y at least 50% when co -administered with FPV and b y at least 75% 
when co -administered with FPV/RTV. Caution should be used and subjects should be 
monitored closely  for signs of toxicity .
Systemic corticosteroid effects, including Cushing' s syndrome and adrenal suppression, 
have been reported in patients receiving ritonavir and inhaled or intranasally  administered 
fluticasone propi[INVESTIGATOR_16847]; this interaction is also expected with other corticosteroids 
metabolized via the P450 3A pathway .
Concom itant use of fluticasone propi[INVESTIGATOR_227324].
GD2001/[ZIP_CODE]/[ADDRESS_273765]. John’s Wort because the PI [INVESTIGATOR_227325] y decreased, reducing efficacy. FPV and RTV should also not be co -
administered with hepatitis C virus (HCV) protease inhibitors telaprevir and boceprevir 
becau se both APV and HCV PI  [INVESTIGATOR_227326], with the 
possibility  of sub -therapeutic concentrations.    
APV and RTV interact with CYP3A4 and are predominantly  CYP3A4 inhibitors.  
Medications which interact with CYP3A4, either as s ubstrates, inhibitors, or inducers of 
the isozy me, or medicinal products with narrow therapeutic windows that are substrates 
of cy tochrome P450 3A4 (CYP 3A4) should be used with caution include, but are not 
limited to:  alprazolam, amlodipi[INVESTIGATOR_050], atorvastatin , cerivastatin, cimetidine , clarithromy cin, 
clindamy cin, clonazepam, codeine, dapsone, diltiazem, disopy ramide, ery thromy cin, 
estrogens and progestogens, felodipi[INVESTIGATOR_050], fluvastatin, glucocorticoids, imipramine, 
isradipi[INVESTIGATOR_050], itraconazole, loratadine, miconazole , nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nimodipi[INVESTIGATOR_050], 
nisoldipi[INVESTIGATOR_050], pravastatin, verapamil and zolpi[INVESTIGATOR_6730]. 
The following medications are examples of drugs that require concentration and 
therapeutic effect monitoring when administered in combination with FPV and RTV due 
to the potential for serious and/or life -threatening drug interactions:  cy closporine, 
systemic lidocaine, rapamy cin, tacrolimus, tricy clic antidepressants, theophy lline, and 
warfarin.  International Normalized Ratio (I NR) monitoring is recommended when 
warfa rin is used concomitantly  with FPV and RTV.
RTV is not recommended for use with digoxin, voriconazole, blonanserin, salmeterol and 
other drugs not recommended for use with FPV above. RTV is an inhibitor of CYP2D6 
and an inducer of CYP1A2, CYP2C9 and glucu ronosy l transferase. Medications which 
interact with CYP2D6, CYP1A2, CYP2C9, and/or glucuronosy l transferase should be 
used with caution and include but are not limited to: bisoprolol, codeine, chlorpromazine, 
cyclobenzaprine, desipramine, doxepin, fluphen azine, fluoxetine, haloperidol, 
hydrocodone, methamphetamine, metoprolol, mexilitine, morphine, propranolol, 
oxycodone, paroxetine, perphenazine, risperidone, thioridazine, timolol, tramadol, 
trazodone, and venlafaxine.  
Because RTV oral solution contains alcohol, drugs such as metronidazole that may  
inhibit alcohol metabolism should be avoided.
IMPORTANT :For further information refer to local product information or the 
International Product Information for more complete information.
[IP_ADDRESS]. [COMPANY_004] Supplied Backgrou nd NRTI Options
Interactions Relevant to Abacavir
Based on the results of in vitro experiments and the known major metabolic pathway s of 
ABC, the potential for drug interactions involving ABC is low. 
ABC shows no potential to inhibit metabolism mediated b y the cy tochrome P450 3A4 
enzy me. It has also been shown in vitro not to interact with drugs that are metabolised by  
[CONTACT_86467]2001/[ZIP_CODE]/[ADDRESS_273766] shown that there are no clinically  significant interactions between 
ABC, zidovudine and 3TC.
Ethanol -The metabo lism of ABC is altered by  [CONTACT_227401] 41%.  Given the safet y profile of ABC, these findings 
are not considered clinically  significant.  ABC has no effect on the metabolism of 
ethanol.
Methadone -In aPK study , co-administration of 60 0 mg ABC twice dail y with 
methadone showed a 35% reduction in ABC Cmax and a one hour delay  in tmax, but 
AUC was unchanged.  The changes in ABC PK are not considered clinically  relevant.  In 
this study , ABC increased the m ean methadone systemic clearance b y 22%.  This change 
is not considered clinically  relevant for the majority  of patients, however occasionall y 
methadone dose re -titration may  be required.
Retinoids -Retinoid compounds such as isotretinoin, are eliminated via alcohol 
dehy drogenase. Interaction with ABC is possible but has not been studied.
Refer to the local prescribing information for additional information on concurrent 
therapi[INVESTIGATOR_014].
Interactions Relevant to Lamivudine
The likelihood of interactions is low d ue to limited metabolism and plasma protein 
binding and almost complete renal elimination of unchanged lamivudine.
Lamivudine is predominantly  eliminated b y active organic cationic secretion. The 
possibility  of interactions with other medicinal products ad ministered concurrentl y 
should be considered, particularly  when their main route of elimination is active renal 
secretion via the organic cationic transport s ystem, e.g. trimethoprim. Other medicinal 
products (e.g. ranitidine, cimetidine) are eliminated on ly in part b y this mechanism and 
were shown not to interact with lamivudine.
Active substances shown to be predominatel y excreted either via the active organic 
anionic pathway , or b y glomerular filtration are unlikely  to yield clinicall y significant 
intera ctions with lamivudine.
Zidovudine -A modest increase in Cmax (28%) was observed for zidovudine when 
administered with lamivudine, however overall exposure (AUC) was not significantly  
altered. Zidovudine had no effect on the pharmacokinetics of lamivudine . 
Trimethoprim/sulphamethoxazole -Administration of trimethoprim/sulphamethoxazole 
160 mg/800 mg (co -trimoxazole) causes a 40% increase in lamivudine exposure because 
of the trimethoprim component. However, unless the patient has renal impairment, no 
dosage adjustment of lamivudine is necessary  (see Dosage and Administration).  
Lamivudine has no effect on the pharmacokinetics of trimethoprim or 
sulphamethoxazole. The effect of co -administration of lamivudine with higher doses of 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
67co-trimoxazole for the tre atment of Pneumocy stis carinii pneumonia and toxoplasmosis 
has not been studied. 
Zalcitabine -Lamivudine may  inhibit the intracellular phosphory lation of zalcitabine 
when the two medicinal products are used concurrently .  Lamivudine is therefore not 
recommended to be used in combination with zalcitabine.
Emtricitabine : Lamivudine may  inhibit the intracellular phosphory lation of emtricitabine 
when the two medicines are used concurrentl y. Additionally , the mechanism of viral 
resistance for both lamivudine a nd emtricitabine is mediated via mutation of the same 
viral reverse transcriptase gene (M184V) and therefore the therapeutic efficacy  of these 
medicines in combination therap y ma y be limited. 3TC is not recommended for use in 
combination with emtricitabine .
Refer to the local prescribing information for additional information on concurrent 
therapi[INVESTIGATOR_014].
Packaging and Labeling of [COMPANY_004] Supplied Background NRTI Options
[COMPANY_004] will provide ABC and/or 3TC as optional background NRTIs for subjects whose 
screening HIV -1 genoty pe, if available, shows susceptibility  to ABC and/or 3TC, or per 
investigator discretion.
The contents of the label will be in accordance with all applicable regulatory  
requirements. 
ABC and 3TC will be supplied in their own bottle and labeled with the following 
information: protocol number, container contents, batch/inventory  number, quantity , 
dosing instructions and storage conditions/instructions.  Qualified study  site personnel 
should calculate the drug dose at the site. 
[COMPANY_004] supplied background NRTI s will be packaged such that the site investigator or 
pharmacist can dispense sufficient drug for each subject until the next scheduled study  
visit.  
Handling of [COMPANY_004] Supplied Background NRTI Options
[COMPANY_004] supplied background NRTI s will be dispatched to a site only  after receipt of 
required documents in accordance with all applicable regulatory  requirements and [COMPANY_004] 
procedures.  These documents include, but are not limited to the signed FDA Form 1572 
or equivalent, signed Financial Disclosure Agreement, si gned protocol agreement and 
IEC/IRB approval letter.
ABC and 3TC will be shipped to the investigational sites by  [CONTACT_23983].  At each visit the 
investigator or designated site staff should dispense sufficient amount of background 
NRTI s to provide adequate supply  for each subject until the next scheduled visit.  All 
[COMPANY_004] supplied background NRTI s that are not utilized during the study  will be destro yed 
at the completion of the trial.  Drug disposition records will be regularl y reviewed b y the 
study  monitor.
GD2001/[ZIP_CODE]/[ADDRESS_273767] be dispensed or administered according to 
procedures described below.  Only  subjects whose HIV -1 genot ype shows susceptibility  
to ABC and/or 3TC and who meet the minimum age requirements may  receive [COMPANY_004] 
supplied background NRTI s,in accordance with all applicable regulatory  requirements. 
Only  authorized site personnel may  suppl y or administer [COMPANY_004] supplied background 
NRTI s.  All [COMPANY_004] supplied background NRTIs must be stored in a secure area with access 
limited to the investigator an d authorized study  site personnel and under phy sical 
conditions that are consistent with study  drug -specific requirements.
All [COMPANY_004] supplied background NRTI s should be stored until the time of dispensing as 
follows:
Abacavir oral solution US/Canada/Latin Am erica –Store between 20 C -25C 
(68F -77F) DO NOT FREEZE. May be refrigerated .
Europe/ South Africa –Store below 30 C DO NOT 
FREEZE
Abacavir tablet * South Africa –Store at or below 30 C.
Lamivudine oral solution US/Canada/Latin America –Store in tightly closed bottles 
at 25 C (77 F)
Europe/ South Africa –Store at or below 25 C
Lamivudine tablet South Africa –Store at or below 30 C.
*Only supplied when licensed in South Africa.
Accountability Procedures for [COMPANY_004] Supplied Background NRTI Option s
The investigator is responsible for [COMPANY_004] supplied background NRTIs accountability , 
reconciliation, and record maintenance.  In accordance with all applicable regulatory  
requirements, the investigator or designated stud y site personnel must maintain drug 
accountability  records throughout the course of the study .  This person(s) will document 
the amount of background NRTI s received from [COMPANY_004], the amount supplied and/or 
administered to and returned by  [CONTACT_1766], if applicable.
All [COMPANY_004] supplied background NRTI s will be handled and stored in accordance with the 
product label or information provided by [CONTACT_23983].
Within each subject’s CRF, start and stop dates of each background ART (both [COMPANY_004] 
supplied and those supplied by  [CONTACT_227402]) must be recorded o n the 
background antiretroviral therap y page.  In addition, dose changes and interruptions of 
greater than 24hours duration must be recorded.
Separate from the CRF, the site will maintain [COMPANY_004] Supplied Background NRTI  
Accountability  Logs to include the fol lowing:
subject number
treatment number 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
69quantity  of drug dispensed/returned (the unit of accountability  will be 
full/partial/empty  bottles)
dispensing/return date
signature [CONTACT_227473]
comment area for noting discrepancie s
Subjects must be instructed to return all [COMPANY_004] supplied background NRTIs to the site at 
each stud y visit for volume assessments.  This includes bottles that are empty, partiall y 
full and completel y full.  
At the end of the stud y and at appropriate interv als during the study , all unused 
background NRTIs must be returned to [COMPANY_004] according to procedures dictated by  [CONTACT_227403] y documented.  
The investigator is responsible for assuring that [COMPANY_004] supplied background NRTI s are 
stored, dispensed and returned appropriatel y.  [COMPANY_004] monitors will regularly access 
pharmacy /dispensing records.  Cases of suspected negligence will be investigated.
4. STUDY DRUG M ANAGEMEN T
4.1. Stud y Drug Packaging and Labeling
The contents of the label on a ll study  drugs will be in accordance with all applicable 
regulatory  requirements.
FPV 5 0 mg /mL oral suspension will be supplied in its own bottle and labeled with the 
following information: protocol number, container contents, batch/inventory  number and 
quantity , storage conditions/instructions, dosing instructions and shaking instructions to 
ensure adequate redispersal of the oral suspension prior to dosing.  Qualified study  site 
personnel should calculate the drug dose at the site.
RTV oral solution , powd er, tablets or capsules will be provided locall y by [CONTACT_227404].
[COMPANY_004] will provide RTV by [CONTACT_227405], or [COMPANY_004] 
may provide RTV if local sup plies are not available and RTV is able to be obtained from 
other countries.
In this trial, ‘stud y drugs’ are defined as FPV and RTV for the purposes of recording 
adverse events and serious adverse events.  The FPV oral suspension will be packaged 
such t hat the site investigator or pharmacist can dispense sufficient drug for each subject 
until the next scheduled study  visit.
4.2. Stud y Drug Handling
Study  drug will be dispatched to a site onl y after receipt of required documents in 
accordance with all applicab le regulatory  requirements and [COMPANY_004] procedures.  These 
documents include but are not limited to the signed FDA Form 1572 or equivalent, 
signed Financial Disclosure Agreement, signed protocol agreement and IEC/I RB 
approval letter.
GD2001/[ZIP_CODE]/[ADDRESS_273768]’s CRF.
Both FPV oral suspension and RTV oral solution should be measured and administered 
using separate appropriately  sized oral dosing s yringes.   Administration via dosing cups 
is not allowed as residual FPV oral suspension and RTV oral solution could remain in the 
cups. 
Note per Amendment 12; for subjects weighing less than 33 kg, if RTV oral solution is 
not available, the RTV powder can be substituted .  For doses less than 100 mg or partial 
doses between 100 mg increments the following instructions should be followed. Mix 1 
packet/sachet of oral powder (100 mg) with 9.4 mL  of liquid (such as water, chocolate 
milk, or infant formula) in a mixing cup. Once mixed, use an oral dosing syringe to 
measure and administer the prescribed volume.  Once the powder is mixed, the dosage 
must be consumed within [ADDRESS_273769] an y mixture remaining in the mixing cup.
Additional guidance is provided in Section 11.6.
IMPORTANT:   Do NOT mix FPV with RTV or other background NRTI medications in 
the same s yringe.
Study  medications should be stored until the time of dispensing as follows:
FPV 5 0 mg/mL oral suspension Store below 30 C (86 F)DO NOT FREEZE
RTV 8 0 mg /mL oral solution Store according to local product information
RTV oral powder Store according to local product information
RTV [ADDRESS_273770] information
GD2001/[ZIP_CODE]/[ADDRESS_273771] maintain study  drug accountabilit y records 
throughout the course of the study .  This person(s) will document the amount of study  
drug received from [COMPANY_004], the amount supplied and/or administered to and returned b y 
subjects, if applicable.
All study  drugs will be handled and stored in accordance with the product label or 
information provided by [CONTACT_23983].
Within each subject’s CRF, the Study  Drug Record page will list the name [CONTACT_227474] y drug.  Start and st op dates of each stud y drug must be recorded on 
this page.  In addition, dose changes and interruptions of greater than 24hours duration 
must be recorded.
Separate from the CRF, the site will maintain a Study  Drug Accountability L og to 
include the followi ng:
subject number
treatment number 
batch/inventory  number
quantity  of drug dispensed/returned (the unit of accountability  will be 
full/partial/empty  bottles)
dispensing/return date
signature [CONTACT_227473]
comment area for noting discrepancies
Subjects must be instructed to return all stud y drug to the site at each stud y visit for 
volume assessments.  This includes bottles that are empty , partially  full and completely  
full.
At the end of the stud y and at appropriate interval s during the stud y, all unused drug must 
be returned to [COMPANY_004] according to procedures dictated by  [CONTACT_227406].
The investigator is responsible for assuring that study  medications are stored, dispensed 
and returned appropriately .  [COMPANY_004] monitors will regularl y access pharmacy /dispensing 
records.  Cases of suspected negligence will be investigated.
5. MEA SUREMENTS A ND EV ALUATIONS
5.1. Time and Events Schedule
Schedules showing the timing of stud y procedures and laborat ory evaluations for all 
subjects are shown in Section 10.
GD2001/[ZIP_CODE]/[ADDRESS_273772]’s parent/guardian must be obtained bef ore any  investigations 
are performed which are for the sole purposes of this study .
Subjects will attend the clinic at Screening, Day  1 (Baseline), and Weeks 2, 4, 8, 12, 16, 
24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects may continue to receive FPV until they no 
longer derive clinical benefit or according to prior agreements between [COMPANY_004] and 
participating stud y sites for provision of ART.   A follow -up visit will be performed 
4weeks after the permanent discontinuation of study  drug.
The scheduled laboratory evaluations will involve collection of a maximum blood 
volume of 7mL /kg in any 56 -day period in all subjects.  Additionally , a maximum of 
3mL /kg of blood will be collected at an y one study visit from children 4 weeks to 
<6months old.
5.2. Screening and Enrolm ent
Subjects will undertake the procedures listed in the schedules in Section 10.  Screening 
will be within approximately  21 day s of Baseline/Day  1 for all subjects.  As per 
amendments 5 and 7, SDV assessments a re no longer required for Cohort 1 Arm A and 
Cohort 2 Arm A.
Reports of screening assessments of ly mphocy te subsets, HIV -1 RNA PCR and HIV -1 
resistance testing (if performed) should be reviewed prior to Baseline/Day  [ADDRESS_273773] meets the full eligibility  criteria.  
5.3. Demographic and Baseline Characteristics
Demograph y:  Subject date of birth, gender and race will be collected at the 
Screening visit.
Baseline characteristics : 
Information to be collected will include:
HIV risk factors and mo de of transmission (collected at Screening visit)
CDC classification (collected at the Screening visit and summarised at Baseline)
Current medical conditions (collected at Day  1)
HIV-associated conditions (collected from Day  1)
Prior antiretroviral therapy (collected at Day  1 or the initial Single Dose Visit if 
applicable)
Background antiretroviral therap y (collected from Day 1 or the initial Single 
Dose Visit if applicable) 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
73Height, weight, head circumference and vital signs (blood pressure and pulse, 
collected at all visits)
5.4. Stud y Drugs and Background NRTIs
The start and stop date for all study  drugs and background NRTIs, an y temporary  
interruptions or dose changes >24 hours, and information on premature discontinuation 
of study  drug and background NRTI s will be collected on Day  1 and throughout the study  
period. In this trial, study drugs are defined as FPV and RTV, whereas ABC and 3TC are 
[COMPANY_004] supplied background NRTI s.
5.5. Efficacy
All evaluations listed below will be performed at Screening, Day  1 and at Week s 4, 12, 
24, 36, 48, every  12 weeks thereafter, and Withdrawal.  Refer to the study  manual 
provided b y the central laboratory for specific instructions on sample collection, 
preparation and shipment.
Quantitative plasma HIV -1 RNA ([COMPANY_002] Amplicor HIV -[ADDRESS_273774]; version 1.5, 
ultrasensitive limit of detection (LOD) = 50 copi[INVESTIGATOR_014] /mL).  Samples with >75,000
copi[INVESTIGATOR_014]/mL  will be retested using the [COMPANY_002] Amplicor HIV -[ADDRESS_273775] assay  LOD = 400 copi[INVESTIGATOR_014]/mL.  (NOTE:  At the Screening and Bas eline 
(Day  1) visits, the [COMPANY_002] Amplicor HIV -[ADDRESS_273776] assay  
will be used). Per Protocol Amendment 12: the [COMPANY_002] Amplicor HIV -[ADDRESS_273777] 
Version 1.5 was subsequently  discontinued after the July  2011 cut -off date for the 
week 48 CSR.  By [CONTACT_36466]  2013 , only two APV20002 study  sites, both in South 
Africa had actively  enrolled subjects; and efficacy for these subjects was evaluated 
using the Abbott Realtime HIV -[ADDRESS_273778], which has a LOD of 40 copi[INVESTIGATOR_014]/mL .  
Lym phocy te subsets to incl ude total ly mphocy tes, absolute and percent CD4+ and 
CD8+ cell counts.  
HIV associated conditions: The subject will be assessed for any  new or recurring 
HIV-associated conditions at all study  visits from Baseline.
Genoty pic HIV -1 resistance testing: Plasm a samples may  be collected at the 
Screening visit at the investigator’s discretion if needed to guide selection of 
background ART.  Resistance anal ysis will also include an assessment of the HIV -1 
protease (PRO) coding region.  Where blood volumes permit, a sample will also be 
collected if the subject meets one of the criteria described in Section 3.3.8 with 
results provided to the investigator.
Additional storage samples may  be collected at Day  1, Weeks 12, 24, 3 6, 48, every  
12 weeks thereafter, and Withdrawal and stored for possible HIV 
genot ype/phenot ype testing in the future or for repeat laboratory assessments as 
needed. 
GD2001/[ZIP_CODE]/[ADDRESS_273779]’s parent or guardian via 
completion of an adherence questionnaire.  The adherence questionnaire will be 
completed in order to quantify  the number of doses of FPV BID and/or FPV/RTV BID 
that were missed during the course of the stud y.  The adherence questionnaire will be 
administered on Day  1 (Baseline practice questionnaire), Weeks 2, 12, 24, 48 and at the 
time of premature stud y discontinuation.
Parent/Guardian Perception of Study  Medication
Parent/guardian’s attitude or perceptions of medications can impact on the acceptability  
of a medication to a child, affecting adherence and the subsequent drug efficacy  in the 
pediatric population.  Parent/guardian perceptions of FPV BID and FPV/RTV BID will 
be assessed using a Parent/Guardian P erception of Study  Medication assessment 
administered during Weeks 2, 24 and 48/premature study  discontinuation.  
Administration of the Humanistic Questionnaires
Completeness and Accuracy of Subject Questionnaire Responses
The parent/guardian should be as ked to complete the questionnaires as completely  and as 
accuratel y as possible.  If a parent/guardian is unable to complete a questionnaire b y him 
or herself, stud y site personnel may  administer the questionnaire via an interview at the 
discretion of the i nvestigator.  With the exception of helpi[INVESTIGATOR_227327]/guardians identify  
which antiretroviral drugs the subjects are supposed to be taking, the investigator will not 
provide an answer to an y question nor interpret any portion of the question.  If the 
parent/ guardian requests help or clarification of any question, he or she should be asked 
to read the instructions again, or to listen again as the instructions and question are 
repeated if administration is undertaken via interview, and to give the best answer 
possible to each question.  Parents/guardians should be encouraged that it is their 
experiences and opi[INVESTIGATOR_227328], and that the subject’s treatment during the 
study  will not be affected by  [CONTACT_227407].
Recording of Data
Black ink should be u sed to complete the questionnaires.  Parents/guardians must be 
instructed to make an y changes b y drawing a line through the undesired response, dating 
the change, and then recording the desired response.
Collection and Storage of Subject Questionnaires
Upon completion of the questionnaires, the investigator will retrieve the questionnaires 
from the parent/guardian, check that the header sections (Subject Number, Visit Date, 
etc.) are complete, ensure the parent/guardian did not unintentionally skip question s or a 
GD2001/[ZIP_CODE]/[ADDRESS_273780]’s CRF notebook.  At this point, the 
subject questionnaires are considered complete, and they  should not be given back to the 
parent/guardian.  No changes should be registered once they  have been comp leted and 
returned to the investigator. Investigators are to record the method of administration of 
the questionnaires on the "Method of Administration for Questionnaires and Subject 
Dosing Card" CRF page.  If respondents experience difficulties or are una ble to answer 
any question, then the investigator should document the reason in the investigator 
comments log.   Possible reasons for not completing the questionnaires are the 
parent/guardian refused, parent/guardian unable to understand a question or other .
Source Documents and Monitoring Procedures for Subject Questionnaires
Each questionnaire completed by  [CONTACT_423]’s parent/guardian serves as a source 
document; therefore there are no other source documents for data validation by  [CONTACT_227408].
No attempt should be made by  [CONTACT_227409]’s 
parent/guardian questionnaire booklets with data recorded on the clinical CRF, except for 
subject identification data (e.g., Subject Number, Treatment Numb er, Visit Date, Gender, 
etc.).  Neither the investigator nor an y member of the clinical research team is under an y 
obligation to validate the accuracy  of the parent/guardian completed sections of the 
questionnaires.
5.7. Bioanal ysis and Pharmacokinetic Samples
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluation of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Plasma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
every  12 weeks thereafter.
Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected over 8 -12 
hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks th ereafter. 
To measure the unbound concentration of APV, additional plasma trough PK samples 
will be collected prior to FPV/RTV BID dosing at Weeks 2, 16 and 36 for Cohort 1 Arm 
A subjects and at Weeks 8 and 16 for Cohort 2 Arm A subjects.
A maximum of 7mL /kg of blood for PK, safety , and virological assessments will be 
collected during an y 56-day period for all subjects.  A maximum of 3mL /kg of blood will 
be collected at an y one study visit for subjects 4 weeks to <6 months old.
Single Dose Visit (SDV)
Cohor t 1 (6 months -<2 years)
Per protocol amendment 5, no additional subjects in this age group are required to 
undertake SDV assessments.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
76Cohort 2 (4 weeks -<6 months)
Per protocol amendment 7, no additional subjects in this age group are required to 
undert ake SDV assessments.
Week 2 PK Sampling
Subjects enrolled in both cohorts (Arm A, FPV/RTV BID) will undergo plasma PK 
sampling on Week 2.  Plasma concentrations of APV, FPV and RTV will be determined: 
Cohort 1 Arm A: A plasma trough PK sample of 1.0mL  who le blood will be 
collected prior to FPV/RTV dosing.  A 2.0mL whole blood sample will be collected 
prior to dosing to determine plasma concentrations of unbound APV.  Three 1.0mL  
whole blood samples will be collected at 0, 2, and [ADDRESS_273781] -dosing.
Cohort 2 Arm A: Seven whole blood samples of 0.5mL  each will be collected at 0, 1, 
2, 4, 6, 8, and [ADDRESS_273782] -dosing (optional 12 -hour sample).
Week [ADDRESS_273783] -dosing (optional 12 hour sample).  
One mL  whole blood samples will be drawn at each time point specified.
Subjects in Cohort [ADDRESS_273784] a plasma trough PK sample of 1.0mL  whole blood 
collected prior to FPV/RTV BID dosing.  A 2.0mL whole blood sample will be collected 
prior to dosing to measure t he unbound APV concentration.
Weeks 12, 16, 24, 36, 48 and every  12 weeks thereafter
All subjects will undergo additional plasma trough PK sampling of 1.0mL of whole blood 
(just prior to receiving a scheduled dose of FPV/RTV BID) at Weeks 12, 16, 24, 36, 4 8
and every  12 weeks thereafter.  
In addition, at Week 16 (both Cohorts) and Week 36 (Cohort 1 only ), subjects will have a 
plasma trough PK sample of 2.0mL whole blood collected (prior to receiving the 
scheduled dose of FPV/RTV BID) to determine the unbou nd concentration of APV.
In consultation with the investigator, [COMPANY_004] may  discontinue PK sampling and monitoring 
of plasma APV, FPV and RTV concentration on an individual basis once a subject has 
reached and exceeded 2 years and has initiated the 23/ 3 mg /kg BID dosing regimen after 
Week 48 .  Any  further dosing changes would follow the approved dosing 
recommendations without PK sampling, including a transition to FPV/RTV 18/ 3 mg /kg 
BID at 6 y ears.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
77Directly  Observed Therapy
Because plasma PK sampling needs to o ccur at steady -state, it is imperative that subjects 
consistently  receive their medications prior to PK sampling.  To improve the quality  of 
the serial PK samples, it is strongl y recommended that the administration of study drugs 
on the evening prior to th e serial PK visits and on the morning of the serial PK visits 
(after the pre -dose PK sample is collected) be directly  observed by  [CONTACT_24355].  The 
actual method of observation will be at the discretion of the investigator and may  require 
the subject t o attend the clinic for dosing or may  require study  personnel or a home 
healthcare provider to visit the subject at their home to observe the dosing.
Logistical Considerations
Site personnel will contact [CONTACT_6992]’s parent/guardian [ADDRESS_273785] the doses, dates, and times of the three FPV/RTV doses 
administered prior to attending the stud y site.  Site personnel will need to sch edule each 
subject’s visits so that the plasma PK trough sample is collected within 10 -14 hours 
following a dose of FPV/RTV.  All subject’s parents/guardians will be provided with a 
“dosing card” as a tool to help them record doses for the [ADDRESS_273786] spit up or vomited these three doses.  If the “dosing card” is missing, 
blank or incomplete, then the corresponding PK CRF pages “Prior Dosing GW433908 
and “Prior Dosing Ritonavir” may  be completed by  [CONTACT_227410] w at the site at the 
discretion of the investigator.  The investigator should document the reason in the 
investigator comments log.
Information regarding partial dosing and subsequent re -dosing, if required, due to 
subjects either spi[INVESTIGATOR_227329]/or RTV oral 
solution doses will be collected for the 3 doses prior to any  PK sampling and for the dose 
administered immediately following the pre -dose (0 hour) PK sample on the SDV and 
Week 2 PK. 
GD2001/[ZIP_CODE]/[ADDRESS_273787] compliance should be carefull y reviewed prior to all PK 
sampling.  If a significant deviation affecting kinetic sampling is noted, the investigator is 
advised to counsel the parent/caregiver as to the importance of compliance and 
reschedule the samp ling until the specific issue is resolved. 
For details on collection, processing and shippi[INVESTIGATOR_227330].
5.8. Safet y
The following safet y evaluations will be performed during the stud y (see Section 10for 
schedule of events). 
Hematology :  including hemoglobin, white blood cell (WBC) count with differential, 
mean corpuscular volume (MCV) and platelet count to be performed at the Screen 
visit, Day  1 and Weeks 4, 12, 24, 36, 48, ever y 12 weeks thereafter, and Withdrawal.
Clinical chemistry : including sodium, potassium, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), total bilirubin, creatinine, albumin, glucose, 
alkaline phosphatase and creatine phosphokinase (CPK) t o be performed at the 
Screen visit, Day  1 and Weeks 4, 12, 24, 36, 48, every  12 weeks thereafter, and 
Withdrawal.
Lipid measures to include trigl ycerides, total cholesterol, high density  lipoprotein 
(HDL), low density  lipoprotein (LDL) to be collected at D ay 1 and Weeks 24 and 48, 
every  12 weeks thereafter, and Withdrawal.
Clinical adverse events to be collected at the Screen visit, the Single Dose Visit, Day  
1 and Weeks 2, 4, 8, 12, 16, 24, 36, 48, every  12 weeks thereafter, and Withdrawal: 
Refer to Sectio n 7for details.
Concurrent medications/blood products and background antiretroviral medication to 
be collected at the Single Dose Visit, Day  [ADDRESS_273788] local 
procedures.
GD2001/[ZIP_CODE]/[ADDRESS_273789] does not permanently 
stop study  drug dosing prior to end of the study  and completes all scheduled stud y visits.
Subjects may  be prematurely  discontinued from the study  for any  of the following 
reasons:
Subject, subject’s parent/guardian or investigator non -compliance.
At the request of the subject’s parent/guardian, investigator or [COMPANY_004].
Progression of an y medical condition which, in the opi[INVESTIGATOR_110407], should preclude further participation.
If the subject requires treatment with any  of the medications listed in the Exclusion 
Criteria (Section 3.2.2 ).
If the subject requires cy totoxic chemotherapy  or radiation therapy  (with the 
exception of local treatment for Kaposi’s sarcoma).
If the subject requires another investigational drug which when combined with the 
study  drug would, in the opi[INVESTIGATOR_1649] o f the investigator or [COMPANY_004], jeopardize the validity  
of the subject’s continued participation.
Subjects who prematurely discontinue from the study  will not be replaced unless 
<8subjects from each treatment regimen in each cohort have completed PK anal ysis after 
2weeks on their selected regimen.  In this case, additional subjects will be added to the 
cohorts as replacement subjects.
Withdrawal
Subjects who prematurely discontinue from the study , whether voluntaril y or not, should 
have the Withdrawal visit as sessments performed (refer to Section 10).  Once a subject’s 
weight has increased to 39 kg or more, they  should be withdrawn from the study (refer to 
Section 3.1).  A Follow -up visit will be performed [ADDRESS_273790] from the study .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
80Clinical Evaluations
Body weight and height
Head circumference
Vital Signs
Concurrent medications/blood products
Background ART
HIV-associated conditions
Adverse events
Questionnaires for humanistic outcomes
Laboratory  Evaluations
Hematology  (hemoglobin, WBC with differential, MCV and platelet count).
Lym phocy te subsets by  [CONTACT_190961]  (total ly mphocy tes and absolute and 
percentage CD4+ and CD8+ ly mphocy te counts).
Clinical chemistry  panel and transaminase levels (sodium, potassium, AST, AL T, 
total bilirubin, creatinine, albumin, glucose, alkaline phosphatase, and CPK).
Lipid measures including trigl ycerides, and total cholesterol, HDL, and LDL 
cholesterol.
Quantitative plasma HIV -1 RNA P CR.
Plasma for storage where permitted by  [CONTACT_227411].  This sample may  
be used for HIV -[ADDRESS_273791] is prematurel y discontinued from the stud y at an y time due to 
an AE (as defined in Section 7.1, “Definition of an AE”) or SAE (as defined in 
Section 7.2, “Definition of a SAE”), the procedures stated in Section 7, (“AEs and 
SAEs”) must be followed.
5.10. Follow Up
All study  subjects should have a follow up stud y visit 4 weeks following permanent 
discontinuation of study  drug.  The follow up assessments required are detailed below 
and in Section 10.
Clinical Evaluations
Concurrent medications/blood products
Current ART
HIV-associated conditions
Adverse events
Serious adverse events
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
81Laboratory  Evaluations
Hematology  (hemoglobin, WBC with differential, MCV and platelet count).
Clinic al chemistry  panel and transaminase levels (sodium, potassium, AST, AL T, 
total bilirubin, creatinine, albumin, glucose, alkaline phosphatase, and CPK).
6. DATA ANALYSIS METHOD S
6.1. Sample Size Determination
The sample size of 48 subjects was selected as an approp riate number to allow an 
accurate description of plasma APV PK, safet y and tolerability  of FPV BID, Arm B 
(N=24 for PK and safet y; enrolment closed per Amendment 10) and FPV/RTV BID, Arm 
A (N=24 for PK and safety ).  Safet y and tolerability assessment of th e FPV/RTV BID 
regimen (Arm A) will be for the duration of the study  or until a subject permanently  
discontinues study  drug.  If less than [ADDRESS_273792] deviation of log e(AUC) was 0.42.  Assuming 12 subjects provide plasma APV 
PK data for the each regimen, the width of the 95% CI  for pla sma APV AUC τ,ss will be 
54% of the geometric mean; therefore, the 95% CI for a FPV/RTV BID regimen 
geometric mean of 33.8 g*h/mL (the value estimated in adults) will be 25.9 -
44.2g*h/mL , and the 95% CI  for a FPV BID geometric mean of 16.5 g*h/mL  (the 
value estimated in adults) will be 12.6 -21.5g*h/mL .
6.2. General Considerations
Only  descriptive methods will be used in the analy sis of the data obtained from this 
study .  No statistical hy pothesis testing will be performed.
Data will be summarized by  [CONTACT_3148] (F PV and FPV/RTV) and may  be further 
summarized by  [CONTACT_227412] -experience.
6.2.1. Analysis Populations
All subjects receiving FPV or FPV/RTV at an y dose will be included in the safet y 
population.  This will be the primary  population for any  efficacy  and safety  analyses.
Other populations, such as “per -protocol” population may  also be considered as 
secondary  populations for efficacy  anal ysis.  Per -protocol anal yses will only  include 
subject data collected during treatment with FPV or FPV/RTV and will exclude data 
following major protocol deviations (these will be defined in the data anal ysis plan).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
82Pharmacokinetic Population
All subjects for whom a plasma PK sample has been anal yzed will be included in the 
listing of plasma APV, FPV and RTV concentration -time data.
Pharmacokinetic Summary  Population
All subjects for whom a plasma APV, RTV and/or FPV PK parameter value is estimated 
will be included in the listings and summaries of derived plasma APV, FPV and RTV PK 
parameters and the summaries of plasma APV and FPV c oncentration -time data.
Pharmacokinetic/Pharmacody namic Population
The pharmacokinetic/pharmacod ynamic population will consist of all subjects with 
Baseline factors including age, bod y weight, height, sex, race, CD4+ cell percentage, 
plasma HIV -[ADDRESS_273793] 6 -10 subjects enrolled in each cohort, rapid turn -around plasma APV, RTV 
and FPV PK anal ysis will occur in order to provide individual dosage regimen 
recommendations to investigators.  In addition, expedited anal ysis of plasma APV, RTV 
and FPV may  be undertaken on a case -by-case basis on PK trough samples collected to 
allow for dose regimen adjustment due to the physiol ogical development with age.
Interim anal yses of safety , antiviral activity , and plasma APV, FPV and RTV PK data 
will be performed as required for regulatory  submissions.  No stoppi[INVESTIGATOR_227331].
6.2.3. Other Issues
For an y analyses which use HIV -1 RNA levels as a continuous measure (e.g., change 
from Baseline) the values will be logged to the base 10.  HIV -1 RNA values recorded as 
<400copi[INVESTIGATOR_014]/mL (using the [COMPANY_002] HIV -[ADDRESS_273794] assay  LOD = 
400copi[INVESTIGATOR_014]/mL ) will be given a value of 399copi[INVESTIGATOR_014]/mL .  Similarly , HIV -1 RNA values 
recorded as <50copi[INVESTIGATOR_014]/mL will be given a value of 49copi[INVESTIGATOR_014]/mL .  For plasma HIV -1 
RNA, ly mphocy te subsets and other clinical laboratory  parameters, the Baseline value 
will be defined as the value observed on Day  1(or, if this value is missing, the last value 
observed before the start of multiple dosing with FPV or FPV/RTV). 
Response to treatment within various subgroups (e.g. age, gender, background 
antiretroviral therap y) may be investigated descriptively  by [CONTACT_227413].
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
836.3. Efficacy
No formal inferential analy ses are planned. Data will be presented in summary  or 
graphical form.
6.3.1. Efficacy  Measurements
Proportions of subjects with plasma HIV -1 RNA levels <400 copi[INVESTIGATOR_014]/mL at each 
study visit
Change from Baseline in plasma HIV -1 RNA at each study  visit (absolute values and 
time-averaged)
Prop ortion of subjects with ≥1.0 log10 decrease in HIV -1 RNA at each study  visit
Change from Baseline in CD4+ % at each stud y visit (absolute values and time -
averaged)
These efficacy  measures will be summarized by  [CONTACT_3148] (FPV and FPV/RTV) and visit, 
and may be further summarized by  [CONTACT_227412] -experience.
6.4. Viral Resistance Testing
Viral resistance testing may  be performed for subjects at Screening at the investigator’s 
discretion if needed to guide selection of background ART.
Where permitted b y blood volu me restrictions, viral resistance testing may also be 
performed on samples collected at Baseline/Day  1, Week s12, 24, 36, 48, every  12 weeks 
thereafter, and Withdrawal (time of premature discontinuation).  In addition, where blood 
volumes permit, viral res istance testing may  be performed if the subject meets one of the 
criterion described in Section 3.3.8 .
Analy sis of viral resistance data, including an investigation of any  potential correlations 
between clinical response and genot ype/phenotype data, will be performed in at least a 
subset of subjects.  Viral resistance testing will evaluate pre -existing or emerging viral 
resistance in both the PI [INVESTIGATOR_227332] g region of the gag gene.  Viral mutations at codons associated with drug resistance 
will be evaluated with the HIV RNA response.  In addition, any  difference in emerging 
resistance patterns between FPV alone or FPV enhanced with RTV will be assessed.
6.5. Heal th Outcomes
6.5.1. Humanistic Outcomes
Adherence Questionnaire
Items [ADDRESS_273795]’s parent/guardian will 
respond “y es/no” to questi ons 1 -4, assessing whether the subjects were adherent with 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
84FPV or FPV/RTV.  The frequency  of yes/no responses will be summarized per treatment 
group for questions 1 -4, by  [CONTACT_765].  I tem 5 asks about the number of doses of FPV or 
FPV/RTV missed since the subj ect’s last study  visit.  Number of doses missed will be 
summarized per treatment group, b y visit. 
Perfect adherence: Answering “no” to items 1 -4 (must respond “no” to all four items) and 
answering “0” to item [ADDRESS_273796] adherence may  be further anal yzed, looking at 
the number of subjects per treatment group who were per fectly adherent across all visits 
and relationship to viral load and C min.
Parent/Guardian Perception of Study  Medication
Parent/guardian’s attitude or perceptions of medications can impact on the acceptability  
of a medication to a child, affecting adheren ce and the subsequent drug efficacy  in the 
pediatric population.  Parent/guardian perceptions of FPV BID and FPV/RTV BID will 
be assessed using a Parent/Guardian Perception of Study  Medication assessment 
administered during Weeks 2, 24 and 48/premature stu dy discontinuation. Data from the 
Parent/Guardian Perception of Study  Medication questionnaire will be summarized by  
[CONTACT_227414].  Between treatment group comparisons will be made, adjusting 
for country  if the data permit.
6.6. Pharmacokinetics
6.6.1. Bioa nalysis
Plasma PK samples will be anal yzed for APV, RTV and where plasma volumes allow 
FPV concentrations using a validated anal ytical method.
6.6.2. Pharmacokinetic Parameters
The [COMPANY_004] division of Clinical Pharmacology  will conduct noncompartmental PK anal ysis 
ofplasma APV and RTV concentration -time data using Winnonlin Professional, Version 
3.0 (or higher), computer software (Pharsight Corporation, Mountain View, CA.)
Values for the following single -dose plasma APV PK parameters will be estimated:
The maximum pl asma concentration (Cmax) and the first time to reach Cmax (tmax) 
will be the actual observed values.
The apparent terminal plasma elimination rate -constant ( z) will be estimated from 
log-linear regression analy sis of the terminal phase of the plasma conc entration -time 
profile.  The associated apparent terminal elimination half -life (t1/2) will be 
calculated as t1/2=ln2/ z.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
85The area under the plasma concentration -time curve to the last sample time 
(AUClast) and to infinity (AUC 0-) will be calculated by  [CONTACT_63450] -linear trapezoidal 
method.
The apparent plasma clearance (CL /F) will be calculated as Dose/AUC .
Values for the following steady -state plasma APV and RTV PK parameters will be 
estimated:
The maximum concentration at steady -state (Cmax,ss), the first time to reach 
Cmax,ss (tmax,ss), the minimum concentration during a dosing interval (Cmin,ss), 
and the time that Cmin,ss occurs (tmin,ss) will be the actual observed values.
The concentration at the end of a dosing interval, , at steady -state (C ,ss) will be 
calculated as the mean of the pre -dose and 12 -hour plasma APV concentrations.
The area under the concentration -time curve during a dosing interval, , at steady -
state (AUC ,ss) will be calculated b y the log -linear trapezoidal method.
The average concen tration during a dosing interval, , at stead y-state (Cavg,ss) will 
be calculated as AUC ,ss/.
The apparent plasma clearance at stead y-state (CLss/F) will be calculated as Dose/ 
AUC ,ss.
PK analy sis of plasma FPV concentrations will not be conducted becau se were few 
quantifiable FPV concentrations are expected based on data in adults and older children.
Plasma APV and RTV concentration data may  be also anal yzed using population PK 
methods.
6.6.3. Statistical A nalysis
[IP_ADDRESS]. Descriptive Statistics
Plasma APV, FPV and RTV concentrations will be listed by  [CONTACT_227415], dose (mg/kg), cohort, and planned 
sampling time.  Plasma APV, FPV and RTV concentrations may  also be summarized by  
[CONTACT_71397], dose (mg/kg) and planned sampling time (combined cohorts).  Plasma 
APV and RTV PK parameter values will be listed by  [CONTACT_227416], dose (mg/kg) and cohort and may  be plotted.  Plasma APV and RTV 
PK values may  also be summarized by  [CONTACT_3148] ( combined cohorts).  Plasma APV PK 
parameters collected for this study  will be plotted with plasma APV PK data collected in 
adult subjects in FPV studies.
[IP_ADDRESS]. Assessment of Variables Correlated with Plasma A PV PK
The relationship between age, bod y weight, sex, height, race, Baseline CD4+ percentage, 
Baseline plasma HIV -1 RNA concentration, treatment and steady -state plasma APV PK 
parameters will be examined.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
866.7. Pharmacokinetics/Pharmacody namics
The pharmacokinetic/pharmacod ynamic population will consist of all sub jects with 
baseline factors including age, bod y weight, height, sex, race, CD4+ cell percentage, 
plasma HIV -[ADDRESS_273797] one 
evaluable plasma APV trough concentration.
The association of the above men tioned baseline factors, treatment, plasma APV trough 
concentration, and the ratio of plasma APV trough concentration to baseline viral 
resistance with changes in HIV -1 RNA concentrations, CD4+ cell counts and adverse 
events may  be explored to determine wh ich factors are important for predicting 
virological response, immunologic response and the occurrence of adverse events.  
Categorical analy sis and stepwise logistic regression anal ysis may  be used to estimate 
these relationships.
6.8. Safet y
No formal inferent ial analy ses are planned.  Data will be presented in summary  or 
graphical form.
6.8.1. Adverse Events
Adverse events (AEs) will be coded and assigned sy stem organ classifications, which 
will be used when summarizing the data.  The verbatim text will be used in li stings 
together with the preferred and group terms.
Summaries of treatment -emergent AEs b y treatment group will be produced for all AEs, 
drug-related AEs, serious AEs, AEs leading to permanent discontinuation of study  drug, 
and Grade 3/[ADDRESS_273798] dose of study  
drug, and on or before the date of the final dose of study  drug.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
877. AEsAND S AEs
The investigator is respon sible for the detection and documentation of events meeting the 
definition of an AE or SAE as provided in this protocol.  During each treatment period, 
when there is a safety  evaluation, the investigator or study  site personnel will be 
responsible for dete cting AEs and SAEs, as detailed in this section of the protocol.  I n 
order to fulfill international safet y reporting obligations, the investigator will include in 
his or her assessment an y SAEs resulting from study  participation (e.g., complications 
result ing from the taking of a blood sample).
7.1. Definition of an A E
An AE is an y untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily  have a causal 
relationship with this tr eatment.
An AE can therefore be any  unfavorable and unintended sign (that could include a 
clinically  significant abnormal laboratory  finding), sy mptom, or disease temporally  
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.
An AE does include a/an:
exacerbation of a pre -existing illness.
increase in frequency  or intensity  of a pre -existing epi[INVESTIGATOR_3756].
condition detected or diagnosed after stud y drug administration even though it may  
have been present prior to the start of the study .
continuous persistent disease or s ymptoms present at Baseline that worsen following 
the start of the stud y.
An AE does not include a/an:
medical or surgical procedure (e.g., surgery , endoscopy , tooth extra ction, 
transfusion); the condition that leads to the procedure is an AE.
pre-existing disease or conditions present or detected at the start of the study  that do 
not worsen.
situations where an untoward medical occurrence has not occurred 
(e.g., hospi[INVESTIGATOR_227333], social and/or convenience 
admissions).
the disease or disorder being studied or sign or s ymptom associated with the disease 
or disorder unless more severe than expected for the subject’s condition.
overdose of either s tudy drug or concurrent medication without any  signs or 
symptoms.
GD2001/[ZIP_CODE]/[ADDRESS_273799] -treatment events that 
occur as a result of protocol -mandated procedures (i.e., invasive procedures, modification 
of subject’ s previous therapeutic regimen).
Information on managing an overdose, including drug and non -drug therapi[INVESTIGATOR_014], is 
described in Section 3.3.7 , “Overdose and Toxicity  Management”.
7.2. Definition of a SA E
An SAE is any  adverse event occurring at an y dose that results in an y of the following 
outcomes:
a.Death
b.A life -threatening adverse event
c.Inpatient hospi[INVESTIGATOR_1081]
d.A disability /incapacity
e.A congenital anomal y in the offspring of a subject who received drug
f.Important medical events that may  not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_227334] a serious adverse event when, based upon 
appropriate medical judgment, they  may  jeopardize the patient or s ubject and may  
require medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency  room or at home, blood dy scrasias or 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency  or drug abuse.
g.All presumed h ypersensitivity  reactions to abacavir should be reported as SAEs.
Clarifications:
“Occurring at an y dose” does not imply  that the subject is receiving study  drug.
Life-threatening means that the subject was, in the view of the investigator, at 
immediate risk of death from the event as it occurred.  This definition does not 
include an event that, had it occurred in a more severe form, might have caused 
death.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
during the stud y is not considered an AE.
Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs 
hospi[INVESTIGATOR_12191], the event is an SAE.
“Inpatient” hospi[INVESTIGATOR_227335] a 
hospi[INVESTIGATOR_113979].  This may  or may  not be overnight. It does not include 
presentation at a casualt y or emergency  room.
With regard to crite ria “f” above, medical and scientific judgment should be used in 
deciding whether prompt reporting is appropriate in this situation.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
897.2.1. Events or Outcomes Not Qualify ing as SAEs
The events or outcomes listed in Section 11.1, Appendix 1 will be recorded in the 
“Disease -Related Events” CRF page if they  occur.  However, these individual events or 
outcomes, as well as an y sign, s ymptom, diagnosis, illness, and/or clinical laboratory  
abnormality  that can be linked to any  of these events or outcomes, are not reported to 
[COMPANY_004] as SAEs even though such event or outcome may  meet the definition of SAE, 
unless the following conditions apply :
the investigator determines that the event or outcom e qualifies as an SAE under part 
“f” of the SAE definition (see Section 7.2, “Definition of a SAE”), or 
the event or outcome is in the investigator’s opi[INVESTIGATOR_103650] , frequency  
or duration than expe cted for the individual subject, or
death occurring for an y reason during a stud y, including death due to a 
disease -related event, will alway s be reported promptly .
lymphomas and invasive cervical carcinomas are excluded from this exemption; they  
must be r eported as SAEs even if they  are considered to be HIV related.
7.3. Lack of Efficacy  as an A E or SA E
“Lack of efficacy ” per se will not be reported as an AE. The signs and s ymptoms or 
clinical sequelae resulting from lack of efficacy  will be reported if they  fulfill the AE or 
SAE definition (including clarifications).
7.4. Clinical Laboratory  Abnormalities and Other A bnormal 
Assessments as AEs and SA Es
Abnormal laboratory  findings (e.g., clinical chemistry , hematology , urinaly sis) or other 
abnormal assessments (e.g., electrocardiogram [ECGs], X -rays, vital signs) that are 
judged b y the investigator as clinically significant must be recorded as AEs or SAEs if 
they meet the definition of an AE, as defined in Section 7.1,(“Def inition of an AE”), or 
SAE, as defined in Section 7.2, (“Definition of a SAE”).  Clinically  significant abnormal 
laboratory  findings or other abnormal assessments that are detected after study  drug 
administration or that are present at Baseline and worsen following the start of the study  
are included as AEs or SAEs.  However, clinically  significant abnormal laboratory  
findings or other abnormal assessments that are associated with the disease being studied, 
unless judged b y the investigator as more severe than expected for the subject’s 
condition, or that are present or detected at the start of the study  that do not worsen, are 
notincluded as AEs or SAEs.
The investigator will exercise his or her medical and scien tific judgment in deciding 
whether an abnormal laboratory  finding or other abnormal assessment is clinically  
significant.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
907.5. Method, Frequency , and Time Period for Detecting A Es and 
SAEs
One of the aims of this study  is to assess the safety  and tolerability  of FPV and the 
combination of FPV/RTV.  The investigator (or his/her designee) should record all 
adverse events and serious adverse events as defined above.  At each visit, after the 
subject’s parent/guardian has had an opportunit y to spontaneously  mention any problems, 
the investigator should inquire about the occurrence of adverse events through 
open -ended verbal questioning of the parent/guardian.  Appropriate open -ended verbal 
questions include:
“How is the subject feeling?”
“Has the subject had an y (other) medical problems since his/her last 
visit/assessment?”
“Has the subject taken any new medicines, other than those provided for him/her in 
this study , since his/her last visit/assessment?”
Care must be taken in any instance not to introduce bias when de tecting AEs and/or 
SAEs.  For this reason, the use of checklists for soliciting AEs and SAEs should be 
avoided.
All adverse event and serious adverse event information will be collected at each visit 
starting from SDV/Day  1 through to the Follow -up visit. Only  serious adverse events 
relating to stud y participation will be collected b y the investigator, starting from the 
Screening visit (Screening will be within approximately  21 day s prior to Baseline/Day  1 
for all subjects.) through to the initial dosing v isit (SDV/Day  1 visit).
7.6. Documenting A Es and SA Es
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostic reports) relative 
to the event.  The investigator mu st then record all relevant information regarding an 
AE/SAE on the CRF.
Any AE occurring during the study  must be documented in the subject’s medical records, 
in accordance with the investigator’s normal clinical practice, and on the AE page of the 
CRF.  S AEs that occur during the stud y must be documented in the subject’s medical 
record and on the “SAE” page of the CRF.
A separate set of “SAE” pages should be used for each SAE.  However, if at the time of 
initial reporting, multiple SAEs are present that ar e temporall y and/or clinically related, 
they may  be reported on the same “SAE” page.
The investigator should attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  I n such cases, the diagnosis should be 
documented as the AE and/or SAE and not the individual signs/sy mptoms.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
91If a clinically  significant abnormal laboratory  finding or other abnormal assessment 
meets the definition of an AE or SAE, then the AE CRF page or “SAE” CRF page must 
be completed, as a ppropriate.  A diagnosis, if known, or clinical signs and sy mptoms if 
diagnosis is unknown, rather than the clinically  significant abnormal laboratory  finding, 
should be completed on AE or “SAE” CRF page.  If no diagnosis is known and clinical 
signs and s ymptoms are not present, then the abnormal finding should be recorded.  The 
laboratory  data should either be recorded in Section 1of the “SAE” form with the 
reference range and Baseline value(s) or copi[INVESTIGATOR_227336] “SAE” CRF pages.
The “SAE” pages of the CRF should be completed as thoroughl y as possible and signed 
by [CONTACT_15009]/her designee before transmittal to [COMPANY_004].  I t is very important
that the investigator provide his/her assessme nt of causality  to study  drug at the time of 
the initial SAE report.
AEs and subject -completed questionnaires are independent components of the study .  
Responses to each question in the questionnaires will be treated in accordance with 
standard scoring and statistical procedures detailed by  [CONTACT_227417]’s developer.  The use of a 
single question from a multidimensional health survey  to designate a cause -effect 
relationship to an AE is inappropriate.
7.7. Follow -up of A Es and SA Es
All AEs and SAEs must be followed u ntil resolution, until the condition stabilizes, until 
the event is otherwise explained, or the subject is lost to follow -up.  The investigator is 
responsible to ensure that follow -up includes an y supplemental investigations as may  be 
indicated to elucidat e as completely  as practical the nature and/or causality  of the AE or 
SAE.  This may  include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
[COMPANY_004] may  request that the inves tigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations.  If a subject dies during participation in 
the study  or during a recognized follow -up period, [COMPANY_004] will be provided with a copy  of 
any post -mortem findings, includin g histopathology .
New or updated information will be recorded on the originally  completed “SAE” CRF 
with all changes signed and dated b y the investigator.
7.8. Regulatory  Reporting Requirements For SA Es
The investigator must promptly  report all SAEs to [COMPANY_004] in a ccordance with the 
procedures detailed in Section 7.9, “Prompt Reporting of SAEs to [COMPANY_004]”.  [COMPANY_004] has a 
legal responsibility  to notify  both the local regulatory  authority  and other regulatory  
agencies about the safety of a drug und er clinical investigation.  Prompt notification of 
SAEs by  [CONTACT_227418] y of other subjects are 
met.
GD2001/[ZIP_CODE]/[ADDRESS_273800] (IRB)/Independent Ethics 
Committee (I EC).
This protocol has been filed under an Investigational New Drug (IND) application with 
the US Food and Drug Administration (FDA).  A given SAE may  qualify  as an IND 
Safety  Report if the SAE is both attributable to the investigational product and 
unexpected.   In this case, all investigators filed to the IND (and associated INDs for the 
same compound) will receive an Expedited Investigator Safet y Report (EI SR), identical 
in content to the IND Safety  Report submitted to the FDA.
EISRs are prepared according to [COMPANY_004] policy  and are forwarded to investigators as 
necessary .  An EISR is prepared for a SAE that is both attributable to the investigational 
product and unexpected.  The purpose of the EISR is to fulfill specific regulatory  and 
Good Clinical Practice (GCP) requirements, regarding the product under investigation.
When a site receives from [COMPANY_004] an Initial or Follow -up EISR or other safety  information 
(e.g., Investigator’s Brochure Supplement and local product information or the 
International Product Information ), the responsible person according to local 
requirements is required to promptly  notify  his or her IRB or IEC.
7.9. Prompt Reporting of SA Es to [COMPANY_004]
SAEs must be reported promptly  to [COMPANY_004] as described in the following table once the 
investigator determines that the event meets the protocol definition of an SAE.
7.9.1. Timeframes for Submitting SA E Reports to [COMPANY_004]
Initial SAE Reports Additional Information on a 
Previously Reported SAE
Type of SAE Time Frame Documents Time Frame Documents
All SAEs 24 hrs “SAE” CRF pages 24 hrs Updated “SAE” 
CRF pages
7.9.2. Transmission of the SA E Reports
Facsimile transmission of the “SAE” CRF is the preferred method to transmit this 
information to the project contact [CONTACT_72030].  I n the absence of facsimile 
equipment, notification by t elephone is acceptable for deaths and life -threatening events, 
with a cop y of the “SAE” CRF sent b y overnight mail.  For SAEs that are not deaths or 
life-threatening events, telephone notification, in the absence of facsimile equipment, is 
not acceptable. Instead, a cop y of the “SAE” CRF will be sent b y overnight mail.  [COMPANY_004] 
will provide separately  a list of project contacts for SAE receipt, fax numbers, and 
mailing addresses.
GD2001/[ZIP_CODE]/[ADDRESS_273801] has been 
discharged from the study, and such event(s) is (are) reasonabl y related to the study  drug, 
the investigator will promptly  notify  [COMPANY_004].
7.11. SAEs Related to Study  Participation
An SAE considered related to study  participation (e.g., procedures, invasive tests), even 
if it occurs during the pre -or post -treatment period, will be reported promptly  to [COMPANY_004] 
(see Section 7.9, “Prompt Reporting of SAEs to [COMPANY_004]”).
7.12. SAEs In volvin g a Non -ViiV Healthcare Product
In those instances where an SAE has occurred in a subject receiving a non -ViiV 
Healthcare product as a comparator or concurrent medication, the report must be sent to 
the ap propriate project contact [CONTACT_227419] a 
ViiV Healthcare product (see Section 7.9, “Prompt Reporting of SAEs to [COMPANY_004]”).
8. STUDY A DMINISTRA TION
8.1. Data Collection
All subjects who are screened f or the trial must be documented. The screening pages of 
the CRF will be used for this purpose.  Additionally , each site will keep a log of subjects 
who are screened and not registered.  Further information on the use of this log can be 
found in the Study  Reference Manual.
[COMPANY_004] will provide full CRFs for each subject.  At site -all data on the CRFs must be 
entered legibl y in black ink or typed, in English.  Amendments and errors on the CRFs 
should NOT be erased, covered with correction fluid or white -out, or completely  crossed 
out.  I nstead, a single line should be drawn through the error and the correction initialed 
and dated b y the investigator or his/her authorized designee.  In those countries where the 
Committee for Proprietary  Medicinal Products (CPMP )guidelines are accepted by  [CONTACT_2371], 
an explanatory  note for the change should also be written on the CRF.  The CRF must be 
currentl y maintained and should never bear the study  participant’s name.  Subjects will 
be identified b y subject number and treatment num ber only .
The investigator or designee must record all required subject data using the previously  
specified data collection method defined b y [COMPANY_004].  An explanation must be documented 
for an y missing data.  Entering ‘ND’, ‘UNK’ or ‘NA’ should identify  any requested 
information, which is not obtained or unanswerable.  The investigator must sign and date 
a declaration on the CRF attesting to his/her responsibility  for the quality  of all data 
recorded and that the data represents a complete and accurate record o f each subject’s 
participation in the study .  Details and procedures for the completion of the CRFs are 
specified in the Study  Procedures Manual.
GD2001/[ZIP_CODE]/[ADDRESS_273802] cop y form: Data query  (DQ) form orvia the 
electronic data query  system (eDQ).  If the query  cannot be resolved in house (ie: i s not 
subject to a standard clarification agreement (SCA )or a data processing error), the 
original query  form is sent to the [COMPANY_004] monitor and/or study  site investigator for query  
resolution.  I n such cases the investigator is requested to sign and date any explanation or 
correction.  This signed copy  is the original DQ.  On return, the database will be updated 
appropriatel y and the original DQ stored (and eventually  archived) with the original CRF.  
The database will be subject to agreed Qualit y Control che cks before authorization and 
database lock.
Data management should ensure the completion of the protocol data specifications, which 
are supplied to an approved central laboratory .  A data manager will receive laboratory  
study  files upon an agreed method of transfer (ie: electronically  or via diskette) as noted 
in the specification package from the central laboratory .  The central laboratory  is 
responsible for resolving and documenting validation discrepancies with study site 
personnel and/or project team me mbers.  Discrepancies identified during data 
management validation will be communicated to the central lab.
All data requiring anal ysis retrieved from the site and confirmed will be entered into a 
quality  controlled database.  The data will subsequently  beanalyzed according to the 
methods outlined in Section 6, “Data Anal ysis Methods.”
8.2. Regulatory  and Ethical Considerations
8.2.1. Notification of Primary Care Phy sician
If agreed b y the subject’s parent/guardian, the inve stigator should notify  the subject’s 
primary  care ph ysician (if applicable) of the subject’s participation in the study .  The 
primary  care ph ysician may  contact [CONTACT_227420]’s participation in the study .
8.2.2. Regulatory  Authority  Approval
[COMPANY_004] will obtain approval to conduct the study  from the appropriate regulatory  agency  in 
accordance with an y applicable country -specific regulations prior to a site initiating the 
study  in that country .
GD2001/[ZIP_CODE]/[ADDRESS_273803] of the Study  and Ethics Approval
The study  will be conducted in accordance with “good clinical practice” (GCP) and all 
applicable regulations, including, where applicable, the Declaration of Helsinki.
It is the investigator’s responsibility  to ensure that this p rotocol, the site’s informed 
consent form, and an y other information (e.g., advertisements or information that 
supports or supplements the informed consent) is reviewed and approved by [CONTACT_227421].  [COMPANY_004] must receive copi[INVESTIGATOR_227337].
If, during the stud y, it is necessary to amend either the protocol or the informed consent 
form, the investigator is responsible for ensuring the IEC or IRB reviews and app roves 
these amended documents.  I EC or IRB approval of the amended informed consent form 
must be obtained before new subjects consent to take part in the stud y using this version 
of the form.  Copi[INVESTIGATOR_227338].
8.2.4. Subject Informed Consent
Informed consent will be obtained before the subject can participate in the study .  The 
contents and process of obtaining informe d consent will be in accordance with all 
applicable regulatory  requirements.
If the informed consent form is amended during the study , the investigator must follow 
all applicable regulatory  requirements pertaining to approval of the amended informed 
consen t form b y the IEC or I RB and use of the amended form.
Per protocol amendment 12: Assent forms will also be obtained from subjects still 
enrolled in the study  as of Nov [ADDRESS_273804] the site, including conducting on -site visits.  The extent, nature and 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
96frequency  of on -site visits will be based on such considerations as the study  objective 
and/or endpoints, the purpose of the stud y, study design complexity, and e nrolment rate.
During these contacts, the monitor will:
check and assess the progress of the stud y
review stud y data collected
conduct Source Document Verification
identify  any issues and address their resolution
This will be done in order to verify  that t he:
data are authentic, accurate, and complete
safet y and rights of subjects are being protected
study  is conducted in accordance with the currently approved protocol (and any  
amendments), GCP, and all applicable regulatory  requirements.
The investigator a grees to allow the monitor direct access to all relevant documents and 
to allocate his/her time and the time of his/her staff to the monitor to discuss findings and 
any relevant issues.
In addition to contacts during the stud y, the monitor will also contac t the site prior to the 
start of the study  to discuss the protocol and data collection procedures with site 
personnel.
At study  closure, monitors will also conduct all activities as indicated in Section 8.6, 
“Study and Site Closure”. 
The monitor is also responsible for reviewing parent/guardian -completed health outcome 
questionnaires.  The monitor will review the parent/guardian -completed health outcome 
questionnaires for extraneous written comments that could in dicate possible AEs.  
Information collected in the CRF and in the parent/guardian -completed health outcome 
questionnaires are independent components of this study .  Except for header section 
information (e.g., subject number, treatment number, visit date), and other information as 
defined in the standard clarification agreement (SCA), neither the monitor nor the 
investigator will reconcile data recorded on the parent/guardian -completed health 
outcome questionnaire with data recorded in the CRFs. Parent/guar dian-completed health 
outcome questionnaires generall y serve as the source document; therefore, unless 
otherwise specified in the source document verification agreement, no other source 
document is available for data validation.
8.5. Qualit y Assurance
At its di scretion, [COMPANY_004] may  conduct a quality  assurance audit of this study .  If such an 
audit occurs, the investigator agrees to allow the auditor direct access to all relevant 
documents and to allocate his/her time and the time of his/her staff to the auditor to 
discuss findings and an y relevant issues.
GD2001/[ZIP_CODE]/[ADDRESS_273805] access to 
all relevant documents and to alloca te his/her time and the time of his/her staff to the 
inspector to discuss findings and an y relevant issues.
8.6. Stud y and Site Closure
Upon completion of the study , the monitor will conduct the following activities in 
conjunction with the investigator, as appr opriate: 
Return of all study  data to [COMPANY_004].
Data clarifications and/or resolutions.
Accountability , reconciliation, and arrangements for unused study  drugs.
Review of site study  records for completeness.
Return of treatment codes to [COMPANY_004].
Shipment of pharmac okinetic and/or pharmacodynamic samples to assay  laboratory
In addition, [COMPANY_004] reserves the right to temporarily  suspend or prematurel y discontinue 
this study  either at a single site or at all sites at any  time and for reasons including, but are 
not limited to, safety  or ethical issues or severe non -compliance.  If such action is taken, 
[COMPANY_004] will discuss this with the investigator (including the reasons for taking such action) 
at that time.  [COMPANY_004] will promptly  inform all other investigators and/or institutions 
conducting the study  if the study  is suspended or terminated for safet y reasons, and will 
also inform the regulatory authorities of the suspension or termination of the study  and 
the reason(s) for the action.  If required b y applicable regulations, the inv estigator must 
inform the I RB or IEC promptly  and provide the reason for the suspension or 
termination.
If the stud y is prematurely discontinued, all stud y data must be returned to [COMPANY_004].  I n 
addition, arrangements will be made for all unused study  drugs in accordance with [COMPANY_004] 
procedures for the study .
Financial compensation to investigators and/or institutions will be in accordance with the 
agreement established between the investigator and [COMPANY_004].
8.7. Records Retention
In accordance with applicable regulatory  requ irements, following closure of the study , 
the investigator will maintain a cop y of all site study  records in a safe and secure 
location.  [COMPANY_004] will inform the investigator of the time period for retaining these records 
in order to compl y with applicable reg ulatory  requirements.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
988.8. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
[COMPANY_004] will provide the investigator with a cop y of the CRF data collected from the site.  
When a clinica l study  report is completed, [COMPANY_004] will provide the major findings of the 
study  to the investigator.
In addition, details of the study  treatment assignment will be provided to the investigator 
to enable him/her to review the data to determine the outcome of the study  for his/her 
subject.
[COMPANY_004] aims to post a results summary  to the [COMPANY_004] Clinical Study  Register and other 
publicly  available registers no later than [ADDRESS_273806]’s last visit (L SLV) 
[this applies to each data anal ysis phase for stud ies with multiple phases, e.g., primary  
analysis, follow up anal ysis etc]. I n addition, the aim is to submit a manuscript to a peer -
reviewed journal for publication within 18 months of L SLV. [COMPANY_004] also aims to publish 
the full study  protocol on the [COMPANY_004] Clini cal Study  Register at the time the results of the 
study  are published as a manuscript in the scientific literature. 
When manuscript publication in a peer -reviewed journal is not feasible, further study  
information will be posted to the [COMPANY_004] Clinical Study  Register to supplement the results 
summary .
8.9. Information Disclosure and Inventions
Ownership:
All data and records provided by  [CONTACT_227422]  (other than a 
subject’s medical records) and all inventions discovered in the course of conducti ng the 
study  are the propert y of ViiV Healthcare. If a written contract for the conduct of the 
study  which includes ownership provisions inconsistent with this statement is executed, 
that contract’s ownership provisions shall apply  rather than this stateme nt.
Confidentiality :
The investigator and other study  site personnel will keep confidential any  information 
provided b y [COMPANY_004] (including this protocol) related to this study  and all data and records 
generated in the course of conducting the study , and will n ot use the information, data, or 
records for an y purpose other than conducting the study .  These restrictions do not apply  
to:  (1) information which becomes publicl y available through no fault of the investigator 
or study  site personnel; (2) information w hich it is necessary  to disclose in confidence to 
an IEC or IRB solely  for the evaluation of the study ; (3) information which it is necessary  
to disclose in order to provide appropriate medical care to a stud y subject, or (4) stud y 
results which may  be pub lished as described in the next paragraph.  If a written contract 
for the conduct of the study  which includes confidentiality  provisions inconsistent with 
GD2001/[ZIP_CODE]/[ADDRESS_273807]’s confidentiality  provisions shall apply  rather 
than this s tatement.
Publication:
For multi -center studies, the first publication or disclosure shall be a complete, joint 
multi -center publication or disclosure that [COMPANY_004] will coordinate. Thereafter, any  
secondary  publications will reference the original publication( s).
The investigator shall inform [COMPANY_004] of an y publication plans.  Prior to submitting for 
publication, presenting, using for instructional purposes or otherwise disclosing the 
results of the study , the investigator shall allow [COMPANY_004] a period of at least thirt y (30) days 
or, for abstracts, at least five (5) working day s, to review the proposed publication or 
disclosure prior to its submission for publication or other disclosure.  Publications or 
disclosures of study  results shall not include other, confidential information of [COMPANY_004]’s.  If 
the proposed publication/disclosure risks [COMPANY_004]’s ability  to patent any  invention related to 
the study , the publication or disclosure will be modified or delay ed, at the investigator’s 
option, a sufficient time to allow [COMPANY_004] to seek patent protection of the invention.  This 
statement does not give [COMPANY_004] any  editorial rights over the content of a publication or 
disclosure, other than to restrict the disclosure of [COMPANY_004]’s confidential information.  I f a 
written contract for the conduct of the study , which includes publication provisions 
inconsistent with this statement is executed, that contract’s publication provisions shall 
apply  rather than this statement.
8.10. External Review Committee
As per Amendment 9, an External Review Committee (ERC) w ill be established and 
utilized in this study . The ERC will provide external oversight of study  conduct and 
medical review of safet y and/or efficacy  issues in order to protect the ethical and safety  
interests of subjects and to protect the scientific valid ity of the study . The schedule of any  
planned interim anal ysis and the anal ysis plan for ERC review is described in the charter, 
which is available upon request.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
1009. REFERENCES
Agenerase (amprenavir) Product I nformation. May , 2005. 
Chadwick EG, Borkowsky  W, F ortun y Guasch C, et al. Antiviral activity of 
fosamprenavir/ritonavir (FpV/RtV) QD regimens in HIV -infected pediatric subjects ages 
2 to 18 y ears (48 week interim data, study  ApV20003). In: 14th Conference on 
Retroviruses and Opportunistic I nfections (CROI ), Los Angeles, CA, February  25–28, 
2007. Abstract 719.
Cotton M, Cassim H, Pavía -Ruz N, et al.Pharmacokinetics, safet y and antiviral activity  
of fosamprenavir/ritonavir -containing regimens in HIV -infected children aged [ADDRESS_273808] Dis J. 2014; 33:57 -62. doi: 
10.1097/I NF.0b013e3182a1123a.
Department of Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV -1-Infected Adults and Adolescents. Updated July  10, 2019. 
Available at http: //www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL .pdf 
Accessed August 19, 2019 .
Dube M, Stein J, Aberg J. Guidelines for the evaluation and management of dy slipi[INVESTIGATOR_227339] (HIV) -infected adults receiving antiretroviral the rapy: 
Recommendations of the HIV Medicine Association of the Infectious Disease Societ y of 
America and the Adult AIDS Clinical Trial Group. Clin I nfect Dis. 2003;37:613 -627.
Durham and Swenberg. Risk Assessment:  The Changing Paradigm. In: Handbook of 
Toxi cologic Pathology , Vol 1 (Eds.: Haschek WM, Rousseaux CG and Wallig MA), 
Academic Press, San Diego, 2002: 437 -445.
European AIDS Clinical Society  (EACS) guidelines,V9.[ADDRESS_273809] 2018. Available 
at: http://www.eacsociet y.org/files/guidelines_9.[ADDRESS_273810] Dis J. 2014 ; 33:50 -6. doi: 1 0.1097/I NF.0b013e3182a1126a.
Gibb D, for the PENTA 5 Executive and the PENTA Steering Committee. A randomised 
trial evaluating 3 NRTI regimens (3TC/ZDV or ABC/ZDV or ABC/3TC) with and 
without nelfinavir in previously  untreated HIV -infected children: 48 -week follow -up 
data. (abstract) 5th International Congress on Drug Therapy  in HIV Infection, Glasgow, 
[LOCATION_006], 2000a. also published in AIDS 2000, Vol 14, supp4 p.58 (abstractPL6.8) 
Gibb D, Giaquinto C et.al., A randomized trial evaluating nucleoside reverse tran scriptor 
inhibitor (NRTI ) regimens with and without nelfinavir (NFV) in HIV -infected children –
preliminary  results from the PENTA 5 Trial. (abstract) 13thWorld AI DS Conference, 
Durban, South Africa, 2000b. Accessable at 
http://gateway .nlm.nih.gov/Meetin gAbstracts/102239155.html .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
101GlaxoSmithKline Document Number GM2002/[ZIP_CODE]/00 Study  APV30002. A 
Randomized, Open -Label, Two Arm Trial to Compare the Safet y and Antiviral Efficacy 
of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination with 
Abacav ir and Lamivudine BID for 48 Weeks in Antiretroviral Therapy  Naïve HIV -1 
Infected Subjects. Effective date: 6 November 2002.
GlaxoSmithKline Document Number RD1999/[ZIP_CODE]/00 Study  R40576.  GW433908: 
Oral Gavage Pi[INVESTIGATOR_227340]. Effecti ve date: 18 October 2001.
GlaxoSmithKline Document Number RD2000/[ZIP_CODE]/00 Study  R40877 GW433908: Two 
Week Oral Gavage Pi[INVESTIGATOR_227341]. 
Effective date: 5 October 2001.
GlaxoSmithKline Document Number RD2002/0004 5/01 Thirteen Week Oral Gavage 
Toxicity  Study  in Neonatal and Juvenile Wistar Hannover Rats. Effective date: 12 July  
2004.
GlaxoSmithKline Document Number RM2001/[ZIP_CODE]/[ADDRESS_273811] six weeks -Open -Label Phase Report of: A Randomize d, Multicenter, Partially  
Double -Blinded, Repeat Dose, Cross -Over Study  to Assess the Safet y, Tolerability, 
Pharmacokinetics, and Antiviral Effect of Two Doses of GW433908 Compared With 
Agenerase (120 0 mg BID) when Given for 28 Day s to Subjects Infected Wi th HIV -1. 
Effective date: [ADDRESS_273812] 2001.
GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/[ADDRESS_273813] of Food on the Bioavailability  of 
These Formulations in Healthy  Adult Subjects Effective date: 04 November 2002.
GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/00 Study  APV30001. A Phase III 
Randomized, Multicenter, Parallel, Open -Label to Compare the Efficacy , Safet y and 
Tolerability  of GW433908 (140 0 mg BID) and Nelfinavir (1250 mg BID) Over 48 
Weeks in Antiretroviral Therap y-Naïve HIV -1 Infected Adults. Effective date: 28 
October 2002.
GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/00 Study  APV30003. A Phase III, 
Randomized, Multicenter, Parallel Group, Open -Label, Three Arm Study  to Compare the 
Efficacy  and Safet y of Two Dosing Regimens of GW433908/ritonavir (70 0 mg /100 mg
twice da ily or 140 0 mg /200 mg once dail y) versus lopi[INVESTIGATOR_054]/ritonavir (40 0 mg /100 mg
twice dail y) for 48 Weeks in Protease Inhibitor Experienced HIV -Infected Adults 
Experiencing Virological Failure. Effective date: 11 November 2002.
GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00 Study  ESS100732.   A Phase 
IIIB, Randomized, Open -Label, Multicenter Stud y of the Safet y and Efficacy of 
GW433908 (70 0 mg BID) plus ritonavir (10 0 mg BID) Versus Lopi[INVESTIGATOR_054]/ritonavir (40 0 
mg/100 mg BID) when Administered in Combination with t he Abacavir/Lamivudine 
(600 mg /300 mg ) Fixed -Dose Combination Tablet QD in Antiretroviral -Naive HIV -1 
Infected Adults Over 48 Weeks. Effective date: August 2006.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
102GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00 Study  APV10024.  A Pi[INVESTIGATOR_22735], 
Phase I, Open -label, Randomized, Four -Period, Two -Part, Crossover Study  to Assess the 
Relative Bioavailability  of the Fosamprenavir 5 0 mg /mL Oral Suspension and 70 0 mg
Oral Film -coated Tablet Formulations Following Administration of Single 140 0 mg
Doses and Following Admini stration of 140 0 mg BID for 10 day s in Healthy  Adult 
Subjects Effective date: 26 July  2006.
Kaletra (lopi[INVESTIGATOR_054]/ritonavir) Product Information August , 2019.
Mallal S, Phillips E, Carosi G, et al.  HLA -B*5701 screening for h ypersensitivity  to 
abacavir.   N En gl J Med. 2008; 358:568 -79. doi: 10.1056/NEJMoa0706135 . 
Norvir (ritonavir) Product I nformation June, 2019 .
Panel on Antiretroviral Therap y and Medical Management of HIV -Infected Children. 
Use of Antiretroviral Agents in Pediatric HIV Infection.  Updated A pril 16, 2019. 
Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf .
Accessed August 20, 2019.
Pelton S., Stanley  K., et al. First large US study  of efficacy  and tolerability of ritonavir in 
HIV-infected children. (abstr act) 12thWorld AI DS Conference, Geneva, 1998. 
Accessable at http://gateway .nlm.nih.gov/MeetingAbstracts/102227274.html   
Pi[INVESTIGATOR_1946] J, Robbins B, Chen, J et al.  Pharmacokinetics and 24 -Week Efficacy and Safet y of 
Lopi[INVESTIGATOR_054]/Ritonavir in HIV -1-infected Infants <[ADDRESS_273814] 716, 
CROI , Los Angeles, 2007. Accessable at 
http://www.retroconference.org/2007/PDFs/716.pdf
Post FA, Moy le GJ, Stellbrink HJ et al. Randomized comparison of renal effects, 
efficacy , and safet y with once -daily abacavir/la mivudine versus tenofovir/emtricitabine, 
administered with efavirenz, in antiretroviral -naive, HIV -1-infected adults: [ADDRESS_273815]. 2010; 55:49 -57. doi: 
10.1097/QAI.0b013e3181dd911e.
Ross LL, Cotton MF , Cassim H, et al.Treatment -Emergent Mutations and Resistance in 
HIV-Infected Children Treated with Fosamprenavir -Containing Antiretroviral Regimens.
Open AIDS J. 2015; 9:38-44. doi: 10.2174/1874613601509010038
Saez -Llorens X, Violari A, Deetz C, et al.  Forty-eight -week evaluation of 
lopi[INVESTIGATOR_054]/ritonavir, a new protease inhibitor, in human immunodeficiency  virus -infected 
children. Pediatr Infect Dis J, 2003;22:216 –23.
South Africa Guidelines for the management of HIV -infected children -2010.  Accessible 
at https://sahivsoc.org/Files/Guidelines_for_Management_of_HIV_in_Children_2010.pdf
.Accessed Oct 24, 2019.
Squires KE, Young B, Dejesus E, et al.  Similar efficacy  and tolerability  of atazanavir 
compared with atazanavir/ritonavir, each with abacavir/lamivudi ne after initial 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
103suppression with abacavir/lamivudine plus ritonavir -boosted atazanavir in HIV -infected 
patients.  AIDS. 2010; 24:2019 -27. doi: 10.1097/QAD.0b013e32833bee1b.
Sustiva (efavirenz) Product I nformation January , 2010.
Violari A, Saez –Llorens X , et al.  ABT -378 / ritonavir in HIV -1 infected children. 
(abstract) 13thWorld AIDS Conference, Durban, 2000. Accessable at 
http://gateway .nlm.nih.gov/MeetingAbstracts/102237697.html
Viramune (nevirapi[INVESTIGATOR_050]) Product Information June, 2010.
Working Group on Antiretroviral Therapy  and Medical Management of HIV -Infected 
Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 
October 26, 2006. Accessable at 
http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE]. TABLES
Revise d Flow Chart of Clinical Scheduled A ssessments (Per A mendments 5 and 7)
CLINCAL EVALUATIONScreening 
Visit 1Single 
Dose 
Visit 2Day 1 
(Baseline) 3Week 
2 4 8 12 16 24 36 48Every 12 
weeks 
thereafterWith-
drawalFollow -up 
4
Written Infor med Consent
Inclusion/Exclusion Criteria
Demography (date of birth, sex, and race)
HIV Risk Factors
CDC HIV -1 Classifica tion
Current Medical Conditions
Body Weight , Height and Vital Signs       
Head Circumference       
Prior Antiretroviral Th erapy History
Background Antiretroviral Therapy      
Concurrent Medications/Blood Products      
HIV-associated Conditions     
Adverse Experience Surveillance
 5  
 
Adherence Questionnaire      
Parent/Guardi an Perception of Study Medication    
1.Screening will be within approximately 21 days prior to Baseline/Day 1 for all subjects.  At screening only, the evaluation o f the hematology, clinical chemistry and liver function 
tests may be undertake n at a local accredited laboratory at the discretion of the investigator and with approval of GlaxoSmithKline.
2.SDVs are no longer needed for Cohort 1 Arm A and Cohort 2 Arm A. .  
3.Subjects will initiate multiple dosing on Day 1 (Baseline)
4.[ADDRESS_273816] serious adverse events related to study participation only during screening.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
105Revised Flow Chart of Laboratory  Scheduled A ssessments (Per A mendments 5 and 7)
LABORATORY EVALUATION 2Screening 
Visit 1Single 
Dose 
VisitDay1 
(Baseline)Week
2 4 8 12 16 24 36 48Every 12 
weeks 
thereafter 12Withdrawal Follow -
up
Lipi[INVESTIGATOR_805] 3
 
Hematology 4 
 
Clinical Chemistry and Liver Function 
Tests 5

Lymphocyte subsets
 
Quanatitative plasma HIV -1 RNA PCR
 
Plasma for storage 6
 
Pharmacokinetic Sampling 10, 11789 
HIV-1 resistance testing 13
1.Screening will be within approximately 21 days pr ior to Baseline/Day 1 for all subjects. 
2.Laboratory assessments for all cohorts are prioritized as follows: hematology, chemistry, PK, plasma HIV -1 RNA PCR, lymphocyte subsets, HIV -1 RNA resistance testing, lipi[INVESTIGATOR_805], 
and plasma for storage. 
3.Lipid measures i nclude: triglycerides and total, high density lipoprotein (HDL), and LDL cholesterol. 
4.Hematology includes: hemoglobin, WBC with differential, MCV and platelet count.
5.Clinical chemistry panel and transaminase levels (sodium, potassium, AST, ALT, total bili rubin, creatinine, albumin, glucose, alkaline phosphatase, and CPK). 
6.Plasma collected for storage where permitted by [CONTACT_227423] 1 and Week 12, 24, 36, 48, every 12 weeks th ereafter and Withdrawal.  This sample may be 
used for HIV -1 resistance testing in subjects experiencing virologic failure.
7.SDV plasma PK sampling no longer required for Cohort 1 Arm A and Cohort 2 Arm A.
8.Week 2: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, and 12 hours (12 hour sample optional ) post -dosing for Cohort 2 Arm A subjects and over 4 hours (at 
0 [pre -dose], 2 and 4 hours) post -dosing for subjects in Cohort 1 Arm A 
9.Week 8: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, and 12 hours (12 hour sample optional) post -dosing for subjects in Cohort 1 Arm A.
10.Samples for APV/RTV trough concentration determination collected [ADDRESS_273817] dose at Week 8 (Cohort 2 Arm A only) and Weeks 12, 16, 24, 36, 48, and every 12 
weeks thereafter (both cohorts).   In consultatio n with the investigator, [COMPANY_004] may discontinue PK sampling and monitoring of plasma APV, FPV and RTV concentration on an 
individual basis once a subject has reached and exceeded 2 years and has initiated the 23/ 3 mg /kg BID dosing regimen after Week 48.  Any further dosing changes would follow 
the approved dosing recommendations without PK sampling, including a transition to FPV/RTV 18/ 3 mg /kg BID at [ADDRESS_273818] dose at W eek 2 (Cohort 1 Arm A), Week 8 (Cohort 2 Arm A), Week 16 (both 
cohorts), and Week 36 (Cohort 1 Arm A).
12.After Protocol Amendment [ADDRESS_273819] had comple tedtheir 48 week visit, PK sample collection was discontinued .
13. A sample for HIV -1 RNA resistance testing may be collected at Screening at the investigator’s discretion if needed to guide selection of backg round ART.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE]. APPENDICES
11.1. Appendix 1:  1994 CDC Revised Classification Sy stem for 
HIV Infection in Children < 13 y ears of A ge
Reference –1994 revised classification s ystem for human immunodeficiency  virus 
infection in children less than 13 y ears of age. MMWR 1994: 43 (No. RR -12): 1 -10.
Pediatric Human Immunodeficiency  Virus (HIV) Classification1
Immunologic 
Categorie sClinical Categories
N:  No 
signs/symptomsA:  Mild
signs/symptomsB:2 Moderate 
signs/symptomsC:2Severe 
signs/symptoms
1.  No evidence of 
suppressionN1 A1 B1 C1
2.  Evidence of 
moderate 
suppressionN2 A2 B2 C2
3.  Severe 
suppressionN3 A3 B3 C3
1.Children whose HIV infection status is not confirmed are classified by [CONTACT_227424] a letter E (for 
perinatally exposed) placed before the appropriate classification code (e.g., EN2).
2.Both Category C and lymphoid interstitial pneumonitis in Cat egory B are reportable to state and local health 
departments as acquired immunodeficiency syndrome.
Immunologic Categories Based on A ge-Specific CD4+ T -Lymphocyte Counts and 
Percent of Total Ly mphocy tes
Age of Child
< 12 Months 1-5 Years 6-12 Years
Immunologic Categories µl   (%) µl    (%) µl     (%)
1.  No evidence of 
suppression1,500     ( 25) 1,000       ( 25) 500         ( 25)
2.  Evidence of moderate 
suppression750-1,499   (15 -24) 500-999     (15 -24) 200-499     (15 -24)
3.  Severe supp ression < 750 (< 15) < 500   (< 15) < 200          (< 15)
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
107Box 2.  Clinical Categories for Children with Human Immunodeficiency Virus (HIV) Infection
CATEGORY N:  NOT SYMPTOMATIC
Children who have no signs or symptoms considered to be the result of HIV infection or who have 
only one of the conditions listed in Category A.
CATEGORY A:  MILDLY SYMPTOMATIC
Children with two or more of the conditions listed below but none of the conditions listed in 
Categories B and C.
 Lymphadenopathy ( 0.5 cm at more than two sites:  bilateral -one site)
Hepatomegaly
Splenomegaly
Dermatitis
Parotitis
Recurrent or persistent upper respi[INVESTIGATOR_4416], sinusitis, or otitis media
CATEGORY B:  MODERATELY SYMPTOMATIC
Children who have symptomatic conditions other tha n those listed for Category A or C that are 
attributed to HIV infection.  Examples of conditions in clinical Category B include but are not limited 
to: 
 Anemia (< 8gm/dl), neutropenia (< 1,000/mm 3) or thrombocytopenia (< 100,000/mm 3) 
persisting 30 days
Bacterial meningitis, pneumonia, or sepsis (single epi[INVESTIGATOR_1865])
Candidiasis, oropharyngeal (thrush), persisting (>2 months) in children >6 months of age
Cardiomyopathy
Cytomegalovirus infection with onset before  one month of age
Diarrhea, recurrent or chronic
Hepatitis
Herpes simplex virus (HSV) stomatitis, recurrent (more than two epi[INVESTIGATOR_227342])
HSV bronchitis, pneumonitis, or esophagitis with onset before one month of age
Herpes zoster (shingles) involving at least two distinct epi[INVESTIGATOR_227343] n one dermatome
Leiomyosarcoma
Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex
Nephropathy
Nocardiosis
Persistent fever (lasting >1 month)
Toxoplasmosis, onset before 1 month of age
Varicella, disseminated (complicated chick enpox)
CATEGORY C:  SEVERELY SYMPTOMATIC
Children who have any condition listed in the 1987 surveillance case definition for acquired 
immunodeficiency syndrome (10), with the exception of LIP (Box 3).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
108Box 3.  Conditions Included in Clinical Categor y C for Children Infected with Human 
Immunodeficiency Virus (HIV)
CATEGORY C:  SEVERELY SYMPTOMATIC
 Serious bacterial infections, multiple or recurrent (i.e., any combination of at least two culture -
confirmed infections within a two -year period) of the f ollowing types:  septicemia, pneumonia, 
meningitis, bone or joint infection, or abscess of an internal organ or body cavity (excluding 
otitis media, superficial skin or mucosal abscesses, and indwelling catheter -related infections)
 Candidiasis, esophageal or pulmonary (bronch, trachea, lungs)
 Coccidioidomycosis, disseminated (at site other than or in addition to lungs or cervical or hilar 
lymph nodes)
 Cryptococcosis, extrapulmonary
 Cryptosporidiosis or isosporiasis  with diarrhea persisting greater than one month
 Cytomegalovirus disease with onset of symptoms at age greater than one month (at a site 
other than liver, spleen, or lymph nodes)
 Encephalopathy (at least one of the following progressive findings present for at least two 
months in the absence of a concurrent illness other than HIV infection that could explain the  
findings):
A.Failure to attain or loss of developmental milestones or loss of intellectual ability, verified 
by [CONTACT_124797];  
B.Impaired bra in growth or acquired microcephaly demonstrated by [CONTACT_227425] (serial imaging is required for children < two years of age);
C.Acquired symmetric motor deficit manifested by [CONTACT_227426]:
1.Paresis
2.Pathologic reflexes
3.Ataxia
4.Gait disturbance
Herpes simplex virus infection causing a mucocutaneous ulcer that persists for greater than 
one month, or bronchitis, pneumonitis, or esophagitis for any duration affecting a child greater 
than one  month of age  
 Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or hilar 
lymph nodes)
 Kaposi’s sarcoma
 Lymphoma, primary, in brain
 Lymphoma, small, noncleaved cell ( Burkitt’s), or immunoblastic or large cell lymphoma of b -
cell or unknown immunologic phenotype
 Mycobacterium tuberculosis, disseminated or extrapulmonary 
 Mycobacterium, other species or unidentified species, disseminated (at a site other than or in 
addition to lungs, skin, or cervical or hilar lymph nodes)
 Mycobacterium avium complex or Mycobacterium kansasii, disseminated (at site other than or 
in addition to lungs, skin, or cervical or hilar lymph nodes)
 Pneumocystis carinii pneumonia
 Progressive mu ltifocal leukoencephalopathy
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
109 Salmonella (nontyphoid) septicemia, recurrent
 Toxoplasmosis of the brain with onset at greater than one month of age
 Wasting syndrome in the absence of a concurrent illness other than HIV infection that could 
explain the fol lowing findings:
A.Persistent weight loss greater than 10% of baseline , or  
B.Downward crossing of at least two of the following percentile lines on the weight -for-age 
chart (e.g., 95th, 75th, 50th, 25th, 5th) in a child greater than or equal to one year of age ; 
or
C.Less than 5th percentile on weight -for-height chart on two consecutive measurements.  
Greater than or equal to 30 days apart PLUS (1) chronic diarrhea (i.e., at least two loose 
stools per day for greater than or equal to 30 days; OR (2) documented fever (for greater 
than or equal to 30 days, intermittent or constant)
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].2. Appendix 2:  Declaration of Helsinki (Only  Applicable to 
European Sites)
Initiated:  1964 17.C Original:  English
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
Ethical Prin ciples
for
Medical Research Involving Human Subjects
Adopted by  [CONTACT_941] 18th WMA General Assembl y
Helsinki, Finland, June [ADDRESS_273820], Republic of South Africa, October 1996
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
111AIntroduction / I.Basic Principles / II.Medical Research Combined with Medical Care /
III. Non -Therapeutic Biomedical Resear ch / Other Options
INTRODUCTION
It is the mission of the phy sician to safeguard the health of the people.  His or her 
knowledge and conscience are dedicated to the fulfilment of this mission.
The Declaration of Geneva of the World Medical Association binds the physician with 
the words:  “The health of my  patient will be m y first consideration”, and the 
International Code of Medical Ethics declares that “A phy sician shall act only  in the 
patient’s interest when providing medical care which might have the eff ect of weakening 
the phy sical and mental condition of the patient.”
The purpose of biomedical research involving human subjects must be to improve 
diagnostic, therapeutic and prophy lactic procedures and the understanding of the 
aetiology  and pathogenesis o f disease.
In current medical practice most diagnostic, therapeutic or proph ylactic procedures 
involve hazards.  This applies especiall y to biomedical research.
Medical progress is based on research which ultimately  must rest in part on 
experimentation inv olving human subjects.
In the field of biomedical research a fundamental distinction must be recognized between 
medical research in which the aim is essentially  diagnostic or therapeutic for a patient, 
and medical research, the essential object of which is purely  scientific and without direct 
diagnostic or therapeutic value to the person subjected to the research.
Special caution must be exercised in the conduct of research which may  affect the 
environment, and the welfare of animals used for research must be respected.
Because it is essential that the results of laboratory experiments be applied to human 
beings to further scientific knowledge and to help suffering humanit y, the World Medical 
Association has prepared the following recommendations as a guide to every  physician in 
biomedical research involving human subjects.  They  should be kept under review in the 
future.  It must be stressed that the standards as drafted are onl y a guide to physicians all 
over the world.  Ph ysicians are not relieved from cri minal, civil and ethical 
responsibilities under the laws of their own countries.
I. BASIC PRINCIPLES
1.Biomedical research involving human subjects must conform to generally  accepted 
scientific principles and should be based on adequately  performed laborator y and 
animal experimentation and on a thorough knowledge of the scientific literature.
2.The design and performance of each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol which should be 
transmitted f or consideration. Comment and guidance to a specially  appointed 
committee independent of the investigator and the sponsor provided that this 
independent committee is in conformity  with the laws and regulations of the country  
in which the research experimen t is performed.
GD2001/[ZIP_CODE]/[ADDRESS_273821]’s phy sical and mental integrit y 
and on the personality  of the subject.
7.Physicians should abstain from engaging in research projects involving human 
subjects unless they  are satisfied that the hazards involved ar e believed to be 
predictable. Ph ysicians should cease any  investigation if the hazards are found to 
outweigh the potential benefits.
8.In publication of the results of his or her research, the phy sician is obliged to 
preserve the accuracy  of the results. Rep orts of experimentation not in accordance 
with the principles laid down in this Declaration should not be accepted for 
publication.
9.In an y research on human beings, each potential subject must be adequately 
informed of the aims, methods, anticipated benefi ts and potential hazards of the 
study  and the discomfort it may  entail.  He or she should be informed that he or she 
is at liberty  to abstain from participation in the study  and that he or she is free to 
withdraw his or her consent to participation at an y time.  The phy sician should then 
obtain the subject’s freely -given informed consent, preferabl y in writing.
10.When obtaining informed consent for the research project the ph ysician should be 
particularl y cautious if the subject is in a dependent relationship to him or her or may  
consent under duress. In that case the informed consent should be obtained by  a 
physician who is not engaged in the investigation and who is completel y independent 
of this official relationship.
11.In case of legal incompetence, informed consent should be obtained from the legal 
guardian in accordance with national legislation.  Where phy sical or mental 
incapacit y makes it impossible to obtain informed consent, or when the subject is a 
minor, permission from the responsible relative repla ces that of the subject in 
accordance with national legislation.  Whenever the minor child is in fact able to 
give a consent, the minor’s consent must be obtained in addition to the consent of the 
minor’s legal guardian.
GD2001/[ZIP_CODE]/[ADDRESS_273822] scontain a statement of the ethical considerations 
involved and should indicate that the principles enunciated in the present Declaration 
are complied with.
II. MEDICA L RESEA RCH COMBINED WITH PROFESSIONA L CA RE 
(Clinical Research)
1.In the treatment of the s ick person the ph ysician must be free to use a new diagnostic 
and therapeutic measure, if in his or her judgement it offers hope of saving life, re -
establishing health or alleviating suffering.
2.The potential benefits, hazards and discomfort of a new method should be weighed 
against the advantages of the best current diagnostic and therapeutic methods.
3.In an y medical stud y, every patient –including those of a control group, if any  –
should be assured of the best proven diagnostic and therapeutic method. Thi s does 
not exclude the use of inert placebo in studies where no proven diagnostic or 
therapeutic method exists.
4.The refusal of the Patient to participate in the study must never interfere with the 
physician -patient relationship.
5.If the ph ysician considers it essential not to obtain informed consent the specific 
reasons for this proposal should be stated in the experimental protocol for 
transmission to the independent committee (I. 2).
6.The phy sician can combine medical research with professional care, the ob jective 
being the acquisition of new medical knowledge, only  to the extent that medical 
research is justified b y its potential diagnostic or therapeutic value for the patient.
III. NON -THERA PEUTIC BIOMEDICA L RESE ARCH INVOLVING HUMA N 
SUBJECTS (Non -clinical biomedical research)
1.In the purel y scientific application of medical research carried out on a human being, 
it is the duty  of the phy sician to remain the protector of the life and health of that 
person on whom biomedical research is being carried out.
2.Thesubjects should be volunteers –either healthy persons or patients for whom the 
experimental design is not related to the patient’s illness.
3.The investigator or the investigating team should discontinue the research if in 
his/her or their judgement it may , if continued, be harmful to the individual.
4.In research on man, the interest of science and society  should never take precedence 
over considerations related to the wellbeing of the subject.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].3. Appendix 3:  Grading of Laboratory  Test A bnormalities -DAIDS T able for Grading the Severity  of 
Adult and Pediatric A dverse Events, Publish Date: December [ADDRESS_273823] International Units are listed in italics
Absolute CD4+ count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY )300 –400/mm3
300 –400/µL200 –299/mm3
200 –299/µL100 –199/mm3
100 –199/µL< 100/mm3
< 100/µL
Absolute ly mphocyte
count
–Adult and Pediatric
> 13 years
(HIV NEGATIVE ONLY )600 –650/mm3
0.600 x 109–
0.650 x 109/L500 –599/mm3
0.500 x 109–
0.599 x 109/L350 –499/mm3
0.350 x 109–
0.499 x 109/L< 350/mm3
<0.350 x 109/L
Absolute neutrophil count (ANC)
Adult and Pediatric,
> 7 days1,000 –1,300/mm3
1.000 x 109 –
1.300 x 109/L750 –999/mm3
0.750 x 109 –
0.999 x 109/L500 –749/mm3
0.500 x 109 –
0.749 x 109/L< 500/mm3
< 0.500 x 109/L
Infant  1,2, 2 –7 days 1,250 –1,500/mm3
1.250 x 109 –
1.500 x 109/L1,000 –1,249/mm3
1.000 x 109 –
1.249 x 109/L750 –999/mm3
0.750 x 109–
0.999 x 109/L< 750/mm3
< 0.750 x 109/L
Infant  1,2, 1 day 4,000 –5,000/mm3
4.000 x 109–
5.000 x 109/L3,000 –3,999/mm3
3.000 x 109–
3.999 x109/L1,500 –2,999/mm3
1.500 x 109–
2.999 x 109/L< 1,500/mm3
< 1.500 x 109/L
Fibrinogen, decreased 100 –200 mg/dL
1.00 –2.00 g/L
OR
0.75 –0.99 x LLN75 –99 mg/dL
0.75 –0.99 g/L
OR
0.50 –0.74 x LLN50 –74 mg/dL
0.50 –0.74 g/L
OR
0.25 –0.[ADDRESS_273824]< 50 mg/dL
< 0.50 g/L
OR
< 0.[ADDRESS_273825]
OR
Associated with gross bleeding
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
115LABORA TORY
PARAMETER GRA DE 1
MILDGRA DE 2
MODERA TEGRA DE 3
SEVEREGRA DE 4
POTENTIA LLY
LIFE -THREA TENING
Hemoglobin (Hgb)
Adult and Pediatric
57 days
(HIV POSITIVE ONLY )8.5 –10.0 g/dL
1.32 –1.55 mmol/L7.5 –8.4 g/dL
1.16 –1.31 mmol/L6.50 –7.4 g/dL
1.01 –1.15 mmol/L< 6.5 g/dL
< 1.01 mmol/L
Adult and Pediatric
57 days
(HIV NEGATIVE ONLY )10.0 –10.9 g/dL
1.55 –1.69 mmol/L
OR
Any decrease
2.5 –3.4 g/dL
0.39 –0.53 mmol/L9.0 –9.9 g/dL
1.40 –1.54 mmol/L
OR
Any decrease
3.5 –4.4g/dL
0.54 –0.68 mmol/L7.0 –8.9 g/dL
1.09 –1.39 mmol/L
OR
Any decrease
4.5 g/dL
0.69 mmol/L< 7.0 g/dL
< 1.09 mmol/L
Infant  1,2, 36 –56 
days
(HIV POSITIVE OR 
NEGATIVE)8.5 –9.4 g/dL
1.32 –1.46 mmol/L7.0 –8.4 g/dL
1.09 –1.31 mmol/L6.0 –6.9 g/dL
0.93 –1.08 mmol/L< 6.00 g/dL
< 0.93 mmol/L
Infant  1,2, 22 –35 
days
(HIV POSITIVE OR 
NEGATIVE )9.5 –10.5 g/dL
1.47 –1.63 mmol/L8.0 –9.4 g/dL
1.24 –1.46 mmol/L7.0 –7.9 g/dL
1.09 –1.23 mmol/L< 7.00 g/dL
< 1.09 mmol/L
Infant  1,2, 1 –21 days
(HIV POSITIVE OR 
NEGATIVE )12.0 –13.0 g/dL
1.86 –2.02 mmol/L10.0 –11.9 g/dL
1.55 –1.85 mmol/L9.0 –9.9 g/dL
1.40 –1.54 mmol/L< 9.0 g/dL
< 1.40 mmol/L
International Normalized
Ratio of prothrombin time
(INR)1.1 –1.[ADDRESS_273826] 1.6 –2.[ADDRESS_273827] 2.1 –3.[ADDRESS_273828] > 3.[ADDRESS_273829]
Methemoglobin 5.0 –10.0% 10.1 –15.0% 15.1 –20.0% > 20.0%
Prothrombin Time (PT) 1.1 –1.[ADDRESS_273830] 1.26 –1.[ADDRESS_273831] 1.51 –3.[ADDRESS_273832] > 3.[ADDRESS_273833]
Partial Thromboplastin
Time (PTT)1.1 –1.[ADDRESS_273834] 1.67 –2.[ADDRESS_273835] 2.34 –3.[ADDRESS_273836] > 3.[ADDRESS_273837]
Platelets, decreased 100,000 –
124,999/mm3
100.000 x 109–
124.999 x 109/L50,000 –
99,999/mm3
50.000 x 109–
99.999 x 109/L25,000 –
49,999/mm3
25.000 x 109–
49.999 x 109/L< 25,000/mm3
< 25.000 x 109/L
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
116LABORA TORY
PARAMETER GRA DE 1
MILDGRA DE 2
MODERA TEGRA DE 3
SEVEREGRA DE 4
POTENTIA LLY
LIFE -THREA TENING
Continued
WBC, decreased 2,000 –2,500/mm3
2.000 x 109–
2.500 x 109/L1,500 –1,999/mm3
1.500 x 109–
1.999 x 109/L1,000 –1,499/mm3
1.000 x 109–
1.499 x 109/L< 1,000/mm3
< 1.000 x 109/L
CHEMISTRIES Standard International Units are listed in italics
Acidosis NA pH < normal, but 7.3 pH < 7.3 without life -
threatening consequencespH < 7.3 with life -threatening 
consequences
Albumin, serum, low 3.0 g/dL –< LLN
30 g/L –< LLN2.0 –2.9 g/dL
20 –29 g/L< 2.0 g/Dl
< 20 g/LNA
Alkaline Phosphatase 1.25 –2.5 x ULN22.6 –5.0 x ULN25.1 –10.0 x ULN2> 10.0 x ULN2
Alkalosis NA pH > normal, but 7.5 pH > 7.5 without life -
threatening consequencespH > 7.5 wit h life -threatening 
consequences
ALT (SGPT) 1.25 –2.[ADDRESS_273838] 2.6 –5.[ADDRESS_273839] 5.1 –10.[ADDRESS_273840] > 10.[ADDRESS_273841] (SGOT) 1.25 –2.[ADDRESS_273842] 2.6 –5.[ADDRESS_273843] 5.1 –10.[ADDRESS_273844] > 10.[ADDRESS_273845]
Bicarbonate, serum, low 16.0 mEq/L –< LLN
16.0 mmol/L –< LLN11.0 –15.9 mEq/L
11.0 –15.9 mmol/L8.0 –10.9 mEq/L
8.0 –10.9 mmol/L< 8.0 mEq/L
< 8.0 mmol/L
Bilirubin (Total)
Adult and Pediatric 
>14 days1.1 –1.[ADDRESS_273846] 1.6 –2.[ADDRESS_273847] 2.6 –5.[ADDRESS_273848] > 5.[ADDRESS_273849]
Infant  1,2, 14 days
(non-hemolytic)NA 20.0 –25.0 mg/ dL
342 –428 µmol/L25.1 –30.0 mg/dL
429 –513 µmol/L> 30.0 mg/dL
>513.0 µmol/L
Infant  1,2, 14 days
(hemolytic)NA NA 20.0 –25.0 mg/dL
342 –428 µmol/L> 25.0 mg/dL
> 428 µmol/L
Calcium, serum, high (corrected for albumin)
Adult and Pediatric 7 
days10.6 –11.5 mg/dL
2.65 –2.88 mmol/L11.6 –12.5 mg/dL
2.89 –3.13 mmol/L12.6 –13.5 mg/dL
3.14 –3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol/L
Infant  1,2, < 7 days 11.5 –12.4 mg/dL
2.88 –3.10 mmol/L12.5 –12.9 mg/dL
3.11 –3.23 mmol/L13.0 –13.5 mg/dL
3.245 –3.38 mmol/L> 13.5 mg/dL
> 3.38 mmol/L
Calcium, serum, low (corrected for albumin)
Adult and Pediatric 7 
days7.8 –8.4 mg/dL
1.95 –2.10 mmol/L7.0 –7.7 mg/dL
1.75 –1.94 mmol/L6.1 –6.9 mg/dL
1.53 –1.74 mmol/L< 6.1 mg/dL
< 1.53 mmol/L
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
117LABORA TORY
PARAMETER GRA DE 1
MILDGRA DE 2
MODERA TEGRA DE 3
SEVEREGRA DE 4
POTENTIA LLY
LIFE -THREA TENING
Infant  1,2, < 7 days 6.5 –7.5 mg/dL
1.63 –1.88 mmol/L6.0 –6.4 mg/dL
1.50 –1.62 mmol/L5.50 –5.90 mg/dL
1.38 –1.51 mmol/L< 5.50 mg/dL
< 1.38 mmol/L
Cardiac troponin I (cTnI) NA NA NA Levels consistent with 
myocardial infarction or unstable 
angina as def ined by [CONTACT_227427] T (cTnT) NA NA NA 0.20 ng/mL
OR
Levels consistent with 
myocardial infarction or unstable 
angina as defined by [CONTACT_227428] (fasting)
Adult 18 years 200 –239 mg/dL
5.18 –6.19 mmol/L240 –300 mg/dL
6.20 –7.77 mmol/L> 300 mg/dL
> 7.77 mmol/LNA
Pediatric < 18 years 170 –199 mg/dL
4.40 –5.15 mmol/L200 –300 mg/dL
5.16 –7.77 mmol/L> 300 mg/dL
> 7.77 mmol/LNA
Creatine Kinase 3.0 –5.9 x ULN26.0 –9.9 x ULN210.0 –19.9 x ULN220.0 x ULN2
Creatinine 1.1 –1.3 x ULN21.4 –1.8 x ULN21.9 –3.4 x ULN23.5 x ULN2
Glucose, serum, high
Nonfasting 116 –160 mg/dL
6.44 –8.88 mmol/L161 –250 mg/dL
8.89 –13.88 mmol/L251 –500 mg/dL
13.89 –27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Fasting 110 –125 mg/dL
6.11 –6.94 mmol/L126 –250 mg/dL
6.95 –13.88 mmol/L251 –500 mg/dL
13.89 –27.75 mmol/L> 500 mg/dL
> 27.75 mmol/L
Glucose, serum, low
Adult and Pediatric 1 
month55 –64 mg/dL
3.05 –3.55 mmol/L40 –54 mg/dL
2.22 –3.06 mm ol/L30 –39 mg/dL
1.67 –2.23 mmol/L< 30 mg/dL
< 1.67 mmol/L
Infant1,  2, < 1 month 50 –54 mg/dL
2.78 –3.00 mmol/L40 –49 mg/dL
2.22 –2.77 mmol/L30 –39 mg/dL
1.67 –2.21 mmol/L< 30 mg/dL
< 1.67 mmol/L
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
118LABORA TORY
PARAMETER GRA DE 1
MILDGRA DE 2
MODERA TEGRA DE 3
SEVEREGRA DE 4
POTENTIA LLY
LIFE -THREA TENING
Lactate < 2.[ADDRESS_273850] without
acidosis2.[ADDRESS_273851] without
acidosisIncreased lactate with pH < 
7.3 without life -threatening 
consequencesIncreased lactate with pH <7.3 
with life -threatening 
consequences
LDL cholesterol (fasting)
Adult 18 years 130 –159 mg/dL
3.37 –4.12 mmol/L160 –190 mg/dL
4.13 –4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Pediatric > 2 -< 18 
years110 –129 mg/dL
2.85 –3.34 mmol/L130 –189 mg/dL
3.35 –4.90 mmol/L190 mg/dL
4.91 mmol/LNA
Lipase 1.1 –1.[ADDRESS_273852] 1.6 –3.[ADDRESS_273853] 3.1 –5.[ADDRESS_273854] > 5.[ADDRESS_273855]
Magnesium, serum, low 1.2 –1.4 mEq/L
0.60 –0.70 mmol/L0.9 –1.1 mEq/L
0.45 –0.59 mmol/L0.6 –0.8 mEq/L
0.30 –0.44 mmol/L< 0.60 mEq/L
< 0.30 mmol/L
Pancreatic am ylase 1.1 –1.[ADDRESS_273856] 1.6 –2.[ADDRESS_273857] 2.1 –5.[ADDRESS_273858] > 5.[ADDRESS_273859]
Phosphate, serum, lo w
Adult and Pediatric > 
14 years2.5 mg/dL –< LLN
0.81 mmol/L –< LLN2.0 –2.4 mg/dL
0.65 –0.80 mmol/L1.0 –1.9 mg/dL
0.32 –0.64 mmol/L< 1.00 mg/dL
< 0.32 mmol/L
Pediatric 1 year –14 
years3.0 –3.5 mg/dL
0.97 –1.13 mmol/L2.5 –2.9 mg/dL
0.81 –0.96 mmol/L1.5 –2.4 mg/dL
0.48 –0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Pediatric < 1 year 3.5 –4.5 mg/dL
1.13 –1.45 mmol/L2.5 –3.4 mg/dL
0.81 –1.12 mmol/L1.5 –2.4 mg/dL
0.48 –0.80 mmol/L< 1.50 mg/dL
< 0.48 mmol/L
Potassium, serum, high 5.6–6.0 mEq/L
5.6 –6.0 mmol/L6.1 –6.5 mEq/L
6.1 –6.5 mmol/L6.6 –7.0 mEq/L
6.6 –7.0 mmol/L> 7.0 mEq/L
> 7.0 mmol/L
Potassium, serum, low 3.0 –3.4 mEq/L
3.0 –3.4 mmol/L2.5 –2.9 mEq/L
2.5 –2.9 mmol/L2.0 –2.4 mEq/L
2.0 –2.4 mmol/L< 2.0 mEq/L
<2.0 mmol/L
Sodium, serum, high 146 –150 mEq/L
146 –150 mmol/L151 –154 mEq/L
151 –154 mmol/L155 –159 mEq/L
155 –159 mmol/L160 mEq/L
160 mmol/L
Sodium, serum, low 130 –135 mEq/L
130 –135 mmol/L125 –129 mEq/L
125 –129 mmol/L121 –124 mEq /L
121 –124 mmol/L120 mEq/L
120 mmol/L
Trigly cerides (fasting) NA 500 –750 mg/dL
5.65 –8.48 mmol/L751 –1,200 mg/dL
8.49 –13.56 mmol/L> 1,200 mg/dL
> 13.56 mmol/L
Uric acid 7.5 –10.0 mg/dL
0.45 –0.59 mmol/L10.1 –12.0 mg/dL
0.60 –0.71 mmol /L12.1 –15.0 mg/dL
0.72 –0.89 mmol/L> 15.0 mg/dL
> 0.89 mmol/L
Continued
GD2001/[ZIP_CODE]/[ADDRESS_273860] International Units are listed in italics
Hematuria (microscopic) 6 –10 RBC/HPF > 10 RBC/HPF Gross, with or without clots 
OR with RBC castsTransfusion in dicated
Proteinuria, random
Collection1 + 2 –3 + 4 + NA
Proteinuria, 24 hour collection
Adult and Pediatric  
10 years200 –999 mg/24 h
0.200 –0.999 g/d1,000 –1,999 mg/24 h
1.000 –1.999 g/d2,000 –3,500 mg/24 h
2.000 –3.500 g/d> 3,500 mg/24 h
> 3.500 g/d
Pediatric > 3 mo -< 10 
years201 –499 mg/m2/24 h
0.201 –0.499 g/d500 –799 mg/m2/24 h
0.500 –0.799 g/d800 –1,000 mg/m2/24 h
0.800 –1.000 g/d> 1,000 mg/ m2/24 h
> 1.000 g/d
1.Values are for term infants.
2.Use age and sex appropriate v alues (e.g., bilirubin), including preterm infants
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].4. Appendix 4:  Grading of Clinical A dverse Experiences -DAIDS Table for Grading the Severity  of 
Adult and Pediatric A dverse Events, Publish Date: December 2004
CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse event NOT 
identified elsewhere in this DAIDS 
AE grading tableSymptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions OR Medical or 
operative in tervention indicated to 
prevent permanent impairment, 
persistent disability, or death
SYSTEMIC
Acute systemic allergic reaction Localized urticaria (wheals) with 
no medical intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild bronchospasmAcute anaphylaxis OR Life -threatening 
bronchospasm OR laryngeal edema
Chills Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesNA
Fatigue
MalaiseSymptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesIncapacitating fatigue/malaise 
symptoms
causing inability to perform basic self -
care functions
Fever (nonaxillary) 37.7 –38.6C 38.7 –39.3C 39.4 –40.5C > 40.5 C
Pain (indicate body site)
DO NOT use for pain due to 
injection (See Injection Site 
React ions: Injection site pain)
See also Headache, Arthralgia, 
and MyalgiaPain causing no or minimal 
interference with usual social & 
functional activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing i nability to perform 
usual social & functional activitiesDisabling pain causing inability to 
perform basic self -care functions OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
121CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Unintentional weight loss NA 5 –9% loss in body weigh t from 
baseline10 –19% loss in body weight from 
baseline20% loss in body weight from 
baseline OR Aggressive intervention 
indicated [e.g., tube feeding or total 
parenteral nutrition (TPN)]
INFECTION
Infection (any other than HIV 
infection)Localized, no systemic 
antimicrobial treatment indicated 
AND Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antimicrobial treatment 
indicated OR Symptoms causing 
greater than minimal interference 
with usual social & fu nctional 
activitiesSystemic antimicrobial treatment 
indicated AND Symptoms causing 
inability to perform usual
social & functional activities OR 
Operative intervention (other than 
simple incision and drainage) 
indicatedLife-threatening consequences (e.g.,
septic shock)
INJECTION SITE REACTIONS
Injection site pain (pain without 
touching)
Or
Tenderness (pain when area is 
touched)Pain/tenderness causing no or 
minimal limitation of use of limbPain/tenderness limiting use of limb 
OR Pain/tenderness causin g greater 
than minimal interference with usual 
social & functional activitiesPain/tenderness causing inability to 
perform usual social & functional 
activitiesPain/tenderness causing inability to 
perform basic self -care function OR 
Hospi[INVESTIGATOR_059] (other than emergency 
room visit) indicated for management of 
pain/tenderness
Injection site reaction (localized)
Adult > 15 years Erythema OR Induration of 5x5 cm 
–9x9 cm (or 25 cm 2–81cm 2)Erythema OR Induration OR Edema 
> 9 cm any diameter (or > 81 cm 2)Ulceration OR Secondary infection 
OR Phlebitis OR Sterile abscess OR 
DrainageNecrosis (involving dermis and deeper
tissue)
Pediatric 15 Years Erythema OR Induration OR 
Edema present but 2.5 cm 
diameterErythema OR Induration OR Edema 
> 2.5 cm diameter but < 50% 
surface area of the extremity 
segment (e.g., upper arm/thigh)Erythema OR Induration OR Edema 
involving 50% surface area of the 
extremity segment (e.g., upper 
arm/thigh) OR Ulceration OR 
Secondary infection OR Phlebitis 
OR Sterile abscess OR D rainageNecrosis (involving dermis and deeper 
tissue)
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
122CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Pruritis associated with injection
See also Skin: Pruritis (itching -no 
skin lesions)Itching localized to injection site 
AND Relieved spontaneously or 
with < 48 hours treatmentItching be yond the injection site but 
not generalized OR Itching localized 
to injection site requiring 48 hours 
treatmentGeneralized itching causing inability 
to perform usual social & functional 
activitiesNA
SKIN –DERMATOLOGICAL
Alopecia Thinning detectable by [CONTACT_8712] (or by [CONTACT_227429])Thinning or patchy hair loss 
detectable by [CONTACT_227430] –rash Localized macular rash Diffuse macular, maculopapular, or 
morbill iform rash OR Target lesionsDiffuse macular, maculopapular, or 
morbilliform rash with vesicles or 
limited number of bullae OR 
Superficial ulcerations of mucous 
membrane limited to one siteExtensive or generalized bullous 
lesions OR Stevens -Johnson syndro me 
OR Ulceration of mucous membrane 
involving two or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_194] 
(TEN)
Hyperpi[INVESTIGATOR_227344] (itching –no skin lesions)
(See also Injection Site Reactions: 
Pruritis associated with injection)Itching causing no or minimal 
interference with usual social & 
functional activitiesItching causing greater than minimal 
interference with usual socia l & 
functional activitiesItching causing inability to perform 
usual social & functional activitiesNA
CARDIOVASCULAR
Cardiac arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -urgent 
medical i ntervention indicatedSymptomatic, non -life-threatening 
AND Non -urgent medical 
intervention indicatedLife-threatening arrhythmia OR Urgent 
intervention indicated
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
123CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Cardiac -ischemia/infarction NA NA Symptomatic ischemia (stable 
angina) OR Testing consistent with 
ischemiaUnstable angina OR Acute myocardial 
infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No transfusion 
indicatedSymptomatic AND Transfusion of 
2 units packed RBCs (for children 
10 cc/kg) indicatedLife-threatening hypotension OR 
Transfusion of > 2 units packed RBCs 
(for children >10 cc/kg) indicated
Hypertension
Adult > 17 years
(with repeat testing at same 
visit)> 140 –159 mmHg systolic
OR
> 90 –99 mmHg diastolic> 160 –179 mmHg systolic
OR
> 100 –109 mmHg diastolic> 180 mmHg systolic
OR
> 110 mmHg diastolicLife-threatening consequences (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit)
Pediatric 17 Years
(with repeat testing at same 
visit)NA 91st –94thpercentile adjusted for 
age, height, and gender (systolic 
and/or diastolic)95thpercentile adjusted for age, 
height, and gender (systolic and/or 
diastolic)Life-threatening consequences (e.g., 
malignant hypertension) OR 
Hospi[INVESTIGATOR_207100] (other than 
emergency room visit)
Hypotension NA Symptomatic, corrected with oral 
fluid replacementSymptomatic, IV fluids indicated Shock requiring use of vasopressors or 
mechanical assistance to maintain 
blood pressure
Pericardial effusion Asympto matic, small effusion 
requiring no interventionAsymptomatic, moderate or larger 
effusion requiring no interventionEffusion with non -life threatening 
physiologic consequences OR 
Effusion with non -urgent 
intervention indicatedLife-threatening consequences (e.g., 
tamponade) OR Urgent intervention 
indicated
Prolonged PR interval
Adult > 16 years PR interval
0.21 –0.25 secPR interval
> 0.25 secType II 2 nddegree AV block OR 
Ventricular pause > 3.0 secComplete AV block
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
124CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Pediatric 16 Years 1stdegree AV block (PR > normal 
for age and rate)Type I 2 nddegree AV block Type II 2nddegree AV block Complete AV block
Prolonged QTc
Adult > 16 years Asymptomatic, QTc interval 0.45 –
0.47 sec OR Increase interval < 
0.03 sec above baselineAsympt omatic, QTc interval 0.48 –
0.49 sec OR Increase in interval 
0.03 –0.05 sec above baselineAsymptomatic, QTc interval 0.50 
sec OR Increase in interval 0.06 
sec above baselineLife-threatening consequences, e.g. 
Torsade de pointes or other associated 
serious ventricular dysrhythmia
Pediatric 16 years Asymptomatic, QTc
interval 0.450 –
0.464 secAsymptomatic, QTc
interval 0.465 –
0.479 secAsymptomatic, QTc
interval 0.480 secLife-threatening consequences, e.g. 
Torsade de pointes or other associate d 
serious ventricular dysrhythmia
Thrombosis/embolism NA Deep vein thrombosis AND No 
intervention indicated (e.g., 
anticoagulation, lysis filter, invasive 
procedure)Deep vein thrombosis AND 
Intervention indicated (e.g., 
anticoagulation, lysis filter, inv asive 
procedure)Embolic event (e.g., pulmonary 
embolism, life -threatening thrombus)
Vasovagal epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousnessPresent with transient loss of 
consciousnessNA NA
Ventricular dysfunct ion 
(congestive heart failure)NA Asymptomatic diagnostic finding 
AND intervention indicatedNew onset with symptoms OR 
Worsening symptomatic congestive 
heart failureLife-threatening congestive heart failure
GASTROINTESTINAL
Anorexia Loss of appetite wi thout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight lossLoss of appetite associated with 
significant weight lossLife-threatening consequences OR 
Aggressive intervention indicated [e.g., 
tube feedi ng or   total parenteral 
nutrition (TPN)]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (e.g., diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_227345]-threatening consequences
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
125CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Cholecystitis NA Symptomatic AN D Medical 
intervention indicatedRadiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences (e.g., 
sepsis or perforation)
Constipation NA Persistent constipation requiring 
regular use of dietary modifications, 
laxatives, or enemasObstipation with manual evacuation 
indicatedLife-threatening consequences (e.g., 
obstruction)
Diarrhea
Adult and
Pediatric 1 yearTransient or intermittent epi[INVESTIGATOR_227346] 
3 stools over baseline per 24 -hour 
periodPersistent epi[INVESTIGATOR_227347] 4 –6 
stools over baseline per 24 -hour 
periodBloody diarrhea OR Increase of 7 
stools per 24 -hour period OR IV 
fluid replacement indicatedLife-threatening consequences (e.g., 
hypotensive shock)
Pediatric < 1 year Liquid stools (more unformed than 
usual) but usual number of stoolsLiquid stools with increased number 
of stools OR Mild dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in severe 
dehydration with aggressiv e rehydration 
indicated OR Hypotensive shock
Dysphagia -
OdynophagiaSymptomatic but able to eat usual 
dietSymptoms causing altered dietary 
intake without medical intervention 
indicatedSymptoms causing severely altered 
dietary intake with medical 
interve ntion indicatedLife-threatening reduction in oral intake
Mucositis/stomatitis (clinical exam)
Indicate site (e.g., larynx, oral)
See Genitourinary for 
Vulvovaginitis 
See also Dysphagia -Odynophagia 
and ProctitisErythema of the mucosa Patchy pseudomem branes or 
ulcerationsConfluent pseudomembranes or 
ulcerations OR Mucosal bleeding 
with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding OR 
Life-threatening consequences (e.g., 
aspi[INVESTIGATOR_1516], choking)
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
126CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Nausea Transient (< 24 hou rs) or 
intermittent nausea with no or 
minimal interference with oral 
intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for > 48 hours 
OR Aggressive rehydration 
indicated (e.g., IV fluids)Life-threatening consequences (e.g., 
hypotensive shock)
Pancreatitis NA Symptomatic AND Hospi[INVESTIGATOR_227348] (other than emergency 
room visit)Symptomatic AND Hospi[INVESTIGATOR_373] (other than emergency 
room visit)Life-threatening consequences (e.g., 
circulatory failure, hemorrhage, sepsis)
Proctitis (functional -symptomatic)
Also see Mucositis/stomatitis for 
clinical examRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual
social & functional activities OR 
Medical intervention indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Operative intervention 
indicatedLife-threatening consequences (e.g., 
perforation)
Vomiting Transient or interm ittent vomiting 
with no or minimal interference 
with oral intakeFrequent epi[INVESTIGATOR_227349] 
(e.g., IV fluids)Life-threatening conse quences (e.g., 
hypotensive shock)
NEUROLOGIC
Alteration in personality -behavior 
or in mood (e.g., agitation, anxiety, 
depression, mania, psychosis)Alteration causing no or minimal 
interference with usual social & 
functional activitiesAlteration causing greater than 
minimal interference with usual 
social & functional activitiesAlteration causing inability to 
perform usual social & functional 
activitiesBehavior potentially harmful to self or 
others (e.g., suicidal and homicidal 
ideation or attempt, acut e psychosis) 
OR Causing inability to perform basic 
self-care functions
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
127CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Altered Mental Status
For Dementia, see Cognitive and 
behavioral/attentional disturbance 
(including dementia and attention 
deficit disorder)Changes causing no or minimal 
interference with usual social & 
functional activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social & 
functional activitiesConfusion, memory impairment, 
lethargy, or somnolence causing 
inability to perform usual s ocial & 
functional activitiesDelirium OR obtundation, OR coma
Ataxia Asymptomatic ataxia detectable 
on exam OR Minimal ataxia 
causing no or minimal interference 
with usual  social & functional 
activitiesSymptomatic ataxia causing greater 
than minimal in terference with usual 
social & functional activitiesSymptomatic ataxia causing inability 
to perform usual social & functional 
activitiesDisabling ataxia causing inability to 
perform basic self -care functions
Cognitive and 
behavioral/attentional disturba nce 
(including dementia and attention 
deficit disorder)Disability causing no or minimal 
interference with usual social & 
functional activities OR 
Specialized resources not 
indicatedDisability causing greater than 
minimal interference with usual 
social & functional activities OR 
Specialized resources on part -time 
basis indicatedDisability causing inability to perform 
usual social & functional activities 
OR Specialized resources on a full -
time basis indicatedDisability causing inability to perform 
basic s elf-care functions OR 
Institutionalization indicated
CNS ischemia (acute) NA NA Transient ischemic attack Cerebral vascular accident (CVA, 
stroke) with neurological deficit
Developmental delay
–Pediatric 16 YearsMild developmental delay, either 
motor or cognitive, as determined 
by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingModerate developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7425] a 
developmental screening tool 
appropriate for the settingSevere developmental delay, either 
motor or cognitive, as determined by 
[CONTACT_7425] a developmental 
screening tool appropriate for the 
settingDevelopmental regression, either motor 
or cognitive, as determined by 
[CONTACT_7425] a developmental 
screeni ng tool appropriate for the 
setting
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
128CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Headache Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing ina bility to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions OR 
Hospi[INVESTIGATOR_374] (other than 
emergency room visit) OR Headache 
with significant impairment of alertness 
or other neurologic f unction
Insomnia NA Difficulty sleepi[INVESTIGATOR_227350] & functional activitiesDifficulty sleepi[INVESTIGATOR_227351] & functional 
activitiesDisabling insomnia causing inability to 
perfo rm basic self -care functions
Neuromuscular weakness 
(including myopathy & 
neuropathy)Asymptomatic with decreased 
strength on exam OR Minimal 
muscle weakness causing no or 
minimal interference with usual 
social & functional activitiesMuscle weakness caus ing greater 
than minimal interference with usual 
social & functional activitiesMuscle weakness causing inability 
to perform usual social & functional 
activitiesDisabling muscle weakness causing 
inability to perform basic self -care 
functions OR Respi[INVESTIGATOR_13521] y muscle 
weakness impairing ventilation
Neurosensory Alteration (including 
paresthesia and painful 
neuropathy)Asymptomatic with sensory 
alteration on exam or minimal 
paresthesia causing no or minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing greater than minimal 
interference with usual social & 
functional activitiesSensory alteration or paresthesia 
causing inability to perform usual 
social & functional activitiesDisabling sensory alteration or 
pares thesia causing inability to perform 
basic self -care functions
Seizure: ( new onset )
–Adult 18 years
See also Seizure: (known pre -
existing seizure disorder)NA 1 seizure 2 –4 seizures Seizures of any kind which are 
prolonged, repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi[INVESTIGATOR_002])
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
129CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Seizure: ( known pre -existing 
seizure disorder )
–Adult 18 years
For worsening of existing epi[INVESTIGATOR_227352] a ny of these levels.NA Increased frequency of pre -existing 
seizures (non -repetitive) without 
change in seizure character OR 
Infrequent break -through seizures 
while on stable medication in a 
previously controlled seizure 
disorderChange in seizure character from 
baseline either in duration or quality 
(e.g., severity or focality)Seizures of any kind which are 
prolonged, repetitive (e.g., status 
epi[INVESTIGATOR_7397]), or difficult to control (e.g., 
refractory epi[INVESTIGATOR_002])
Seizure
–Pediatric < 18 yearsSeizure, generali zed onset with or 
without secondary generalization, 
lasting < 5 minutes with < [ADDRESS_273861] ictal stateSeizure, generalized onset with or 
without secondary generalization, 
lasting 5 –20 minutes with <[ADDRESS_273862] ictal stateSeizure, generalized onset with or 
without secondary generalization, 
lasting >20 minutesSeizure, generalized onset with or 
without Secondary generalization, 
requiring intubation and sedation
Syncope (not associated with a 
procedure)NA Present NA NA
Vertigo Vertigo causing no or minimal 
interference with usual social & 
functional activitiesVertigo causing greater than 
minimal interference with usual 
social & functional activitiesVertigo causing inability to perform 
usual social & functional activitiesDisabling vertigo causing i nability to 
perform basic self -care Functions
RESPI[INVESTIGATOR_111092] (acute) FEV1 or peak flow reduced to 70 –
80%FEV1 or peak flow 50 –69% FEV1 or peak flow 25 –49% Cyanosis OR FEV1 or peak flow < 25% 
OR Intubation
Dyspnea or respi[INVESTIGATOR_111093] 14 years Dyspnea on exertion with no or 
minimal interference with usual 
social & functional activitiesDyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activitiesDyspnea at rest causing inability to 
perform usual social & functional 
activitiesRespi[INVESTIGATOR_227353] < 14 years Wheezing OR minimal increase in 
respi[INVESTIGATOR_227354] 90 –
95%Dyspnea at rest causing inability to 
perform usual social & functional 
activities OR Pulse oximetry < 90%Respi[INVESTIGATOR_227355]2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
130CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
MUSCULOSKELETAL
Arthralgia
See also ArthritisJoint pain causing no or minimal 
interference with usual social & 
functional activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability to 
perform usual social & functional 
activitiesDisabling joint pain causing inability to
perform basic self -care Functions
Arthritis
See also ArthralgiaStiffness or joint swelling causing 
no or minimal interference with 
usual social & functional activitiesStiffness or joint swelling causing 
greater than minimal interference 
with usual soc ial & functional 
activitiesStiffness or joint swelling causing 
inability to perform usual social & 
functional activitiesDisabling joint stiffness or swelling 
causing inability to perform basic self -
care functions
Bone Mineral Loss
Adult 21 years BMD t-score -2.5 to -1.0 BMD t -score < -2.5 Pathological fracture (including loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Pediatric < 21 years BMD z -score -2.5 to -1.0 BMD z -score < -2.5 Pathological fracture (includin g loss 
of vertebral height)Pathologic fracture causing life -
threatening Consequences
Myalgia ( non-injection site ) Muscle pain causing no or minimal 
interference with usual social & 
functional activitiesMuscle pain causing greater than 
minimal interferen ce with usual 
social & functional activitiesMuscle pain causing inability to 
perform usual social & functional 
activitiesDisabling muscle pain causing inability 
to perform basic self -care functions
Osteonecrosis NA Asymptomatic with radiographic 
finding s AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR Operative 
intervention indicatedDisabling bone pain with radiographic 
findings causing inability to perform 
basic self -care functions
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
131CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
GENITOURINARY
Cervicitis ( symptoms )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infection)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions
Cervicitis ( clinical exam )
(For use in studies evaluating 
topi[INVESTIGATOR_144491])
For other cervicitis see Infection: 
Infection (any other than HIV 
infection)Minimal cervical abnormalities on 
examination (erythema,
Mucopurulent discharge, or 
friability) OR Epi[INVESTIGATOR_111100] < 
25% of total surfaceModerate cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or friability) 
OR Epi[INVESTIGATOR_111101] 25 –49% 
total surfaceSevere cervical abnormalities on 
examination (erythema, 
mucopurulent discharge, or friability) 
OR Ep ithelial disruption 50 –75% 
total surfaceEpi[INVESTIGATOR_111100] > 75% total surface
Inter-menstrual bleeding (IMB) Spotting observed by [CONTACT_227431]-menstrual bleeding not greater 
in duration or amount than usual 
menstrual cycleInter-menstrual bleeding greater in 
duration or amount than usual 
menstrual cycleHemorrhage with life -threatening 
hypotension OR Operative intervention 
indicated
Urinary tract obstruction (e.g., 
stone)NA Signs or symptoms of urinary tract 
obstruction without hydronephrosis 
or renal dysfunctionSigns or symptoms of urinary tract 
obstruction with hydronephrosis or 
renal dysfunctionObstruction causing life -threatening 
consequences
Continued
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
132CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Vulvovaginitis (symptoms )
(Use in studies evaluating topi[INVESTIGATOR_111097]) 
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Symptoms causing no or minimal 
interference with usual social & 
functional activitiesSymptoms causing greater t han 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & functional 
activitiesSymptoms causing inability to perform 
basic self -care functions
Vulvovaginitis ( clinical exam )
(Use in studies e valuating topi[INVESTIGATOR_111097])
For other vulvovaginitis see 
Infection: Infection (any other than 
HIV infection)Minimal vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111098] <25% of total surfaceModerate vaginal abnormalities on 
examination OR E pi[INVESTIGATOR_227356] 25 -49% total surfaceSevere vaginal abnormalities on 
examination OR Epi[INVESTIGATOR_111100] 
50 -75% total surfaceVaginal perforation OR Epi[INVESTIGATOR_111098] > 75% total surface
OCULAR/VISUAL
Uveitis Asymptomatic but detectable on 
examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention indicatedDisabling visual loss in affected eye(s)
Visual changes (from baseline) Visual changes causing no or 
minimal interference w ith usual 
social & functional activitiesVisual changes causing greater than 
minimal interference with usual 
social & functional activitiesVisual changes causing inability to 
perform usual social & functional 
activitiesDisabling visual loss in affected e ye(s)
ENDOCRINE/METABOLIC
Abnormal fat accumulation (e.g., 
back of neck, breasts, abdomen)Detectable by [CONTACT_111186] (or 
by [CONTACT_227432])Detectable on physical exam by 
[CONTACT_227433]2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
133CLINICAL
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -THREATENING
Diabetes mellitus NA New onset without need to initiate 
medication OR Modification of 
current medications to regain 
glucose controlNew onset with initiation of 
medication indicated OR Diabetes 
uncontroll ed despi[INVESTIGATOR_10820]-threatening consequences (e.g., 
ketoacidosis, hyperosmolar non -ketotic 
coma)
Gynecomastia Detectable by [CONTACT_114836] (for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_227434] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inabil ity to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences (e.g., 
thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & fu nctional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & functional 
activities OR Uncontrolled despi[INVESTIGATOR_111102]-threatening consequences (e.g., 
myxedema coma)
Lipoatrophy (e.g., f at loss from the 
face, extremities, buttocks)Detectable by [CONTACT_111186] (or 
by [CONTACT_227432])Detectable on physical exam by 
[CONTACT_227435]
1.Basic Self -care Functions –Adult: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
2.Basic Self -care Functions –Young Children: Activities that are age and culturally appropriate (e.g., feeding self with culturally appropriate eating implement).
3.Usual Social & Functional Activities –Adult: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a h obby, etc.
4. Usual Social & Functional Activities –Young Children: Activi ties that are age and culturally appropriate (e.g., social interactions, play activities, learning tasks, etc.).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].5. Appendix 5:  Dosing Table for FPV Oral Suspension
FPV 4 5 mg /kg BID (<2 years old)
Weight (kg) Dose (mg): 4 5 mg /kgAmount of 5 0 mg /mL 
suspens ion (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
3 135 2.7 1
3.5 158 3.2 1
4 180 3.6 1
4.5 203 4.1 2
5 225 4.5 2
5.5 248 5.0 2
6.0 270 5.4 2
6.5 293 5.9 2
7.0 315 6.3 2
7.5 338 6.8 2
8 360 7.2 2
8.5 383 7.7 3
9 405 8.1 3
9.5 428 8.6 3
10 450 9.0 3
10.5 473 9.5 3
11 495 9.9 3
11.5 518 10.4 3
12 540 10.8 3
12.5 563 11.3 4
13 585 11.7 4
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
135FPV 6 0 mg /kg BID (<2 years old)
Weight (kg) Dose (mg): 6 0 mg /kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
3 180 3.6 1
3.5 210 4.2 2
4 240 4.8 2
4.5 270 5.4 2
5 300 6 2
5.5 330 6.6 2
6.0 360 7.2 2
6.5 390 7.8 3
7.0 420 8.4 3
7.5 450 9 3
8 480 9.6 3
8.5 510 10.2 3
9 540 10.8 3
9.5 570 11.4 4
10 600 12 4
10.5 630 12.6 4
11 660 13.2 4
11.5 690 13.8 4
12 720 14.4 4
12.5 750 15 5
13 780 15.6 5
As per Section [IP_ADDRESS] , for subjects exceeding 6 y ears of age ,the following weight -based 
dosing for FPV should be used:
FPV 18mg/kg BID (>6 years old)
Weight (kg) Dose (mg): 18 mg/kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
25 450 9 3
26 468 9.4 3
27 486 9.7 3
28 504 10.1 3
29 522 10.4 3
30 540 10.8 3
31 558 11.2 3
32 576 11.5 4
33 594 11.9 4
34 612 12.2 4
35 630 12.6 4
36 648 13 4
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
136Weight (kg) Dose (mg): 18 mg/kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
37 666 13.3 4
38 684 13.7 4
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].6. Appendix 6:  Dosing Table for RTV Oral Solution , Powder, 
Capsules and Tablets
RTV Oral Solution 7 mg /kg BID (<2 years old)
Weight (kg)Dose (mg): 7 
mg/kgAmount of 8 0 mg /mL solution 
(mL) per Dose
3 21 0.26
3.5 24.5 0.31
4 28 0.35
4.5 31.5 0.39
5 35 0.44
5.5 38.5 0.48
6.0 42 0.53
6.5 45.5 0.57
7.0 49 0.61
7.5 52.5 0.66
8 56 0.70
8.5 59.5 0.74
9 63 0.79
9.5 66.5 0.83
10 70 0.88
10.5 73.5 0.92
11 77 0.96
11.5 80.5 1.01
12 84 1.05
12.5 87.5 1.09
13 91 1.14
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
138As per Section [IP_ADDRESS] , for subjects exceeding 6 y ears of age ,the following weight -based 
dosing for RTV oral solution should be used:
RTV Oral Solution 3mg/kg BID (>6 years old)
Weight (kg) Dose (mg): 3 mg /kgAmount of 80 mg /mL 
suspension (mL) per Dose
25 75 0.9
26 78 1.0
27 81 1.0
28 84 1.1
29 87 1.1
30 90 1.1
31 93 1.2
32 96 1.2
≥33a99 1.2
Subjects who are ≥33kg and are receiving RTV oral solution at a dose of 3mg/kg should 
remain at the recommended optimal dose for ≥33kg (99mg BID for 3mg/kg dosing) even 
as their weight increases above 33kg. The maximum allowed total daily  dose for RTV 
oral solution is 200mg .
The following weight -based dosing for RTV oral powder can be used if RTV oral 
solution is not available.  For d oses less than 100 mg or partial doses between 100 mg 
increments: Mix 1 packet/sachet of oral powder (100 mg) w ith 9.4 mL of liquid (such as 
water, chocolate milk, or infant formula) in a mixing cup. Once mixed, use an oral dosing 
syringe to measure and administer the prescribed volume .  Once the powder is mixed, the 
dosage must be consumed within [ADDRESS_273863] any mixture remaining in the mixing 
cup.
RTV Oral Powder (100 mg sachets) 3 mg/kg BID (>6 year old)
Weight (kg) Dose (mg): 3 mg /kgAmount of liquid per dose 
once the sachet with 100 mg
powder is dissolved in 9.4 
mL of liquid (10 mg/mL)
25 75 7.5 mL
26 78 7.8 mL
27 81 8.1 mL
28 84 8.4 mL
29 87 8.7 mL
30 90 9.0 mL
31 93 9.3 mL
32 96 9.6 mL
≥33a99 10.0 mL
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
139As per Section [IP_ADDRESS] , for subjects exceeding 6 y ears of age who weigh ≥33kg and can 
swallow capsules or tablets whole ,the following weight -based dosing for RTV oral 100 
mg tablets or 100 mg capsules should be used: 1 capsule or tablet (dose of 100 mg) BID.  
The maximum allowed total daily  dose of RTV capsules or tablets is 200 mg. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].7. Appendix 7:  Country  Specific Requirements
Country -Specific Requirements
No country -specific requirements exist.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].8. Appendix 8:  Pr otocol A mendment 1
A summary  of protocol changes for Amendment 1 are listed below.  These changes were 
incorporated into the protocol at the time Amendment was issued and are incorporated 
into Amendment 7. 
STUDY DESIGN CHANGES
To change the lower age lim it for subject participation from 6 weeks to 4 weeks.
To revise the stud y design.
To revise the stratification within the two age cohorts.
To revise the details of the study  population in line with the revised study  design.
To describe stud y measuremen ts and evaluations.
To revise the stud y objectives.
To revise the stud y endpoints.
To revise details of subject allocation to treatment groups.
To add details of screening and enrolment procedures.
To reschedule the administration of the adherence que stionnaire from week 4 to 
week 2.
To revise details of scheduled safet y assessments and selected safet y laboratories.
To revise details of planned interim anal ysis.
To revise details of dose volumes required.
To revise the flow chart of scheduled asses sments.
To revise the timelines for cohort recruitment and Dosing of Subjects with 
GW433908 and / or GW433908/RTV.
To revise the rash management table.
ADDITION OF NEW DATA FROM OTHER FPV STUDIES
To update information pertaining the phase III pi[INVESTIGATOR_22735] a dult studies.
To update study  background and rationale.
To update the FPV neonatal toxicology  section.
CHANGES RELATING TO DOSE SELECTION AND PHARMACOKINETIC 
ASSESSMENTS
To revise the dose selection for FPV and RTV.
To describe the revised starting an d maximum doses of FPV and RTV.
To describe stud y drug dose adjustment criteria.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
142 To revise the definition of a study  drug overdose.
To revise the details of PK sampling and bioanal ysis.
To change details of analytes for PK samples to allow for anal ysisand RTV 
concentrations and to clarify  the concentrations of FPV will only  be measured where 
plasma volumes allow.
To update the analy sis plan for PK samples collected.
To revise the target plasma APV exposures.
OTHER CHANGES
To revise subject manageme nt options.
To include details of additional references.
To add additional items the L ist of Abbreviations.
To update the list of concurrent medications and non drug therapi[INVESTIGATOR_014].
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].9. Appendix 9:  Protocol A mendment 2
There was one change to the protocol as a result of Protocol Amendment 2.  Exclusion 
criteria number 8 was modified as follows:
Original W ording:
Any acute laboratory  abnormality  at screen which, in the opi[INVESTIGATOR_871], 
should preclude the subject’s participation in the study  of an i nvestigational compound.  
Any Grade [ADDRESS_273864] from study  
participation.
Revised Wording:
Any acute laboratory  abnormality  at screen which, in the opi[INVESTIGATOR_871], 
should preclude the subject’s par ticipation in the study  of an investigational compound.  
Any Grade [ADDRESS_273865] from study  
participation.
This change is incorporated into Amendment 7.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].10. Appendix 10:  Protocol A mendment 3
A summary  of protocol changes for Amendment 3 are listed below.  These changes were 
incorporated into the protocol at the time Amendment 3 was issued and are thus 
incorporated into Amendment 7. 
1.To add the revised dose recommendation for Cohort 1A (PI -naïve or PI -experi enced 
subjects 6 months to < 2 y ears of age receiving boosted GW433908 (908) + RTV).  
The revised dose recommendation is 908 45 mg/kg BID + RTV 7 mg/kg BID, which 
represents a 25% increase from the original dose of 908 30 mg/kg BID and 16% 
increase from th e original RTV 6 mg/kg BID dose.  Consequently , screening was re -
opened to PI -naïve and PI-experienced subjects to enro l within Arm A2 of Cohort 
1A.  Any  further subjects randomized into Cohorts 1A Arm A2 and receiving 908 
oral suspension + RTV should be placed on the revised dosing recommendation 
listed above.  It is recommended that subjects already  randomized should remain on 
their current 908+RTV BID dosing regimen.
2.Reason for change:  Following PK analy sis of the first 9 subjects from Cohort 1A1, a 
revised dose recommendation was determined and communicated to the sites. I t is 
now being added to the protocol for completeness.
3.To update information regarding closing of the unboosted GW433908 Arm B for 
Cohort 1 pending discussions with regulatory  authori ties around dosing volumes.  
4.Reason for change:  In the original study  design, Cohort [ADDRESS_273866] been completed.
5.To amend the current study  design to allow the simultaneous enrolment of Cohort 2 
Arms A and B. 
6.Reason for change: Due to the increasing non -availability  of RTV OS in several 
participating countries, we are allowing the parallel enrolment of Arm A and Arm B 
of Cohort [ADDRESS_273867] 
their treatment switched from the 908 BID regimen to the 908/RTV BID regimen at 
any time after the Week 2 visit by  [CONTACT_227436] “onl y in countries where RTV 
solution is local ly available for long -term use”.
8.Reason for change:  After the study  started RTV oral solution became unavailable in 
some participating countries. 
9.To update the Study  Drugs and Dosages and Dosage Regimen Adjustment Criteria
10.Reason for change:  To provide updated information per protocol amendment No 3.
GD2001/[ZIP_CODE]/[ADDRESS_273868] Week 48.
12.Reason for change:  To provide details surrounding the continuation of study visits 
and laboratory  assessments past Week 48.  S ubjects may  remain in the study  until 
[ADDRESS_273869] is no longer deriving any  
clinical benefit from 908.
13.To provide clarification regarding the maximum age allowed for each cohort. 
14.Reason for change: The ex isting inclusion criteria number 1 was unclear as to which 
study  visit the age criteria applied.  Inclusion criteria 1 has been revised to state that 
Cohort 1 (6 months -<2 years) subjects must be <2 y ears of age at the Week 2 visit 
therefore the maximum age at screening is 22 months, and Cohort 2 (4 weeks -<6 
months) subjects must be <[ADDRESS_273870] minor inconsistencie s.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].11. Appendix 11:  Protocol A mendment 4
Protocol Amendment 4 was sent to the FDA for review and comment but because of 
the outcome of discussions with FDA, this amendment was not sent to the sites for 
implementation.  The change suggested in Amendment 4 is also incorporated into 
Amendment 5.
This amendment consisted of the following changes:
1.To add information regarding removal of the unboosted GW433908 Arm B for 
Cohort 1.  
Reason for change:  Due to the required increase in 908 dose in Cohort 1A (6 months 
to 2 y ears of age) to 45 mg/kg BID, the unboosted dose would have also increased 
from 15 mg/kg BID to 22.5 mg/kg BID and resulted in unacceptable dosing volumes 
for these children.  Based on the weight range of the currently  enrolled subjects in 
Cohort 1A (6 kg to 12.6 kg, range 9 months to 2 years of age) and using the CDC 
weight for age percentile growth charts (6 kg to 13.4 kg), the required dosing 
volumes for the unboosted 908 dose(s) is estimated to be in the range of 10.8 mls to 
24.1 mls per dose for Cohort 1B.  Phy sician feedback has indicated that these dosing 
volumes would lead to unacceptabl y low levels of adherence in this age group.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].12. Appendix 12:  Protocol A mendment 5
Title: A 48 Week Phase II, Open -label, 2 -cohort, Multicentre Study  to Evaluat e the 
Pharmacokinetics, Safety, Tolerability  and Antiviral Activity  of GW433908 and 
GW433908/RTV When Administered to HIV -1 Infected Protease Inhibitor (PI) Naïve 
and PI -Experienced Pediatric Subjects aged 4 weeks to <[ADDRESS_273871]/management of the stud y.  
This amendment is being implemented to defer the enrolment of subjects in the 
unboosted FPV cohorts (Cohort 1 Arm B and Cohort 2 Arm B), to increase the dose of 
FPV at the Week 2 visit and revise the PK visits and sampling times for subjects in 
Cohort 1 Arm A (FPV/RTV BID), to include trough PK samples to determine the 
concentration of unbound APV, to revise the doses given to Cohort [ADDRESS_273872] of excluded concurrent medications to remove rifabutin and 
pheny toin, and to update the DAIDS toxicity  grading tables (2004), information on rash, 
abacavir h ypersensitivity reaction, background information, and to correct minor 
inconsistencies in the protocol.  As all new sites will be receiving this protocol and 
amendments for the first time, the content and organization of the protocol were also 
update d and revised to simplify  and improve clarity .
This amendment consists of the following changes:
1.Defer the enrolment of subjects in the unboosted FPV cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B)
2.Reason for change:  Enrolment into Cohort 1 Arm B and Cohort 2 Arm B is deferred 
until serial PK data from the age -specific FPV/RTV cohorts are available to assist in 
the dose selection for the corresponding unboosted FPV cohort and an y concerns 
regarding the high FPV dosing volumes have been addressed.
3.Increasing th e FPV dose to 6 0 mg /kg at the Week 2 visit for subjects in Cohort 1 
Arm A only .
4.Reason for change:  Data from five 6 months to <2 y ear old subjects who received 
the revised dose of FPV 4 5 mg /kg BID + RTV 7 mg /kg BID were compared with the 
historical adult population (based on a FPV 70 0 mg BID + RTV 10 0 mg BID 
regimen and an average weight of 77kg).  Despi[INVESTIGATOR_227357] 5 -fold increase in 
FPV and RTV doses, plasma APV AUC(0 -) was approximately  48% lower, Cmax 
26% lower, and C 29% lower in the pediatric subjects.  In addition, high APV and 
RTV CL /F values were observed in these 5 pediatric subjects suggesting that 
children 6 months to <2 years old may  require higher doses of FPV and RTV.  
Therefore new subjects will increase the FPV dose from 4 5 mg /kg BID to 60 mg /kg 
BID with RTV 7 mg /kg BID after the PK evaluations at the Week 2 visit.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
1485.Revision to the PK visits and sampling times for subjects in Cohort 1 Arm A and the 
addition of trough PK samples to determine the concentration of unbound APV for 
all subj ects. 
6.Reason for change:  Subjects in Cohort 1 will start at baseline receiving FPV 4 5 
mg/kg BID + RTV 7 mg /kg BID, and a “mini” PK profile will be conducted over 4 
hours at Week 2 to confirm adequate exposure after attaining stead y-state.  The dose 
of FP V will be then be increased to 6 0 mg /kg BID + RTV 7 mg /kg BID after the 
Week 2 PK, and serial PK sampling will be conducted over 8 -12 hours at Week 8 to 
confirm the target exposure after attaining stead y-state.
7.Current PK data from children <2 years old in APV20002 is highl y variable.  Since 
subjects who are <[ADDRESS_273873] reduced protein binding, it is possible that 
these pediatric subjects may  achieve therapeutic plasma unbound APV 
concentrations even if plasma total APV concentrations are below ta rget when 
compared to adult exposure.  Therefore, measuring plasma unbound APV 
concentrations may  help to determine dosing recommendations at acceptable dosing 
volumes.
8.The single doses administered in Cohort 2 Arm A SDV changed from FPV 3 0 mg /kg 
and RTV 6 mg/kg to FPV 4 5 mg /kg and RTV 7 mg/kg to be aligned with dosing in 
Cohort [ADDRESS_273874] of excluded medications.
10.Updated information on rash and abacavir h ypersensitivity  reaction
11.Updated DAIDS table for the grading of adult and pediatric adverse events to the 
2004 version.
12.Updated background information, removal of redundant wording, and correction of 
minor inconsistencies throughout the protocol.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
149Summary  of Pr imary  Changes for A mendment 5
Section 1 Introduction
Section 1.1 Backgrond and Section 1.2 Rationale were updated with current 
information, reorganized, and condensed.
Section 1.3 Fosamprenavir was condensed, Section 1.3.1 FPV Neonatal Toxicology  
was revis ed with current information and condensed, and Section 1.3.2 FPV 
Pediatric Clinical Data was added.
Section 1.4 Ritonavir, Section 1.5 Abacavir, and Section 1.6 Lamivudine were 
updated and condensed.
Section 2 Study  Objectives and Endpoints
Section 2.1 Stu dy Objectives and Section 2.2 Study  Endpoints were revised to 
indicate which of the objectives and endpoints are deferred as a result of the deferral 
of the unboosted FPV Arm B cohorts.  One new primary  study  endpoint was added: 
Plasma unbound APV C ,ss and percent protein binding
Section 3 Investigational Plan
Section 3.1 Study  Design
Study  center regions revised to include Africa. 
Statement about subjects continuing on study  until commercial supplies of FPV 
are available locally  was updated to include a statement about continued FPV 
according to agreements between [COMPANY_004] and participating stud y sites.  
Updated with text and a revised table to state approximately  how man y 
additional subjects are required. 
Schematics were revised according to the changes in this amendment, moved to 
follow the Overview section and renamed Figure 1and Figure 2.
Overview: Updated to explain the terminology  of Arm A SDV and Arm A.
Cohort 1 Arm A SDV -original wording deleted as it is no longer 
applicable; wording added to clarif y that no additional subjects in this 
Cohort are required to undergo SDV assessments.
Cohort 2 Arm A SDV -Single doses changed from FPV 3 0 mg /kg and RTV 
6mg/kg to FPV 4 5 mg /kg and RTV 7 mg/kg. Wording added to explain that 
the 12 hour sample may  be omitted with prior agreement of the sponsor.
Cohort 1 Arm A -dosing updated as fol lows: All new subjects who enro l in 
Cohort 1 Arm A should commence multiple dosing with FPV 4 5 mg /kg 
BID + RTV 7 mg /kg BID at the Baseline visit.  After the Week [ADDRESS_273875] b een collected (sampling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo plasma 
PK serial sampling at Week 8 (over 8 -12 hours).  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
150Cohort 1 Arm B and Cohort 2 Arm B -wording added to explain these 
cohorts are de ferred and the rationale for deferment.
Figure 1and Figure 2were revised
Section 3.2 Study  Population clarifies the approximate number of additional subjects 
to be enrolled.
Section 3.2.2 Exclusion Criteria 
#3 revised to state that the exclusion of subj ects receiving PI [CONTACT_157835] y within 5 
days prior to study  drug administration is applicable only  for subjects 
undergoing single dose visits
#5 CDC Class C event criteria revised
#7 revised to include clinically  relevant pancreatitis
#8 lab abnormality  criteri a revised
former #9 criteria about serum lipase removed
Section 3.3.2 Background NRTI  options, the manufacturing sites of abacavir oral 
solution and lamivudine oral solution were changed from Speke, [LOCATION_006] to Mississauga, 
Ontario, Canada. Section 3.3.3 was rev ised to Background ART Not Provided by  
[CONTACT_23983], and new wording added to state that [COMPANY_004] will not provide or reimburse 
background ART other than ABC or 3TC.
Section 3.3.4 was updated with current information and condensed.  Previous 
sections Original Dose Selec tion and Revised Dose Selection were removed as the 
data was no longer applicable. 
Section 3.3.5 Study  Drugs and Dosages -condensed and redundant text removed; 
instructions added for sites in case of vomiting after administration of study drug. 
Section 3. 3.5.1 Dosage Regimen Adjustment Criteria -text updated and condensed.
Section [IP_ADDRESS] Rash and Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction 
sections updated to provide the most current information and guidance to 
investigators. 
Section 3.3.[ADDRESS_273876] of care.
Section 3.3.10 Concurrent Medications -rifabutin and pheny toin were removed as 
excluded medications.  Additional guidance added for co-administration of rifabutin.
Section 4 Study  Drug Management -No changes
Section 5 Measurements and Evaluations
Section 5.5 Efficacy -Collection of plasma samples at screening for reistance testing, 
formerl y required, was revised per this amendment to s tate collection of this sample 
is left to the investigator’s discretion if needed to guide selection of background 
ART.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
151Section 5.[ADDRESS_273877] the new dosing and new PK sample schedule implemented with this 
amendment; paragraph added regarding directl y observed therap y
Section 5.8 Safety -collection of samples for serum lipase testing and serum 1-Acid 
Glycoprotein (AAG) concentrations removed as these parameters will no longer be 
tested .  Lipid measures will no longer be collected at the Screening visit. 
Section [ADDRESS_273878] the changes per 
the current amendment
Section 11 A ppendices
Appendix 3 -The previous DAIDS table for the grading of adult and pediatric 
adverse events was replaced with the more current DAIDS 2004 version.
Appendix 5 a nd Appendix 6 -The dosing tables were revised according to the 
updated dosing schedule.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].13. Appendix 13:  Protocol A mendment 6
Title: APV20002: A 48 Week Phase II, Open -label, 2 -cohort, Multicentre Study  to 
Evaluate the Pharmacokinetics, Safet y, Tolerability a nd Antiviral Activity  of GW433908 
and GW433908/RTV When Administered to HIV -1 Infected Protease Inhibitor (PI ) 
Naïve and PI -Experienced Pediatric Subjects aged 4 weeks to <[ADDRESS_273879]/management of the study .  The inaccurate RTV dosing table was provided in 
amendment [ADDRESS_273880] inaccuracies in the FPV and RTV 
dosing tables and in exclusion criteria No 9 (per amendment 5).
1.In the FPV 4 5 mg /kg BID dosing table, revisions were made to the number of bottles 
of FPV OS required b y the subject per month based on their weight.  In the RTV 7 
mg/kg BID dosing table, corrections were made to the amount of RTV oral solution 
administered per dose to each subject based on their weight.
2.In exclusion criteria No. 9 (per amendment 5), the ULN (>10x ULN) stated for a 
Grade 3 ALT and/or AST was changed to (>5x ULN) to correctl y represent a Grade 
3.
Change 1:  To update the FPV 4 5 mg /kg BID dosing table to reflect the correct suppl y of 
FPV OS required per month and to correct the dose of RTV oral solution to be 
administered per dose to each subject based on their weight.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
153Amend:
11.15, Appendix 5:  Dosing Table for FPV Oral Su spension, FPV 4 5 mg /kg BID
Original Table:
Dosing Table for FPV Oral Suspension
FPV 4 5 mg /kg BID
Weight (kg) Dose (mg): 4 5 mg /kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
3 135 2.7 1
3.5 158 3.2 1
4 180 3.6 1
4.5 203 4.1 2
5 225 4.5 2
5.5 248 5.0 2
6.0 270 5.4 2
6.5 293 5.9 2
7.0 315 6.3 2
7.5 338 6.8 2
8 360 7.2 2
8.5 383 7.7 2
9 405 8.1 2
9.5 428 8.6 2
10 450 9.0 2
10.5 473 9.5 3
11 495 9.9 3
11.5 518 10.4 3
12 540 10.8 3
12.5 563 11.3 3
13 585 11.7 3
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
154Revised Table:
FPV 4 5 mg /kg BID
Weight (kg) Dose (mg): 4 5 mg /kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
3 135 2.7 1
3.5 158 3.2 1
4 180 3.6 1
4.5 203 4.1 2
5 225 4.5 2
5.5 248 5.0 2
6.0 270 5.4 2
6.5 293 5.9 2
7.0 315 6.3 2
7.5 338 6.8 2
8 360 7.2 2
8.5 383 7.7 3
9 405 8.1 3
9.5 428 8.6 3
10 450 9.0 3
10.5 473 9.5 3
11 495 9.9 3
11.5 518 10.4 3
12 540 10.8 3
12.5 563 11.3 4
13 585 11.7 4
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
155Amend:
11.16, Appendix 6:  Dosing Table for RTV O ral Solution, RTV 7 mg /kg BID
Original Table:
Dosing Table for RTV Oral Solution
RTV 7 mg /kg BID
Weight (kg)Dose (mg): 7 
mg/kgAmount of 8 0 mg /mL solution 
(mL) per Dose
3 21 0.42
3.5 24.5 0.49
4 28 0.56
4.5 31.5 0.63
5 35 0.70
5.5 38.5 0.77
6.0 42 0.84
6.5 45.5 0.91
7.0 49 0.98
7.5 52.5 1.05
8 56 1.12
8.5 59.5 1.19
9 63 1.26
9.5 66.5 1.33
10 70 1.40
10.5 73.5 1.47
11 77 1.54
11.5 80.5 1.61
12 84 1.68
12.5 87.5 1.75
13 91 1.82
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
156Revised Table:
RTV 7 mg /kg BID
Weight (kg)Dose (mg): 7 
mg/kgAmount of 8 0 mg /mL solution 
(mL) per Dose
3 21 0.26
3.5 24.5 0.31
4 28 0.35
4.5 31.5 0.39
5 35 0.44
5.5 38.5 0.48
6.0 42 0.53
6.5 45.5 0.57
7.0 49 0.61
7.5 52.5 0.66
8 56 0.70
8.5 59.5 0.74
9 63 0.79
9.5 66.5 0.83
10 70 0.88
10.5 73.5 0.92
11 77 0.96
11.5 80.5 1.01
12 84 1.05
12.5 87.5 1.09
13 91 1.14
Change 2:   To correct the ULN for Grade 3 ALT and /or AST to (>5x ULN)
Amend:
Section 3.1.2, Exclusion Criteria, bullet # 9 (per amendment 5)
Original Text:
9.Grade 3 or higher (>10x U LN) serum aminotransferase levels (alanine 
aminotransferase, ALT and/or aspartate aminotransferase, AST) within 28 day s prior 
to study  drug administration and / or clinically  relevant hepatitis within the previous 
6months.
Revised Text:
9.Grade 3 or higher (>5x ULN ) serum aminotransferase levels (alanine 
aminotransferase, ALT and/or aspartate aminotransferase, AST) within 28 day s prior 
to study  drug administration and / or clinically  relevant hepatitis within the previous 
6months.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].14. Appendix 14:  Protocol A mendment 7
Title:  APV20002 -A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safet y, tolerability and antiviral activit y of GW433908 
and GW433908/RTV when administered to HIV -1 infected protease inhibitor (PI) n aïve 
and PI -experienced pediatric subjects aged 4 weeks to <2 y ears.
This protocol amendment will apply  to all study  sites.
This amendment is being implemented to provide the dose recommendation for new 
subjects enrolled in Cohort 2 Arm A, to remove the Si ngle Dose Visit (SDV) for subjects 
enrolled into this cohort and to increase the overall number of subjects to be enrolled into 
Cohort [ADDRESS_273881] of the 
study .
This amendment consists of the following changes:
1.Add a dose recommendation for subjects recruited into Cohort 2 Arm A.
Reason for chang e:  Following the anal ysis of available PK data from the first 12 
subjects enrolled in Cohort 2 Arm A (4 weeks to <6 months), a FPV/RTV dose 
regiment of 45/ 10 mg /kg BID is being recommended for all new subjects enrolled 
into this cohort.
Dose rationale:  P lasma APV PK data are available from the first 12 subjects enrolled 
in Cohort 2 Arm 1 (4 week to <6 month age group).  On both single dose and repeat 
dose administration of FPV/RTV, pediatric subjects 4 weeks to<6month old had 
higher plasma APV Cmax and AUC values, but similar C12 (single dose) and lower 
C(repeat dose) values than historically  observed for adults.  Repeat dose plasma 
RTV Cmax and AUC values were similar to historical adult data, but plasma RTV C 
values were lower in the pediatric subje cts.  Because plasma APV C is important for 
long-term efficacy  and minimization of resistance development, it is important to try  
to achieve plasma APV C values in pediatric subjects similar to those achieved with 
the FPV/RTV 700/10 0 mg BID regimen that has demonstrated efficacy  in adults.  I t 
is possible that the lower plasma RTV C values are responsible for the lower plasma 
APV C values; therefore, an increase in the RTV dose for all subsequently enrolled 
subjects is being recommended.  Therefore, the recommended dosage regimen for 4 
weeks to <6month old subjects enrolled into Study  APV20002 is FPV/RTV 45/ 10 
mg/kg BID.  Newly  enrolled subjects will not undergo the SDV, but will have serial 
PK sampling on Week 2 and trough sampling on subsequent visits .
2.Single Dose Visit is deleted from the assessments, and Flow Chart of Clinical 
Scheduled Assessments for subjects recruited into Cohort 2 Arm A.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
158Reason for change:   As per Section 3.3.4 of the protocol, sufficient PK data is now 
available to inform on the dose recommendation for subjects enrolled into Cohort 2 
Arm A and therefore this visit is no longer required.
3.Update to the number of subjects to be recruited into Cohort 2 Arm A.
Reason for change:   Additional subjects need to be enrolled into Cohort 2 A rm A to 
provide sufficient data on the FPV/RTV 45/ 10 mg /kg BID dose.
4.Include the option to use a local accredited laboratory  for hematology  and clinical 
chemistry  at the discretion of the investigator and with approval of [COMPANY_004].
Reason for change:   To add th e option to use local accredited laboratories for 
hematology  and clinical chemistry  to aid subject management.
5.Correction of some t ypographical errors.
Individual Changes:
Change 1:  
Amend:
Sponsor Information Page
Original Text:
Sponsor Medical Representatives:
, MD
GlaxoSmithKline
891-[ADDRESS_273882], Middlesex, UB6 0HE, [LOCATION_006]
Telephone: 
, MD
GlaxoSmithKline
Five Moore Drive
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]- 3398, [LOCATION_003]
Telephone: 
Revised Text:
, MD
GlaxoSmithKline
891-[ADDRESS_273883], Middlesex, UB6 0HE, [LOCATION_006]
Telephone: 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
159Change 2:
Amend:
Protocol Summary, Dose Rationale, 5thparagraph
Original Text:
Plasma APV PK data ar e not available for the 4 week to <6 month age group (Cohort 2).  
Based on the higher doses required in the 6 month to <2 y ear age group (Cohort 1), a 
single dose of FPV/RTV 45/ 7 mg /kg will be administered at the SDV for Cohort 2 Arm 
A SDV.  Further dose m odification is described in Section 3.1 and Section [IP_ADDRESS].  When 
sufficient data are available to provide a dose recommendation for Cohort 2 Arm A, the 
information will be communicated to the sites through a letter, followed by a formal 
protocol amendment.
Revised Text:
Plasma APV PK dat a are available from the first 12 subjects enrolled in Cohort 2 Arm 1 
(4 week to <6 month age group).  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat administration of FPV/RTV BID at 
individualized dosage reg imens ranging from FPV 30 -60 mg /kg and RTV 7 -10 mg /kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 week to <6month old had higher 
plasma APV Cmax and AUC values, but simi lar C12 (single dose) and lower C (repeat 
dose) values compared with that historically  observed for adults.  Repeat dose plasma 
RTV Cmax and AUC values were similar to historical adult data, but plasma RTV C 
values were lower in the pediatric subjects.  As plasma APV C is important for long -
term efficacy  and minimization of resistance development, it is important to try  to 
achieve plasma APV C values in pediatric subjects similar to those achieved with the 
approved FPV/RTV 700/10 0 mg BID regimen in adul ts.  It is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefore, 
an increase in the RTV dose for all subsequently  enrolled subjects is  recommended.
Per Protocol Amendment 7, a SDV is no longer required for newl y enrolled 4 week to <6 
month age subjects (Cohort 2 Arm A).  These subjects will initiate dosing with FPV/RTV 
45/10 mg /kg BID and have serial PK sampling at Week 2 and trough sampling on 
subsequent visits.
Change 3: 
Amend:
Protocol Summary, Stud y Design
Original Text:
As per Amendment 5, the approximate number of subjects required in APV20002 in 
addition to the 13 previously  enrolled is illustrated in the following table.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
160Approximate Number of A dditional Subjects Required in A PV20002 (as of Proto col 
Amendment 05)
Approximate Number of Additional 
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227359]
1 6 months –<2 years 12 NA1
2 4 weeks –<6 months 12 NA1
1. Not Applicable as Arm B enrolment is defer red
Revised Text:
As per Amendments 5 and 7, the approximate number of additional subjects required in 
APV20002 in addition to the 13 previously  enrolled is illustrated in the following table.
Number of A dditional Subjects Required in A PV20002 (as of Pro tocol 
Amendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment complete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate multiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects initiate mul tiple dosing with FPV/RTV 45/ 10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
Change 4:
Amend:
Protocol Summary, Study Design, Overview, 2ndparagraph onwards
Original Text:
The initial group of subjects enrolled who undergo single dose visit (SDV) assessments 
before commencing multiple dosing with for example FPV/RTV at Baseline are referred 
to as Arm A SDV.  The subsequent group of subjects enrolled that do not undertake 
single dose visit assessments and begin multi ple dosing with FPV/RTV at Baseline are 
simply  referred to as Arm A. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
161Refer to Section 3.1 ( Figure 1and Figure 2) for schematics outlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
The first 6 -10 subjects in Cohort 2 Arm A will undergo one Single Dose Visit (SDV). 
The SDV will be undertaken a minimum of 15 days prior to the Baseline visit/Day  1. At 
the SDV, the subject will receive a single dose of FPV 4 5 mg /kg and a single dose of 
RTV 7 mg /kg administered simultaneously  and undergo serial plasma PK sampling over 
8-[ADDRESS_273884] an individualized dosing regimen prior to initiation of multiple dosing 
at Baseline/Day  1 (See Section 3.3.4). Every  effort will be made to ensure that the 
investigator is advised, within 14 day safter completion of the SDV evaluations of the 
individualized dose regimen selected.  Multiple dosing with FPV/RTV may  not be 
initiated until the subject’s single dose PK data are available. 
The first 6 -10 subjects in Cohort 2 Arm A will also undertake f urther plasma PK 
sampling over 8 -12hours (12 hour sample optional) after attaining stead y-state at the 
Week [ADDRESS_273885] should remain on the current regimen or undergo a dosage regimen adjustment at 
the Week 4 visit.  The Week 4 visit should not be undertaken until W eek 2 PK data are 
available.
Arm A: Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 5, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit. After 
the Week [ADDRESS_273886] been collected (sampling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo plasma PK serial 
sampling at Week 8 (over 8 -12 hours; 12 hour sample optional). Refer to Section 3.3.4 
for further information.  Approximately  12 PI -naïve or PI -experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
162Cohort 2 (4 weeks to <6 months)
Additional PI -experienced or PI -naïve subjects will subsequently  be recruited into Cohort 
2 Arm A and will commence multiple dosing with FPV/RTV BID on study Day  1 
without undertaking a SDV.  The dose will be based on the Week 2 plasma PK data from 
the initial 6 -10 subjects in Arm A SDV of Cohort 2 who unde rwent single dose 
assessments.  Subjects in Cohort 2 Arm A will undergo plasma PK serial sampling over 
8-12 hours (12 hour sample optional) at the Week 2 visit. 
Revised Text:
The initial group of subjects who were enrolled into the study  underwent a singl e dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments. Refer to Section 3.1 ( Figure 1and Figure 2) 
for schematics outlining the study  design for Cohort 1 Arm A and Cohort 2 Arm A, 
respectivel y.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additi onal subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments.
Arm A: Subjects Not Undertaking Single Dose Visi t Assessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 5, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit. After 
the Week [ADDRESS_273887] been collected (samp ling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo plasma PK serial 
sampling at Week 8 (over 8 -12 hours; 12 hour sample optional). Refer to Section 3.3.4 
for further information.  Approximately  12 PI -naïve o r PI-experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, all new subjects who enrol in Cohort 2 Arm A will commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the initial 12 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
163subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in 
Cohort 2 Arm A will undergo plasma PK serial sampling ov er 8-12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experienced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen.
Change 5:
Amend:
Protocol Summary, Study Population, 2ndparagraph
Original Text:
As of Amendment 5, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l approximately  12 
additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks to <6 months) 
will enro l approximately  12 subjects to receive FPV/RTV BID. Enrolment in the 
unboosted FPV BID cohorts (Arm B) is deferred.
Revised Text:
As per Amendments 5 and 7, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  12 additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A 
(4weeks to <6 months) will enro l approx imately  20-24 subjects to receive FPV/RTV 
BID. Enrolment in the unboosted FPV BID cohorts (Arm B) is deferred.
Change 6:
Amend:
Protocol Summary, Measurements and Evaluations
Original Text:
Schedules showing the timing of stud y procedures and laboratory ev aluations for all 
subjects are shown in Section 10.  Subjects will attend the clinic at Screening (within 
approximately  21 day s prior to Baseline/Day  1), the Single Dose Visit (first 6 -10 
subjects, Cohort 2 Arm A SDV only ), Day  1 (Baseline), and Weeks 2, 4 , 8, 12, 16, 24, 
36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral suspension 
are available locally  and pediatric dosing is approved in the relevant age groups. I n 
countries where local availability  is delay ed or the drug is not y et available through 
national treatment programs, subjects may  continue to receive FPV until they  no longer 
derive clinical benefit or according to prior agreements between [COMPANY_004] and participating 
study  sites for provision of ART.  A follow -up visit will be performed 4 weeks after the 
permanent discontinuation of study  drug.
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluation of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Pl asma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
every  12 weeks thereafter. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
164Cohort 2 (4 weeks to <6 months) Arm A SDV/ Arm A: Plasma samples for evaluation of 
PK parameters will be collected at the Single Dose Visit for the first 6 -10 subjects (Arm 
A SDV).  For all subjects in Cohort 2 Arm A, plasma PK samples will be collected over 
8-12 hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be 
collected at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks thereafter .
Revised Text:
Schedules showing the timing of stud y procedures and laboratory evaluations for all 
subjects are shown in Section 10.  Subjects will attend the clinic at Screening (within 
approximately  21 day s prior to Baseline/Day  1),  Day  1 (Baseline), a nd Weeks 2, 4, 8, 12, 
16, 24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects may continue to receive FPV until they  no 
longer derive clinical benefit or according to prior agreements between [COMPANY_004] and 
participating stud y sites for provision of ART.  A follow -up visit will be performed 
4weeks after the permanent discontinuation of study  drug.
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluation of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Plasma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
every  12 weeks thereafter. 
Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected over 8 -12 
hours (12 hour sample optional) at Week 2.  Plasma trou gh PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks thereafter.
Change 7:
Amend:
Section 3.1 Study Design, 2ndparagraph onwards
Original Text:
As per Amendment 5, the approximate number of subjects required in APV20002 in 
addition to the 13 previously  enrolled is illustrated in Table 1.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
165Table 1. Approximate Number of A dditional Subjects Required in A PV20002 
(as of Protocol A mendment 05)
Approximate Number of Additional 
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227359]
1 6 months –<2 years 12 NA1
2 4 weeks –<6 months 12 NA1
1. Not Applicable as Arm B enrolment is deferred
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 mont hs) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects enrolled who undergo single do se visit (SDV) assessments 
before commencing multiple dosing with for example FPV/RTV at Baseline are referred 
to as Arm A SDV.  The subsequent group of subjects enrolled that do not undertake 
single dose visit assessments and begin multiple dosing with FP V/RTV at Baseline are 
simply  referred to as Arm A. 
Refer to Figure 1and Figure 2for schematics outlining the stud y design for Cohort 1 
Arm A and Cohort 2 Arm A, respectivel y.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
The first 6 -10 subjects in Cohort 2 Arm A will undergo one Single Dose V isit (SDV). 
The SDV will be undertaken a minimum of 15 days prior to the Baseline visit/Day  1. At 
the SDV, the subject will receive a single dose of FPV 4 5 mg /kg and a single dose of 
RTV 7 mg /kg administered simultaneously  and undergo serial plasma PK samp ling post -
dosing over [ADDRESS_273888] an individualized dosing regimen prior to initiation of 
multiple dosing at Baseline/Day  1. (See Section 3.3.4) Every  effort will be made to 
ensure that the investigator is advised, within 14 day s after completion of the SDV 
assessments, of the individualized dose regimen selected.  Multiple dosing with 
FPV/RTV may  not be initiated until the subject’s single dose PK data are available. 
GD2001/[ZIP_CODE]/[ADDRESS_273889] 6 -10 subjects in Cohort 2 Arm A will also undertake further plasma PK 
sampling over 8 -12hours (12 -hour sample optional) after attaining steady -state at the 
Week [ADDRESS_273890] should remain on the current regimen or undergo a dosage regimen adjustment at 
the Week 4 visit.  The Week 4 visit should not be undertaken until Week 2 PK data are 
available.
Arm A:  Subjects Not Undertaking Single Dose Visit A ssessments 
Cohort 1 (6 months to <2 years) 
Per Amendme nt 5, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit.  After 
the Week [ADDRESS_273891] been collected (sampling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo serial plasma PK 
sampling at Week 8 (over 8 -12 hours; 12 hour sample optional).  Refer to Sect ion 3.3.4 
for further information.  Approximately  12 PI -naïve or PI -experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen .
Cohort 2 (4 weeks to <6 months) 
Additional PI -experienced or PI -naïve subjects will subsequently  be recruited into Cohort 
2 Arm A and will commence appropriate multiple dosing with FPV/RTV BID on study 
Day 1 without undertaking a SDV.  The dose will be based on the Week 2 plasma PK 
data from the initial 6 -10 subjects in Arm A SDV of Cohort 2 who under went single dose 
assessments.  Subjects in Cohort 2 Arm A will undergo serial plasma PK sampling over 
8-12 hours (12 hour sample optional) at the Week 2 visit. 
Revised Text:
As per Amendments 5 and 7, the approximate number of additional subjects required in 
APV20002 in addition to the 13 previously  enrolled is illustrated in Table 1 . 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
167Table 1 Number of A dditional Subjects Required in A PV20002 (as of 
Protocol A mendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment complete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate mul tiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects initiate multiple dosing with FPV/RTV 45/ 10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.
Refer to Figure 1and Figure 2for schematics outlining the stud y design for Cohort 1 
Arm A and Cohort 2 Arm A, respectivel y.
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no addition al subjects in this age group are required to undertake SDV 
assessments.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
168Arm A:  Subjects Not Undertaking Single Dose Visit A ssessments 
Cohort 1 (6 months to <2 years) 
Per Amendment 5, all new subjects who enrol in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit.  After 
the Week [ADDRESS_273892] been collected (sampling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo serial plasma PK 
sampling at We ek 8 (over 8 -12 hours; 12 hour sample optional).  Refer to Section 3.3.4 
for further information.  Approximately  12 PI -naïve or PI -experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen .
Cohort 2 (4 weeks to <6 months) 
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will commence  
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is be based on the Week 2 plasma PK data from the initial 
12 subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  
Subjects in Cohort 2 Arm A will undergo serial plasma PK sampling over 8 -12 hours (12 
hour sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -
experienced subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
Change 8:
Amend:
Section 3.3.4, 6thparagraph
Original Text:
Plasma APV PK data are not y et available for the 4 week to <6 month age group (Cohort 
2).  Based on the higher doses required in the 6 month to <2 y ear age group, a single dose 
of FPV/RTV 45/ 7 mg /kg will be administered at the SDV for Cohort 2 Arm A SDV (4 
weeks to <6 months).  Further dose modification is described in Section 3.1 and 
Section [IP_ADDRESS].  When sufficient data are available to provide a dose recommendation for 
Cohort 2 Arm A, the information will be communicated to the sites through a letter, 
followed b y a formal protocol amendment.
Revised Text:
Plasma APV PK data are available from the first 12 subjects enrolled in Cohort 2 Arm 1 
(4 week to <6 month age group).  Overall, pediatric subjects 4 week to <6month old had 
higher plasma APV Cmax and AUC values, but similar C12 (single dose, Table 2) and 
lower C (repeat dose, Table 3) values than historically  observed for adults.  Repeat dose 
plasma RTV Cmax and AUC values were similar to historical adult data, but plasma 
RTV C values were lower in the pediatric subjects overall (Table 4).  Because plasma 
APV C is important for long -term efficacy  and minimization of resistance dev elopment, 
it is important to try  to achieve plasma APV C values in pediatric subjects similar to 
those achieved with the FPV/RTV 700/10 0 mg BID regimen that has demonstrated 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
169efficacy  in adults.  Although FPV/RTV 60/ 10 mg/kg exhibited APV C ,ss most simila r to 
adults (Figure 3), the APV Cmax for this regimen was considered unnecessarily  high 
(Figure 4).   The RTV 10 mg /kg in the FPV/RTV 60/ 10 mg /kg regimen provided the 
most consistently  high RTV C ,ss values as compared to 30/7 and 45/ 7 mg /kg (Figure 5).  
It is possible that the lower plasma RTV C values resulted in the lower plasma APV C 
values for the lower two regimens.  Therefore, all subjects < 6 month s in age subsequentl y 
enrolled in the study  will receive FPV/RTV 45/ 10 mg /kg to maximize RTV C while 
maintaining APV Cmax values that are not excessively  high. 
Per Protocol Amendment 7, newly  enrolled 4 week to <6 month age subjects (Cohort 2 
Arm A) will initiate dosing with FPV/RTV 45/10 mg /kg BID.  Newly  enrolled subjects 
will not undergo the SDV, but will have serial PK sampling on Week 2 and trough 
sampling on subsequent visits.
Table 2 Summary  of Single Dose Plasma A PV PK in Pediatric Subjects <6 
months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV 45/ 7 mg/kg
(N=11)1Adult Subjects
FPV/RTV 700/10 0 mg
(N=17)
Cmax ( g/mL) 9.74
(5.67, 16.2)3.65
(2.54, 6.76)
AUC(0 -) (g.h/mL) 57.5
(20.2, 111)35.2
(20.8, 114)
C8h (g/mL) 2.64
(0.819, 5.86)1.10
(0.451, 2.20)
C12h ( g/mL)2 1.13
(0.41, 3.76)1.19
(0.659, 1.92)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Data for pediatric Subject  was excluded because exposures were very high: Cmax: 30.9 g/mL, AUC(0- ): 
335g.h/mL, C8hr: 16.9 g/mL.
4. C12h is extrapolated value for pediatric subjects and observed value for adult subjects
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
170Table 3 Summary  of Repeat Dose Plasma A PV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV BID1
(N=9)2Adult Subjects
FPV/RTV 700/10 0 mg
(N=14)
Cmax ( g/mL) 8.90
(2.07, 12.1)4.76
(2.47, 7.68)
AUC(0 -) (g.h/mL) 41.0
(16.2, 70.4)28.3
(17.9, 43.1)
C8h (g/mL) 2.05
(1.10, 3.25)1.58
(0.816, 2.64)
C(g/mL)3 0.970
(0.438, 1.95)1.46
(1.06, 2.20)
1. Pediatric data from S tudy APV20002
2. Adult data from Study APV10013
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject  was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
Table 4 Summary  of Repeat Dose Plasma RTV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma RTV
PK ParameterPediatri c Subjects 
1 to <6 months
FPV/RTV BID1Adult Subjects
FPV/RTV
700/10 0 mg BID
(N=9)2 (N=8)2,3 (N=24)
Cmax ( g/mL) 1.28
(0.228, 7.70)0.999
(0.228, 2.11)1.24
(0.520, 3.84)
AUC(0 -) 
(g.h/mL)6.66
(0.922, 28.8)4.67
(0.922, 14.30)5.59
(2.88, 14.4 )
C8h (g/mL) 0.270
(0.021, 1.05)0.239
(0.021, 1.05)0.260
(0.068, 0.614)
C(g/mL)3 0.075
(NQ, 0.496)0.069
(NQ, 0.496)0.165
(0.010, 0.610)
1. 2. Pediatric data from Study APV20002
3. Adult data from Study APV10010
4. Pediatric FPV/RTV dosage regimens includ ed: 30/7 mg/kg BID (N=2), 
45/7 mg/kg BID (N=4), 45/10 mg/kg BID (N=1), and 60/ 10 mg/kg BID 
(N=4).
5. Data for pediatric Subject was excluded because pre -dose APV 
concentration was non -quantifiable (NQ).
6. Data summarized excluding Subject who had high RTV Cmax and 
AUC values.
7. Ccalculated as the mean of the pre -dose and C12h (extrapolated) 
values.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
171Figure 3 Week 2 Plasma A PV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/ 100 mg )
FPV/ RTV dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/ 100 (n=14)APV Ctau,ss (ug/mL)
[IP_ADDRESS].02.5
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
172Figure 4 Week 2 Plasma A PV Cmax Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=14)APV Cmax (ug/mL)
[IP_ADDRESS].510.012.5
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
173Figure 5 Week 2 Plasma RTV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Su bjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=24)RTV Ctau,ss (ug/mL)
[IP_ADDRESS].[IP_ADDRESS]
Change 9:
Amend:
Section 5.1 Time and Events Schedule, 1stto 3rdparagraphs
Original Text:
Schedules showing the timing of stud y procedures and laboratory evaluations for al l 
subjects are shown in Section 10.
After determining that a subject is potentially  eligible for enrolment, written informed 
consent from each subject’s parent/guardian must be obtained before any  investigations 
are performed which are for the sole purpose s of this study .
Subjects will attend the clinic at Screening, the Single Dose Visit (first 6 -10 subjects, 
Cohort 2 Arm A only ), Day  1 (Baseline), and Weeks 2, 4, 8, 12, 16, 24, 36, 48, and every  
12 weeks thereafter until commercial supplies of FPV oral su spension are available 
locally  and pediatric dosing is approved in the relevant age groups.  In countries where 
local availability  is delayed or the drug is not y et available through national treatment 
programs, subjects may  continue to receive FPV until t hey no longer derive clinical 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
174benefit or according to prior agreements between [COMPANY_004] and participating study  sites for 
provision of ART.   A follow -up visit will be performed 4 weeks after the permanent 
discontinuation of study  drug.  
Revised Text:
Schedules showing the timing of stud y procedures and laboratory evaluations for all 
subjects are shown in Section 10.
After determining that a subject is potentially  eligible for enrolment, written informed 
consent from each subject’s parent/guardian must be obtain ed before an y investigations 
are performed which are for the sole purposes of this study .
Subjects will attend the clinic at Screening, Day  1 (Baseline), and Weeks 2, 4, 8, 12, 16, 
24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects may continue to receive FPV until they  no 
longer derive clinical benefit or according to prior agreements between [COMPANY_004] and 
participating stud y sites for provision of ART.   A follow -up visit will be performed 
4weeks after the permanent discontinuation of study  drug.  
Change 10:
Amend:
Section 5.2 Screening and Enrolment
Original Text:
Subjects will undertake the procedures listed in the schedules in Section 1  Screening will 
be within approximately  21 day s of Baseline/Day  [ADDRESS_273893] eligibility  are available.
Reports of screening assessments of ly mphocy te subsets, HIV -1 RNA PCR and HIV -1 
resistance testing (if performed) should be reviewed prior to Baseline/Day  [ADDRESS_273894] meets the full eligibility  criteria.  Subjects who undertake the Single Dose 
Visit but whose subsequently  reported screening assessments of lymphocy te subsets, 
HIV-1 RNA PCR and HIV -1 resistance testing (if performed) do not meet with the 
eligibility  criteria may  not initiate multiple dosing with FPV.
Revised Text:
Subjects will undertake the procedures listed in the schedules in Section 10.  Screening 
will be within approximately  21 day s of Baseline/Day  1 for all subjects.   As per 
amendments 5 and 7, SDV assessments are no longer required for Cohort 1 Arm A and 
Cohort 2 Arm A.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
175Reports of screening assessments of ly mphocy te subsets, HIV -1 RN A PCR and HIV -1 
resistance testing (if performed) should be reviewed prior to Baseline/Day  [ADDRESS_273895] meets the full eligibility  criteria.  
Change 11:
Amend:
Section 5.7  Bioanalysis and Pharmacokinetic Samples, 2ndparagraph
Original T ext:
Cohort 2 (4 weeks to <6 months) Arm A: Plasma samples for evaluation of PK 
parameters will be collected at the Single Dose Visits for the first 6 -10 subjects (Arm A 
SDV).  For all subjects in Cohort 2 Arm A, plasma PK samples will be collected over 8 -
12 hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be 
collected at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks thereafter. 
To measure the unbound concentration of APV, additional plasma trough PK samples 
will be collected prio r to FPV/RTV BID dosing at Weeks 2, 16 and 36 for Cohort 1 Arm 
A subjects and at Weeks 8 and 16 for Cohort 2 Arm A subjects.
A maximum of 7mL /kg of blood for PK, safety , and virological assessments will be 
collected during an y 56-day period for all subject s.  A maximum of 3mL /kg of blood will 
be collected at an y one study visit for subjects 4 weeks to <6 months old.
Single Dose Visit (SDV)
Cohort 1 (6 months -<2 years)
Per protocol amendment 5, no additional subjects in this age group are required to 
under take SDV assessments.
Cohort 2 (4 weeks -<6 months)
The first 6 -10 subjects in Arm A, who may  be either PI -experienced or PI -naïve, will 
undergo one Single Dose Visit (SDV).  The SDV will be undertaken a minimum of 15 
days prior to the Baseline visit/Day  1.  At the SDV, the subject will receive a single 4 5 
mg/kg dose of FPV and a single 7 mg /kg dose of RTV and undergo plasma PK sampling 
over 8 -12hours (s even whole blood samples of 0.5mL  each will be collected at 0, 1, 2, 4, 
6, 8, and [ADDRESS_273896] -dosing) .  With prior agreement of the sponsor, the 12 -hour sample 
may be omitted if logistical reasons do not allow collection of this sample.
Revised Text:
Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected over 8 -12 
hours ([ADDRESS_273897] e optional) at Week 2.  Plasma trough PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks thereafter. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
176To measure the unbound concentration of APV, additional plasma trough PK samples 
will be collected prior to FPV/RTV BID dosing at Weeks 2, 16 and 36 for Cohort 1 Arm 
A subjects and at Weeks 8 and 16 for Cohort 2 Arm A subjects.
A maximum of 7mL /kg of blood for PK, safety , and virological assessments will be 
collected during an y 56-day period for all subjects.  A maximum of 3mL /kgof blood will 
be collected at an y one study visit for subjects 4 weeks to <6 months old.
Single Dose Visit (SDV)
Cohort 1 (6 months -<2 years)
Per protocol amendment 5, no additional subjects in this age group are required to 
undertake SDV assessments.
Cohort 2 (4 weeks -<6 months)
Per protocol amendment 7, no additional subjects in this age group are required to 
undertake SDV assessments.
Change 12:
Amend:
Section 5.7  Bioanalysis and Pharmacokinetic Samples, Logistical Considerations, 
4th paragraph
Original Text:
Where expedited anal ysis of PK samples is required to construct individualized dose 
regimens or undertake individualized dose adjustments (see Section 3.3.4), every  effort 
will be made to ensure that the investigator is advised, within 14 day s after completion of 
the Single Dose Visit evaluations of the individualized dose regimen selected. (On receipt 
of samples at the nominated bioanal ytical laboratory , [COMPANY_004] has contracted that 
preliminary  APV, RTV and where plasma volumes allow FPV concentrati ons will be 
made available within 5 working day s.  It is anticipated that [COMPANY_004] evaluation of the 
preliminary  PK data will be complete and released to the investigator following a further 
2 working day s.)
Revised Text:
Paragraph deleted
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
177Change 13:
Amend:
Section 5.8 Safety, 2ndand 3rdparagraphs
Original Text:
All routine scheduled laboratory  evaluations within the study  will be undertaken b y a 
central laboratory  nominated by  [CONTACT_456].  However, evaluation of hematology , 
clinical chemistry  and liver funct ion tests at screening onl y ma y be undertaken at a local 
accredited laboratory  at the discretion of the investigator and with the approval of [COMPANY_004].
Refer to the central laboratory  manual for specific instructions on sample collection, 
processing, storage an d shippi[INVESTIGATOR_227361].   Screening hematology , clinical 
chemistry  and liver function tests undertaken at a local laboratory  should be handled 
according the standard local procedures.
Revised Text:
Scheduled laboratory  evaluations within the s tudy will be undertaken b y a central 
laboratory  nominated b y the sponsor.  However, evaluation of hematology  and clinical 
chemistry  may  be undertaken at a local accredited laboratory  with the approval of [COMPANY_004].
Refer to the central laboratory  manual for spec ific instructions on sample collection, 
processing, storage and shippi[INVESTIGATOR_227361].  Hematology  and clinical 
chemistry  undertaken at a local laboratory  should be handled according the standard local 
procedures.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
178Change 14:
Amend
Figure 2:  S tudy Design for Cohort 2 Arm A: PI -naïve or PI -experienced subjects 4 weeks to <6 months of age
Original Figure:
ARM A SDV: The initial [ADDRESS_273898] their dose determined on the basis of t he 
initial subjects’ Week 2 PK and will initiate multiple dosing wi th 
FPV/RTV BID from baseline.
≤21 DAYS
≥15 DAYS 14 DAYSSUBSEQUENTLY≤[ADDRESS_273899] or loc al
LabSDV
FPV/ RTV
8-12 Hr PKBASELINE/ 
DAY  1
Initiate 
FPV/RTV BID 
multiple dosingWE EK 2
8-12 Hr PKWE EK 4
Potential
Dose
Adjustment
Based on
Week 2 PKARM A: Subjects will initiate multiple dosing with FPV/RTV BID from baseline.
Approximately 12 additional subjects will be enrolled.
SCREENING WE EK 2
8-12 Hr PK14 DAYS14 DAYS
BASELINE/ 
DAY  1
Initiate 
FPV/RTV BID 
multiple dosing
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
179Revised Figure:
ARM A SDV : The initial [ADDRESS_273900] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYNote:   Cohort 2 A rm A  SDV is complete.  
Further subjects will enroll in Cohort 2 A rm A and initiate multiple dosing with FPV/RTV BID from Baseline
ARM A SDV : The initial [ADDRESS_273901] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYARM A SDV : The initial [ADDRESS_273902] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYNote:   Cohort 2 A rm A  SDV is complete.  
Further subjects will enroll in Cohort 2 A rm A and initiate multiple dosing with FPV/RTV BID from Baseline
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
180Change 15:
Amend:
Section 10, Original Chart
Revised Flow Chart of Clinical Scheduled A ssessments (Per A mendment 5)
CLIN CAL EVALUATIONScreening 
Visit 1Single 
Dose 
Visit 2Day 1 
(Baseline) 3Week 
2 4 8 12 16 24 36 48Every 12 
weeks 
thereafterWith-
drawalFollow -up 
4
Written Informed Consent
Inclusion/Exclusion Criteria
Demo graphy (date of birth, sex, and race)
HIV Risk Factors
CDC HIV -1 Classification
Current Medical Conditions
Body Weight , Height and Vital Signs      
Head Circumference      
Prior Antiretroviral Therapy History
Background Antiretroviral Therapy     
Concurrent Medications/Blood Products     
HIV-associated Conditions    
Adverse Experience Surveillance
 5  
 
Adherence Questionnaire      
Parent/Guardian Perception of Study Medication    
1.Screening will be within approximately 21 days prior to Baseline/Day [ADDRESS_273903] 6 -10 subjects in Cohort 2 Arm A will undergo a Single Dose Visit (SDV).  The SDV will be undertaken a minimum of 15 days prior to B aseline/Day 1.  Note: 
SDVs are no longer needed for Cohort 1 Arm A .  
3.Subjects will initiate multiple dosing on Day 1 (Baseline)
4.[ADDRESS_273904] serious adverse events related to study participation only during screening.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
181Revised Flow Chart of Laboratory  Scheduled A ssessments (Per A mendment 5)
LABORATORY EVALUATION 2Screening 
Visit 1Single 
Dose 
Visit Day1 
(Baseline) Week
2 4 8 12 16 24 36 48Every 12 weeks 
thereafterWithdrawal Follow -
up 
Lipi[INVESTIGATOR_805] 3

Hematology 4 
 
Clinical Chemistry and Liver Function 
Tests 5

Lymphocyte subsets
 
Quanatitative plasma HIV -1 RNA PCR
 
Plasma for storage 6

Pharmacokinetic Sampling 10, 11789
HIV-1 resistance testing 12
1.Screening will be within approximately 21 days prior to Baseline/Day 1 for all subjects. 
2.Laboratory assessments for all cohorts are prioritized as follows: hematology, chemistry, PK, plasma HIV -1 RNA PCR, lymphocyte subsets, HIV -1 RNA resistance testing, lipi[INVESTIGATOR_805], 
and plasma for storage. 
3.Lipid measures include: triglycerides and total, high density lipoprotein (HDL), and LDL cholesterol. 
4.Hematology includes: hemoglobin, WBC with differential, MCV and platelet count.
5.Clinical chemistry panel and transaminase levels (sodium, potassium, AST, ALT, total bilirubin, creatinine, albumin, glucose, alkaline phosphatase, and CPK). 
6.Plasma collected for storage where permitted by [CONTACT_227423] 1 and Week 12, 24, 36, 48, every 12 weeks th ereafter and Withdraw al.  This sample may be 
used for HIV -1 resistance testing in subjects experiencing virologic failure.
7.SDV: Plasma PK sampling over 8 -12 hours (at 0 [pre dose], 1, 2, 4, 6, 8, and 12 hours (12 hour sample optional) post -dosing following a single dose of FPV and RTV 
administered simultaneously for the first 6 -10 subjects in Cohort 2 Arm A SDV.
8.Week 2: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, and 12 hours (12 hour sample optional) post -dosing for Cohort 2 Arm A subjects and over 4 
hours (at 0 [pre -dose], 2 and 4 hours) post -dosing for subjects in Cohort 1 Arm A 
9.Week 8: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, and 12 hours (12 hour sample optional) post -dosing for subjects in Cohort 1 Arm A.
10.Samples for APV/ RTV trough concentration determination collected [ADDRESS_273905] dose at Week 8 (Cohort 2 Arm A only) and Weeks 12, 1 6, 24, 36, 48, and 
every 12 weeks thereafter (both cohorts).
11.Samples for unbound APV concentration evaluation should be collected [ADDRESS_273906] dose at Week 2 (Cohort 1 Arm A), Week 8 (Cohort 2 Arm A), Week 16 
(both cohorts), and Week 36 (Cohort 1 Arm A).
12. A sample for HIV -1 RNA resistance testing may be collected at Screening at the investigator’s discretion if needed to gui de selection of background ART.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
182Revised Chart:
Revised Flow Chart of Clinical Scheduled A ssessments (Per A mendments 5 and 7)
CLINCAL EVALUATIONScreening 
Visit 1Single 
Dose 
Visit 2Day 1 
(Baseline) 3Week 
2 4 8 12 16 24 36 48Every 12 
weeks 
thereafterWith-
drawalFollow -up 
4
Written Informed Consent
Inclusion/Exclusion Criteria
Demography (date of birth, sex, and race)
HIV Risk Factors
CDC HIV -1 Classification
Current Medical Conditions
Body Weight , Height and Vital Signs      
Head Circumference      
Prior Antiretroviral Therapy History
Background Antiretroviral Therapy     
Concurrent Medications/Blood Products     
HIV-associated Conditions    
Adverse Experience Surveillance
 5  
 
Adherence Questionnaire      
Parent/Gu ardian Perception of Study Medication    
1.Screening will be within approximately 21 days prior to Baseline/Day 1 for all subjects.  At screening only, the evaluation o f the hematology, clinical chemistry and liver function 
tests may be under taken at a local accredited laboratory at the discretion of the investigator and with approval of GlaxoSmithKline.
2.SDVs are no longer needed for Cohort 1 Arm A and Cohort 2 Arm A .  
3.Subjects will initiate multiple dosing on Day 1 (Baseline)
4.[ADDRESS_273907] serious adverse events related to study participation only during screening.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
183Revised Flow Chart of Laboratory  Scheduled A ssessments (Per A mendments 5 and 7)
LABORATORY EVALUATION 2Screening 
Visit 1Single 
Dose 
Visit Day1 
(Baseline) Week
2 4 8 12 16 24 36 48Every 12 weeks 
thereafterWithdrawal Follow -
up 
Lipi[INVESTIGATOR_805] 3

Hematology 4 
 
Clinical Chemistry and Liver Function 
Tests 5

Lymphocyte subsets
 
Quanatitative plasma HIV -1 RNA PCR
 
Plasma for storage 6

Pharmacokinetic Sampling 10, 11789
HIV-1 resistance testing 12
1.Screening will be within approximately 21 days prior to Baseline/Day 1 for all subjects. 
2.Laboratory assessments for all cohorts are prioritized as follows: hematology, chemistry, PK, plasma HIV -[ADDRESS_273908] asma for storage. 
3.Lipid measures include: triglycerides and total, high density lipoprotein (HDL), and LDL cholesterol. 
4.Hematology includes: hemoglobin, WBC with differential, MCV and platelet count.
5.Clinical chemistry panel and transaminase levels (sodi um, potassium, AST, ALT, total bilirubin, creatinine, albumin, glucose, alkaline phosphatase, and CPK). 
6.Plasma collected for storage where permitted by [CONTACT_227423] 1 and Week 12, 24, 36, 48, every 12 weeks th ereafter and Withdrawal.  This sample may be 
used for HIV -1 resistance testing in subjects experiencing virologic failure.
7.SDV plasma PK sampling no longer required for Cohort 1 Arm A and Cohort 2 Arm A..
8.Week 2: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, a nd 12 hours (12 hour sample optional) post -dosing for Cohort 2 Arm A subjects and over 4 
hours (at 0 [pre -dose], 2 and 4 hours) post -dosing for subjects in Cohort 1 Arm A 
9.Week 8: Plasma PK sampling over 8 -12 hours (at 0 [pre -dose], 1, 2, 4, 6, 8, and 12 h ours (12 hour sample optional) post -dosing for subjects in Cohort 1 Arm A.
10.Samples for APV/RTV trough concentration determination collected [ADDRESS_273909] dose at Week 8 (Cohort 2 Arm A only) and Weeks 12, 16, 24, 36, 48, and 
every 12 weeks therea fter (both cohorts).
11.Samples for unbound APV concentration evaluation should be collected [ADDRESS_273910] dose at Week 2 (Cohort 1 Arm A), Week 8 (Cohort 2 Arm A), Week 16 
(both cohorts), and Week 36 (Cohort 1 Arm A).
12. A sample for HIV -1 RNA resista nce testing may be collected at Screening at the investigator’s discretion if needed to guide selection of background ART.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
184Change 16:
Amend:
Appendix 6:  Dosing Table for RTV Oral Solution
Change:
Add a dosing 
table for RTV 10 mg /kg BID
RTV 10 mg /kg BI D
Weight (kg)Dose (mg): 10 
mg/kgAmount of 8 0 mg /mL solution 
(mL) per Dose
3 30 0.38
3.5 35 0.44
4 40 0.50
4.5 45 0.56
5 50 0.63
5.5 55 0.69
6.0 60 0.75
6.5 65 0.81
7.0 70 0.88
7.5 75 0.94
8 80 1.00
8.5 85 1.06
9 90 1.13
9.5 95 1.19
10 100 1.25
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].15. Appendix 15:  Protocol A mendment 8
Title:  APV20002 -A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safet y, tolerability and antiviral activit y of GW433908 
and GW433908/RTV when administered to HIV -1 infected protease inhibitor (PI) naïve 
and PI -experienced pediatric subjects aged 4 weeks to <[ADDRESS_273911] of the study . 
This amendment consists of the following changes:
a.Revision of the dose recommendation for new subjects enrolled into Cohort 1, Arm A 
to FPV/RTV 45/ 7 mg /kg with no increase to 60/ 7 mg /kg at week 2 and up date the 
number of subjects to be recruited into Cohort 1, Arm A.
Reason for change:   An anal ysis of available PK data in [ADDRESS_273912] five
subjects enrolled in Cohort 1 Arm A (6 months to 2 y ears) and from 11 newly  
enrolled  subjects indicated that  exposure in t his age group was closer to adult target 
exposure with  a dose of 45/7 mg/kg BID than 60/7 mg/kg BID. Therefore, it is 
recommended that for all new subjects enrolled into this cohort, the dose of FPV 
remains 4 5 mg /kg BID at week 2. 
b.Additional dosing advic e for existing subjects in Cohort 1 Arm A, receiving 
FPV/RTV 60/ 7 mg /kg .
Reason for change:   Following the anal ysis of available PK data from the first five  
subjects enrolled in Cohort 1 Arm A (6 months to <2 years) and 11 newl y enrolled 
subjects,  guida nce is provided to allow individual dose adjustments , based on viral 
load, pharmacokinetic and safet y assessments
c.Guidance on  dosing for subjects when reaching 2 and 6 y ears of age during the study   
Reason for change:   Dosing recommendations for patient s reaching 2 years of age 
and 6 y ears of age to allow staged dose reductions to the recommended doses for 
these ages.
d.Guidance to allow individual dose adjustments
Reason for change:   To allow flexibility  to make individual dose adjustments based 
on result s and review of available PK data from Cohort 1 and 2.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
186e.Provision for a single repeat testing for liver enzymes  in the event of grade 3 or 
higher within 28 day s prior to study  drug administration  to determine eligibility
Reason for change:   To allow retesting of eligible patients with an unexpected acute 
sporadic raised liver enzy me result at screening.
Individual Changes:
Change 1:  
Amend:
SPONSOR INFORMATION PAGE
Original Text:
Sponsor Medical Representatives:
, MD
GlaxoSmithKline
891-[ADDRESS_273913], Middlesex, UB6 0HE, [LOCATION_006]
Telephone: 
Revised Text:
Sponsor Medical Representatives:
, MD
GlaxoSmithKline
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, [LOCATION_006]
Telephone:  
Mobile: 
Change 2:  
Amend:
INVESTIGATOR AGREEMENT PAGE
Original Text:
I confirm agreement to conduct the study  in compliance with the protocol, as amended by  
[CONTACT_227437].
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
187Investigator Name:  ___________________ __________
Investigator Signature [CONTACT_227475]:
For protocol number APV20002
I confirm agreement to conduct the study  in compliance with the protocol, as amended by  
[CONTACT_227437].
I acknowledge that I am responsible for overall study conduct. I agree to personall y 
conduct or supervise the described clinical study .
I agree to ensure that all associates, colleagues and employ ees assisting in the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:  _____________________________
Investigator Signature [CONTACT_227476] 3:  
Amend:
ABBREVIATIONS
Original Text:
FPV fosamprenavir, GW433908, 908
Revised Te xt:
FPV fosamprenavir, GW433908, 908, Telzir, L exiva
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
188Change 4:  
Amend:
PROTOCOL SUMMARY, Dose Rationale
Original Text:
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspension formulation. I n children, the FPV oral suspension is recommended 
to be administered with food. 
Per protocol amendment 5, the FPV/RTV doses being studied are based on data from 
previously  enrolled subjects in APV20002.  All 13 previously  enrolled subjects 
underwent PK sampling duri ng the stud y and 12 subjects provided evaluable PK data.  
Only  two subjects below the age of 6 months provided PK data. Ten subjects between the 
ages of 6 months to <2 years provided PK data. 
Plasma APV PK parameter values were highl y variable (CVb rangin g from 113 to 165% 
across the PK parameters) for the subjects 6 months to <2 y ears of age (Cohort 1).  Nine 
of these subjects 6 months to <2 y ears of age receiving FPV/RTV BID regimens ranging 
from 29.4/5.6 to 51.1/8.2mg/kg BID had stead y-state plasma APV CL/F values 
approximately  7-fold and RTV CL /F values approximately  4.2-fold higher than those 
observed in the historical adult population.  Compared to the historical adult population, a 
subset of five pediatric subjects ages 6 months to <2 y ears receiving FPV/RTV 45/ 7 
mg/kg BID demonstrated that despi[INVESTIGATOR_227357] 5 -fold increase in FPV and RTV 
doses on a mg/kg basis, plasma APV AUC(0 -) was approximately  48% lower, Cmax 
26% lower, and C 29% lower in the pediatric subjects.  This data suggest that chi ldren 6 
months to <2 y ears of age old require higher doses of FPV and RTV than were 
previously  explored in this study .
Per Protocol Amendment 5, newly  enrolled 6 month to <2 y ear old subjects (Cohort 1 
Arm A) will initiate dosing with FPV/RTV 45/ 7 mg /kg BI D for two weeks and then 
increase to FPV/RTV 60/ 7 mg /kg BID.  This will allow additional PK data for the 
FPV/RTV 45/ 7 mg /kg BID regimen and also for an increased dosage regimen.  However, 
further dose increases could be problematic because they  would requi re high volumes of 
the FPV oral suspension.  Thus, plasma unbound APV concentrations (free drug) are 
being measured in order to determine if these concentrations are similar to historical adult 
values even if plasma total concentrations are lower.
Plasma A PV PK data are available from the first 12 subjects enrolled in Cohort 2 Arm 1 
(4 week to <6 month age group).  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat administration of FPV/RTV BID at 
individualized d osage regimens ranging from FPV 30 -60 mg /kg and RTV 7 -10 mg /kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 week to <6month old had higher 
plasma APV Cmax and AUC values, but similar C12 (single dose) and lower C (repeat 
dose) values compared with that historically  observed for adults.  Repeat dose plasma 
RTV Cmax and AUC values were similar to historical adult data, but plasma RTV C 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
189values were lower in the pediatric su bjects.  As plasma APV C is important for long-
term efficacy  and minimization of resistance development, it is important to try  to 
achieve plasma APV C values in pediatric subjects similar to those achieved with the 
approved FPV/RTV 700/10 0 mg BID regime n in adults.  I t is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefore, 
an increase in the RTV dose for all subsequently  enrolled subjects is  recommended.
Per Protocol Amendment 7, a SDV is no longer required for newl y enrolled 4 week to <6 
month age subjects (Cohort 2 Arm A).  These subjects will initiate dosing with FPV/RTV 
45/10 mg /kg BID and have serial PK sampling at Week 2 and trough sampling on 
subsequent visits.
Per Protocol Amendment 5, enrol ment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age- specific FPV/RTV cohorts 
are available to assist in the dose selection for the corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
Revised Text:
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspension formulation. I n children, the FPV oral suspension is recommended 
to be administered with food. 
APV20002 was designed to determine FPV/RTV regimens for pediatric subjects 4 weeks 
to<2 years of age that would deliver plasma APV exposures proven to be safe and 
effective in adults. 
In a small subset of five subjects aged 6 months to <2 y ears ( Cohort 1, Arm A) who 
received FPV/RTV 45/ 7 mg /kg BID, plasma APV AUC(0 -) was approximately  48% 
lower, Cmax 26% lower, and C 29% lower than the adult target values.  Conversel y, 
RTV levels appeared to be similar between these pediatric subjects and adult 
comparators.  Based on these results, Amendment 5 (05 -Jul-2007) was undertaken to 
initiate dosing with FPV/RTV 45/7 mg /kg BID for two weeks (to allow collection of 
additional data on this regimen) and then increase the dose to FPV/RTV 60/ 7 mg /kg BID 
(to collect data on a higher dose regimen) for the duration of the study .  
Subsequent to Amendment 5, eleven additional subjects have been enrolled in Cohort 1, 
Arm A.  APV PK was evaluated at Week 2 (sampling predose, 2h, and 4h post dose) for 
the FPV/RTV 45/ 7mg/kg BID regimen and at Week 8 (sampling predose, 1, 2, 4, 6, 8h 
post dose) for the FPV/RTV 60/ 7 mg /kg BID regimen.  Plasma APV C values were 
collected at all subsequent visits.  APV PK parameters for newl y enrolled subjects in 
Cohort 1A (6 months to <2 years) are compared to those for the subjects of this age group 
previously  report as well as adult counterparts.
APV Cmax and C following FPV/RTV 45/ 7 mg /kg BID were higher in the eleven 
newly  enrolled subjects than in the original five subjects who rece ived the same dose.  
However, upon re -evaluation of data for the original subjects who received 45/ 7 mg /kg 
BID, one subject ( ) had extremely  low PK parameter values at Week 2 that appear to 
[COMPANY_003]
GD2001/[ZIP_CODE]/[ADDRESS_273914] 
from the originally  enrolled group,the  geometric mean Cmax for the remaining 4 
subjects is increased from 4.16 g/mL to 6.07 g/mL, more consistent with adult values 
and more similar to the geometric mean Cmax at 7.5ug.mL of th e newl y enrolled subjects 
receiving 45/ 7 mg /kg BID at Week 2.  Geometric mean AUC(0 -) is increased from 
19.3g*h/mL  (n=5) to 31.2 g*h/mL  (n=4), again much closer to the adult target values;  
AUC(0 -) following 45/ 7 mg /kg BID could not be determined at Wee k 2 for newly  
enrolled subjects due to limited sampling scheme.  Overall geometric mean (95% CI) C 
was increased from 1.54 g/mL (1.13, 2.09 g/mL, n=5) to 1.81 g/mL (1.40, 2.33 g/mL  
n=4), also closer to adult targets and newly  enrolled subjects.
APV parame ters following FPV/RTV 60/ 7 mg /kg BID in subjects 6 months to <2 y ears 
were significantly  higher than adult target parameters.  Geometric mean APV AUC(0 -) 
and Cmax following FPV/RTV 60/ 7 mg /kg BID were 1.8 -fold and 2.6 -fold higher than 
the geometric mean values in adults.  
Per protocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24 month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consist ently  high C values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator a nd Sponsor.   
Plasma APV PK data are available from the first 12 subjects enrolled in Cohort 2 Arm A 
(4 week to <6 month age group)  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat administration of FPV/RTV B ID at 
individualized dosage regimens ranging from FPV 30 -60 mg /kg and RTV 7 -10 mg /kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 weeks to <6months of age had higher 
plasma APV Cmax and AUC values, but similar C12 (single dose) and lower C (repeat 
dose) values compared with those historically  observed for adults.  Repeat dose plasma 
RTV Cmax and AUC values were similar to historical adult data, but plasma RTV C 
values we re lower in the pediatric subjects.  As plasma APV C is important for long -
term efficacy  and minimization of resistance development, it is important to try  to 
achieve plasma APV C values in pediatric subjects similar to those achieved with the 
approved F PV/RTV 700/10 0 mg BID regimen in adults.  I t is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefore 
per Protocol Amendment 7, an increase in the RTV dose from 7 mg /kg BID to 10 mg/kg 
BID for all subseq uentl y enrolled subjects was  recommended.  These subjects will 
initiate dosing with FPV/RTV 45/ 10 mg /kg BID and have serial PK sampling at Week 2 
and trough sampling on subsequent visits. Additionally  a SDV is no longer required for 
newly  enrolled 4 week to <6 month age subjects (Cohort 2 Arm A).  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
191Per Protocol Amendment 5, enrolment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age -specific FPV/RTV cohorts 
are available to assist in the dose selecti on for the corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
Change 5:  
Amend:
PROTOCOL SUMMARY, STUDY DESIGN
Original Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort , multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects su ccessfully  completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in the relevant age groups.  In countries whe re local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV until they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART. 
As per Amendments 5 and 7, the approximate number of additional subjects required in 
APV20002 in addition to the 13 previously  enrolled is illustrated in the following table.  
Number of A dditional Subjects Required in A PV20002 ( as of Protocol 
Amendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment complete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate multiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects ini tiate multiple dosing with FPV/RTV 45/ 10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
192Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.  
Refer to Section 3.1 (Figure 1and Figure 2) for schematics outlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A: Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 5, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit. After 
the Week [ADDRESS_273915] been collected (samplin g over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BID + RTV 7 mg /kg BID and will undergo plasma PK serial 
sampling at Week 8 (over 8 -12 hours; 12 hour sample optional). Refer to Section 3.3.4 
for further information.  Approximately  12 PI -naïve or PI -experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen.
Cohort 2 (4 weeks to <6 months)
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will co mmence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the initial 12 
subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in 
Cohort 2 Arm A will undergo plasma PK serial sampling over 8 -12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experienced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
193Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 y ears) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
Revised Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2–cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Su bjects successfully completing 
[ADDRESS_273916] been modified in this and previous protocol amendments (3, 
5, 7 and 8).  The evaluable PK data for approximately  [ADDRESS_273917] been on different dosing 
regimens.
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been 
deferred.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
194Recruitment Status for APV20002 –from (FSFV) Oct 03 to 21 Sep. 09
Age
(yrs)
CohortsNo. of Subjects 
originally plannedCumulative enrolment 
and current statusNo. still to be 
recruited to receive 
latest dose as per 
current protocol
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV
(boosted)12211enrolled
12 ongoing Approx 4 more 
subjects
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV
(boosted)        
12 251enrolled
22OngoingApprox 4 more 
subjects
1.Current total enrolled patients exceeds the original cohort target because of dose changes in previous 
amendments
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
195Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months ) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.  
Refer to Section 3.1 (Figure 1and Figure 2) for schematics outlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
PerAmendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A: Subjects Not Unde rtaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK ser ial sampling at Week 2 (over 4 hours) and Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information.  Per 
Amendment 8, approximately  4  new subjects will be enrolled at this dose regimen (45/7 
mg/kg BID) .
Cohort 2 (4 weeks to <6 months)
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the i nitial 12 
subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in 
Cohort 2 Arm A will undergo plasma PK serial sampling over 8 -12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experien ced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
196Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 y ears) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes hav e 
been addressed.
Change 6:  
Amend:
PROTOCOL SUMMARY, PLANNED SAMPLE SIZE, Additional 2ndParagraph
Revised Text:
Revisions to the planned sample size have been made following dose adjustments as 
specified in previous amendments.
Change 7:  
Amend:
PROTOC OL SUMMARY, STUDY POPULATION, 2ndParagraph
Original Text:
As per Amendments 5 and 7, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  12 additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A 
(4weeks to <6 months) will enro l approximat ely 20-24 subjects to receive FPV/RTV 
BID. Enrolment in the unboosted FPV BID cohorts (Arm B) is deferred.
Revised Text:
Following Amendments 5 and 8, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  25 subjects in total to receive FPV/RTV BI D.  Cohort 2 Arm A ( 4weeks 
to <6 months) will enro l approximately  29 subjects in total to receive FPV/RTV BID. 
Enrolment in the unboosted FPV BID cohorts (Arm B) is deferred.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
197Change 8:  
Amend:
3.1 Study Design
Original Text:
APV20002 is an international, 48-week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in ot her regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in th e relevant age groups. In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV until they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART. 
As per Amendments 5 and 7, the approximate number of additional subjects required in 
APV20002 in addition to the 13 previously  enrolled is illustrated in Table 1 . 
Table 1 Number of A ddition al Subjects Required in A PV20002 (as of Protocol 
Amendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment complete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate multiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects initiate multiple dosing with FPV/RTV 45/ 10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
Revised Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicente r study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully c ompleting 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
GD2001/[ZIP_CODE]/[ADDRESS_273918] been modified in this and previous prot ocol amendments (3, 
5, 7 and 8).  The evaluable PK data for approximately  [ADDRESS_273919] been on different dosing 
regimens.
Arm B (unboosted FPV cohorts 1 and 2) as per amendmen t 5 has been deferred.
Table 1 Recruitment Status for A PV20002 –from (FSFV) Oct 03 to 21 Sep. 09
Age
(yrs)
CohortsNo. of Subjects 
originally plannedCumulative enrolment 
and current statusNo. still to be 
recruited to receive 
latest dose as per 
curre nt protocol
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV
(boosted)12211enrolled
12 ongoing Approx 4 more 
subjects
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV
(boosted)        
12 251enrolled
22 OngoingApprox 4 more 
subjects
Notes
1.Current total enro lled patients exceeds the original cohort target because of dose changes in previous 
amendments
2. Approximately 8 more subjects required to complete the study
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
199Table 2 Number of A dditional Subjects Required in A PV20002 (as of Protocol 
Amendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment co mplete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate multiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects initiate multiple dosing with FPV/RTV 45 /10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
Change 9:  
Amend:
3.1 Study  Design, A rm A :  Subjects Not Undertaking Single Dose Visit 
Assessments
Original Text:
Cohort 1 (6 months to <2 years) 
Per Amendme nt 5, a ll new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit.  After 
the Week [ADDRESS_273920] been collected (sampling over 4 hours), these subjects will 
receive FPV 6 0 mg /kg BI D + RTV 7 mg /kg BID and will undergo serial plasma PK 
sampling at Week 8 (over 8 -12 hours; 12 hour sample optional).  Refer to Section 3.3.4 
for further information.  Approximately  12 PI -naïve or PI -experienced subjects are to be 
enrolled in Cohort 1 Arm A to receive this dosing regimen .
Revised Text:
Cohort 1 (6 months to <2 years) 
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and  Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for fu rther information.  
Approximately  4 PI -naïve or PI -experienced subjects are to be enrolled in Cohort 1 Arm 
A to receive this dosing regimen following amendment 8 .  Existing subjects in Cohort 1 
Arm A whose dose of FPV was increased to 6 0 mg /kg BID at Week [ADDRESS_273921] their dose adjusted based on ongoing viral load, pharmacokinetic and safet y 
assessments. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
200Change 10:  
Amend:
3.2 Study Population, 1stParagraph
Original Text: 
HIV-1 infected pediatric subjects 4 weeks to <2 years of age w ith screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 5, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l approximately  12 
additional subjects to receive FPV/RTV BID.  Cohort 2 Ar m A ( 4weeks to <6 months) 
will enro l approximately  12 subjects to receive FPV/RTV BID.  Enrolment in the 
unboosted FPV BID cohorts (Arm B) is deferred.
Revised Text:
HIV-1 infected pediatric subjects 4 weeks to <2 years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l approximately  4 
additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A (4 weeks to <6 months ) 
will enro l approximately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is deferred.
Change 11:  
Amend:
3.2.2 Exclusion Criteria, 9thCriterium
Original Text:
9. Grade 3 or higher (>5x ULN) serum aminotr ansferase levels (alanine 
aminotransferase, ALT and/or aspartate aminotransferase, AST) within 28 day s 
prior to study  drug administration and / or clinically  relevant hepatitis within the 
previous 6 months.
Revised Text:
9. Grade 3 or higher (>5x ULN) seru m aminotransferase levels (alanine 
aminotransferase, ALT and/or aspartate aminotransferase, AST) within 28 day s 
prior to study  drug administration and / or clinically  relevant hepatitis within the 
previous [ADDRESS_273922] is allowed to deter mine eligibility .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
201Change 12:  
Amend:
3.3.4 Rationale for Study Drug Dose Selection
Original Text:
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspension formulation.  I n children, the FPV oral suspensi on is recommended 
to be administered with food due to the following considerations:
Children tend to eat frequently  throughout the day
Parents may  wish to enhance adherence, medication intake and mask taste by 
[CONTACT_227438]
FPV will be co -administered with ritonavir, which is recommended to be 
administered with food.
In adults, the FPV oral suspension formulation delivered an equivalent plasma APV 
AUC(0 -) and 14.5% higher Cmax compared to the FPV tablet formulation 
[GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00, Study  APV10024] 
Administration of the FPV suspension with food reduced plasma APV AUC(0 -) by 
29% and C max by 46% [GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/00, Study
APV10016].
Per protocol amendment 5, the FPV/RTV doses being studied are based on data from 
previously  enrolled subjects in APV20002 [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/00, Study  APV20002]. All 13 previously  enrolled subjects underwent 
PK sampling during the study  and 12 subjects provided evaluable PK dat a.  Only  two 
subjects below the age of 6 months provided PK data; one subject was 3 months and the 
other was 4 months of age at study  entry .  Ten subjects between the ages of 6 months to 
<2 years of age provided PK data.  Of these 10 subjects, study  entry  ages ranged from 8 
to 23 months, weights from 6 to 12kg, and heights from 65 to 87cm.  All 10 subjects 
were Hispanic and 5 (50%) were female and 5 (50%) were male.
Plasma APV PK parameter values were highl y variable (CVb ranging from 113 to 165% 
across the PK parameters) for the pediatric subjects 6 months to <2 y ears of age.  Nine of 
these subjects ages 6 month to <2 y ears receiving FPV/RTV BID regimens ranging from 
29.4/5.6 to 51.1/8.2mg/kg BID had stead y-state plasma APV CL /F values approximately  
7-fold and RTV CL /F values approximately  4.2-fold higher than those observed in the 
historical adult population.  Compared to the historical adult population, a subset of five 
pediatric subjects ages 6 months to <2 years of age receiving FPV/RTV 45/ 7 mg /kg BID 
demonstrated that despi[INVESTIGATOR_227357] 5 -fold increase in FPV and RTV doses on a 
mg/kg basis, plasma APV AUC(0 -) was approximately  48% lower, Cmax 26% lower, 
and C 29% lower in the pediatric subjects.  This data suggest that children 6 months to 
<[ADDRESS_273923] information and subsequent APV20002 study  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
202publications for safet y and antiviral response data in this initial group of subjects from 
APV2000 2[Cotton, 2014] .
Per Protocol Amendment 5, newly  enrolled subjects in Cohort 1 Arm A (6 months to <2 
years) will initiate dosing with FPV/RTV 45/ 7 mg /kg BID for two weeks and then 
increase to FPV/RTV 60/ 7 mg /kg BID.  This will allow additional PK data for the 
FPV/RTV 45/ 7 mg /kg BID regimen and also for an increased dosage regimen.  However, 
further dose increases could be problematic because they  would require high volumes of 
the FPV oral suspension.  Thus, plasma unbound APV concentrations (free drug) are
being measured in order to determine if these concentrations are similar to historical adult 
values even if plasma total concentrations are lower.
Plasma APV PK data are available from the first 12 subjects enrolled in Cohort 2 Arm 1 
(4 week to <6 month a ge group).  Overall, pediatric subjects 4 week to <6month old had 
higher plasma APV Cmax and AUC values, but similar C12 (single dose, Table 2 and 
lower C (repeat dose, Table 5) values than historically  observed for adults.  Repeat dose 
plasma RTV Cmax a nd AUC values were similar to historical adult data, but plasma 
RTV C values were lower in the pediatric subjects overall (Table 4).  Because plasma 
APV C is important for long -term efficacy  and minimization of resistance development, 
it is important to try to achieve plasma APV C values in pediatric subjects similar to 
those achieved with the FPV/RTV 700/10 0 mg BID regimen that has demonstrated 
efficacy  in adults.  Although FPV/RTV 60/ 10 mg /kg exhibited APV C ,ss most similar to 
adults (Figure 3), the A PV Cmax for this regimen was considered unnecessarily  high 
(Figure 4).   The RTV 10 mg /kg in the FPV/RTV 60/ 10 mg /kg regimen provided the 
most consistently  high RTV C ,ss values as compared to 30/7 and 45/ 7 mg /kg (Figure 5).  
It is possible that the lower plasma RTV C values resulted in the lower plasma APV C 
values for the lower two regimens.  Therefore, all subjects <6 months in age subsequentl y 
enrolled in the study  will receive FPV/RTV 45/ 10 mg /kg to maximize RTV C while 
maintaining APV Cmax values t hat are not excessively  high. 
Per Protocol Amendment 7, newly  enrolled 4 week to <6 month age subjects (Cohort 2 
Arm A) will initiate dosing with FPV/RTV 45/ 10 mg /kg BID.  Newly  enrolled subjects 
will not undergo the SDV, but will have serial PK sampling on Week 2 and trough 
sampling on subsequent visits.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
203Table 2 Summary  of Single Dose Plasma A PV PK in Pediatric Subjects <6 
months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV 45/ 7 mg/kg
(N=11)1Adul t Subjects
FPV/RTV 700/10 0 mg
(N=17)
Cmax ( g/mL) 9.74
(5.67, 16.2)3.65
(2.54, 6.76)
AUC(0 -) (g.h/mL) 57.5
(20.2, 111)35.2
(20.8, 114)
C8h (g/mL) 2.64
(0.819, 5.86)1.10
(0.451, 2.20)
C12h ( g/mL)2 1.13
(0.41, 3.76)1.19
(0.659, 1.92)
1. Pediatric d ata from Study APV20002
2. Adult data from Study APV10013
3. Data for pediatric Subject was excluded because exposures were very high: Cmax: 30.9 g/mL, AUC(0- ): 
335g.h/mL, C8hr: 16.9 g/mL.
4. C12h is extrapolated value for pediatric subjects and observed val ue for adult subjects
Table 3 Summary  of Repeat Dose Plasma A PV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV BID1
(N=9)2Adult Subjects
FPV/RTV 700/10 0 mg
(N=14)
Cmax ( g/mL) 8.90
(2.07, 12.1)4.76
(2.47, 7.68)
AUC(0 -) (g.h/mL) 41.0
(16.2, 70.4)28.3
(17.9, 43.1)
C8h (g/mL) 2.05
(1.10, 3.25)1.58
(0.816, 2.64)
C(g/mL)3 0.970
(0.438, 1.95)1.46
(1.06, 2.20)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject  was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
204Table 4 Summary  of Repeat Dose Plasma RTV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma RTV
PK ParameterPediatric Subjects 
1 to <6 mont hs
FPV/RTV BID1Adult Subjects
FPV/RTV
700/10 0 mg BID
(N=9)2 (N=8)2,3 (N=24)
Cmax ( g/mL) 1.28
(0.228, 7.70)0.999
(0.228, 2.11)1.24
(0.520, 3.84)
AUC(0 -) (g.h/mL) 6.66
(0.922, 28.8)4.67
(0.922, 14.30)5.59
(2.88, 14.4)
C8h (g/mL) 0.270
(0.021 , 1.05)0.239
(0.021, 1.05)0.260
(0.068, 0.614)
C(g/mL)3 0.075
(NQ, 0.496)0.069
(NQ, 0.496)0.165
(0.010, 0.610)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10010
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject  was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Data summarized excluding Subject who had high RTV Cmax and AUC values.
6. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
Figure 3 Week 2 Plasma A PV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 months (30/7, 45/7 and 60/10 mg/kg) Compared 
to Adults (700/10 0 mg )
FPV/ RTV dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=14)APV Ctau,ss (ug/mL)
[IP_ADDRESS].02.5
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
205Figure 4 Week 2 Plasma A PV Cmax Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=14)APV Cmax (ug/mL)
[IP_ADDRESS].510.012.5
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
206Figure 5 Week 2 Plasma RTV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/ 7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=24)RTV Ctau,ss (ug/mL)
[IP_ADDRESS].[IP_ADDRESS]
Per Protocol Amendment 5, enrolment of the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age -specific FPV/RTV cohorts 
are available to assist i n the dose selection for the corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
Revised Text:
Given the young age of the children enrolled into this study , subjects will receive the 
FPV oral suspe nsion formulation.  I n children, the FPV oral suspension is recommended 
to be administered with food due to the following considerations:
Children tend to eat frequently  throughout the day
Parents may  wish to enhance adherence, medication intake and mask t aste by  
[CONTACT_227438]
FPV will be co -administered with ritonavir, which is recommended to be 
administered with food.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
207In adults, the FPV oral suspension formulation delivered an equivalent plasma APV 
AUC(0 -) and 14.5% higher Cmax compared t o the FPV tablet formulation 
[GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00, Study  APV10024] 
Administration of the FPV suspension with food reduced plasma APV AUC(0 -) by 
29% and C max by 46% [GlaxoSmithKline Document Number RM2002/[ZIP_CODE]/00, Study
APV100 16].
Rationale for Drug Dose Selection for Cohort 1 (6 months to 2 y ears)
APV20002 was designed to determine FPV/RTV regimens for pediatric subjects 
1to24months of age that would deliver plasma APV exposures proven to be safe and 
effective in adults.
Ina small subset of five subjects aged 6 months to <2 y ears (Cohort 1, Arm A) who 
received FPV/RTV 45/ 7 mg /kg BID, plasma APV AUC(0 -) was approximately  48% 
lower, Cmax 26% lower, and C 29% lower than the adult target values.  Conversel y, 
RTV levels appear ed to be similar between these pediatric subjects and adult 
comparators.  Based on these results, Amendment 5 (05 -Jul-2007) was undertaken to 
initiate dosing with FPV/RTV 45/ 7 mg /kg BID for two weeks (to allow collection of 
additional data on this regimen) and then increase the dose to FPV/RTV 60/ 7 mg /kg BID 
(to collect data on a higher dose regimen) for the duration of the study .  
Subsequent to Amendment 5, eleven additional subjects have been enrolled in Cohort 1, 
Arm A.  APV PK was evaluated at Week 2 ( sampling predose, 2h, and 4h post dose) for 
the FPV/RTV 45/ 7 mg /kg BID regimen and at Week 8 (sampling predose, 1, 2, 4, 6, 8h 
post dose) for the FPV/RTV 60/ 7 mg /kg BID regimen.  Plasma APV C values were 
collected at all subsequent visits.  APV PK paramet ers for newl y enrolled subjects in 
Cohort 1A ( 6 month s to <2 y ears) are compared to those for the subjects of this age group 
previously  report as well as adult counterparts in Table 3.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
208Table 3 Summary  of Plasma A PV PK in pediatric subjects for Cohort 1 ( 6 
months to 2 y ears)
APV 
ParameterNewl y enrolled 
6 month s to <2 y earsOriginal 6 month s to <2 
years
FPV/RTV
45/7 mg /kg
BIDHistorical 
Adult
FPV/RTV 
700/100 mg 
BID
(n=159)5FPV/RTV 
45/7 mg /kg 
BID 
(n=11)FPV/RTV 
60/7 mg /kg 
BID
(n=7)2
(n=5)3(n=4)4
AUC(0 -)
g*h/mLNA66.9
(31.5, 142)
[82]
(19.2 – 140)19.3
(4.64, 79.9)
[165]
(2.77 – 58.1)31.2
(15.7, 62.1)
[45]
(21.8 – 58.1)37.0
(35.1, 38.9)
[33]
(15.7 – 95.9)
Cmax
g/mL7.50
(5.27, 10.7)
[56]
(4.54 – 28.6)14.8
(8.09, 27.1)
[73.0]
(4.79 – 29.6)4.16
(1.35, 12.8)
[113]
(0.92 – 9.29)6.07
(3.27, 11.3)
[40]
(4.07 – 9.29)5.62
(5.35, 5.92)
[33]
(2.47 – 13.3)
C
g/mL1.92
(1.12, 3.31)
[96]
(0.48 – 5.28)3.57
(2.42, 5.25)
[99]
(1.09 – 16.4)1.54
(1.13, 2.09)
[117]
(0.055 –
8.15)1.81
(1.40, 2.33)
[80]
(0.246 –
8.15)2.17
(2.05, 2.30)
[38]
(0.75 – 5.83)
1. Geometric Mean (95% CI) [CVb%] (min –max)
2. N=6 for AUC(0 -) and N=20 for C (across Weeks 8 - 24)
3. N=38 for C (across Weeks 2 - 48)
4. N=32 for C (across Weeks 2 - 48)
5. N=158 for AUC(0 -)
APV Cmax and C following FPV/RTV 45/ 7 mg /kg BID were higher in the eleven 
newly  enrolled subjects than in the original five subjects who received the same dose.  
However, upon re -evaluation of data for the original subjects who received 45/ 7 mg /kg 
BID, one subjec t ( ) had extremely  low PK parameter values at Week [ADDRESS_273924] 
from the originally  enrolled group,the  geometric mean Cmax for the remaining 4 
subjects is increased from 4.16 g/mL to 6.07 g/mL, more consistent with adult values 
and more similar to the geometric mean Cmax at 7.5ug.mL of the newl y enrolled subjects 
receiving 45/ 7 mg /kg BID at Week 2.  Geometric mean AUC(0 -) is increased from 
19.3g*h/mL(n=5) to 31.2 g*h/mL(n=4), again much closer to the adult target values;  
AUC(0 -) following 45/ 7 mg /kg BID could not be determined at Week 2 for newly  
enrolled subjects due to limited sampling scheme.  Overall geometric mean (95% CI) C 
was increased from 1.54 g/mL (1.13, 2.09 g/mL, n=5) to 1.81 g/mL (1.40, 2.33 g/mL , 
n=4), also closer to adult targets and newly  enrolled subjects.
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
209APV parameters following FPV/RTV 60/ 7 mg /kg BID in subjects 6 month s –2 years old 
were significantly  higher than adult target parame ters.  Geometric mean APV AUC(0 -) 
and Cmax following FPV/RTV 60/ 7 mg /kg BID were 1.8 -fold and 2.6 -fold higher than 
the geometric mean values in adults.  
Per protocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consistently  high C values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/RTV 45/ 7 
mg/kg BID.  Other subjec ts previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator and Sponsor.   
[IP_ADDRESS] Rationale for Drug Dose Selection for Cohort 2 (4 weeks to 6 months)
Plasma APV PK data are availa ble from the first 12 subjects enrolled in Cohort 2 Arm A 
(4 week to <6 month age group).  All 12 subjects received FPV/RTV 45/ 7 mg /kg as a 
single dose, and 11 subjects underwent repeat administration of FPV/RTV BID at 
individualized dosage regimens rangin g from FPV 30 -60 mg /kg and RTV 7 -10 mg /kg 
based on each subject’s single dose PK data.  On both single dose and repeat dose 
administration of FPV/RTV, pediatric subjects 4 weeks to <6months of age had higher 
plasma APV Cmax and AUC values, but similar C12 (single dose, Table 4) and lower C 
(repeat dose, Table 5) values compared with those historically  observed for adults.  
Repeat dose plasma RTV Cmax and AUC values were similar to historical adult data, but 
plasma RTV C values were lower in the pediatric subjects (Table 6).  As plasma APV 
Cis important for long -term efficacy  and minimization of resistance development, it is 
important to try  to achieve plasma APV C values in pediatric subjects similar to those 
achieved with the approved FPV/RTV 700/10 0 mgBID regimen in adults. Although 
FPV/RTV 60/ 10 mg /kg exhibited  APV C ,ss, most similar to adults (Figure 3), the APV 
Cmax for this regimen was considered unnecessarily  high (Figure 4).  The RTV 10 
mg/kg in the FPV/RTV 60/ 10 mg /kg  regimen provided the m ost consistently  high RTV 
C,ss values as compared to 30/7 and 45/ 7 mg /kg (Figure 5).  It is possible that the lower 
plasma RTV C values are responsible for the lower plasma APV C values; therefore 
per Protocol Amendment 7, an increase in the RTV dose fr om 7 mg /kg BID to 10 mg/kg 
BID for all subsequentl y enrolled subjects was  recommended.  These subjects will 
initiate dosing with FPV/RTV 45/ 10 mg /kg BID and have serial PK sampling at Week 2 
and trough sampling on subsequent visits. Additionally  a SDV is no longer required for 
newly  enrolled 4 week to <6 month age subjects (Cohort 2 Arm A).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
210Table 4 Summary  of Single Dose Plasma A PV PK in Pediatric Subjects <6 
months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 m onths
FPV/RTV 45/ 7 mg/kg
(N=11)1Adult Subjects
FPV/RTV 700/10 0 mg
(N=17)
Cmax ( g/mL) 9.74
(5.67, 16.2)3.65
(2.54, 6.76)
AUC(0 -) (g.h/mL) 57.5
(20.2, 111)35.2
(20.8, 114)
C8h (g/mL) 2.64
(0.819, 5.86)1.10
(0.451, 2.20)
C12h ( g/mL)2 1.13
(0.41, 3.76)1.19
(0.659, 1.92)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Data for pediatric Subject  was excluded because exposures were very high: Cmax: 30.9 g/mL, AUC(0- ): 
335g.h/mL, C8hr: 16.9 g/mL.
4. C12h is extrapolated value fo r pediatric subjects and observed value for adult subjects
Table 5 Summary  of Repeat Dose Plasma A PV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma APV
PK ParameterPediatric Subjects 1 to <6 months
FPV/RTV BID1
(N=9)2Adult Subjects
FPV/RTV 700/10 0 mg
(N=14)
Cmax ( g/mL) 8.90
(2.07, 12.1)4.76
(2.47, 7.68)
AUC(0 -) (g.h/mL) 41.0
(16.2, 70.4)28.3
(17.9, 43.1)
C8h (g/mL) 2.05
(1.10, 3.25)1.58
(0.816, 2.64)
C(g/mL)3 0.970
(0.438, 1.95)1.46
(1.06, 2.20)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10013
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject  was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
211Table 6 Summary  of Repeat Dose Plasma RTV PK in Pediatric Subjects 
<6months old and A dults (median [min, max])
Plasma RTV
PK ParameterPediatric Subjects 
1 to <6 months
FPV/RTV BID1Adult Subjects
FPV/RTV
700/10 0 mg BID
(N=9)2 (N=8)2,3 (N=24)
Cmax ( g/mL) 1.28
(0.228, 7.70)0.999
(0.228, 2.11)1.24
(0.520, 3.84)
AUC(0 -) (g.h/mL) 6.66
(0.922, 28.8)4.67
(0.922, 14.30)5.59
(2.88, 14.4)
C8h (g/mL) 0.270
(0.021, 1.05)0.239
(0.021, 1.05)0.260
(0.068, 0.614)
C(g/mL)3 0.075
(NQ, 0.496)0.069
(NQ, 0.496)0.165
(0.010, 0.610)
1. Pediatric data from Study APV20002
2. Adult data from Study APV10010
3. Pediatric FPV/RTV dosage regimens included: 30/ 7 mg/kg BID (N=2), 45/ 7 mg/kg BID (N=4), 45/10 mg /kg BID 
(N=1), and 60/10 mg/kg BID (N=4).
4. Data for pediatric Subject was excluded because pre -dose APV concentration was non -quantifiable (NQ).
5. Data summarized excluding Subject who h ad high RTV Cmax and AUC values.
6. Ccalculated as the mean of the pre -dose and C12h (extrapolated) values.
Figure 3 Week 2 Plasma A PV Ctau,ss Follo wing Repeat A dministration in 
Pediatric Subjects < 6 months (30/7, 45/7 and 60/10 mg/kg) Compared 
to Adults (700/10 0 mg )
FPV/ RTV dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=14)APV Ctau,ss (ug/mL)
[IP_ADDRESS].02.5
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
212Figure 4 Week 2 Plasma A PV Cmax Follo wing Repeat A dministration in 
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=14)APV Cmax (ug/mL)
[IP_ADDRESS].510.012.5
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
213Figure 5 Week 2 Plasma RTV Ctau,ss Follo wing Repeat A dministration in
Pediatric Subjects < 6 month s (30/7, 45/7 and 60/ 10 mg /kg) Compared 
to Adults (700/10 0 mg )
FPV/RTV Dose30/7 (n=2) 45/7 (n=4) 60/10 (n=3) 700/100 (n=24)RTV Ctau,ss (ug/mL)
[IP_ADDRESS].[IP_ADDRESS]
Per Protocol Amendment 5, enrolment of the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age -specific FPV/ RTV cohorts 
are available to assist in the dose selection for the corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
Following receipt and review of PK results from subjects in Cohorts [ADDRESS_273925] basis. 
Change 13:  
Amend:
[IP_ADDRESS] Dosage Regimen Adjustment Criteria, additional paragraphs
Original Text:
GD2001/[ZIP_CODE]/[ADDRESS_273926] Weight
Due to subjects’ growth throughout the duration of the study , the dose of all drugs 
administered must be recalculated at each visit and the total daily  dose adjusted according 
to the child’s weight and the recommended dosage regimen.  Dose adjustments should 
occur when the dose would change b y 10% from the subject’s prior calculated dose.
Dose adjustments due to weight change should be delay ed until after completion of the 
PK sampling to ensure that sampling is conducted at steady -state.
Dose A djustment Due to Subject Phy siological Development
Subjects will not automatically  change dosage regimens as they  increase in age and grow 
out of their age assigned cohort.  However, because subjects may  require dose 
adjustments as they  grow and develop, plasma PK samples collected throughout the study  
will be assa yed on an ongoing basis, and if individualized dose adjustments are needed to 
maintain target concentrations, data will be provided to the investigators. 
Revised Text:
Dose A djustment Due to Subject Weight
Due to subjects’ growth throughout the duration o f the study , the dose of all drugs 
administered must be recalculated at each visit and the total daily  dose adjusted according 
to the child’s weight and the recommended dosage regimen.  Dose adjustments should 
occur when the dose would change b y 10% from the subject’s prior calculated dose.
Dose adjustments due to weight change should be delay ed until after completion of the 
PK sampling to ensure that sampling is conducted at steady -state.
Dose A djustment Due to Subject Phy siological Development
Subjects w ill not automatically  change dosage regimens as they  increase in age and grow 
out of their age assigned cohort.  However, because subjects may  require dose 
adjustments as they  grow and develop, plasma PK samples collected throughout the study  
will be assay ed on an ongoing basis, and if individualized dose adjustments are needed to 
maintain target concentrations, data will be provided to the investigators. 
Dose A djustment Due to Subject A ge
Subjects reaching and exceeding 2 years of age during the stud y in Cohort 1 should 
transition to the lower dose of FPV and RTV to 2 3 mg /kg and 3 mg /kg  BID respectively , 
in accordance with the  dosage regimen recommended  for this age group in protocol 
APV29005.  The change in dosage can  be staged graduall y over multiple visits and will 
be based on ongoing viral load, pharmacokinetic and safet y assessments, at the 
investigator’s discretion.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
215Subjects reaching and exceeding 6 years of age in Cohort 2 may  transition to the lower 
dosage regimen (FPV 18 mg/kg and RTV 3 mg /kg B ID) in accordance with the regimen 
approved for this age group. This dose change can be implemented gradually as the 
subject ‘grows into’ the new dose or at the time of their 6thbirthday  at the investigator’s 
discretion.
Change 14:  
Additional text added :
8.3   Posting of Information on Clinicaltrials.gov
Study  information from this protocol will be posted on clinicaltrials.gov. 
Change 15:
Amend:
8.7 Investigator A ccess to Data and Provision of Study  Results
Original Text:
[COMPANY_004] will provide the investigat or with a copy  of the CRF data collected from the site.  
When a clinical study  report is completed, [COMPANY_004] will provide the major findings of the 
study  to the investigator.
In addition, details of the study  treatment assignment will be provided to the investi gator 
to enable him/her to review the data to determine the outcome of the stud y for his/her 
subject.
Revised Text:
8.8 Investigator A ccess to Data and Provision of Study  Results
[COMPANY_004] will provide the investigator with a cop y of the CRF data collected from the site.  
When a clinical study  report is completed, [COMPANY_004] will provide the major findings of the 
study  to the investigator.
In addition, details of the study  treatment assignment will be provided to the investigator 
to enable him/her to review the data to determine the outcome of the study  for his/her 
subject.
The results summary  will be posted to the Clinical Study  Register no later than [ADDRESS_273927]’s last visit (L SLV) or sooner if required by  [CONTACT_227439], 
local law or regulation. In addition, a manuscript will be submitted to a peer -reviewed 
journal for publication within 18 months of L SLV. When manuscript publication in a 
peer-reviewed journal is not feasible, further study  information will be posted to the [COMPANY_004] 
Clinical Study  Regi ster to supplement the results summary .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].16. Appendix 16:  Protocol A mendment 9
Title:  APV20002 - A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safety, tolerability and antiviral activit y of GW433908 
and GW433908 /RTV when administered to HIV -1 infected protease inhibitor (PI) naïve 
and PI -experienced pediatric subjects aged 4 weeks to <2 y ears.
This protocol amendment will apply  to all study  sites.
This amendment is being implemented to specify  a change of study  sponsor, to provide 
information on an external review committee, to update recruitment status and to clarify 
guidance on dosing for subjects reaching 2 years and 6 years of age during the study .
The amendment consists of the following changes:
1.Change of stu dy sponsor
Reason for change: ViiV Healthcare was established as a new specialist HIV 
compan y by [CONTACT_227440].  Sponsorship of this study  transfers from [COMPANY_004] to ViiV 
Healthcare.
2.Establishment of an External Review Committee
Reason for change: An External Review Committee (ERC) will be establis hed and 
utilized in this study  to provide external oversight of study  conduct and medical 
review of safet y and/or efficacy  issues.
3.Update on recruitment status
Reason for change: Further subjects have been recruited s ince Protocol Amendment 
8 became effective.
4. Clarification of guidance on dosing for subjects reaching 2 years and 6 years of age 
during the stud y
Reason for change: Dosing recommendations for patients reaching 2 and 6 y ears of 
age during the stud y to allow staged dose reductions to the recommended doses of 
these ages apply  to all subjects regardless of the cohort they  were originally  enrolled 
into.
Individual Changes:
Change 1:
Amend:
TITLE PAGE
Original Text:
Author:  
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
217Copy right 2009 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
Revised Text:
Author:  
Copy right 2010 ViiV Healthcare and the GlaxoSmithKline group of companies.  All 
rights reserved.  Unauthorised cop ying or use of this information is prohibited.
Change 2:
Amend:
SPONSOR SIGNATORY PAGE :
Original Text:
Sponsor Signatory :
Judith Ng -Cashin, MD
Vice President, Infectious Diseases Medicine Development Centre
Revised Text:
Sponsor Signatory :
James M. Goodrich, Ph.D., M.D.
Vice President Global Medical Strategy, ViiV Healthcare
Change 3:
Amend:
SPONSOR INFORMATION PAGE
Original Text:
Title: A 48 Week Phase II, Open- label, 2 -cohort, Multicentre Study to 
Evaluate the Pharmacokinetics, Safet y, Tolerability and Antiviral 
Activity  of GW433908 and GW433908/RTV When Administered 
to HIV -1 Infected Proteas e Inhibitor (PI) Naïve and PI -Experienced 
Pediatric Subjects aged 4 weeks to <2 years.
Study  Number: APV20002
[COMPANY_003]
GD2001/[ZIP_CODE]/[ADDRESS_273928] 
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]- 3398, [LOCATION_003]
Telephone: + 001 -[PHONE_4806].
GlaxoSmithKline
891-[ADDRESS_273929], Middlesex, UB6 0HE, [LOCATION_006]
Telephone: + 44 -(0)20 -8422 -3434.
Sponsor Medical Representatives:
, MD
GlaxoSmithKline
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, [LOCATION_006]
Telephone:  
Mobile: 
Revised Text:
Title: A 48 Week Phase II, Open- label, 2 -cohort, Multicentre Study to 
Evaluate the Pharmacokinetics, Safet y, Tolerability and Antiviral 
Activity  of GW433908 and GW433908/RTV When Administered 
to HIV -1 Infected Prot ease Inhibitor (PI) Naïve and PI -Experienced 
Pediatric Subjects aged 4 weeks to <2 years.
Study  Number: APV20002
This study is sponsored by [CONTACT_103673].  GlaxoSmithKline is responsible for 
implementing and managing all aspects of this study.
ViiV He althcare
[ADDRESS_273930]
Middlesex
TW8 9GS
[LOCATION_006]
Telephone: +44 (0)[ADDRESS_273931]
Research Triangle Park
North Carolina [LOCATION_003]
[ZIP_CODE] -3398
Telephone: +[PHONE_4805]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/[ADDRESS_273932] 
P.O. [ZIP_CODE]
Researc h Triangle Park, NC [ZIP_CODE] -3398, [LOCATION_003]
Telephone: + 001 -[PHONE_4806].
GlaxoSmithKline
Iron Bridge Road
Stockley Park, Uxbridge, Middlesex, UB11 1BT, [LOCATION_006]
Telephone: +44(0)[PHONE_4807]
In some countries, the clinical trial sponsor may be the local GlaxoSmithKlin e 
affiliate company (or designee).  Where applicable, the details of [COMPANY_004] and contact 
[CONTACT_227441].
Medical Monitor Contact [CONTACT_7171]:
, MD
GlaxoSmithK line
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, [LOCATION_006]
Telephone:  
Mobile: 
Regulatory Agency Identifying Number(s): US IND 58,627.
Change 4:
Amend:
TRADEMARK INFORMATION
Original Text:
Trademar ks of the GlaxoSmithKline
group of companiesTrademarks not owned by [CONTACT_227442][INVESTIGATOR_227362] R
TRIZIV IR
ZIAGEN
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
220Revised Text:
Trademarks of ViiV Healthcare Trademarks no t owned by [CONTACT_227380][INVESTIGATOR_227363] R Kaletra
TRIZIV IR Winnonlin
ZIAGEN
Change 5:
Amend:
PROTOCOL SUMMARY PAGE, 3rdparagraph
Original Text:
Amprenavir, delivered as AGENERASE oral solution, requires large dosing vol umes and 
is approved for restricted use by  [CONTACT_227443] 4 y ears of age who are unable to 
swallow AGN capsules.  This restriction in use is due mainly  to concerns about the large 
volume of excipi[INVESTIGATOR_840], including PEG400 and propylene gly col, required for dosing 
[Agenerase Package Insert, 2005]. Further, due to the high prop ylene gl ycol content in 
AGN oral solution and the high ethanol content of ritonavir (RTV) oral solution, co -
administration of AGN oral solution and RTV oral solution is co ntraindicat ed.
Revised Text:
Amprenavir, delivered as Agenerase oral solution, requires large dosing volumes and is 
approved for restricted use by  [CONTACT_227443] 4 y ears of age who are unable to 
swallow AGN capsules.  This restriction in use is due mainly  to co ncerns about the large 
volume of excipi[INVESTIGATOR_840], including PEG400 and propylene gly col, required for dosing 
[Agenerase Package Insert, 2005]. Further, due to the high prop ylene gl ycol content in 
AGN oral solution and the high ethanol content of ritonavir (RTV) oral solution, co -
administration of AGN oral solution and RTV oral solution is contraindicated. At the 
holder’s request, the Marketing Authorisation for AGN was withdrawn in the EU 
on April 29, [ADDRESS_273933] 18, 2009.
Change 6:
Amend:
PRO TOCOL SUMMARY , Dose Rationale, 7thparagraph
Original Text:
Per protocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24 month olds upon exclus ion of the one low outlier and since APV parameters following 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
221FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BI D at Week 2.  Some subjects with consistently  high C values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator and sponsor.
Revised Text:
Per protocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24 month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult targets, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consistently  high C values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose mo dified at the discretion of the investigator and [COMPANY_004] .
Change 7:
Amend:
PROTOCOL SUMMARY , STUDY DESIGN
Original Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
[ADDRESS_273934] been modified in this and previous protocol amendments (3, 
5, 7 and 8).  The evaluable PK data for approximately  [ADDRESS_273935] been on different dosing 
regimens.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
222Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been 
deferred.
Recruitment Status for APV20002 –from (FSFV) Oct 03 to 21 Sep. 09
Age
(yrs)
CohortsNo. of Subjects 
originally plannedCumulative 
enrolment and 
current statusNo. still to be 
recruited to 
receive latest 
dose as per 
current protocol
1A
6 mon ths -<2yr
PI-naïve/exp
FPV/RTV
(boosted)12 211enrolled
12 ongoingApprox 4 more 
subjects
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV
(boosted)12 251enrolled
22 OngoingApprox 4 more 
subjects
1.Current total enrolled patients exceeds the original c ohort target because of dose changes in previous 
amendments
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FP V/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.  
Refer to Section 3.1(Figure 1and Figure 2) for schematics outlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively .  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessme nts.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
223Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A: Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 8, all ne w subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information .  Per 
Amendment 8, approximately  4 new subjects will be enrolled at this dose regimen (45/7 
mg/kg BID) .
Cohort 2 (4 weeks to <6 months)
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will comme nce 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the initial 12 
subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in
Cohort 2 Arm A will undergo plasma PK serial sampling over 8 -12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experienced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
Enrolment ofArm B(FPV BID)
Cohort 1 (6 months to <2 y ears) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
Revised Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subje cts successfully  completing 
[ADDRESS_273936] udy sites for provision of ART. 
GD2001/[ZIP_CODE]/[ADDRESS_273937] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273938] been on different dosing regimens.
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been 
deferred.
Recruitment Status for APV20002 –from (FSFV) Oct [ADDRESS_273939]. 10
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumulative enrolment and 
current status
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
12 ongoing
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
15 on going
1.Current total enrolled patients exceeds the original cohort target because of dose changes in previous 
amendments
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Co hort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.  As per Amendments 5 and 7, no additional subjects 
are required to undergo SDV assessments.  
Refer to Section 3.1(Figure 1and Figure 2) for schematics outlining the study  design for 
Cohort 1 Arm A and Cohort 2 Arm A, respectively.  
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
225Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional su bjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A: Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information.
Cohort 2 (4 weeks to <6 months)
Per Amendme nt 7, all new subjects who enro l in Cohort 2 Arm A will commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  1 without 
undertaking a SDV.  The dose is based on the Week 2 plasma PK data from the initial 12 
subjects in Arm A SDV of Cohort 2 who underwent single dose assessments.  Subjects in 
Cohort 2 Arm A will undergo plasma PK se rial sampling over 8 -12 hours (12 hour 
sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve or PI -experienced 
subjects are to be enrolled in Cohort 2 Arm A to receive this dosing regimen. 
Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
Change 8:
Amend:
1.2 Rationale, 2ndand 3rdparagraph
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
226Original Text:
In the NNRTI class, no liquid formulation of efav irenz is currentl y available 
[Sustiva Package Insert, 2007], and the other NNRTI  approved for use in children, 
nevirapi[INVESTIGATOR_050] (NVP), is available as an oral solution but is associated with rare but 
potentially  life threatening adverse reactions [ Viramune Pack age Insert, 2007]. 
In the PI [CONTACT_71963], onl y five agents -APV, indinavir (IDV), nelfinavir (NFV), RTV, and 
lopi[INVESTIGATOR_054]/ritonavir (L PV/RTV) -are currentl y approved for use in HIV -1 infected 
children.  The lower age limits for which these PI s are approved for us e differ between 
countries but range from >1 month (RTV) or 6 months (L PV/RTV) in some countries, 
to 2 y ears of age or older for the other currently  approved PIs.
Revised Text:
In the NNRTI class, efavirenz (EFZ) and nevirapi[INVESTIGATOR_050] (NVP) are available as liqu id 
formulations.  NVP is associated with rare but potentially life threatening adverse 
reactions whilst EFZ is associated with neuropsychiatric adverse reactions
[Viramune Package Insert, 2010] [ Sustiva Package I nsert, 2010]. 
In the PI [CONTACT_71963], sixagents -APV, indinavir (IDV), nelfinavir (NFV), RTV 
lopi[INVESTIGATOR_054]/ritonavir (L PV/RTV), and darunavir -are currentl y approved for use in HIV -1 
infected children.  The lower age limits for which these PI s are approved for use differ 
between countries but range from >1 month (RTV) or 6 months (L PV/RTV) in some 
countries, to 2 y ears of age or older for the other currentl y approved PIs (6 years or older 
for darunavir) .
Change 9:
Amend:
3.1 Study Design
Original Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriat e.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in the relevant age groups. In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV until they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and particip ating study  sites for provision of ART. 
As per Amendments 7 and 8, the approximate number of additional subjects required in 
APV20002 is illustrated in Table 1.
GD2001/[ZIP_CODE]/[ADDRESS_273940] been modifie d in this and previous protocol amendments (3, 
5, 7 and 8).  The evaluable PK data for approximately  [ADDRESS_273941] been on different dosing 
regimens.
Arm B (unboosted FPV cohor ts 1 and 2) as per amendment 5 has been deferred.
Table 1 Recruitment Status for A PV20002 –from (FSFV) Oct 03 to 21 Sep. 09
Age
(yrs)
CohortsNo. of Subjects 
originally plannedCumulative 
enrolment and 
current statusNo. still to be 
recruited to 
recei ve latest 
dose as per 
current protocol
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV
(boosted)12 211enrolled
12 ongoingApprox 4 more 
subjects
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV
(boosted)12 251enrolled
22 OngoingApprox 4 more 
subjects
1.Notes
2.1.  Current total enrolled patients exceeds the original cohort target because of dose changes in previous 
amendments
3. 2.   Approximately 8 more subjects required to complete the study 
Table 2 Number of A dditional Subjects Required in A PV20002 (as of 
Protocol Amendments 5 and 7)
Approximate Number of  
Subjects Required
Cohort Age Arm A 
FPV/ RTV BID
PI [INVESTIGATOR_227358]ïve or ExperiencedArm B
FPV BID
PI [INVESTIGATOR_227360]1Initiate multiple -
dosing at baseline
1 6 months –<2 years 6-10 122NA4
2 4 weeks –<6 months 6-10 8-123NA4
1.Recruitment complete for Cohort  1 Arm A SDV and Cohort 2 Arm A SDV
2.Subjects initiate multiple dosing with FPV/RTV 45/ 7 mg /kg BID from baseline, after Week 2 PK, subjects will 
receive FPV/RTV 60/ 7 mg /kg BID (Amendment 5)
3.Subjects initiate m ultiple dosing with FPV/RTV 45/ 10 mg /kg BID from baseline (Amendment 7)
4. Not Applicable as Arm B enrolment is deferred
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
228Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single dose 
visit ( SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.   As per Amendments 5 and 7, no additional 
subjects are required to undergo SDV assessments.
Refer to Figure 1and Figure 2for schematics outlin ing the stud y design for Cohort 1 
Arm A and Cohort 2 Arm A, respectivel y.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age g roup are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A:  Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years) 
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and  Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information.  
Approximately  4 additional PI -naïve or PI -experienced subjects are to be enrolled in 
Cohort 1 Arm A to receive this dosing regimen following amendment 8 .  Existi ng 
subjects in Cohort 1 Arm A whose dose of FPV was increased to 6 0 mg /kg BID at Week 
[ADDRESS_273942] their dose adjusted based on ongoing viral load, 
pharmacokinetic and safety  assessments. 
Cohort 2 (4 weeks to <6 months)
Per Amendme nt 7, a ll new subjects who enro l in Cohort 2 Arm A will commence 
appropriate multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  
1 without undertaking a SDV.  The dose is be based on the Week 2 plasma PK data from 
the initial 12 subjects in Arm A SDV of Cohort 2 who underwent single dose 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
229assessments.  Subjects in Cohort 2 Arm A will undergo serial plasma PK sampling over 
8-12 hours (12 hour sample optional) at the Week 2 visit.  Approximately  8-12 PI -naïve 
or PI -experienced subjects are to be enr olled in Cohort 2 Arm A to receive this dosing 
regimen.
Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B ) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
230Figure 1 Study  Design for Cohort 1 A rm A : PI-naïve or PI -experienced subjects 6 months to <2 y ears of age
Note:  Cohort 1 Arm  A SDV is com plete.  Further subjects w ill en roll in Cohort 1 Arm  A and initiate multiple 
dosing with FPV/RTV BID from  Baseline.
ARM A SDV: The initial subjects in Cohort 1 Arm A SDV  
underwent single dose visits. S ubsequently enrolled subjects in 
Cohort 1 Arm A initiate m ultiple dosing with FPV/RTV BID from 
base line (w ith no SDV ) and their dose is determined on the basis
of the initial subjects’ W eek 2 PK.
≤21 DAYS
≥15 DAYS
≥14 DAYS 14 DAYSSUBSEQUENTLY≤[ADDRESS_273943] or local
LabSDV
FPV/RTV
Peak/trough
PKSDV
FPV
12 Hr PKBASELINE/ 
DAY 1
Initiate 
FPV/RTV BID  
multiple 
dosingWEEK 2
12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PKSCREENING WEEK 2
4 Hr PKWEEK 8
8-12 Hr PKARM A: Subjects initiate multiple dosing 
with FPV/RTV BID from baseline
Approximately 12 additional subjects will 
be enrolled.
28 DAYS 14 DAYS
BASELINE/ 
DAY 1
Initiate 
FPV/RTV BID 
multiple 
dosing14 DAYS
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
231Figure 2 Study  Design for Cohort 2 A rm A : PI-naïve or PI -experienced subjects 4 weeks to <6 months of age
ARM A SDV : The initial [ADDRESS_273944] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYNote:   Cohort 2 A rm A  SDV is complete.  
Further subjects will enroll in Cohort 2 A rm A and initiate multiple dosing with FPV/RTV BID from Baseline
ARM A SDV : The initial [ADDRESS_273945] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYARM A SDV : The initial [ADDRESS_273946] their dose determined 
on the basis of the initial subjects’ Week 2 PK and will initiat e 
multiple dosing with FPV/RTV BID from baseline.ARM A : Subjects will initiate multiple dosing
With FPV/RTV BID from baseline.
Approximately 8 -12 subjects will be enolled .
21DAYS
SCREENING
Quest or local
LabSDV
FPV/RTV
8-12 Hr PKBASELINE/
DAY 1
Initiate
FPV/RTV BID
Multiple dosingWEEK 2
8-12 Hr PKWEEK 4
Potential
Dose
Adjustment
Based on
Week 2 PK15 DAYS 14DAYS 14DAYS
BASELINE/
DAY 1
Initiate
FPV/RTV BID
multiple dosingWEEK 2
8-12 Hr PK21 DAYS 14DAYS
SCREENINGSUBSEQUENTLYNote:   Cohort 2 A rm A  SDV is complete.  
Further subjects will enroll in Cohort 2 A rm A and initiate multiple dosing with FPV/RTV BID from Baseline
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
232Revised Text:
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully  completing 
[ADDRESS_273947] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273948] been on different dosing regimens.
Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been deferred.
Table 1 Recruitment Status for A PV20002 –from (FSFV) Oct [ADDRESS_273949] 10
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumulative enrolment and 
current status
1A
6 month s -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
12 ongoing
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
15 ongoing
1.Current total enrolled patients exceeds the original cohort target because of dose changes in previous 
amendments
Overview
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel .  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
The initial group of subjects who were enrolled into the study  underwent a single do se 
visit (SDV) before commencing multiple dosing with for example FPV/RTV at Baseline 
and were referred to as Arm A SDV.   As per Amendments 5 and 7, no additional 
subjects are required to undergo SDV assessments.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
233Refer to Figure 1and Figure 2for schemat ics outlining the stud y design for Cohort 1 
Arm A and Cohort 2 Arm A, respectivel y.  
Enrolment of Arm A (FPV/RTV BID)
Arm A SDV: Subjects Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years)
Per Amendment 5, no additional subjects in this age group are required to undertake SDV 
assessments.
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, no additional subjects in this age group are required to undertake SDV 
assessments. 
Arm A:  Subjects Not Undertaking Single Dose Visit A ssessments
Cohort 1 (6 months to <2 years) 
Per Amendme nt 8, all new subjects who enro l in Cohort 1 Arm A should commence 
multiple dosing with FPV 4 5 mg /kg BID + RTV 7 mg /kg BID at the Baseline visit and 
will undergo plasma PK serial sampling at Week 2 (over 4 hours) and  Week 8 (over 8 -12 
hours; 12 hour sample optional). Refer to Section 3.3.4 for further information.  Existing 
subjects in Cohort 1 Arm A whose dose of FPV was increased to 6 0 mg /kg BID at Week 
[ADDRESS_273950] their dose adjusted based on ongoing viral load, 
pharmacokinetic and safety  assessments. 
Cohort 2 (4 weeks to <6 months)
Per Amendment 7, all new subjects who enr ol in Cohort 2 Arm A will commence 
appropriate multiple dosing with FPV 4 5 mg /kg BID + RTV 10 mg /kg BID on study  Day  
1 wit hout undertaking a SDV.  The dose is be based on the Week 2 plasma PK data from 
the initial 12 subjects in Arm A SDV of Cohort 2 who underwent single dose 
assessments.  Subjects in Cohort 2 Arm A will undergo serial plasma PK sampling over 
8-12 hours (12 h our sample optional) at the Week 2 visit.
Enrolment of Arm B (FPV BID)
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be defe rred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
234Figure 1 Study  Design for Cohort 1 A rm A : PI-naïve or PI -experienced subjects 6 months to <2 y ears of age

GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
235Figure 2 Study  Design for Cohort 2 A rm A : PI-naïve or PI -experienced subjects 4 weeks to <6 months of age

GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
236Change 10:
Amend:
3.2. Study Population , 1stParagraph
Origi nal Text:
HIV-1 infected pediatric subjects 4 weeks to <2 years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A (6 months to <2 y ears) will enrol a pproximately  4 
additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A (4 weeks to <6 months) 
will enrol approximately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is deferred.
Revised Text:
HIV-1 infected pediatric subjects 4 weeks to <2 years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A (6 months to <2 y ears) was to enrol approximately  
4additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A (4 weeks to <6 months) 
will enrol approximately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is deferred.
Change 11:
Amend:
3.2.2. Exclusion Criteria
Original Text:
13. Treatment with other investigational drugs/therapi[INVESTIGATOR_6523] 28 day s prior to 
receiving stud y medication (note: treatments available through a Treatment IND 
or other expanded -access mechanism will be evaluated on a case -by-case basis in 
consultation with the sponsor).
Revised Text:
13. Treatment with other investigational drugs/therapi[INVESTIGATOR_6523] 28 day s prior to 
receiving stud y medication (note: treatments available through a Treatment IND 
or other expanded -access mechanism will b e evaluated on a case -by-case basis in 
consultation with [COMPANY_004] ).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
237Change 12:
Amend:
3.3.4. 1Rationale for Drug Dose Selection for Cohort 1 (6 months to 2 years), last 
paragraph
Original Text:
Per protocol amendment 8, since APV parameters following FPV/RTV 45 /7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult target s, subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consistently  high C  values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV /RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator and Sponsor.
Revised
Per protocol amendment 8, since APV parameters following FPV/RTV 45/ 7 mg /kg BID 
were closer to adult targets in the newly  enrolled subjects and in the original 6 month to 
24month olds upon exclusion of the one low outlier and since APV parameters following 
FPV/RTV 60/ 7 mg /kg BID were significantly  higher than adult targets , subjects enrolled 
in the future will receive FPV/RTV 45/ 7 mg /kg BID continuously  without an increase to 
FPV/RTV 60/ 7 mg /kg BID at Week 2.  Some subjects with consistently  high C values 
following FPV/RTV 60/ 7 mg /kg BID have had their dose reduced to FPV/ RTV 45/ 7 
mg/kg BID.  Other subjects previously  enrolled and currentl y receiving FPV/RTV 60/ 7 
mg/kg may  have their dose modified at the discretion of the investigator and [COMPANY_004] .
Change 13:
Amend:
[IP_ADDRESS]. Dosage Regimen Adjustment Criteria , 
Original Text:
Dose Adjustment Due to Subject Age exceeding 2 and 6 years
Subjects reaching and exceeding 2 years of age during the stud y in Cohort 1 should 
transition to the lower dose of FPV and RTV to 2 3 mg /kg and 3 mg /kg  BID respectively , 
in accordance with the  dosag e regimen recommended  for this age group in protocol 
APV29005.  The change in dosage can be staged graduall y over multiple visits and will 
be based on ongoing viral load, pharmacokinetic and safet y assessments, at the 
investigator’s discretion.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
238Subjects r eaching and exceeding 6 years of age in Cohort 2 may  transition to the lower 
dosage regimen (FPV 18 mg/kg and RTV 3 mg /kg BID) in accordance with the regimen 
approved for this age group. This dose change can be implemented gradually as the 
subject ‘grows i nto’ the new dose or at the time of their 6th birthday  at the investigator’s 
discretion.
Revised Text:
Dose Adjustment Due to Subject Age exceeding 2 and 6 years
Subjects reaching and exceeding 2 years of age during the stud y should transition to the 
lower dose of FPV and RTV to 2 3 mg /kg and 3 mg /kg  BID respectivel y, in accordance 
with the  dosage regimen recommended  for this age group in protocol APV29005.  The 
change in dosage can be staged gradually  over multiple visits and will be based on 
ongoing vir al load, pharmacokinetic and safet y assessments, at the investigator’s 
discretion.
Subjects reaching and exceeding 6 years of age may  transition to the lower dosage 
regimen (FPV 18 mg/kg and RTV 3 mg /kg BID) in accordance with the regimen 
approved for this age group. This dose change can be implemented gradually as the 
subject ‘grows into’ the new dose or at the time of their 6th birthday  at the investigator’s 
discretion.
Change 14:
Amend:
[IP_ADDRESS]. Toxicity Management
Original Text:
Grade 4 Toxicity/Adverse Event
Study  drug will be permanently  discontinued in subjects who develop a Grade 4 AE or 
toxicity .  However, if the investigator has compelling evidence that the AE is not causally  
related to the stud y drug(s), dosing may continue after discussion with a nd assent from 
the sponsor.  Subjects experiencing Grade [ADDRESS_273951] dose of study  drug.
Subjects with Grade 4 clinically  asymptomatic laboratory  abnormalities should be 
investigated for all potentially  non-drug related causes and study  drug(s) may  be 
continued if the investigator has compelling evidence that the toxicity  is NOT related to 
the study  drug, following discussion with the sponsor.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
239Revised Text:
Grade 4 Toxicity/Adverse Event
Study  drug will be permanently  discontinued in subjects who develop a Grade 4 AE or 
toxicity .  Howe ver, if the investigator has compelling evidence that the AE is not causally  
related to the stud y drug(s), dosing may continue after discussion with and assent from 
[COMPANY_004] .  Subjects experiencing Grade [ADDRESS_273952] dose of study  drug.
Subjects with Grade 4 clinically  asymptomatic laborato ry abnormalities should be 
investigated for all potentially  non-drug related causes and study  drug(s) may  be 
continued if the investigator has compelling evidence that the toxicity  is NOT related to 
the study  drug, following discussion with [COMPANY_004] .
Change 15:
Amend:
3.3.8. Subject Management Options , last Paragraph
Original Text:
If a subject develops an AIDS diagnosis (CDC stage C) or other evidence of disease 
progression such that the treating clinician believes that changing therap y is required 
even though the above criteria have not been met, the investigator should contact [CONTACT_227444] a case b y case basis.
Revised Text:
If a subject develops an AIDS diagnosis (CDC stage C) or other evidence of disease 
progression such that the tre ating clinician believes that changing therap y is required 
even though the above criteria have not been met, the investigator should contact [CONTACT_227445] a case b y case basis.
Change 16:
Amend:
[IP_ADDRESS]. [COMPANY_004] Supplied Background NRTI Option s, 10thParagraph
Original Text:
All [COMPANY_004] supplied background NRTI s will be handled and stored in accordance with the 
product label or information provided by  [CONTACT_456].
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
240Revised Text:
All [COMPANY_004] supplied background NRTI s will be handled and stored in accorda nce with the 
product label or information provided by  [CONTACT_23983].
Change 17:
Amend:
4.3. Study Drug Accountability Procedures , 2ndParagraph
Original Text:
All study  drugs will be handled and stored in accordance with the product label or 
information provided b y the sponsor.
Revised Text:
All study  drugs will be handled and stored in accordance with the product label or 
information provided b y [COMPANY_004] .
Change 18:
Amend:
5.8. Safety , 2ndParagraph
Original Text:
Scheduled laboratory  evaluations within the study  will be undertaken b y a central 
laboratory  nominated b y the sponsor.  However, evaluation of hematology  and clinical 
chemistry  may  be undertaken at a local accredited laboratory  with the approval of [COMPANY_004].
Revised Text:
Scheduled laboratory  evaluations within the s tudy will be undertaken b y a central 
laboratory  nominated b y [COMPANY_004] .  However, evaluation of hematology  and clinical 
chemistry  may  be undertaken at a local accredited laboratory  with the approval of [COMPANY_004].
Change 19:
Amend:
5.9.1. Premature Discontinuation from the Study , 2ndParagraph
Original Text:
Subjects may  be prematurely  discontinued from the study  for any  of the following 
reasons:
•Subject, subject’s parent/guardian or investigator non -compliance.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
241•At the request of the subject’s parent/guardian, investiga tor or sponsor.
•Progression of an y medical condition which, in the opi[INVESTIGATOR_110407], should preclude further participation.
•If the subject requires treatment with any  of the medications listed in the Exclusion 
Criteria (Section 3.2.2).
•If the subject requires cy totoxic chemotherapy  or radiation therapy  (with the exception 
of local treatment for Kaposi’s sarcoma).
•If the subject requires another investigational drug which when combined with the 
study  drug would, in the opi[INVESTIGATOR_227364], jeopardize the validity  
of the subject’s continued participation.
Revised Text:
Subjects may  be prematurely  discontinued from the study  for any  of the following 
reasons:
•Subject, subject’s parent/guardian or investigator non -complianc e.
•At the request of the subject’s parent/guardian, investigator or [COMPANY_004].
•Progression of an y medical condition which, in the opi[INVESTIGATOR_110407], should preclude further participation.
•If the subject requires treatment with any  of the medi cations listed in the Exclusion 
Criteria (Section 3.2.2).
•If the subject requires cy totoxic chemotherapy  or radiation therapy  (with the exception 
of local treatment for Kaposi’s sarcoma).
•If the subject requires another investigational drug which when comb ined with the 
study  drug would, in the opi[INVESTIGATOR_227365], jeopardize the validity  of 
the subject’s continued participation.
Change 20:
Amend:
7.1. Definition of an AE , 5thParagraph
Original Text:
For [COMPANY_004] clinical trials, AEs may  include p re-or post -treatment events that occur as a 
result of protocol -mandated procedures (i.e., invasive procedures, modification of 
subject’s previous therapeutic regimen).
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
242Revised Text:
For ViiV Healthcare clinical trials, AEs may  include pre -or post -treatme nt events that 
occur as a result of protocol -mandated procedures (i.e., invasive procedures, modification 
of subject’s previous therapeutic regimen).
Change 21:
Amend:
7.12. SAEs Involving a Non -[COMPANY_004] Product
Original Text:
7.12. SAEs Involving a Non -[COMPANY_004] Product
In those instances where an SAE has occurred in a subject receiving a non -[COMPANY_004] product 
as a comparator or concurrent medication, the report must be sent to the appropriate 
project contact [CONTACT_227419] a [COMPANY_004] prod uct (see 
Section 7.8, “Prompt Reporting of SAEs to [COMPANY_004]”).
Revised Text:
7.12. SAEs Involving a Non -ViiV Healthcare Product
In those instances where an SAE has occurred in a subject receiving a non-ViiV 
Healthcare product as a comparator or concurrent medic ation, the report must be sent to 
the appropriate project contact [CONTACT_227419] a 
ViiV Healthcare product (see Section 7.8, “Prompt Reporting of SAEs to [COMPANY_004]”).
Change 22:
Amend:
8.8. Investigator Access to Data and P rovision of Study Results , 3rdParagraph
Original Text:
The results summary  will be posted to the Clinical Study  Register no later than [ADDRESS_273953]’s last visit (L SLV) or sooner if required by  [CONTACT_227439], 
local law or regulation. In addition, a manuscript will be submitted to a peer -reviewed 
journal for publication within 18 months of L SLV. When manuscript publication in a 
peer-reviewed journal is not feasible, further study  information will be posted to the [COMPANY_004] 
Clinical Study  Regi ster to supplement the results summary .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
243Revised Text:
A results summary will be posted to a publicly available study register no later than 
[ADDRESS_273954]’s last visit (L SLV) or sooner if required b y legal 
agreement, local law or regulati on. In addition, a manuscript will be submitted to a peer -
reviewed journal for publication within 18 months of L SLV.
Change 23:
Amend:
8.9. Information Disclosure and Inventions
Original Text:
Ownership:
All data and records provided by  [CONTACT_227446] y (other than a 
subject’s medical records) and all inventions discovered in the course of conducting the 
study  are the propert y of [COMPANY_004]. If a written contract for the conduct of the study which 
includes ownership provisions inconsistent with th is statement is executed, that contract’s 
ownership provisions shall apply  rather than this statement.
Revised Text:
Ownership:
All data and records provided by  [CONTACT_227422]  (other than a 
subject’s medical records) and all inventions d iscovered in the course of conducting the 
study  are the propert y of ViiV Healthcare . If a written contract for the conduct of the 
study  which includes ownership provisions inconsistent with this statement is executed, 
that contract’s ownership provisions s hall apply  rather than this statement.
Change 24:
Additional text added:
8.10. External Review Committee
As per Amendment 9, an External Review Committee (ERC) will be established and 
utilized in this study . The ERC will provide external oversight of study conduct and 
medical review of safet y and/or efficacy  issues in order to protect the ethical and safety  
interests of subjects and to protect the scientific validity  of the study . The schedule of any  
planned interim anal ysis and the anal ysis plan for ERC re view is described in the charter, 
which is available upon request.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].17. Appendix 17 :  Protocol A mendment 10
Title:  APV20002 -A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safet y, tolerability and antiviral activ ity of GW433908 
and GW433908/RTV when administered to HIV -1 infected protease inhibitor (PI) naïve 
and PI -experienced pediatric subjects aged 4 weeks to <[ADDRESS_273955] stud y sponsor 
information.
This amendment is considered su bstantial since a Dear Investigator Letter was sent to 
active study  sites informing them of new information on the overall propy lene gl ycol 
content of FPV oral suspension.
The amendment consists of the following changes:
1.Amend information on overall pro pylene gly col content in FPV oral suspension
Reason for change: FPVoral suspension contains 10 mg /ml of propy lene gly col as a 
solubilis ing agent for the preservatives.  The contribution of propy lene gl ycol arising 
from the two flavouring agents has recent ly been identified.  P ropylene gl ycol is 
present in these flavouring agents at 10 mg /ml, resulting in a total propy lene gl ycol 
concentration o f 20 mg /ml in the oral suspension.
2.Close unboosted FPV Cohorts 1B and 2B and remove objectives and endpoints 
pertaining to unboosted FPV.
Reason for change: Based on the PK data from the age -specific FPV/RTV cohorts, 
the dose volumes of unboosted FPV oral suspension necessary  to administer the 
calculated therapeutic dose in children aged <2 years would be approxi mately twice 
the boosted dose volumes.  Enrolment into the unboosted FPV cohorts is therefore 
not advised due to these large volumes of FPV oral suspension that would need to be 
administered as they  could result in poor adherence, likely  leading to an inad equate 
virologic response and subsequent resistance.
3.Change of stud y sponsor information
Reason for change: Study  APV20002 is sponsored by  [CONTACT_227378] L imited 
and ViiV Healthcare Company .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
245Individual Changes:
Change 1:
Amend:
TITLE PAGE
Original T ext:
Author:  
Revised Text:
Author:  
Change 2:
Amend:
SPONSOR INFORMATION PAGE
Original Text:
This study  is sponsored by  [CONTACT_103673].  GlaxoSmithKline is responsible for 
implementing and managing all aspects of this study .
ViiV Healthcare
[ADDRESS_273956]
Middlesex
TW8 9GS
[LOCATION_006]
Telephone: +44 (0)[ADDRESS_273957]
Research Triangle Park
North Carolina [LOCATION_003]
[ZIP_CODE] -3398
Telephone: +[PHONE_4805]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
246Revised Text:
This study  is sponsored by  [CONTACT_227447].   GlaxoSmithKline is responsible for implementing and ma naging all aspects 
of this study .
ViiV Healthcare [LOCATION_006] Limited
[ADDRESS_273958]
Middlesex
TW8 9GS
[LOCATION_006]
Telephone: +44 (0)[ADDRESS_273959]
Research Triangle Park
North Carolina [LOCATION_003]
[ZIP_CODE] -3398
Telephone: +[PHONE_4805]
Change 3:
Amend:
PROTOCOL SUMMARY , 4thParagraph
Original Text:
The FPV oral sus pension incorporates minimal propy lene gly col thereby  [CONTACT_227448] -administration with RTV oral 
solution.  
Revised Text:
The FPV oral suspension incorporates lesspropy lene gl ycol than AGN oral solution
thereb y facilitating its administration to children of all ages and allows co -administration 
with RTV oral solution.
Change 4:
Amend:
PROTOCOL SUMMARY , Dose Rat ionale , 9thParagraph
Original Text:
Per Protocol Amendment 5, enrolment in the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age -specific FPV/RTV cohorts 
are available to assist in the dose selection for t he corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
247Revised Text:
Per Protocol Amendment 10, enrolment in the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) is closed.  Based on the PK d ata from the age -specific 
FPV/RTV cohorts, the dose volumes of unboosted FPV oral suspension necessary to 
administer the calculated therapeutic dose in children aged <2 years would be 
approximately twice the boosted dose volumes.  Enrolment into the unboos ted FPV 
cohorts is therefore not advised due to these large volumes of FPV oral suspension 
that would need to be administered as they could result in poor adherence, likely 
leading to an inadequate virologic response and subsequent resistance .
Change 5:
Amend:
STUDY OBJECTIVES 
Original Text:
Primary
To define the FPV BID dosage regimens which will provide target stead y-state 
plasma APV exposure to HIV -1 infected PI -naïve pediatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5)
To define the FPV/RTV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the safet y and tolerability  of FPV (deferred per amendment 5) and
FPV/RTV when administered as a component of combination therapy  in HIV -1 
infected pediatric subjects aged 4 weeks to <2 years
Secondary
To evaluate the antiviral activity  of FPV (deferred per amendment 5) and FPV/RTV 
in combination with NRTI  therapy  in HIV -[ADDRESS_273960] s aged 4 weeks 
to <2 y ears
To evaluate the immunologic activity  of FPV (deferred per amendment 5) and 
FPV/RTV in combination with NRTI  therapy  in HIV -1 infected pediatric subjects 
aged 4 weeks to <2 years
To assess sy stemic exposure to FPV when administere d to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose 
administration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in pla sma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrence of 
adverse events
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
248To assess subject adherence and parent/guardian perceptions of stud y medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381]) 
Revised Text:
Primary
To define the FPV BID dosage regimens which will provide target stead y-state 
plasma APV exposure to HIV -1 infected PI -naïve pediatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5) .  This objective has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
To define the FPV/RTV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HI V-1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the safet y and tolerability  of FPV/RTV when administered as a 
component of combination therap y in HIV -1 infected pediatric subjects aged 
4weeks to <2 years.The objective to evaluate th e safety and tolerability of FPV 
BID dosage regimens has been removed as per Protocol Amendment 10.
Secondary
To evaluate the antiviral activity  of FPV/RTV in combination with NRTI  therap y in 
HIV-1 infected pediatric subjects aged 4 weeks to <2 y ears
To ev aluate the immunologic activity  of FPV/RTV in combination with NRTI  
therap y in HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To assess sy stemic exposure to FPV when administered to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose 
administration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in plasma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrenc e of 
adverse events
To assess subject adherence and parent/guardian perceptions of stud y medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381]) 
The secondary objectives to evaluate the antiviral and immunologic activity of FPV 
have been removed as per Protocol Amendment 10.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
249Change 6:
Amend:
STUDY ENDPOINTS, Primary
Original Text:
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV BID (deferre d per amendment 5).
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unbound APV C ,ss and percent protein binding
The incidence and nature of adverse events, laboratory  abnormalities, and treatment 
–limiti ng toxicities
Proportion of subjects who permanentl y discontinue FPV (deferred per 
amendment 5) or FPV/RTV due to adverse events.
Revised Text:
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV BID (deferred per amendment 5). This endpoint has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unboun d APV C ,ss and percent protein binding
The incidence and nature of adverse events, laboratory  abnormalities, and treatment 
–limiting toxicities
Proportion of subjects who permanentl y discontinue FPV/RTV due to adverse 
events .  The endpoint ‘Proportion of subjects who permanently discontinue FPV 
due to adverse events’ has been removed as per Protocol Amendment 10.
Change 7:
Amend:
STUDY DESIGN , 4thParagraph
Original Text:
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been 
deferred.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
250Revised Text:
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10has been 
closed .
Change 8:
Amend:
STUDY DESIGN , Overview , 1stParagraph
Original Text:
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV , 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred .
Revised Text:
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 10, enrolment in the 
Arm B cohorts (unboosted FPV) is closed .
Change 9:
Amend:
STUDY DESIGN , Overview , Enrolment of Arm B (FPV BID)
Original Text:
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
Revised Text:
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 10, enrolment in the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) is closed.  Based on the PK data from the age -specific 
FPV/RTV cohorts, the do se volumes of unboosted FPV oral suspension necessary to 
administer the calculated therapeutic dose in children aged <2 years would be 
approximately twice the boosted dose volumes.  Enrolment into the unboosted FPV 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
251cohorts is therefore not advised due to t hese large volumes of FPV oral suspension 
that would need to be administered as they could result in poor adherence, likely 
leading to an inadequate virologic response and subsequent resistance .
Change 10:
Amend:
PLANNED SAMPLE SIZE , 1stParagraph
Original Text:
The sample size of 48 subjects was selected as an appropriate number to allow an 
accurate description of plasma APV PK, safet y and tolerability  of FPV BID, (N=24 for 
PK and safet y; enrolment deferred per Amendment 5) and FPV/RTV BID, Arm A (N=24 
forPK and safet y).  Safety and tolerability assessment of the FPV/RTV BID regimen 
(Arm A) will be for the duration of the study  or until a subject permanentl y discontinues 
study  drug.  If less than 8 subjects in a cohort and dosage regimen complete the stead y-
state PK anal ysis on Week 2, additional subjects may  be enrolled as replacement 
subjects. Additionally , if dose modification to the cohort dose is warranted, a further 8 
subjects in each arm may be recruited to provide stead y-state PK data on the revised
dose.
Revised Text:
The sample size of 48 subjects was selected as an appropriate number to allow an 
accurate description of plasma APV PK, safet y and tolerability  of FPV BID, (N=24 for 
PK and safet y; enrolment closed per Amendment 10 ) and FPV/RTV BID, Ar m A 
(N=24 for PK and safet y).  Safety  and tolerability  assessment of the FPV/RTV BID 
regimen (Arm A) will be for the duration of the study  or until a subject permanently  
discontinues study  drug.  If less than [ADDRESS_273961] ete 
the stead y-state PK anal ysis on Week 2, additional subjects may be enrolled as 
replacement subjects. Additionally , if dose modification to the cohort dose is warranted, a 
further 8 subjects in each arm may  be recruited to provide stead y-state PK data o n the 
revised dose.
Change 11:
Amend:
STUDY POPULATION , 2ndParagraph
Original Text:
Following Amendments 5 and 8, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  25 subjects in total to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks 
to <6 mo nths) will enro l approximately  29 subjects in total to receive FPV/RTV BID. 
Enrolment in the unboosted FPV BID cohorts (Arm B) is deferred .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
252Revised Text:
Following Amendments 5 and 8, Cohort 1 Arm A ( 6 months to <2 y ears) will enro l 
approximately  25 subjec ts in total to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks 
to <6 months) will enro l approximately  29 subjects in total to receive FPV/RTV BID. 
Enrolment in the unboosted FPV BID cohorts (Arm B) is closed .
Change 12:
Amend:
1.2 Rationale , 7thParagraph
Original Text:
The FPV oral sus pension incorporates minimal propy lene gly col which allows 
administration to children of all ages and co -administration with RTV oral solution.
Revised Text:
The FPV oral suspension incorporates lesspropy lene glycol than AGN oral solution
which allows administration to children of all ages and co -administration with RTV oral 
solution.
Change 13:
Amend:
2. STUDY OBJECTIVES AND ENDPOINTS
Original Text:
2.1 Study Objectives
Primary
To define the FPV BID dosage regimens which will provide target stead y-state 
plasma APV exposure to HIV -1 infected PI -naïve pediatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5)
To define the FPV/RTV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the safet y and tolerability  of FPV (deferred per amendment 5) and
FPV/RTV when administered as a component of combination therapy  in HIV -1 
infected pediatric subjects aged 4 weeks to <2 years
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
253Secondary
To evaluate the antiviral activity  of FPV (deferred per amendment 5) and FPV/RTV 
in combination with NRTI  therapy  in HIV -1 infected pediatric subjects aged 4 weeks 
to <2 y ears
To evaluate the immunologic activity  of FPV (deferred per amendment 5) and 
FPV/RTV in combination with NRTI  therapy  in HIV -1 infected pediatric subjects 
aged 4 weeks to <2 years
To assess sy stemic exposure to FPV when administered to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, C max,ss and C ,ss following multiple dose 
administration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in plasma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrence of 
adverse events
To asses s subject adherence and parent/guardian perceptions of stud y medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381])
2.2 Study Endpoints
Primary
Plasma APV AUC ,ss, Cmax,ss a nd C ,ss following multiple dose administration of 
FPV BID (deferred per amendment 5) .  
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unbound APV C ,ss and percent protein binding
The incidence and natu re of adverse events, laboratory  abnormalities, and treatment -
limiting toxicities
Proportion of subjects who permanentl y discontinue FPV (deferred per 
amendment 5)or FPV/RTV due to adverse events .  
Revised Text:
2.1 Study Objectives
Primary
To define th e FPV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1 infected PI -naïve pediatric subjects aged 4 weeks to 
<2 years (deferred per amendment 5) .  This objective has been removed with 
enrolment into the unboosted cohor ts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
254To define the FPV/RTV BID dosage regimens which will provide target steady -state 
plasma APV exposure to HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the s afety and tolerability  of FPV/RTV when administered as a 
component of combination therap y in HIV -1 infected pediatric subjects aged 
4weeks to <2 years.  The objective to evaluate the safety and tolerability of FPV 
BID dosage regimens has been removed as p er Protocol Amendment 10.
Secondary
To evaluate the antiviral activity  of FPV/RTV in combination with NRTI  therap y in 
HIV-1 infected pediatric subjects aged 4 weeks to <2 y ears
To evaluate the immunologic activity  of FPV/RTV in combination with NRTI  
therap y in HIV -1 infected pediatric subjects aged 4 weeks to <2 y ears
To assess sy stemic exposure to FPV when administered to HIV -1 infected pediatric 
subjects aged 4 weeks to <2 y ears
To assess plasma RTV AUC ,ss, Cmax,ss and C ,ss following multiple dose 
admin istration of FPV/RTV BID
To investigate the relationship of stead y-state plasma APV PK parameters to changes 
in plasma HIV -1 RNA concentrations, CD4+ percentages and/or the occurrence of 
adverse events
To assess subject adherence and parent/guardian percep tions of study  medications
To assess viral resistance patterns and to compare these patterns with treatment 
outcome (where permissible by  [CONTACT_227381])
The secondary objectives to evaluate the antiviral and immunologic activity of FPV 
have been removed as per Protocol Amendment 10.
2.2 Study Endpoints
Primary
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV BID (deferred per amendment 5) .  This endpoint has been removed with 
enrolment into the unboosted cohorts (Cohort 1 Arm B and Cohort 2 Arm B) 
closed as per Protocol Amendment 10.
Plasma APV AUC ,ss, Cmax,ss and C ,ss following multiple dose administration of 
FPV/RTV BID
Plasma unbound APV C ,ss and percent protein binding
The incidence and nature of adverse events, labo ratory  abnormalities, and treatment -
limiting toxicities
Proportion of subjects who permanentl y discontinue FPV/RTV due to adverse 
events .  The endpoint ‘Proportion of subjects who permanently discontinue FPV 
due to adverse events’ has been removed as per P rotocol Amendment 10.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
255Change 14:
Amend:
3.1. Study Design ,4thParagraph
Original Text:
Arm B (unboosted FPV cohorts 1 and 2) as per amendment 5 has been deferred.
Revised Text:
Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10has been closed .
Change 15:
Amend:
3.1. Study Design , Overview , 1stParagraph
Original Text:
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 5, enrolment in the 
Arm B cohorts (unboosted FPV) is deferred.
Revised Text:
Cohort 1 Arm A (FPV/RTV, 6 months to <2y ears) and Cohort 2 Arm A (FPV/RTV, 
4weeks to <6 months) are open in parallel.  Cohort 1 Arm A and Cohort 2 Arm A will 
recruit either PI -naïve or experienced subjects.  As per Amendment 10, enrolment in the 
Arm B cohorts (unboosted FPV) is closed .
Change 16:
Amend:
3.1. Study Design ,Overview , Enrolment of Arm B (FPV BID)
Original Text:
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 5, the decision to open the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) will be deferred until the Week 2 PK data from the age -specific 
FPV/RTV cohorts are available to assist in the dose selection for the corresponding 
unboosted FPV cohort and any  concerns regarding the high FPV dosing volumes have 
been addressed.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
256Revised Text:
Cohort 1 (6 months to <2 years) and Cohort 2 (4 weeks to <6 months)
Per Protocol Amendment 10, enrolment in the unboosted cohorts (Cohort 1 Arm B 
and Cohort 2 Arm B) is closed.  Based on the PK data from the age -specific 
FPV/RTV cohorts, the dose volumes of unboosted FPV oral suspension necessary to 
administer the calculated therapeutic dose in children aged <2 years would be 
approximately twice the boosted dose volumes.  Enrolment into the unboosted FPV 
cohorts is therefore not advised due to these large volumes of FPV oral suspension 
that would need to be administered as they could result in p oor adherence, likely 
leading to an inadequate virologic response and subsequent resistance .
Change 17:
Amend:
3.2 Study Population , 1stParagraph
Original Text:
HIV-1 infected pediatric subjects 4 weeks to <2 years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A (6 months to <2 y ears) was to enro l approximately  
4 additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks to <6 months) 
willenrol approximately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is deferred.
Revised Text:
HIV-1 infected pediatric subjects 4 weeks to <2 years of age with screening plasma HIV -
RNA 400copi[INVESTIGATOR_014]/mL  and who meet the eligibility  criteria will be recruited into the study . 
As of Amendment 8, Cohort 1 Arm A (6 months to <2 y ears) was to enro l approximately  
4 additional subjects to receive FPV/RTV BID.  Cohort 2 Arm A ( 4weeks to <6 months) 
will enro l approx imately  20-25 subjects in total to receive FPV/RTV BID.  Enrolment in 
the unboosted FPV BID cohorts (Arm B) is closed .
Change 18:
Amend:
3.3.1 Study Drugs , 3rdParagraph
Original Text:
The FPV 5 0 mg /mL (43.2mg/mL  APV molar equivalents) suspension is a whit e to off -
white bubblegum and peppermint flavour ed suspension for oral administration using a 
dosing s yringe.  Each mL of suspension contains 5 0 mg of FPV, equivalent to 
43.2mg/mL  of APV.  The suspension contains the following inactive ingredients: 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
257hydroxypropylmethy l cellulose, poly sorbate 80, methy lparaben, propy lparaben, 
propy lene glycol (overall 10 mg /mL), sucralose, calcium chloride, flavour s and purified 
water.  The FPV oral suspension is manufactured by  [CONTACT_227387], Ontario, 
Canada.
Revised Text:
The FPV 5 0 mg /mL (43.2mg/mL  APV molar equivalents) suspension is a white to off -
white bubblegum and peppermint flavour ed suspension for oral administration using a 
dosing s yringe.  Each mL of suspension contains 5 0 mg of FPV, equivalent to 
43.2mg/mL  ofAPV.  The suspension contains the following inactive ingredients: 
hydroxypropylmethy l cellulose, poly sorbate 80, methy lparaben, propy lparaben , 
propy lene gl ycol (overall 20 mg /mL), sucralose, calcium chloride, flavour s and purified 
water.  The FPV oral sus pension is manufactured by  [CONTACT_227387], Ontario, 
Canada.
Change 19:
Amend:
[IP_ADDRESS]. Rationale for Drug Dose Selection for Cohort 2 (4 weeks to 6 months) , 2nd
Paragraph
Original Text:
Per Protocol Amendment 5, enrolment of the unboosted cohorts (Coho rt 1 Arm B and 
Cohort 2 Arm B) is deferred until serial PK data from the age -specific FPV/RTV cohorts 
are available to assist in the dose selection for the corresponding unboosted FPV cohort 
and an y concerns regarding the high FPV dosing volumes have been addressed.
Revised Text:
Per Protocol Amendment 10, enrolment of the unboosted cohorts (Cohort 1 Arm B and 
Cohort 2 Arm B) is closed.
Change 20:
Amend:
6.1. Sample Size Determination , 1stParagraph
Original Text:
The sample size of 48 subjects was selecte d as an appropriate number to allow an 
accurate description of plasma APV PK, safet y and tolerability  of FPV BID, Arm B 
(N=24 for PK and safet y; enrolment deferred per Amendment 5) and FPV/RTV BID, 
Arm A (N=24 for PK and safet y).  Safet y and tolerability a ssessment of the FPV/RTV 
BID regimen (Arm A) will be for the duration of the study  or until a subject permanentl y 
discontinues study  drug.  If less than 8 subjects in a cohort and dosage regimen complete 
the stead y-state PK anal ysis on Week 2, additional s ubjects may  be enrolled as 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
258replacement subjects.  Additionally , if dose modification to the cohort dose is warranted, 
a further 8 subjects in each arm may  be recruited to provide steady -state PK data on the 
revised dose.
Revised Text:
The sample size of 4 8 subjects was selected as an appropriate number to allow an 
accurate description of plasma APV PK, safet y and tolerability  of FPV BID, Arm B 
(N=24 for PK and safet y; enrolment closedper Amendment 10) and FPV/RTV BID, 
Arm A (N=24 for PK and safet y).  Safe ty and tolerability  assessment of the FPV/RTV 
BID regimen (Arm A) will be for the duration of the study  or until a subject permanentl y 
discontinues study  drug.  If less than 8 subjects in a cohort and dosage regimen complete 
the stead y-state PK anal ysis on Week 2, additional subjects may  be enrolled as 
replacement subjects.  Additionally , if dose modification to the cohort dose is warranted, 
a further 8 subjects in each arm may  be recruited to provide steady -state PK data on the 
revised dose.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].18. Appendix 18:  Protocol A mendment 11
Title:  APV20002 -A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safet y, tolerability and antiviral activit y of GW433908 
and GW433908/RTV when administered to HIV -1 infected protease inh ibitor (PI) naïve 
and PI -experienced pediatric subjects aged 4 weeks to <[ADDRESS_273962] of drugs not to be 
co-administered with FPV and RTV, to provide the option to discontinue PK sampling 
and monitoring of plasma APV, FPV and RTV concentration on an individual basis, and 
to update information on posting study results on publicly  available clinical trials 
registers and publication.
The amendment consists of the following changes:
1.3TC and ABC tablets provided by  [CONTACT_227449]: Some subjects have reached an age and weight that w ould allow 
them to switch from 3TC and ABC solutions to scored tablets .
2.Update dlist of drugs not to be co -administered with FPV and RTV
Reason for change: based on recent drug interaction data studies, the list of drugs not 
to be co -administered with FPV and RTV has been amended .Information on drug 
interactions relevant to abacavir and lamivudine has also been added.
3.Discontinuation of PK sampling and monitoring of plasma APV, FPV and RTV 
concentration on an individual basis
Reason for change:
FPV/RTV re gimens for pediatric subjects 4 weeks to <[ADDRESS_273963] been 
determined based on 24 -week PK, safet y and efficacy results from this study.  
Further collection of plasma APV, FPV and RTV trough concentrations should also 
not inform any  further individu alised dose adjustments as ongoing subjects are 
receiving recommended FPV/RTV regimens and any further dosing changes would 
follow the approved dosing recommendations without PK sampling , including a 
transition to FPV/RTV 18/ 3 mg /kg BID at 6 years.
4.Informa tion on posting study  results on publicly  available clinical trials registers and 
publication update d.
Reason for change: [COMPANY_004] aims to post a results summary  to the [COMPANY_004] Clinical Study  
Register and other publicly  available registers no later than [ADDRESS_273964]’s last visit , to publish the full study  protocol on the [COMPANY_004] Clinical Study  
Register at the time the results of the study  are published as a manuscript in the 
GD2001/[ZIP_CODE]/[ADDRESS_273965] further study  information to the [COMPANY_004] Clini cal Study  
Register to supplement the results summary  when manuscript publication in a peer -
reviewed journal is not feasible.
Individual Changes:
Change 1:
Amend: 3.2.2 Exclusion Criteri a, Exclusion criterion 12
Original Text:
12.Treatment with an y of the following medications within 28 day s prior to receiving 
study  medication or the anticipated need during the study :
Amiodarone, astemizole, bepridil, bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], 
diazepam, dihy droergotamine, encainide, ergonovine, ergotamin e, estazolam, 
flecainide, flurazepam, lovastatin, meperidine, methy lergonovine, midazolam, 
pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], propafenone, propox yphene, quinidine, simvastatin, 
terfenadine, and triazolam (these drugs have been excluded for safety  reasons).
Carbamazepi[INVESTIGATOR_050] , dexamethasone, phenobarbital, primidone, rifampin, St Johns 
Wort, (these drugs have been excluded because they  have the potential to 
decrease plasma protease inhibitor concentrations).
Revised Text:
12.Treatment with an y of the following medications wit hin 28 day s prior to receiving 
study  medication or the anticipated need during the study :
Amiodarone, astemizole, bepridil, bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], 
diazepam, dihy droergotamine, encainide, ergonovine, ergotamine, estazolam, 
flecainide, flurazepam, lovastatin, meperidine, methy lergonovine, midazolam, 
pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], propafenone, propox yphene, quinidine, simvastatin, 
terfenadine, and triazolam (these drugs have been excluded for safety  reasons).
Carbamazepi[INVESTIGATOR_050], dexamethasone, phenobar bital, primidone, rifampin, St Johns 
Wort, (these drugs have been excluded because they  have the potential to 
decrease plasma protease inhibitor concentrations).
Note: per Protocol Amendment 11, the list of drugs not to be co -administered 
with FPV and RTV has been updated (see Section 3.3.10, “Concurrent 
Medications and Non -Drug Therapi[INVESTIGATOR_014]”).  As recruitment is closed, the exclusion 
criteria have not been amended.
Change 2 :
Amend: 3.3.2 Background NRTI Options Provided by [CONTACT_227450]:
Abaca vir and 3TC will be provided by  [CONTACT_227451] 3 months of age who are determined to be susceptible to ABC and/or 3TC. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
261Susceptibility  will be determined by  [CONTACT_227390]/or investigator 
interpretatio n of screening resistance viral genot ype data, if available.  ABC and 3TC are 
licensed for the treatment of pediatric subjects of at least 3 months of age in the [LOCATION_003], the 
European Union, and South Africa.
The ABC oral solution contains 2 0 mg /mL of ABC in a queous solution and the inactive 
ingredients strawberry  and banana flavour s, citric acid (anh ydrous), meth ylparaben, 
propy lparaben, propy lene gl ycol, saccharin sodium, sodium citrate, and sorbitol solution. 
The ABC oral solution is manufactured b y [COMPANY_004] in M ississauga, Ontario, Canada.
The 3TC oral solution contains 10 mg /mL of 3TC in aqueous solution and the inactive 
ingredients strawberry  and banana flavour s, citric acid (anh ydrous), meth ylparaben, 
propy paraben, propy lene gl ycol, sodium citrate (dihy drous) and sucrose (20% w/v).  The 
3TC oral solution is manufactured b y [COMPANY_004] in Mississauga, Ontario, Canada.
In the event that a subject permanentl y discontinues study medication, [COMPANY_004] will no 
longer provide background 3TC and ABC medications.
Revised Text:
Abacav ir and 3TC will be provided by  [CONTACT_227451] 3 months of age who are determined to be susceptible to ABC and/or 3TC. 
Susceptibility  will be determined by  [CONTACT_227390]/or investigator 
interpretation of screening resistance viral genot ype data, if available.    
ABC and 3TC oral solutions are licensed for the treatment of pediatric subjects of at least 
3 months of age in the [LOCATION_003], the European Union, and South Africa.  Scored 3TC tablets 
are licensed i n the [LOCATION_003], the European Union, and South Africa for the treatment of 
pediatric subjects weighing greater than or equal to 14kg for whom a solid dosage 
form is appropriate.  Scored ABC tablets are licensed in the [LOCATION_003] and the European 
Union for the treatment of pediatric subjects weighing greater than or equal to 14kg 
for whom a solid dosage form is appropriate.  Scored ABC tablets will only be 
provided by [CONTACT_227452] a licence has been granted 
there.
The ABC oral solution contains 20 mg /mL of ABC in aqueous solution and the inactive 
ingredients strawberry  and banana flavours, citric acid (anh ydrous), meth ylparaben, 
propy lparaben, propy lene gl ycol, saccharin sodium, sodium citrate, and sorbitol solution. 
The ABC oral solution is manu factured b y [COMPANY_004] in Mississauga, Ontario, Canada.
The ABC tablet contains ABC sulfate equivalent to 30 0 mg ABC and the inactive 
ingredients colloidal anhydrous silica, magnesium stearate, microcrystalline 
cellulose, and sodium starch glycolate, Type A. The tablet is coated with a film that 
is made of methylhydroxypropylcellulose, polysorbate 80, synthetic yellow iron 
oxide, titanium dioxide, and triacetin. ABC tablets are manufactured by [CONTACT_227453], Hertfordshire, [LOCATION_008].
The 3TC oral solution conta ins 10 mg /mL of 3TC in aqueous solution and the inactive 
ingredients strawberry  and banana flavours, citric acid (anh ydrous), meth ylparaben, 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
262propy paraben, propy lene gl ycol, sodium citrate (dihy drous) and sucrose (20% w/v).  The 
3TC oral solution is manufac tured by  [CONTACT_227387], Ontario, Canada.
The 3TC tablet contains [ADDRESS_273966] permanentl y discontinues study medication, [COMPANY_004] will no 
longer provide background 3TC and ABC medications.
Change 3 :
Amend: 3.3.5 Dosages and dosing
Original Text:
FPV and RTV will be administered according to the doses described in Section 3.3.4.
Both the FPV and RTV oral formulations should be administered with food.  If vomiting 
or spi[INVESTIGATOR_227307] 3 0 minutes of administration, parents/guardians should be 
instructed to re -administer the study  medications.
The recommended dose of ABC is 8 mg /kg BID (up to a maximum of 60 0 mg /day).
The recommended dose of 3TC is 4 mg /kg BID (up to a maximum of 30 0 mg /day).
Revised Text:
FPV and RTV will be administered according to the doses described in Section 3.3.4 .
Both the FPV and RTV oral formulations should be administered with food.  If vomiting 
or spi[INVESTIGATOR_227307] 30 minutes of administration, parents/g uardians should be 
instructed to re -administer the study  medications.
The recommended dose of ABC solution is 8 mg /kg BID (up to a maximum of 60 0 
mg/day).
For ABC tablets, the recommended dose is one -half of a scored tablet taken twice 
daily in children w eighing between 14kg and 21kg and one -half of a scored tablet 
taken in the morning and one whole tablet taken in the evening in children weighing 
between 21kg and 30kg.
The recommended dose of 3TC solution is 4 mg /kg BID (up to a maximum of 30 0 
mg/day).
For 3TC tablets, the recommended dose is one -half of a scored tablet taken twice 
daily in children weighing between 14kg and 21kg and one -half of a scored tablet 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
263taken in the morning and one whole tablet taken in the evening in children weighing 
between 21 k g and 30 kg.
Change 4 :
Amend: [IP_ADDRESS] Dosage Regimen Adjustment Criteria , Dose Adjustment Due to 
Subject Age exceeding 2 and 6 years
Original Text:
Subjects reaching and exceeding 2 years of age during the stud y should transition to the 
lower dose of FPV a nd RTV to 2 3 mg /kg and 3 mg /kg  BID respectivel y, in accordance 
with the  dosage regimen recommended  for this age group in protocol APV2 9005.  The 
change in dosage can be staged gradually  over multiple visits and will be based on 
ongoing viral load, pharm acokinetic and safet y assessments, at the investigator’s 
discretion.
Subjects reaching and exceeding 6 years of age may  transition to the lower dosage 
regimen (FPV 18 mg/kg and RTV 3 mg /kg BID) in accordance with the regimen 
approved for this age group. Th is dose change can be implemented gradually as the 
subject ‘grows into’ the new dose or at the time of their 6thbirthday  at the investigator’s 
discretion .
Revised Text:
Subjects reaching and exceeding 2 years of age during the stud y should transition to t he 
lower dose of FPV and RTV to 2 3 mg /kg and 3 mg /kg  BID respectivel y, in accordance 
with the  dosage regimen recommended  for this age group in protocol APV2 9005.  The 
change in dosage can be staged gradually  over multiple visits and will be based on 
ongoing viral load, pharmacokinetic and safet y assessments, at the investigator’s 
discretion.
Subjects reaching and exceeding 6 years of age may  transition to the lower dosage 
regimen (FPV 18 mg/kg and RTV 3 mg /kg BID) in accordance with the regimen 
approved for this age group. This dose change can be implemented gradually  as the 
subject ‘grows into’ the new dose or at the time of their 6thbirthday  at the investigator’s 
discretion.
In consultation with the investigator, [COMPANY_004] may discontinue PK sampling and 
mon itoring of plasma APV, FPV and RTV concentration on an individual basis 
once a subject has reached and exceeded 2 years and has initiated the 23/ 3 mg /kg 
BID dosing regimen after Week 48.  Any further dosing changes would follow the 
approved dosing recommen dations without PK sampling, including a transition to 
FPV/RTV 18/ 3 mg /kg BID at 6 years.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
264Change 5:
Amend: 3.3.10. Concurrent Medications and Non -Drug Therapi[INVESTIGATOR_014] , 7thand 8th
paragraph
Original Text:
FPV and RTV should not be co -administered with amiodarone , astemizole, bepridil, 
bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], diazepam, dihy droergotamine, encainide, 
ergonovine, ergotamine, estazolam, flecainide, flurazepam, lovastatin, meperidine, 
methy lergonovine, midazolam, pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], propafenone, propox yphene, 
quinidine, simvastatin, terfenadine and triazolam.  Co -administration may  result in 
competitive inhibition of metabolism of these medications and may  cause serious or life -
threatening adverse events.  Co -administration of FPV or FPV/RTV with rifabutin results 
in significant increases in plasma rifabutin levels, therefore the dose of rifabutin should 
be reduced b y at least 50% when co -administered with FPV and b y at least 75% when co -
administered with FPV/RTV.  Caution should be used and subjec ts should be monitored 
closely  for signs of toxicity .
FPV and RTV should not be co -administered with carbamazepi[INVESTIGATOR_050], dexamethasone, 
phenobarbital, primidone, rifampin and St. John’s Wort because the PI [INVESTIGATOR_227325] y decreased, reducing efficacy . 
Revised Text:
FPV and RTV should not be co -administered with alfuzosin, amiodarone, astemizole, 
bepridil, bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], diazepam, dihy droergotamine, 
encainide, ergonovine, ergotamine, estazolam, flecainide, flura zepam, halofantrine,
lovastatin, meperidine, methy lergonovine, midazolam, pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], 
propafenone, propox yphene, quinidine, PDE5 inhibitors including sildenafil,
simvastatin, terfenadine and triazolam.  Co -administration may  result in competitive 
inhibition of metabolism of these medications and may  cause serious or life -threatening 
adverse events.   Co-administration of FPV or FPV/RTV with rifabutin results in 
significant increases in plasma rifabutin levels, therefore the dose of rifabutin should be 
reduced b y at least 50% when co -administered with FPV and b y at least 75% when co -
administered with FPV/RTV.  Caution should be used and subjects should be monitored 
closely  for signs of toxicity .
Systemic corticosteroid effects, including Cushing's syn drome and adrenal 
suppression, have been reported in patients receiving ritonavir and inhaled or 
intranasally administered fluticasone propi[INVESTIGATOR_16847]; this interaction is also expected 
with other corticosteroids metabolized via the P450 3A pathway.
Concomitant use of fluticasone propi[INVESTIGATOR_227366].
FPV and RTV should not be co -administered with carbamazepi[INVESTIGATOR_050], dexamethasone, 
phenobarbita l, primidone, rifampin and St. John’s Wort because the PI [INVESTIGATOR_227367]2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
265may be significantl y decreased, reducing efficacy. FPV and RTV should also not be co -
administered with hepatitis C virus (HCV) protease inhibitors telaprevir and 
boceprevir because bo th APV and HCV PI [INVESTIGATOR_227368], with the possibility of sub -therapeutic concentrations.
Change 6:
Amend: [IP_ADDRESS] [COMPANY_004] Supplied Background NRTI Options , Sections on interactions 
relevant to abacavir and lamivudine added
Interactions Relevant to Abacavir
Based on the results of in vitro experiments and the known major metabolic 
pathways of ABC, the potential for drug interactions involving ABC is low. 
ABC shows no potential to inhibit metabolism mediated by [CONTACT_35233] P45 [ADDRESS_273967] shown that there 
are no clinically significant interactions between ABC, zidovudine and 3TC.
Ethanol -The metabolism of ABC is alter ed by [CONTACT_227401] 41%.  Given the safety profile of ABC, these 
findings are not considered clinically significant.  ABC has no effect on the 
metabolism of ethanol.
Methadone -In a PK study, co -admini stration of 60 0 mg ABC twice daily with 
methadone showed a 35% reduction in ABC Cmax and a one hour delay in tmax, 
but AUC was unchanged.  The changes in ABC PK are not considered clinically 
relevant.  In this study, ABC increased the mean methadone system ic clearance by 
22%.  This change is not considered clinically relevant for the majority of patients, 
however occasionally methadone dose re -titration may be required.
Retinoids -Retinoid compounds such as isotretinoin, are eliminated via alcohol 
dehydrog enase. Interaction with ABC is possible but has not been studied.
Refer to the local prescribing information for additional information on concurrent 
therapi[INVESTIGATOR_014].
Interactions Relevant to Lamivudine
The likelihood of interactions is low due to limited metabo lism and plasma protein 
binding and almost complete renal elimination of unchanged lamivudine.
Lamivudine is predominantly eliminated by [CONTACT_227454]. The 
possibility of interactions with other medicinal products administered concurren tly 
should be considered, particularly when their main route of elimination is active 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
266renal secretion via the organic cationic transport system, e.g. trimethoprim. Other 
medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by [CONTACT_227455].
Active substances shown to be predominately excreted either via the active organic 
anionic pathway, or by [CONTACT_227456].
Zidovudine -A modest increase in Cmax (28%) was observed for zidovudine when 
administered with lamivudine, however overall exposure (AUC) was not 
significantly altered. Zidovudine had no effect on the pharmacokinetics of 
lamivudine. 
Trimethoprim/sulp hamethoxazole -Administration of 
trimethoprim/sulphamethoxazole 160 mg/800 mg (co -trimoxazole) causes a 40% 
increase in lamivudine exposure because of the trimethoprim component. However, 
unless the patient has renal impairment, no dosage adjustment of la mivudine is 
necessary (see Dosage and Administration).  Lamivudine has no effect on the 
pharmacokinetics of trimethoprim or sulphamethoxazole. The effect of co -
administration of lamivudine with higher doses of co -trimoxazole for the treatment 
of Pneumocyst is carinii pneumonia and toxoplasmosis has not been studied. 
Zalcitabine -Lamivudine may inhibit the intracellular phosphorylation of 
zalcitabine when the two medicinal products are used concurrently.  Lamivudine is 
therefore not recommended to be used i n combination with zalcitabine.
Refer to the local prescribing information for additional information on concurrent 
therapi[INVESTIGATOR_014].
Change 7:
Amend: [IP_ADDRESS] [COMPANY_004] Supplied Background NRTI Options, Packaging and 
Labeling of [COMPANY_004] S upplied Background NRTI Options, Handling of [COMPANY_004] Supplied 
Background NRTI Options , Table
Original Table :
All [COMPANY_004] supplied background NRTI s should be stored until the time of dispensing as 
follows:
Abacavir oral solution US/Canada/Latin America –Store between 20 C -25C 
(68F -77F) DO N OT FREEZE. May be refrigerated .
Europe/ South Africa –Store below 30 C DO NOT 
FREEZE
Lamivudine oral solution US/Canada/Latin America –Store in tightly closed bottles 
at 25 C (77 F)
Europe/ South Africa –Store at or below 25 C
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
267Revised Table :
All [COMPANY_004] supplied background NRTI s should be stored until the time of dispensing as 
follows:
Abacavir oral solution US/Canada/Latin America –Store between 20 C -25C 
(68F -77F) DO NOT FREEZE. May be refrigerated .
Europe/ South Africa –Store below 30 C DO NOT 
FREEZE
Abacavir tablet* South Africa –Store at or below 30 C.
Lamivudine oral solution US/Canada/Latin America –Store in tightly closed bottles 
at 25 C (77 F)
Europe/ South Africa –Store at or below 25 C
Lamivudine tablet South Africa –Store at or b elow 30 C.
*Only supplied when licensed in South Africa.
Change 8:
Amend: 5.7 Bioanalysis and Pharmacokinetic Samples , Weeks 12, 16, 24, 36, 48 and 
every 12 weeks thereafter
Original Text:
All subjects will undergo additional plasma trough PK sampling o f 1.0mL of whole blood 
(just prior to receiving a scheduled dose of FPV/RTV BID) at Weeks 12, 16, 24, 36, 48
and every  12 weeks thereafter.  
In addition, at Week 16 (both Cohorts) and Week 36 (Cohort 1 only ), subjects will have a 
plasma trough PK sample o f 2.0mL whole blood collected (prior to receiving the 
scheduled dose of FPV/RTV BID) to determine the unbound concentration of APV.
Revised Text:
All subjects will undergo additional plasma trough PK sampling of 1.0mL of whole blood 
(just prior to receivin g a scheduled dose of FPV/RTV BID) at Weeks 12, 16, 24, 36, 48
and every  12 weeks thereafter.  
In addition, at Week 16 (both Cohorts) and Week 36 (Cohort 1 only ), subjects will have a 
plasma trough PK sample of 2.0mL whole blood collected (prior to receiv ing the 
scheduled dose of FPV/RTV BID) to determine the unbound concentration of APV.
In consultation with the investigator, [COMPANY_004] may discontinue PK sampling and 
monitoring of plasma APV, FPV and RTV concentration on an individual basis 
once a subject has r eached and exceeded 2 years and has initiated the 23/ 3 mg /kg 
BID dosing regimen after Week 48.  Any further dosing changes would follow the 
approved dosing recommendations without PK sampling, including a transition to 
FPV/RTV 18/ 3 mg /kg BID at 6 years.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
268Change 9:
Amend: Section 8.8.
Original Text:
8.8. Investigator Access to Data and Provision of Study Results
[COMPANY_004] will provide the investigator with a cop y of the CRF data collected from the site.  
When a clinical study  report is completed, [COMPANY_004] will provide t he major findings of the 
study  to the investigator.
In addition, details of the study  treatment assignment will be provided to the investigator 
to enable him/her to review the data to determine the outcome of the stud y for his/her 
subject.
A results summar y will be posted to a publicly available study register no later than [ADDRESS_273968]’s last visit (L SLV) or sooner if required by  [CONTACT_227439], 
local law or regulation. In addition, a manuscript will be submitted to a peer -reviewed 
journal for publication within 18 months of L SLV.
Revised Text:
8.8. Provision of Study Results to Investigators, Posting of Information on 
Publicly Available Clinical Trials Registers and Publication
[COMPANY_004] will provide the investigator with a cop y of the CRF d ata collected from the site.  
When a clinical study  report is completed, [COMPANY_004] will provide the major findings of the 
study  to the investigator.
In addition, details of the study  treatment assignment will be provided to the investigator 
to enable him/her to review the data to determine the outcome of the study  for his/her 
subject.
[COMPANY_004] aims to post a results summary to the [COMPANY_004] Clinical Study Register and other 
publicly available registers no later than [ADDRESS_273969]’s last visit 
(LSLV) [this applies to each data analysis phase for studies with multiple phases, 
e.g., primary analysis, follow up analysis etc]. In addition, the aim is to submit a 
manuscript to a peer -reviewed journal for publication within 18 months of LSLV. 
[COMPANY_004] also aims to publ ish the full study protocol on the [COMPANY_004] Clinical Study Register 
at the time the results of the study are published as a manuscript in the scientific 
literature. 
When manuscript publication in a peer -reviewed journal is not feasible, further 
study informati on will be posted to the [COMPANY_004] Clinical Study Register to supplement 
the results summary.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
269Change 10:
Amend: 10. TABLES , Revised Flow Chart of Laboratory Scheduled Assessments 
(Per Amendments 5 and 7) , Footnote 10
Original Text:
Samples for APV/RTV trough con centration determination collected [ADDRESS_273970] dose at Week 8 (Cohort 2 Arm A only ) and Weeks 12, 16, 24, 36, 48, and every  12 
weeks thereafter (both cohorts).  
Revised Text:
Samples for APV/RTV trough concentration determination collected [ADDRESS_273971] dose at Week 8 (Cohort 2 Arm A only ) and Weeks 12, 16, 24, 36, 48, and every  12 
weeks thereafter (both cohorts).  In consultation with the investigator, [COMPANY_004] may 
discontinue PK sampling and monitoring of plasma APV, FPV and RTV 
concentr ation on an individual basis once a subject has reached and exceeded 2 
years and has initiated the 23/ 3 mg /kg BID dosing regimen after Week 48.  Any 
further dosing changes would follow the approved dosing recommendations without 
PK sampling, including a tr ansition to FPV/RTV 18/ 3 mg /kg BID at 6 years.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
[ZIP_CODE].19. Appendix 1 9:  Protocol A mendment 1 2
Title:  APV20002 -A 48 week phase II, open -label, 2 -cohort, multicentre study  to 
evaluate the pharmacokinetics, safet y, tolerability and antiviral activit y of GW433908 
and GW433908/RTV when administered to HIV -1 infected protease inhibitor (PI) naïve 
and PI -experienced pediatric subjects aged 4 weeks to <[ADDRESS_273972] amended in 2012, in the amended version, in addition to the 
information regarding additional RTV formulations that can be used, and clarification for 
the still -enrolled South African subjects that they  may  continue  participate in the study  
until they  are of a sufficient weight ( ≥39 Kg) and are able to take FPV tablets, at which 
time they  will be withdrawn .Additional updates have been made to the safety  and dosing 
sections including updating the FPV and RTV dosing tables for children more than [ADDRESS_273973] grammar and punctuation .
The amendment consists of the following changes shown in order of occurrence in 
the protocol :
1.Update name [CONTACT_3669] [CONTACT_227457]: For clarification purposes, the Sponsor of the APV20002 
Study  is ViiV Healthcare.  ViiV Healthcare engages its affiliate, GlaxoSmithKline, to 
perform certain clinical services on its behalf ; the appropriate ViiV Healthcare
medical monitor contact [CONTACT_227458]. 
2.Include additional RTV formulation treatment option s, descriptions and dosing 
instructions for the additional RTV formulati ons and update the RTV and FPV 
dosing tables for heavier weight subjects . 
Reason for the change: S ale of the oral RTV solution is being discontinued by  [CONTACT_227459] .  Subjects enrolled in South Africa sites who 
successfull y completed [ADDRESS_273974] be withdrawn (subjects at 
[ADDRESS_273975] commercial access to FPV tablets outside of the 
APV20002 study ).  As the study  was not originally  anticipated to extend for this 
GD2001/[ZIP_CODE]/[ADDRESS_273976] 
been updated for weights through 38 kg for FPV and up to 100 mg BID for RTV
(maximum recommended dose)
3.In Section 1.3.[ADDRESS_273977] been added here (and in the Reference section) as well 
as referring to local labels for s ummaries of the available data.
Reason for change : The most current information on the primary  endpoint results 
from these pediatric studies are available in the individual publications and in the 
local product information :
4.Updated list of drugs not to be co-administered with FPV and RTV
Reason for change: based on recent drug interaction data studies, the list of drugs not 
to be co -administered with FPV and RTV has been amended. Information on drug 
interactions relevant to abacavir and lamivudine has also been updated .
5.Updated the information on Abacavir HSR
Reason for change: Since the last update, new information became available that t he 
risk for abacavir HSR to occur is significantl y increased for patients who test positive 
for the HLA -B*5701 allele. Additional information regarding HLA-B*[ADDRESS_273978] been updated .  
6.The section regarding prompt reporting of SAES to [COMPANY_004] was moved to Section 
7.9 and the pre vious Section 7.9 ( Regulatory Reporting Requirements For 
SAEs ) was moved to Section 7.8.
Reason for change: to improve flow and understanding.
7.Efficacy :Viral load measurements, after 2013, are being performed using the 
Abbott Realtime HIV -1 assay  instead of the [COMPANY_002] Amplicor assay . 
Reason for change: the [COMPANY_002] assay  was discontinued by  [CONTACT_3455].  The 
Abbott assay  has a LLOD of 40 copi[INVESTIGATOR_014]/mL.  This change onl y impacts subjects 
enrolled in the South African sites.
8.Assent forms will also be obtained from subjects still enrolled in the study  as of 
Nov 1, 2019.
Reason for change:  Informed consent was originally  obtained from the carers as the 
subjects were 2 years or younger at enrolment.  The enrolled subjects who chose to 
participate after successful ly completing 48 weeks of treatment at the South African 
sites are now of an age where they  can also give assent for study  participation.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
272Individual Changes
Note: minor punctuation or grammar corrections have not been included in the list of 
changes .  Updated references are indicated in the individual changes for the sections in 
which they  are cited. Specific revisions to the text are shown in bold.
Change 1 :Medical Monitor Contact [CONTACT_227460]:
, MD
GlaxoSmithKline
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, [LOCATION_006]
Telephone: 
Mobile: 
Revised Text 
, MD PhD
ViiV Healthcare 
[ADDRESS_273979]
P.O. [ZIP_CODE]
Research Triangle Park [LOCATION_003] [ZIP_CODE]
Mobile: 
Change 2
Changes within the Protocol Summary Section
2ndParagraph
Original Text :
Agenerase (AGN, amprenavir, APV) is a protease inhibitor (PI ) developed for the 
treatment of HIV disease.  Although AGN has demonstrated antiviral activity  and is 
generall y safe when given in combination with other antiretroviral agents to subjects at 
all stages of HIV infection, the pi[INVESTIGATOR_227286] (1.5mL/kg BID) are less than optimal and may impact 
long term adherence to therap y.  To reduce the pi[INVESTIGATOR_227294], a t 
and oral suspension formulation of fosamprenavir (FPV, GW433908, LEXIVA™/ 
TELZI R™), the phosphate ester prodrug of APV, have been developed to facilitate 
dosing of adult and pediatric HIV -[ADDRESS_273980] 3 drugs, including either a PI [INVESTIGATOR_1660] a non -
nucleoside reverse t ranscriptase inhibitor (NNRTI), plus a dual nucleoside reverse 
transcriptase inhibitor (NRTI ) backbone is the current standard of care and recommended 
for initial treatment of HIV -infected adults and children [US Department of Health and 
Human Services, 2006; Working Group on Antiretroviral Therapy  and Medical 
Management of HIV -Infected Children, 2006; South Africa Guidelines, 2005].  There 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
GD2001/[ZIP_CODE]/[ADDRESS_273981] agent to be given in combination with two NRTIs, and the 
choices are even more limited in children <2 years of age.
Revised Text 
Agenerase (AGN, amprenavir, APV) wasa protease inhibitor (PI ) developed for the 
treatment of HIV disease.  Although AGN demo nstrated antiviral activity  and was
generall y safe when given in combination with other antiretroviral agents to subjects at 
all stages of HIV infection, the pi[INVESTIGATOR_227286] (1.5mL/kg BID) was less than optimal and could impact 
long term adherence to therap y.  To reduce the pi[INVESTIGATOR_227294], a 
tablet and oral suspension formulation of fosamprenavir (FPV, GW433908, L EXIVA™/ 
TELZI R™), the phosphate ester prodrug of APV , wasdeveloped to facilitate dosing of 
adult and pediatric HIV -1 infected patients. The safet y and efficacy of FPV -containing 
regimens was demonstrated in three Phase III clinical trials in adults .
The use of combination therap y with 3 drugs, including ei ther a PI [INVESTIGATOR_1660] a non -nucleoside 
reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor , plus a dual nucleoside 
reverse transcriptase inhibitor (NRTI) backbone is the current standard of care for and is 
recommended for initial treatment of most HIV-infected adults and children [DHHS, 
2019; EACS, 2018; Panel on Antiretroviral Therapy and Medical Management of 
HIV -Infected Children; 2019].   There remains a need for additional therapi[INVESTIGATOR_227369], in particular there are limited choices for a third agent to be given in 
combination with two NRTI s, and the choices are even more limited in children <2 y ears 
of age.
Protocol Summary, Dose Rationale, 10thParagraph
Original Text :
None 
Revised Text (paragraph added)
Per Protocol Amendment [ADDRESS_273982] been added for 
the South African sites.  The RTV dosing is based upon the weight of the child and 
include RTV supplied as 100 mg tablets, capsules or powders/sachets.
Protocol Summary, Study Design , 1stParagraph
Original Text :
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric sub jects 4 weeks to <2 
years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every  12 weeks 
GD2001/[ZIP_CODE]/[ADDRESS_273983] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273984] been on different dosing regimens.
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10 has been 
closed.
Recruitment Status for APV20002 –from (FSFV) Oct [ADDRESS_273985] 10
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumulative enrolment and 
curre nt status
1A
6months -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
12 ongoing
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
15 ongoing
1.Current total enrolled patients exceeds the original cohort target because of dose ch anges in previous 
amendments
Revised Text
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to <2 
years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in the relevant age groups.  In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV unti l they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART. Per 
protocol amendment 12; only subjects at sites in South Africa remain enrolled as 
supplies of oral FPV suspension a re not commercially available in South Africa. 
Subjects successfully completing 48 weeks of therapy and receiving clinical benefit 
who weigh less than 39 kg may continue to receive FPV oral suspension provided by 
[CONTACT_23983]. Once subjects reach a weight of 39 kg, South African treatment guidelines 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
275permit the use of the FPV tablets in children weighing ≥[ADDRESS_273986] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273987] been on different dos ing regimens.
Enrolment into Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10 has been 
closed.
Recruitment Status for APV20002 –from Oct 2003 (FSFV) to Jul 2011 (cutoff for 48 
week CSR
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumul ative enrolment and 
current status
1A
6 months -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 261enrolled
11 ongoing2
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 281enrolled
14 ongoing2
1.A total of 59 patients were enrolled but 5 were discontin ued after receiving single dose of FPV; current 
total enrolled patients exceeds the original cohort target because of dose changes in previous amendments
2.Ongoing as of cutoff for 48 week CSR (July 2011)
Protocol Summary Study Drugs and Dosages 
Original t ext:
Study  drugs are defined as FPV and RTV.  FPV will be administered as a 50mg/mL  
(43.2mg/mL APV molar equivalents) oral suspension.   RTV will be given as an 
80mg/mL  oral solution.  Both the FPV and RTV oral formulations should be 
administered with food .  If vomiting or spi[INVESTIGATOR_227307] 30 minutes of 
administration, parents/guardians should be instructed to re -administer the study  
medications.
Revised Text
Study  drugs are defined as FPV and RTV.  FPV will be administered as a 5 0 mg /mL 
(43.2 mg/m L APV molar equivalents) oral suspension.  RTV will be administered as an 
80 mg/mL  oral solution, as a 100 mg capsule or tablet, or as a 100 mg powder 
packet/sachet .  Choice of appropriate formulation will depend on participant’s weight, 
availability  of fo rmulation and participant/caregiver preference.  Both the FPV and RTV 
oral formulations should be administered with food.  If vomiting or spi[INVESTIGATOR_227370]2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
276within 30 minutes of administration, parents/guardians should be instructed to re -
administer the st udy medications.   
Protocol Summary Measurements and Evaluations 
Original text:
Schedules showing the timing of stud y procedures and laboratory evaluations for all 
subjects are shown in Section 10.  Subjects will attend the clinic at Screening (within 
approximately  21 day s prior to Baseline/Day  1), Day  1 (Baseline), and Weeks 2, 4, 8, 12, 
16, 24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects may continue to receive FPV until they  no 
longer derive clinical benefit or according to prior agreements between [COMPANY_004] a nd 
participating stud y sites for provision of ART.  A follow -up visit will be performed 
4weeks after the permanent discontinuation of study  drug.
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluation of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Plasma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
every  12 weeks thereafter. 
Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected o ver 8 -12 
hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, 48 and every  12 weeks thereafter. 
Revised Text
Schedules showing the timing of stud y procedures and laboratory evaluations for all 
subjects are shown in Section 10.  Subjects will attend the clinic at Screening (within 
approximately  21 day s prior to Baseline/Day  1), Day  1 (Baseline), and Weeks 2, 4, 8, 12, 
16, 24, 36, 48, and every  12 weeks thereafter until commercial supplies of FPV oral 
suspension are available locally  and pediatric dosing is approved in the relevant age 
groups.  In countries where local availability  is delay ed or the drug is not y et available 
through national treatment programs, subjects who successfully complete 4 8weeks on 
therapy may continue to receive FPV oral suspension provided by [CONTACT_227383] , weigh 39 kg or more, or according to prior agreements 
between [COMPANY_004] and participating stud y sites for provision of ART.  A follow -up visit will 
be performed 4 weeks after the permanent discontinuation of study  drug.
Cohort 1 (6 months to <2 y ears) Arm A: Plasma samples for evaluation of PK parameters 
will be collected over 4 hours at Week 2 and over 8 -12 hours (12 hour sample optional) 
at Week 8.  Plasma trough PK samples will be collected at Weeks 12, 16, 24, 36, 48 and 
every  12 weeks thereafter. Protocol amendment 11 (effective date October 26, 2012) 
provided the option to discontinue PK sampling once a subject had reached and 
exceeded 2 years and had initiated the 23/3 mg/kg FPV/RTV BID dosing regimen.  
PK sampling was discontinued after approval of the amended protocol in South 
Africa.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
277Cohort 2 (4 weeks to <6 months) Arm A:  Plasma PK samples will be collected over 8 -12 
hours (12 hour sample optional) at Week 2.  Plasma trough PK samples will be collected 
at Weeks 8, 12, 16, 24, 36, [ADDRESS_273988] had been enrolled in the study for more than 48 
weeks.
Change 3
Amend: Section 1 Introduction
Section 1.1 Background 
Original text:
Agenerase (AGN, amprenavir, APV) is a protease inhibitor (PI ) for the treatment of HIV 
disease.  Although AGN h as demonstrated antiviral activity  and is generally  safe when 
given in combination with other antiretroviral agents to subjects at all stages of HIV 
infection, the pi[INVESTIGATOR_227293] (1. 5mL/kg BID) are less than optimal and may  impact long term 
adherence to therap y.  To reduce the pi[INVESTIGATOR_227294], a tablet and 
oral suspension formulation of fosam prenavir (FPV, GW433908, L EXIVA/ TELZIR ), 
the phosphate ester prodrug of A PV, have been developed to facilitate dosing of adult 
and pediatric HIV -1 infected patients.
The safet y and efficacy  of three FPV -containing regimens has been demonstrated in three 
Phase III clinical trials, APV30001 (antiretroviral [ART] -naïve subjects), APV30002 
(ART -naïve subjects), and APV30003 (PI -experienced subjects). [GlaxoSmithKline 
Document Number GM2002/[ZIP_CODE]/00 , Study  APV30002; GlaxoSmithKline Document 
Number RM2002/[ZIP_CODE]/00 , Study  APV30001; GlaxoSmithKline Document Number 
RM2002/[ZIP_CODE]/00 , Study APV30003].  Based on these studies, three dosing regimens in 
adults are approved in the [LOCATION_002] (US); for ART -naïve subjects, FPV 1400mg 
BID, FPV 700mg BID + ritonavir (RTV) 100mg BID or FPV 1400mg QD + RTV 200mg 
QD and for PI -experienced subjects, FPV 700mg BID + RTV 100mg BID.  I n Europe, 
the FPV 700mg BID + RTV 100mg BID regimen was approved for PI -naïve or 
experienced HIV -1 infected adults.  A further study  in ART -naïve adults (ESS100732, 
KLEAN) demonstrated non -inferiorit y of FPV 700mg BID + RTV 100mg BID compared 
to lopi[INVESTIGATOR_054] (L PV)/ RTV (Kaletra) BID [GlaxoSmithKline Document Number 
RM2006/[ZIP_CODE]/00 , Study ESS100732].
Revised Text
Agenerase (AGN, amprenavir, APV) wasa protease inhibitor (PI ) for the treatment of 
HIV disease.  Although AGN demons trated antiviral activity  and wasgenerall y safe 
when given in combination with other antiretroviral agents to subjects at all stages of 
HIV infection, the pi[INVESTIGATOR_227293] (1.5mL/kg B ID) were less than optimal and may  have impacted long 
term adherence to therapy.  To reduce the pi[INVESTIGATOR_227294], a tablet 
and oral suspension formulation of fosam prenavir (FPV, GW433908, LEXIVA/ 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
278TELZI R), the phosphate ester prodrug of A PV, were developed to facilitate dosing of 
adult and pediatric HIV -1 infected patients. 
The safet y and efficacy  of three FPV -containing regimens has been demonstrated in three 
Phase III clinical trials, APV30001 (antiretroviral [ART] -naïve subjects), APV3 0002 
(ART -naïve subjects), and APV30003 (PI -experienced subjects). [GlaxoSmithKline 
Document Number GM2002/[ZIP_CODE]/00 , Study  APV30002; GlaxoSmithKline Document 
Number RM2002/[ZIP_CODE]/00 , Study  APV30001; GlaxoSmithKline Document Number 
RM2002/[ZIP_CODE]/00 , Study APV [ZIP_CODE]].  Based on these studies, four dosing regimens in 
adults are approved in the [LOCATION_002] (US) for ART -naïve subjects :FPV 140 0 mg
BID, FPV 700 mg BID + ritonavir (RTV) 10 0 mg BID or FPV 140 0 mg QD + RTV 20 0 
mgQDor FPV 1400 mg QD + RTV 100 mg QD and for PI -experienced subjects :FPV 
700 mg BID + RTV 10 0 mg BID.  In Europe, the FPV 70 0 mg BID + RTV 10 0 mg BID 
regimen was approved for PI -naïve or experienced HIV -1 infected adults.  A further 
study  in ART -naïve adults (ESS100732, KL EAN) demonstrated n on-inferiority  of FPV 
700 mg BID + RTV 10 0 mg BID compared to lopi[INVESTIGATOR_054] (L PV)/ RTV (Kaletra) BID 
[GlaxoSmithKline Document Number RM2006/[ZIP_CODE]/00 , Study ESS100732].
Change 4
Amend Section 1.2 Rationale
Original text:
The use of combination therap y with at least 3 drugs, including either a PI [INVESTIGATOR_1660] a non -
nucleoside reverse transcriptase inhibitor (NNRTI), plus a dual nucleoside reverse 
transcriptase inhibitor (NRTI ) backbone is the current standard of care and recommended 
for initial treatment of HIV -infected a dults and children [US Department of Health and 
Human Services, 2006; Working Group on Antiretroviral Therap y and Medical 
Management of HIV -Infected Children, 2006; South Africa Guidelines, 2005].  There 
remains a need for additional therapi[INVESTIGATOR_227371], in particular there are 
limited choices for a third agent to be given in combination with two NRTIs, and the 
choices are even more limited in children <2 years of age.
Revised Text
The use of combination therap y with 3 drugs, including eithe r a PI [INVESTIGATOR_1660] a non -nucleoside 
reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor , plus a dual nucleoside 
reverse transcriptase inhibitor (NRTI) backbone is the current standard of care for and is 
recommended for initial treatment of most HIV-infected adults and children [DHHS, 
2019; EACS, 2018; Panel on Antiretroviral Therapy and Medical Management of 
HIV -Infected Children; 2019].   There remains a need for additional therapi[INVESTIGATOR_227369], in particular there are limited choices fo r a third agent to be given in 
combination with two NRTI s, and the choices are even more limited in children <2 y ears 
of age.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
279At the time the APV20002 study was collecting the primary outcome data (through 
Week 48), in the NNRTI class, efavirenz (EFZ) and nevirapi[INVESTIGATOR_050] (NVP) were available as 
liquid formulation s.  NVP is associated with rare but potentially  life threatening adverse 
reactions whilst EFZ is associated with neurops ychiatric adverse reactions 
[Viramune Package Insert, 2010] [ Sustiva Package I nsert , 2010].
Similarly, at the time the APV20002 study was collecting the primary outcome data 
(through Week 48), in the PI  [CONTACT_71963] , six agents -APV, indinavir (IDV), nelfinavir (NFV), 
RTV lopi[INVESTIGATOR_054]/ritonavir (LPV/RTV), and darunavir were approved for use in H IV-1 
infected children.  APV has subsequently been discontinued. The lower age limits for 
which these PIs were approved for use varies between countries .Deleted text: but 
range from >1 month (RTV) or  6 months (LPV/RTV) in some countries, to 2 years 
of ag e or older for the other currently approved PIs (6 years or older for darunavir).
LPV/RTV is aPI [INVESTIGATOR_227372].  Several studies support the 
use of L PV/RTV in children.  An earl y stud y in children 6 months to 12 y ears of age 
demo nstrated the antiviral activity  of LPV/RTV over a 24 week period, with plasma 
HIV-1 RNA levels of <400 copi[INVESTIGATOR_014]/mL  being achieved in 82% of ART -naïve children and 
66% of children with a mixture of NRTI -experience and NRTI + PI -experience, and 
accompan ying im provements in CD4+ ly mphocy te counts, after 24 weeks of therap y 
[Violari , 2000] .  In a later study , 100 children ages 6 months to 12 y ears who were either 
ART naïve or ART -experienced but NNRTI naïve, received L PV/RTV as part of an ART 
regimen.  At Week 48 , 79% of subjects had plasma HIV -1 RNA levels of <400 
copi[INVESTIGATOR_014]/mL  with corresponding mean increases in CD4+ cell counts from baseline [ Post, 
2010; Ross , 2015; Saez -Llorens ,2003]. Recently , data on the use of LPV/RTV in infants 
<6 weeks of age has been prese nted.  In this study , 8 infants ages ≥14 days to ≤[ADDRESS_273989] dose LPV/RTV over 24 weeks.  L PV/RTV AUCs were significantl y 
lower than seen in an older cohort ages 6 weeks to 6 months, y et the regimen resulted in 
virological suppression (plasm a HIV -1 RNA <400 copi[INVESTIGATOR_014]/mL )in7/8 subjects [ Pi[INVESTIGATOR_1946] , 
2007]. 
Although these PI [INVESTIGATOR_227296] -[ADDRESS_273990] display  limitations, such as lack of suitable 
formulations, inflexible dosing schedules and clinical side effects. For instance, no liquid 
formulation is available for indinavir and it is more difficult to assure adequate fluid 
intake to avoid renal complications in children than in adults.  The powder formulation of 
nelfinav ir is difficult to administer to children, and consequentl y the adult tablets are used 
which results in a restrictive dosing schedule [ Gibb , 2000b].  The major limitations to the 
pediatric formulation of RTV are the taste, vomiting as an adverse event and high alcohol 
content [ Panel on Antiretroviral Therap y and Medical Management of HIV -Infected 
Children. Use of Antiretroviral Agents in Pediatric HIV Infection.  Updated April 16, 
2019. Available at 
http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatri cguidelines.pdf. Accessed August 
20, 2019.
Pelton ,1998]. Although Kaletra is now widely  used in treating HIV infected children, the 
pediatric liquid formulation of L PV/RTV does have a similar alcohol content (42%) to 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
280that in the RTV liquid (43%) [ Kaletra Package Insert, 2019; Norvir ,Package Insert, 
2017]. Deleted text: ,
Change 5
Amend: 1.3.2. FPV Pediatric Clinical Data
Original Text :
Pharmacokinetic, safet y, and antiviral response data in pediatric subjects 2 to 18 y ears of 
age receiving FPV with or wi thout RTV are available from Study  APV29005 (24 week 
data; BID regimens) and Study  APV20003 (48 week data; QD regimens).  Additionally , 
48 week data from a small number of pediatric subjects <2 years of age receiving 
FPV/RTV in Study  APV20002 have also bee n reported.  Refer to the Fosamprenavir 
Investigator’s Brochure Supplement for summaries of the available data from these 
studies.
Revised Text
Pharmacokinetic, safet y, and antiviral response data in pediatric subjects 2 to 18 y ears of 
age receiving FPV wi th or without RTV are available from Study  APV29005 [Fortuny, 
2014], and Study  APV20003 [Chadwick, 2007].   Additionally , 48 week data from the 
pediatric subjects <2 years of age receiving FPV/RTV in Study  APV20002 have also 
been reported [Cotton, 2014; 201 4; Ross, 2015].   Overall the safet y profile of 
fosamprenavir with and without ritonavir in paediatric patients was comparable to that 
observed in adult clinical studies .  Refer to the local product information for 
summaries of the available data from these studies.
Change 6
Amend: Section 3.1 Study Design
Original Text :
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  centers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commerci al supplies of FPV oral suspension are available locally  and pediatric 
dosing is approved in the relevant age groups. In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may contin ue to receive FPV until they  no longer derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART. 
Single dose visits (SDVs) for both Cohort 1 Arm A and 2 Arm A are complete.  
GD2001/[ZIP_CODE]/[ADDRESS_273991] been modified in previous protocol amendments (3, 5, 7 and 
8).  The evaluable PK data for approximately  [ADDRESS_273992] been on different dosing regimens.
Arm B (unboost ed FPV cohorts 1 and 2) as per amendment 10 has been closed.
Table 6 Recruitment Status for A PV20002 –from (FSFV) Oct [ADDRESS_273993]. 10
Age
(yrs)
CohortsNo. of Subjects originally 
plannedCumulative enrolment and 
current status
1A
6months -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
12 ongoing
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 291enrolled
15 ongoing
1.Current total enrolled patients exceeds the original cohort target because of dose changes in prev ious 
amendments
Revised Text
APV20002 is an international, 48 -week, Phase II, open -label, 2 –cohort, multicenter study  
to be conducted in approximately  48 HIV -1 infected pediatric subjects 4 weeks to 
<2years old.  This study  may  be performed at study  cent ers in North and South America, 
Europe, and Africa or in other regions as appropriate.  Subjects successfully completing 
48 weeks of therap y in APV20002 may continue in the study with visits every 12 weeks 
until commercial supplies of FPV oral suspension a re available locally  and pediatric 
dosing is approved in the relevant age groups. In countries where local availability  is 
delay ed or the drug is not y et available through national treatment programs, subjects 
may continue to receive FPV until they  no long er derive clinical benefit or according to 
prior agreements between [COMPANY_004] and participating study  sites for provision of ART .  Per 
protocol amendment 12; only subjects at sites in South Africa remain enrolled as 
supplies of oral FPV suspension are not commer cially available in South Africa. 
Subjects successfully completing 48 weeks of therapy and receiving clinical benefit 
who weigh less than 39 kg may continue to receive FPV oral suspension provided by 
[CONTACT_23983]. Once subjects reach a weight of 39 kg, South Africa n treatment guidelines 
permit the use of the FPV tablets in children weighing ≥39 kg and these subjects will 
be withdrawn as FPV tablets are commercially available in South Africa.   
Single dose visit s(SDV s)for both Cohort [ADDRESS_273994] been modified in previous protocol amendments (3, 5, 7 and 
8).  Protocol amendment [ADDRESS_273995]
successfully completed 48 weeks of treatment.  Therefore, the evaluable PK data for 
GD2001/[ZIP_CODE]/[ADDRESS_273996] been 
on different dosing regimens.
Arm B (unboosted FPV cohorts 1 and 2) as per amendment 10 has been closed.
Table 7Recruitment Status for A PV20002 –from Oct 2003 (FSFV) to Jul 2011 
(cutoff for 48 week CSR
Age
(yrs)
CohortsNo. of S ubjects originally 
plannedCumulative enrolment and 
current status
1A
6 months -<2yr
PI-naïve/exp
FPV/RTV (boosted)12 261enrolled
11 ongoing2
2A
4wks -<6mo
PI-naïve/exp
FPV/RTV (boosted)12 281enrolled
14 ongoing2
1. A total of 59 patients w ere enrolled but 5 discontinued after receiving single dose of FPV; current total 
enrolled patients exceeds the original cohort target because of dose changes in previous amendments
2. Ongoing as of cutoff for 48 week CSR (July 2011)
Change 7
Amend: Section 3.2.3 Other Study Eligibility Criteria Considerations
Original Text :
In order to assess an y potential impact on subject eligibility  with regard to safet y, the 
investigator must refer to the following document(s) for detailed information regarding 
warnings, precautions, contraindications, adverse events, and other significant data 
pertaining to the stud y drugs: Such documents may include, but are not limited to, the 
Fosamprenavir Investigator’s Brochure Supplement and local product information or the 
Interna tional Product Information.
Revised text:
In order to assess an y potential impact on subject eligibility  with regard to safet y, the 
investigator must refer to the following document(s) for detailed information regarding 
warnings, precautions, contraindicat ions, adverse events, and other significant data 
pertaining to the stud y drugs: Such documents may include, but are not limited to, the 
Text deleted <Fosamprenavir Investigator’s Brochure Supplement>,  local product 
information or the International Product Information.
Change 8
Amend: Section 3.3.1 Study Drugs; 2 -6thparagraphs
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
283Original Text :
In this stud y FPV will be provided b y [COMPANY_004].  In all countries, RTV oral solution will be 
obtained locall y and reimbursed, if acceptable to regulatory authorities.  [COMPANY_004] will 
provide RTV b y other means if reimbursement is not acceptable.  Both FPV and RTV 
will be considered stud y drugs.  Therefore, in the event that a subject permanently  
discontinues FPV, the subject will discontinue from this protocol and [COMPANY_004] will no long er 
supply  FPV or RTV for that subject.
The FPV 50mg/mL  (43.2mg/mL  APV molar equivalents) suspension is a white to off -
white bubblegum and peppermint flavo ured suspension for oral administration using a 
dosing s yringe.  Each mL of suspension contains 50mg o f FPV ,equivalent to 43.2mg/mL  
of APV.  The suspension contains the following inactive ingredients: 
hydroxypropylmethy l cellulose, poly sorbate 80, methy lparaben, propy lparaben, 
propy lene gl ycol ( overall 20mg /mL), sucralose, calcium chloride, flavo urs and p urified 
water.  The FPV oral suspension is manufactured by  [CONTACT_227387], Ontario, 
Canada.
The RTV oral solution manufactured b y Abbott Laboratories contains 80mg/mL of RTV 
in a peppermint and caramel flavo ured vehicle and will be administered via a d osing 
syringe.  The RTV solution contains the following inactive ingredients: ethanol, water, 
polyoxyl 35 castor oil, propy lene gly col, anhy drous citric acid, saccharin sodium, 
peppermint oil, creamy  caramel flavour ing and FD&C Yellow No. 6.
Revised text:
In this stud y,FPV oral suspension will be provided by  [CONTACT_23983].  In all countries, RTV oral 
solution, powder, tablets or capsules will be obtained locall y and reimbursed if 
acceptable to regulatory  authorities.  [COMPANY_004] will provide RTV by  [CONTACT_227461], or [COMPANY_004] may provide RTV if local supplies are not 
available and RTV is able to be obtained from other c ountries. Both FPV and RTV 
will be considered stud y drugs.  Therefore, in the event that a subject permanently  
discontinues FP Voral suspension , the subject will discontinue from this protocol and 
[COMPANY_004] will no longer supply  FPV or RTV for that subject.
The FPV 50 mg/mL (43.2mg/mL  APV molar equivalents) suspension is a white to off -
white bubblegum and peppermint flavo ured suspensio n for oral administration using a 
dosing s yringe.  Each mL of suspension contains 50 mg of FPV ,equivalent to 43.2
mg/mL  of APV.  The suspension contains the following inactive ingredients: 
hydroxypropylmethy l cellulose, poly sorbate 80, methy lparaben, prop ylparaben, 
propy lene gl ycol ( overall 2 0 mg /mL), sucralose, calcium chloride, flavo urs and purified 
water.  The FPV oral suspension is manufactured by  [CONTACT_227387], Ontario, 
Canada.
The RTV oral solution manufactured b y Abbvie contains 8 0 mg /mL of RTV in a 
peppermint and caramel flavo ured vehicle and will be administered via a dosing s yringe.  
The RTV solution contains the following inactive ingredients: ethanol, water, poly oxyl 
35 castor oil, prop ylene gly col, anh ydrous citric acid, saccharin sodium, peppermint oil, 
cream y caramel flavour ing and FD&C Yellow No. 6.
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
284The RTV 100 mg oral powder/sachets manufactured by [CONTACT_227462]: copovidone, sorbitan monolaurate, and colloidal silicon 
dioxide, and are sugar -free.
The 100 mg RTV tablets manufactured by [CONTACT_227463], anhydrous dibasic calcium phosphate, sorbitan monolaurate, colloidal 
silicon dioxide, and sodium stearyl fumarate. The film coating contains: 
hypromellose, titanium dioxide , polyethylene glycol 400, hydroxypropyl cellulose, 
talc, polyethylene glycol 3350, colloidal silicon dioxide, and polysorbate 80. The 100 
mg RTV tablets are white, film -coated, ovaloid tablets and are sugar -free.
The 100 mg soft gelatin RTV capsules manuf actured by [CONTACT_227389] 
100 mg (SSSS enantiomer); other ingredients include ethanol (12 % v/v), butylated 
hydroxytoluene (antioxidant), oleic acid, polyoxyl 35 castor oil, water, gelatin, sugar, 
sorbitol, glycerin, titianium dioxide, medium ch ain triglycerides, lecithin and black 
ink.
Change 9
Amend: Section 3.3.2 Background NRTI Options Provided by [CONTACT_35316] ; 7th
paragraph
Original Text :
The 3TC tablet contains 150mg of 3TC and the inactive ingredients magnesium stearate, 
microcry stallin e cellulose, and sodium starch gl ycolate. The tablet is coated with a film 
that is made of h ypromellose, titanium dioxide, macrogol, and pol ysorbate 80. 3TC 
tablets are manufactured by  [CONTACT_227392], Hertfordshire, [LOCATION_008].
Revised text:
The 3TC table t contains 15 0 mg of 3TC and the inactive ingredients magnesium stearate, 
microcry stalline cellulose, and sodium starch gl ycolate. The tablet is coated with a film 
that is made of h ypromellose, magnesium stearate, microcrystalline cellulose, 
polyethylene g lycol, sodium starch glycolate ,titanium dioxide, and poly sorbate 80. 
3TC tablets are white, diamond -shaped and scored and manufactured b y [COMPANY_004] in Ware, 
Hertfordshire, [LOCATION_008].
Change 10
Amend: Section 3.3. 3 Background ART Not Provided by [CONTACT_227464]: 3.3.3.Background ART Not Provided by 
[CONTACT_35316]/ViiV Healthcare
Original Text:
[COMPANY_004] will not provide or reimburse background ART other than ABC or 3TC.
Revised text:
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
285[COMPANY_004] /ViiV Healthcare will not provide or reimburse backgr ound ART other than ABC 
or 3TC.
Change 11
Amend: Section 3.3.5 Dosages and dosing ;1stand 5thparagraphs
Original Text paragraph 1 :
FPV and RTV will be administered according to the doses described in Section 3.3.4 .
Revised text paragraph 1 :
FPV and RTV w ill be administered according to the doses described in Section 3.3.4 and 
in Section 3.3.5 .1.
Original textparagraph 5
The recommended dose of 3TC solution is 4mg/kg BID (up to a maximum of 
300mg/day ).
Revised text paragraph 5
The recommended dose of 3TC solution is currently 4 mg /kg BID (up to a maximum of 
300mg/day ).The dosing recommendation in the local label should be followed.
Change 12
Amend: Section [IP_ADDRESS] Dosage Regimen Adjustment Criteria in Dose Adjustment 
Due to Subject Age exceeding 2 and 6 years ; 1stand 3rd paragraphs
Original Text paragraph 1 :
Subjects reaching and exceeding 2 years of age during the stud y should transition to the 
lower dose of FPV and RTV to 23mg/kg and 3mg/kg BID respectively , in accordance 
with the  dosage regimen reco mmended  for this age group in protocol APV2 9005.  The 
change in dosage can be staged gradually  over multiple visits and will be based on 
ongoing viral load, pharmacokinetic and safet y assessments, at the investigator’s 
discretion.
Revised text paragraph 1 :
Subjects reaching and exceeding 2 years of age during the stud y should transition to the 
lower dose of FPV and RTV to 23 mg/kg and 3 mg/kg BID respectivel y<Text deletion: 
in accordance with the  dosage regimen recommended  for this age group in 
protocol APV29005 >.  The change in dosage can be staged graduall y over multiple visits 
and will be based on ongoing viral load, pharmacokinetic and safety  assessments, at the 
investigator’s discretion .
Original Text paragraph 3 :
GD2001/[ZIP_CODE]/[ADDRESS_273997] has 
reached and exceeded 2 years and has initiated the 23/3mg/kg BID dosing regimen after 
Week 48.  Any  further dosing changes would follow the approved dosing 
recommendations without PK sampling, including a transition to FPV/RTV 18/3mg/kg 
BID at 6 y ears.
Revised text paragraph 3:
In consultation with the investigator, [COMPANY_004] may  discontinue PK sampling and monitoring 
of plasma APV , FPV and RTV concentration on an individual basis once a subject has 
reached and exceeded 2 years and has initiated the 23/ 3 mg /kg BID dosing regimen after 
Week 48.  Any  further dosing changes would follow the approved dosing 
recommendations without PK sa mpling, including a transition to FPV/RTV 18/3mg/kg 
BID at 6 y ears.  Note: after Protocol Amendment 11 became effective, PK sampling 
and monitoring of plasma APV, FPV and RTV concentration on an individual basis 
was discontinued. 
Change 13
Amend: Section 3.3.7.3Specific Events ; 4th-paragraphs
Original Text
The appearance of rash in the absence of other s ymptoms or signs is not indicative of 
hypersensitivity  to ABC.  Subjects receiving ABC who develop rash of any  grade should 
be evaluated for the possibili ty of hypersensitivity  as outlined below.
Study  treatment should be managed as outlined in the following table:
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
287Rash Management
EventAction to be Taken
FPV BID or FPV/RTV BID ABC 3TC
Grade [ADDRESS_273998] has no 
constitutional symptoms (fever, 
malaise, fatigue, headache), ABC 
may be continued with the warning 
to discontinue immediately and 
permanently if oth er signs and/or 
symptoms consistent with HSR 
appear.Therapy can 
continue
Grade 1 rash with 
symptoms indicating multi -
organ involvement 1Discontinue FPV BID or 
FPV/RTV BID.  Therapy 
should not be reinitiated 
unless the investigator has 
compelling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently 2Therapy can 
continue
Grade 2 rash alone Therapy can continue Follow Grade 1 rash alone 
instructionsTherapy can 
continue
Grade 2 rash with 
symptoms indicating multi -
organ i nvolvement 1Discontinue FPV BID or 
FPV/RTV BID.  Therapy 
should not be reinitiated 
unless the investigator has 
compelling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently 2Discontinue 3TC.  
Therapy should 
not be rein itiated 
unless the 
investigator has 
compelling 
evidence that the 
rash is not caused 
by 3TC.
Grade 3/4 rash alone or 
with symptoms indicating 
multi -organ involvement 1Discontinue FPV BID or 
FPV/RTV BID and do not 
reinitiate therapy 3Discontinue ABC immedia tely and 
permanently 3Discontinue 3TC3
1.Symptoms include: systemic symptoms (fever, GI symptoms including nausea, vomiting, diarrhea or abdominal 
pain) or allergic symptoms, or mucosal involvement, or severe tiredness, achiness or generally ill feeling.  
2.ABC therapy should be permanently stopped and another NRTI therapy should be initiated.
3. Medications should be permanently stopped and the subject withdrawn from the trial. 
Revised text
The appearance of rash in the absence of other s ymptoms or signs is n ot indicative of 
hypersensitivity  to ABC.  Subjects receiving ABC as part of their NRTI background 
regimen should be evaluated for the possibility  of a clinically suspected ABC HSR and 
managed appropriately as outlined in the local prescribing .  Subjects s hould be 
instructed to contact [CONTACT_227465] a rash while on 
study .
Subjects who develop rash of any grade should be evaluated for the possibility of an 
ABC HSR or a serious skin reaction such as Stevens -Johnson Syndr ome (SJS), 
Toxic Epi[INVESTIGATOR_19342] (TEN) or Erythema Multiforme. SJS, TEN and 
Erythema Multiforme have been reported very rarely in patients taking ABC -
containing products.  These patients generally do not have the cluster of additional 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
288symptoms (e.g., gastrointestinal and respi[INVESTIGATOR_696]) that characterize the ABC HSR, 
but they do have features typi[INVESTIGATOR_227310].
If a serious skin reaction develops, ABC (and / or all other concurrent medication(s) 
suspected in the Investigators causali ty assessment) should be discontinued, and the 
subject should not be re -challenged with any ABC -containing medicinal product 
(i.e., TRIUMEQ, ZIAGEN, TRIZIVIR, EPZICOM or KIVEXA).
As many products other than abacavir also cause rash and/or serious skin reac tions, 
all other medicinal products that the subject is receiving should also be reviewed 
and discontinued as appropriate.
Study  treatment should be managed as outlined in the following table:
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
289Rash Management
EventAction to be Taken
FPV BID or FPV/RTV BID ABC 3TC
Grade [ADDRESS_273999] has no 
constitutional symptoms (fever, 
malaise, fatigue, headache), ABC 
may be continued at the
investigators discretion with the 
warning to discontinue immediately 
and permanently if other signs 
and/or sympto ms consistent with 
HSR appear.  The subject should 
be advised to contact [CONTACT_227466], if 
any systemic signs or symptoms 
worsen, or if mucosal 
involvement develops .Therapy can 
continue
Grade 1 rash with 
symptoms indicating multi -
organ involvement 1Discontinue FPV BID or 
FPV/RTV BID.  Therapy 
should not be reinitiated 
unless the investigator has 
compelling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently 2
Subjects should be treated as 
clinically appropriate and 
followed until resolution of the 
AE.Therapy can 
continue
Grade 2 ras h alone Therapy can continue Follow Grade 1 rash alone 
instructionsTherapy can 
continue
Grade 2 rash with 
symptoms indicating multi -
organ involvement 1Discontinue FPV BID or 
FPV/RTV BID.  Therapy 
should not be reinitiated 
unless the investigator has 
comp elling evidence that 
the rash is not caused by 
[CONTACT_227395].Discontinue ABC immediately and 
permanently [ADDRESS_274000] the physician 
immediately if rash fails to 
resolve (after more than two 
weeks), if there is any worsening 
of the rash , if any systemic signs 
or allergic symptoms develop, or 
if mucosal involvement develops.Discontinue 3TC.  
Therapy should 
not be reinitiated 
unless the 
investigator has 
compelling 
evidence that the 
rash is not caused 
by 3TC.
Grade 3/4 rash alone or 
with symptoms indicating 
multi -organ involvement 1Discontinue FPV BID or 
FPV/RTV BID and do not 
reinitiate therapy 3
Subjects should be 
treated as clinically 
appropriate and followed 
until resolution of the AE.Discontinue ABC immediately and 
permanently 3
Subj ects should be treated as 
clinically appropriate and 
followed until resolution of the 
AE.Discontinue 3TC 3
Subjects should 
be treated as 
clinically 
appropriate and 
followed until 
resolution of the 
AE.
1.Symptoms include: systemic symptoms (fever, GI sympto ms including nausea, vomiting, diarrhea or abdominal 
pain) or allergic symptoms, or mucosal involvement, or severe tiredness, achiness or generally ill feeling.  
2.ABC therapy should be permanently stopped and another NRTI therapy should be initiated.
3. Medic ations should be permanently stopped and the subject withdrawn from the trial. .
Change 14
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
290Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , 1stparagraph
Original text
In clinical studies, approximately  5% of subjects receiving ABC develop a 
hypersensitivity  reaction (HSR) that in rare cases has proved fatal.  However, in the 
PENTA 5 study  [Gibb ,2000a] only  1 of the 92 ART -naïve, s ymptomatic children, aged 3 
months to 16 y ears who were treated with a regimen containing ABC developed a 
classical hypersensitivity reaction.  In CNAA3006, which utilized an ABC containing 
backbone, ABC HSR was observed in 2% of pediatric subjects.
Revised text
In clinical studies, conducted before the introduction of screening for the HLA -
B*5701 allele, approximately  5% of subjects receiving ABC develop a hy persensitivity  
reaction (HSR) that in rare cases has proved fatal.  However, in the PENTA 5 study  
[Gibb ,2000a] only  1 of the 92 ART -naïve, s ymptomatic children, aged 3 months to 16 
years who were treated with a reg imen containing ABC developed a classical 
hypersensitivity  reaction.  I n CNAA3006, which utilized an ABC containing backbone, 
ABC HSR was observed in 2% of pediatric subjects. The risk for abacavir HSR to 
occur is significantly increased for patients who t est positive for the HLA -B*[ADDRESS_274001] been reported at a lower frequency in patients 
who do not carry this allele. In the prospective study CNA106030 (PREDICT -1), the 
use of pre -therapy screening for the presence of HLA -B*5701 and subsequently 
avoiding ABC in HLA -B*5701 positive patients, significantly reduced the incidence 
of clinically suspected ABC HSR from 7.8% (66 of 847) to 3.4% (27 of 803) 
(p<0.0001) [ Mallal, 2008]. In clinical studies EPZ108859 (ARIES) and CNA109586 
(ASSERT), 0.8% (4/515) and 3.1% (6/192) of subjects who were HLA -B*5701
negative and who received ABC developed a clinically suspected ABC HSR, 
respectively [ Post, 2010; Squires , 2010].
It is recommended that any HIV -infected patient without prior exposure t o abacavir 
be screened for HLA -B*5701 allele. Screening is recommended prior to re -initiation 
of abacavir in patients of unknown HLA -B*[ADDRESS_274002] previously 
tolerated abacavir. Use of abacavir in patients known to carry the HLA -B*[ADDRESS_274003] remain the basis of clinical 
decision making. Even in the absence of the HLAB* 5701 allele, it is important to 
permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity reaction cannot be ruled out on clinical grounds, due to the 
potential for a severe or even fatal reaction .
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , paragraph [ADDRESS_274004] onset respi[INVESTIGATOR_227314] (pneumonia, bronchitis, phary ngitis), a flu -like illness, gastroenteritis, or 
reactions to other medications.  This delay  in diagnosis of hy persensitivity  has r esulted in 
GD2001/[ZIP_CODE]/[ADDRESS_274005] containing ABC (ZIAGEN, 
TRIZIV IRTMor the ABC/3TC fixed dose combination) should be restarted.
Revised text
Some subjects with hy persensitivity  were initially thought to have onset respi[INVESTIGATOR_227373] (pneumonia, bronchitis, phary ngitis), a flu -like illness, gastroenteritis, or 
reactions to other medications.  This delay  in diagnosis of hy persensitivity  has resulted in 
ABC being continued or re -introduced, leading to more severe hy persensit ivity reaction 
or death.  Therefore, the diagnosis of h ypersensitivity  reaction should be carefull y 
considered for patients presenting with sy mptoms of these diseases.  If h ypersensitivity  
reaction cannot be ruled out, no medicinal product containing ABC ( ZIAGEN, 
TRIZIV IR, KIVEXA, TRIUMEQ or any other ABC -containing product ) should be 
restarted.
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , paragraphs [ADDRESS_274006] that contains ABC (ZIAGEN, 
TRIZIVIR or the ABC/3TC fixed dose combination).   Restarting an y ABC -containing 
product following a h ypersensitivity  reaction results in a prompt return of sy mptoms 
within hou rs.  This recurrence of the hypersensitivity reaction may be more severe 
than on initial presentation and may include life -threatening hypotension and death.   
There have been infrequent reports of h ypersensitivity  reactions following reintroduction 
of ABC , where the interruption was preceded by  a single key  symptom of 
hypersensitivity  (rash, fever, malaise/fatigue, gastrointestinal or a respi[INVESTIGATOR_29197]).
On very  rare occasions hy persensitivity  reactions have been reported in patients who 
have re -starte d therapy , and who had no preceding sy mptoms of a hypersensitivity  
reaction.
Revised text
Subjects who develop a hypersensitivity reaction must discontinue ABC and must 
NEVER be rechallenged with any medicinal product that contains ABC (ZIAGEN, 
TRIZIVIR , KIVEXA, TRIUMEQ or any ABC -containing product) .  Restarting an y 
ABC -containing product following a hy persensitivity  reaction results in a prompt return 
of sy mptoms within hours.  This recurrence of the hypersensitivity reaction may be 
more severe than on i nitial presentation and may include life -threatening 
hypotension and death.   
There have been infrequent reports of h ypersensitivity  reactions following reintroduction 
of ABC, where the interruption was preceded b y a single key s ymptom of 
hypersensitivity  (rash, fever, malaise/fatigue, gastrointestinal or a respi[INVESTIGATOR_29197]).
GD2001/[ZIP_CODE]/[ADDRESS_274007] re -started therap y, and who had no preceding sy mptoms of a hypersensitivity  
reaction (i.e., patients previously considered to be abacavir tolerant) .
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , Management of 
Hypersensitivity Reactions ,3rdparagraph
Original text
Subjects who develop a hypersensitivity reaction must discontinue AB C and must 
NEVER be rechallenged with any medicinal product that contains ABC (ZIAGEN, 
TRIZIVIR or the ABC/3TC fixed dose combination).   Restarting an y ABC -containing 
product following a h ypersensitivity  reaction results in a prompt return of sy mptoms 
within hours.  This recurrence of the hypersensitivity reaction may be more severe 
than on initial presentation and may include life -threatening hypotension and death.
Revised text
Subjects who develop a hypersensitivity reaction must discontinue ABC and must 
NEVER be rechallenged with any medicinal product that contains ABC (ZIAGEN, 
TRIZIVIR , KIVEXA, TRIUMEQ or any ABC -containing product) .  Restarting an y 
ABC -containing product following a hy persensitivity  reaction results in a prompt return 
of sy mptoms within hours.  This recurrence of the hypersensitivity reaction may be 
more severe than on initial presentation and may include life -threatening 
hypotension and death.   
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , Special considerations 
following an interruption of abacavir therapy ,1st-5th paragraph
Original text
If therap y with ABC has been discontinued and restarting therap y is under consideration, 
the reason for discontinuation should be evaluated to ensure that the patient did not have 
symptom s of a h ypersensitivity  reaction.  If hypersensitivity reaction cannot be ruled 
out, no medicinal product containing ABC (ZIAGEN, TRIZIVIR or the ABC/3TC 
fixed dose combination) should be restarted.
There have been infrequent reports of hypersensitivity re action following reintroduction 
of an ABC -containing product where the interruption was preceded by a single key 
symptom of hypersensitivity (rash, fever, malaise/fatigue, gastrointestinal symptoms or a 
respi[INVESTIGATOR_20321]).  If a decision is made to resta rt any ABC -containing product in 
these patients, this should be done only under direct medical supervision. 
On very  rare occasions hy persensitivity  reactions have been reported in patients who 
have re -started therap y, and who had no preceding sy mptoms of a hypersensitivity  
reaction. If a decision is made to re -start an ABC -containing product, this must be done 
only if medical care can be accessed readil y by [CONTACT_227467].
Revised text
GD2001/[ZIP_CODE]/[ADDRESS_274008] containing ABC (ZIAGEN, TRI ZIVIR, KIVEXA, 
TRIUMEQ or any ABC -containing fixed dose combination) should be restarted.
There have been infrequent reports of hypersensitivity reaction following reintroduction 
of an ABC -containing product where the interruption was preceded by a single key 
symptom of hypersensitivity (rash, fever, malaise/fatigue, gastrointestinal symptoms or a 
respi[INVESTIGATOR_20321]).  If a decision is made to restart any ABC -containing product in 
these patients, this should be done only under direct medical supervision. 
Rarely, patients who have stopped ABC for reasons other than symptoms of HSR 
have also experienced life -threatening reactions within hours of re -initiating 
abacavir therapy. Subjects must be made aware that HSR can occur with 
reintroduction of ABC or any other medicinal product containing abacavir and that 
reintroduction of ABC or any other medicinal product containing abacavir should 
be undertaken only if medical care can be readily accessed.
Screening for carriage of the HLA -B*5701 allele is recommended prior to re -
initiation of
ABC in patients of unknown HLA -B*[ADDRESS_274009] positive for the HLA B*5701 
allele is not recommended.
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , Essential Patient 
Information , 3rdparagraph
Original text
Parents/legal guardians must be reminded that subjects who are h ypersensitive to 
ABC must never take any ABC -containing medicinal product (ZIAGEN, TRIZIVIR 
or the ABC/3TC fixed dose comb ination) again.
Revised text
Parents/legal guardians must be reminded that subjects who are h ypersensitive to 
ABC must never take any ABC -containing medicinal product s(ZIAGEN, 
TRIZIV IR, KIVEXA, TRIUMEQ or any ABC -containing fixed -dose 
combination) again.
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction, Reporting of 
Hypersensitivity Reactions
Original text
All cases of potential ABC hy persensitivity  should be reported as Serious Adverse Events 
(SAE) (see Section 7.8).  I n addition to reporting the case as an SAE, the HSR CRF 
should be completed and faxed to [COMPANY_004] within one week of the onset of the 
hypersensitivity  reaction .
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
294Revised text
All cases of potential ABC hy persensitivity  should be reported as Serious Adverse Events 
(SAE) (see Section 7.8). In addition to reporting the case as an SAE, the HSR CRF 
should be completed and sent to [COMPANY_004] within one week of the onset of the 
hypersensitivity  reaction. 
Amend: Section [IP_ADDRESS] Abacavir Hypersensitivity Reaction , Stevens Johnson 
Syndrome, Toxic Epi[INVESTIGATOR_227374] , 2nd paragraph
Original text
If a serious skin reaction develops, the ABC -containing product should be discontinued, 
and the patient should not be rechallenged with any ABC -containing medicinal product 
(ZIAGEN, TRIZIVIR or the ABC/3TC fixed dose combination). 
Revised text
If a serious skin reaction develops, the ABC -containing product should be discontinued, 
and the patient should not be rechallenged with any ABC -containing medicinal product 
(ZIAGEN, TRIZIVIR ,KIVEXA, T RIUMEQ or any ABC -containing fixed dose 
combination).
Change 15
Amend: Section 3.3.[ADDRESS_274010] develops an AIDS diagnosis (CDC stage C) or other evidence of disease 
progression such that the treat ing clinician believes that changing therapy  is required 
even though the above criteria have not been met, the investigator should contact [CONTACT_227468] a case b y case basis.
Revised text
If a subject develops an AIDS diagnosis (CDC stage C ) or other evidence of disease 
progression such that the treating clinician believes that changing therap y is required 
even though the above criteria have not been met, the investigator should contact [CONTACT_227400] a case by  [CONTACT_413].
Change 1 6
Amend: Section 3.3.10, Concurrent Medications and Non -Drug Therapi[INVESTIGATOR_014] .
Fosamprenavir and Ritonavir , 1stparagraph
Original text
FPV and RTV are metabolized in the liver by  [CONTACT_9058] P450 3A4 (CYP3A4).  APV 
and RTV are predominantly  CYP3A 4 inhibitors.  Caution should be used when co -
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
295administering medications that are substrates, inhibitors, or inducers of CYP3A4.  I n 
addition, RTV has an affinity  for other cy tochrome P450 isozy mes including CYP2D6, 
CYP2C9, CYP2C19, CYP2A6, CYP1A2 and CYP2E 1, and appears to increase the 
activity  of glucuronos yl transferases. 
Revised text
FPV and RTV are metabolized in the liver by  [CONTACT_9058] P450 3A4 (CYP3A4).  APV 
and RTV are predominantly  CYP3A4 inhibitors.  When FPV and RTV are co -
administered, the riton avir metabolic drug interaction profile may predominate 
because ritonavir is a more potent CYP3A4 inhibitor. The full prescribing 
information for ritonavir must therefore be consulted prior to initiation of therapy 
with FPV and RTV.
Amend: Section 3.3.10, Concurrent Medications and Non -Drug Therapi[INVESTIGATOR_014] .
Fosamprenavir and Ritonavir , 3rdparagraph
Original text
FPV and RTV should not be co -administered with alfuzosin, amiodarone, astemizole, 
bepridil, bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], diazepam, dihy droergotamine, 
encainide, ergonovine, ergotamine, estazolam, flecainide, flurazepam, halofantrine, 
lovastatin, meperidine, methy lergonovine, midazolam, pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], 
propafenone, propox yphene, quinidine, PDE5 inhibitors including sildenafil, simvast atin, 
terfenadine and triazolam.  Co -administration may result in competitive inhibition of 
metabolism of these medications and may  cause serious or life -threatening adverse 
events.  Co -administration of FPV or FPV/RTV with rifabutin results in significant
increases in plasma rifabutin levels, therefore the dose of rifabutin should be reduced b y 
at least 50% when co -administered with FPV and by  [CONTACT_2669] 75% when co -administered 
with FPV/RTV.  Caution should be used and subjects should be monitored closely  for 
signs of toxicity
Revised text
FPV and RTV should not be co -administered with alfuzosin, amiodarone, astemizole, 
bepridil, bupropi[INVESTIGATOR_2394], cisapride, clorazepate, clozapi[INVESTIGATOR_050], diazepam, dihy droergotamine, 
encainide, ergonovine, ergotamine, estazolam, flecainid e, flurazepam, halofantrine, 
lovastatin, meperidine, methy lergonovine, midazolam, pi[INVESTIGATOR_3924], pi[INVESTIGATOR_18234], 
propafenone, propox yphene, quinidine, ketaconazole, rifampi[INVESTIGATOR_2513] , PDE5 inhibitors 
including sildenafil, simvastatin, terfenadine and triazolam. Co -administ ration may result 
in competitive inhibition of metabolism of these medications and may  cause serious or 
life-threatening adverse events. Co -administration of FPV or FPV/RTV with rifabutin 
results in significant increases in plasma rifabutin levels, therefo re the dose of rifabutin 
should be reduced b y at least 50% when co -administered with FPV and b y at least 75% 
when co -administered with FPV/RTV. Caution should be used and subjects should be 
monitored closely  for signs of toxicity .
Amend: Section 3.3.10, Concurrent Medications and Non -Drug Therapi[INVESTIGATOR_014] .
Fosamprenavir and Ritonavir , 6th paragraph
GD2001/[ZIP_CODE]/[ADDRESS_274011] with CYP3A4, either as substrates, inhibitors, or in ducers of 
the isozy me and which should be used with caution include, but are not limited to:  
alprazolam, amlodipi[INVESTIGATOR_050], atorvastatin, cerivastatin, cimetidine, clarithrom ycin, 
clindamy cin, clonazepam, codeine, dapsone, diltiazem, disopy ramide, ery thromy cin, 
estrogens and progestogens, felodipi[INVESTIGATOR_050], fluvastatin, glucocorticoids, imipramine, 
isradipi[INVESTIGATOR_050], itraconazole, ketoconazole, loratadine, miconazole, nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], 
nimodipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], pravastatin, verapamil and zolpi[INVESTIGATOR_6730]. 
Revised text
APV and R TV interact with CYP3A4 and are predominantly  CYP3A4 inhibitors.  
Medications which interact with CYP3A4, either as substrates, inhibitors, or inducers of 
the isozy me, or medicinal products with narrow therapeutic windows that are 
substrates of cytochrome P450 3A4 (CYP 3A4) should be used with caution include, 
but are not limited to:  alprazolam, amlodipi[INVESTIGATOR_050], atorvastatin , cerivastatin, cimetidine , 
clarithrom ycin, clindam ycin, clonazepam, codeine, dapsone, diltiazem, disopy ramide, 
erythromy cin, estrogens and progestogens, felodipi[INVESTIGATOR_050], fluvastatin, glucocorticoids, 
imipramine, isradipi[INVESTIGATOR_050], itraconazole, loratadine, miconazole, nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], 
nimodipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], pravastatin, verapamil and zolpi[INVESTIGATOR_6730]. 
Amend: Section 3.3.10, Concurrent Medications and Non-Drug Therapi[INVESTIGATOR_014] .
Fosamprenavir and Ritonavir , 8-10thparagraphs
Original text
RTV is an inhibitor of CYP2D6 and an inducer of CYP1A2, CYP2C9 and glucuronosy l 
transferase.  Medications which interact with CYP2D6, CYP1A2, CYP2C9, and/or 
glucuronosy l tran sferase should be used with caution and include but are not limited to: 
bisoprolol, codeine, chlorpromazine, cy clobenzaprine, desipramine, doxepin, 
fluphenazine, fluoxetine, haloperidol, hy drocodone, methamphetamine, metoprolol, 
mexilitine, morphine, propr anolol, oxy codone, paroxetine, perphenazine, risperidone, 
thioridazine, timolol, tramadol, trazodone, and venlafaxine.  
Because RTV oral solution contains alcohol, drugs such as metronidazole that may 
inhibit alcohol metabolism should be avoided.
IMPORTAN T:For further information refer to Fosamprenavir Investigator’s Brochure 
Supplement and local product information or the International Product Information for 
more complete information.
Revised text
RTV is not recommended for use with digoxin, voriconazol e, blonanserin, 
salmeterol and other drugs not recommended for use with FPV above.  RTV is an 
inhibitor of CYP2D6 and an inducer of CYP1A2, CYP2C9 and glucuronosyl transferase. 
Medications which interact with CYP2D6, CYP1A2, CYP2C9, and/or glucuronos yl 
transferase should be used with caution and include but are not limited to: bisoprolol, 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
297codeine, chlorpromazine, cy clobenzaprine, desipramine, doxepin, fluphenazine, 
fluoxetine, haloperidol, hydrocodone, methamphetamine, metoprolol, mexilitine, 
morphine, prop ranolol, oxy codone, paroxetine , perphenazine , risperidone, thioridazine, 
timolol, tramadol, trazodone, and venlafaxine.  
Because RTV oral solution contains alcohol, drugs such as metronidazole that may 
inhibit alcohol metabolism should be avoided.
IMPORTA NT:For further information refer <deleted text Fosamprenavir 
Investigator’s Brochure Supplement and>to local product information or the 
International Product Information for more complete information .
Change 1 7
Amend: Section [IP_ADDRESS], [COMPANY_004] Supplied Backg round NRTI Options , Interactions 
Relevant to Lamivudine , 7thparagraph
Original text
None
Adde d text
Emtricitabine : Lamivudine may inhibit the intracellular phosphorylation of 
emtricitabine when the two medicines are used concurrently. Additionally, the 
mechanism of viral resistance for both lamivudine and emtricitabine is mediated via 
mutation of the same viral reverse transcriptase gene (M184V) and therefore the 
therapeutic efficacy of these medicines in combination therapy may be limited. 3TC 
is not reco mmended for use in combination with emtricitabine.
Change 1 8
Amend: Section 4.1, Study Drug Packaging and Labeling , 3rdparagraph
Original text
RTV oral solution will be provided locall y by [CONTACT_227469] .
Revised text
RTV oral solution will be provided locall y by [CONTACT_227469] .[COMPANY_004] will provide RTV by [CONTACT_227470], or [COMPANY_004] may provide RTV if local 
supplies are not available and RTV is able to be obtained from other countries .  
Change 1 9
Amend: Section 4.2, Study Drug Handling , 2ndparagraph
GD2001/[ZIP_CODE]/[ADDRESS_274012] until the next scheduled visit.  All study  drug that is not utilized during the study  
will be destroy ed at the completion of the trial.  Drug disposition records will be regul arly 
reviewed b y the study  monitor.
Amend: Section 4.2, Study Drug Handling , 6thparagraph
Original text
None
Revised text
Note per Amendment 12; for subjects weighing less than 33 kg, if RTV oral solution 
is not available, the RTV powder can be substitute d.  For doses less than 100 mg or 
partial doses between 100 mg increments the following instructions should be 
followed. Mix 1 packet/sachet of oral powder (100 mg) with 9.4 mL of liquid (such 
as water, chocolate milk, or infant formula) in a mixing cup. O nce mixed, use an 
oral dosing syringe to measure and administer the prescribed volume.  Once the 
powder is mixed, the dosage must be consumed within [ADDRESS_274013] any mixture 
remaining in the mixing cup. Additional guidance is provided in Section 11.6.
Amend: Section 4.2, Study Drug Handling , 8thparagraphs
Original text
Study  medications should be stored until the time of dispensing as follows:
FPV 5 0 mg/mL oral suspension Store below 30 C (86 F) DO NOT FREEZE
RTV 8 0 mg /mL oral solution Store according to local product information
Revised text
Study  medications should be stored until the time of dispensing as follows:
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
299FPV 5 0 mg /mL oral suspension Store below 30 C (86 F) DO NOT FREEZE
RTV 8 0 mg /mL oral solution Store according to local p roduct information
RTV oral powder Store according to local product information
RTV [ADDRESS_274014] information
Change 20
Amend: Section 5.5, Efficacy, 2ndparagraph
Original text
Quantitative plasma HIV -1 RNA ([COMPANY_002] Amplicor HIV -[ADDRESS_274015]; version 1.5, 
ultrasensitive limit of detection (LOD) = 50copi[INVESTIGATOR_014]/mL ).  Samples with 
>75,000copi[INVESTIGATOR_014]/mL will be retested using the [COMPANY_002] Amplicor HIV -[ADDRESS_274016] assay  LOD = 400copi[INVESTIGATOR_014]/mL.  (NOTE:  At the Screening and 
Baseline (Day  1) visits, the [COMPANY_002] Amplicor HIV -[ADDRESS_274017] assay  will be used).
Revised text
Quantitative plasma HIV -1 RNA ([COMPANY_002] Amplicor HI V-[ADDRESS_274018]; version 1.5, 
ultrasensitive limit of detection (LOD) = 50 copi[INVESTIGATOR_014] /mL).  Samples with >75,000
copi[INVESTIGATOR_014]/mL  will be retested using the [COMPANY_002] Amplicor HIV -[ADDRESS_274019] assay  LOD = 400 copi[INVESTIGATOR_014]/mL.  (NOTE:  At the Screening and Baseline 
(Day  1) visits, the [COMPANY_002] Amplicor HIV -[ADDRESS_274020] assay  
will be used). Per Protocol Amendment 12: the [COMPANY_002] Amplicor HIV -[ADDRESS_274021] Version 1.5 was subsequently discontinued after the July 2011 cut -off date 
for the week 48 CSR.  By [CONTACT_36466] 2013, only two APV20002 study sites, both in 
South Africa had actively enrolled subjects; and efficacy for these subjects was 
evaluated using the Abbott Realtime HIV -[ADDRESS_274022], which has a LOD of 40 
copi[INVESTIGATOR_014]/mL.
Change 21
Amend: Se ction 5.9.1, Withdrawal , 1stparagraph
Original text
Subjects who prematurely discontinue from the study , whether voluntaril y or not, should 
have the Withdrawal visit assessments performed (refer to Section 10).  A Follow -up visit 
will be performed [ADDRESS_274023] the Withdrawal visit assessments performed (refer to Section 10).  Once a subject’s 
weight has increased to 39 kg or mor e, they should be withdrawn from the study 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
300(refer to Section 3.1).  A Follow -up visit will be performed 4 weeks after the 
Withdrawal visit.
Change 22
Amend: Section 7.8, Prompt Reporting of SAEs to [COMPANY_004] moved to Section 7.[ADDRESS_274024] be reported promptly  to [COMPANY_004] as described in the following table once the 
investigator determines that the event meets the protocol definition of an SAE.
7.8.1 Timeframes for Submitting SAE Reports to
Initial SAE Reports Additi onal Information on a 
Previously Reported SAE
Type of SAE Time Frame Documents Time Frame Documents
All SAEs 24 hrs “SAE” CRF pages 24 hrs Updated “SAE” 
CRF pages
7.8.2. Transmission of the SAE Reports
Facsimile transmission of the “SAE” CRF is the pre ferred method to transmit this 
information to the project contact [CONTACT_72030].  I n the absence of facsimile 
equipment, notification by [CONTACT_227471] -threatening events, 
with a cop y of the “SAE” CRF sent b y overnight mail. For SAEs that are not deaths or 
life-threatening events, telephone notification, in the absence of facsimile equipment, is 
not acceptable.  Instead, a cop y of the “SAE” CRF will be sent b y overnight mail.  [COMPANY_004] 
will provide separately  a list of project con tacts for SAE receipt, fax numbers, and 
mailing addresses.
Revised text
This section regarding reporting of SAES was moved to Section 7.9 and the previous 
Section 7.9 (Regulatory Reporting Requirements For SAEs ) was moved to Section 7.8.
Change 23
Amend: S ection 8.2.[ADDRESS_274025] Informed Consent, Paragraph 3  
Original text
None 
Revised text
Per protocol amendment 12: Assent forms will also be obtained from subjects still 
enrolled in the study  as of Nov 1, 2019. 
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
301Change 24
Amend: Appendix 5:  Dosing Table for FPV Oral Suspension
Original text
New tables for higher weight subjects were added
Revised text
Appendix 5:  Dosing Table for FPV Oral Suspension
As per Section [IP_ADDRESS], f or subjects exceeding 6 y ears of age ,the following weight -based 
dosing for FPV shou ld be used:
FPV 18mg/kg BID (>6 years old)
Weight (kg) Dose (mg): 18 mg /kgAmount of 5 0 mg /mL 
suspension (mL) per DoseNo. Bottles (225mL) 
Needed Per Month
25 450 9 3
26 468 9.4 3
27 486 9.7 3
28 504 10.1 3
29 522 10.4 3
30 540 10.8 3
31 558 11.2 3
32 576 11.5 4
33 594 11.9 4
34 612 12.2 4
35 630 12.6 4
36 648 13 4
37 666 13.3 4
38 684 13.7 4
Change 2 5
Amend: Appendix 6:  Dosing Table for RTV Oral Solution, Powder, Capsules and
Tablets 
Original text
New tables for higher weight subjects we re added
Additional table and text :
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
302RTV Oral Solution 7 mg/kg BID (<2 years old)
Weight (kg)Dose (mg): 7 
mg/kgAmount of 80 mg/mL solution 
(mL) per Dose
3 21 0.26
3.5 24.5 0.31
4 28 0.35
4.5 31.5 0.39
5 35 0.44
5.5 38.5 0.48
6.0 42 0.53
6.5 45.5 0.57
7.0 49 0.61
7.5 52.5 0.66
8 56 0.70
8.5 59.5 0.74
9 63 0.79
9.5 66.5 0.83
10 70 0.88
10.5 73.5 0.92
11 77 0.96
11.5 80.5 1.01
12 84 1.05
12.5 87.5 1.09
13 91 1.14
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
303As per Section [IP_ADDRESS], for subjects exceeding 6 years of age, the foll owing weight -
based dosing for RTV oral solution should be used:
RTV Oral Solution 3 mg/kg BID (>6 years old)
Weight (kg) Dose (mg): 3 mg/kgAmount of 80 mg/mL 
suspension (mL) per Dose
25 75 0.9
26 78 1.0
27 81 1.0
28 84 1.1
29 87 1.1
30 90 1.1
31 93 1.2
32 96 1.2
≥33a99 1.2
aSubjects who are ≥33kg and are receiving RTV oral solution at a dose of 3mg/kg 
should remain at the recommended optimal dose for ≥33kg (99mg BID for 3mg/kg 
dosing) even as their weight increases above 33kg. The maximum allow ed total daily 
dose for RTV oral solution is 200mg.
The following weight -based dosing for RTV oral powder can be used if RTV oral 
solution is not available.  For doses less than 100 mg or partial doses between 100 
mg increments: Mix 1 packet/sachet of oral powder (100 mg) with 9.4 mL of liquid 
(such as water, chocolate milk, or infant formula) in a mixing cup. Once mixed, use 
an oral dosing syringe to measure and administer the prescribed volume.  Once the 
powder is mixed, the dosage must be consumed within [ADDRESS_274026] any mixture 
remaining in the mixing cup.
RTV Oral Powder (100 mg sachets) 3 mg/kg BID (>6 year old)
Weight (kg) Dose (mg): 3 mg/kgAmount of liquid per dose 
once the sachet with 100 mg 
powder is dissolved in 9.4 
mL of liquid (10 mg/mL)
25 75 7.5 mL
26 78 7.8 mL
27 81 8.1 mL
28 84 8.4 mL
29 87 8.7 mL
30 90 9.0 mL
31 93 9.3 mL
32 96 9.6 mL
≥33a99 10.0 mL
GD2001/[ZIP_CODE]/12 CONFIDENTIA L
APV20002
304As per Section [IP_ADDRESS], for subjects exceeding 6 years of age who weigh ≥33kg and 
can swallow capsules or tablets whole, the following weight -based dosing for RTV 
oral 100 mg tablets or 100 mg capsules should be used: 1 capsule or tablet (dose of 
100 mg) BID.  The maximum allowed total daily dose of RTV capsules or tablets is 
200 mg. 